

; PRIOR FILING DATE: 1993-10-14
; PRIOR APPLICATION NUMBER: 08/197,801
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/237,491
; PRIOR FILING DATE: 1994-04-28
; PRIOR APPLICATION NUMBER: 08/296,757
; PRIOR FILING DATE: 1994-08-26
; PRIOR APPLICATION NUMBER: 08/221,531
; PRIOR FILING DATE: 1994-02-02
; PRIOR APPLICATION NUMBER: 08/435,761
; PRIOR FILING DATE: 1995-05-05
; PRIOR APPLICATION NUMBER: 08/194,317
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: 08/222,611
; PRIOR FILING DATE: 1994-03-31
; PRIOR APPLICATION NUMBER: 08/487,829
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/216,595
; PRIOR FILING DATE: 1994-03-22
; PRIOR APPLICATION NUMBER: 08/499,410
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: 08/271,217
; PRIOR FILING DATE: 1994-06-27
; PRIOR APPLICATION NUMBER: 08/521,383
; PRIOR FILING DATE: 1995-08-16
; PRIOR APPLICATION NUMBER: 08/274,621
; PRIOR FILING DATE: 1994-07-08
; PRIOR APPLICATION NUMBER: 08/413,150
; PRIOR FILING DATE: 1995-03-29
; PRIOR APPLICATION NUMBER: 08/270,638
; PRIOR FILING DATE: 1994-07-01
; PRIOR APPLICATION NUMBER: 08/412,033
; PRIOR FILING DATE: 1995-03-28
; PRIOR APPLICATION NUMBER: 08/276,164
; PRIOR FILING DATE: 1994-07-15
; PRIOR APPLICATION NUMBER: 08/293,347
; PRIOR FILING DATE: 1994-08-19
; PRIOR APPLICATION NUMBER: 08/413,793
; PRIOR FILING DATE: 1995-03-30
; PRIOR APPLICATION NUMBER: 08/303,241
; PRIOR FILING DATE: 1994-09-07
; PRIOR APPLICATION NUMBER: 08/323,523
; PRIOR FILING DATE: 1994-10-14
; PRIOR APPLICATION NUMBER: 08/489,200
; PRIOR FILING DATE: 1995-06-09
; PRIOR APPLICATION NUMBER: 08/320,011
; PRIOR FILING DATE: 1994-10-05
; PRIOR APPLICATION NUMBER: 08/440,743
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/334,881
; PRIOR FILING DATE: 1994-11-04
; PRIOR APPLICATION NUMBER: 08/369,881
; PRIOR FILING DATE: 1995-01-05
; PRIOR APPLICATION NUMBER: 08/373,361
; PRIOR FILING DATE: 1995-01-17
; PRIOR APPLICATION NUMBER: 08/393,220
; PRIOR FILING DATE: 1995-02-23
; PRIOR APPLICATION NUMBER: 08/494,619
; PRIOR FILING DATE: 1995-06-23
; PRIOR APPLICATION NUMBER: 08/972,819
; PRIOR FILING DATE: 1997-11-18
; PRIOR APPLICATION NUMBER: 08/385,268
; PRIOR FILING DATE: 1995-02-07
; PRIOR APPLICATION NUMBER: 08/964,263
; PRIOR FILING DATE: 1997-11-04
; PRIOR APPLICATION NUMBER: 08/392,180
; PRIOR FILING DATE: 1995-02-22
; PRIOR APPLICATION NUMBER: 08/964,265
; PRIOR FILING DATE: 1997-11-04
; PRIOR APPLICATION NUMBER: 08/395,244
; PRIOR FILING DATE: 1995-02-27
; PRIOR APPLICATION NUMBER: 08/972,899
; PRIOR FILING DATE: 1997-11-18

; PRIOR APPLICATION NUMBER: 08/451,242
; PRIOR FILING DATE: 1995-05-25
; PRIOR APPLICATION NUMBER: 08/392,715
; PRIOR FILING DATE: 1995-02-23
; PRIOR APPLICATION NUMBER: 08/963,650
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 08/416,401
; PRIOR FILING DATE: 1995-03-31
; PRIOR APPLICATION NUMBER: 08/404,891
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: 08/406,219
; PRIOR FILING DATE: 1995-03-16
; PRIOR APPLICATION NUMBER: 08/497,967
; PRIOR FILING DATE: 1995-07-03
; PRIOR APPLICATION NUMBER: 08/408,872
; PRIOR FILING DATE: 1995-03-21
; PRIOR APPLICATION NUMBER: 08/413,151
; PRIOR FILING DATE: 1995-03-29
; PRIOR APPLICATION NUMBER: 08/502,242
; PRIOR FILING DATE: 1995-07-13
; PRIOR APPLICATION NUMBER: 08/421,124
; PRIOR FILING DATE: 1995-04-12
; PRIOR APPLICATION NUMBER: 08/446,910
; PRIOR FILING DATE: 1995-05-22
; PRIOR APPLICATION NUMBER: 08/429,361
; PRIOR FILING DATE: 1995-04-26
; PRIOR APPLICATION NUMBER: 08/440,817
; PRIOR FILING DATE: 1995-05-15
; PRIOR APPLICATION NUMBER: 60/000,275
; PRIOR FILING DATE: 1995-06-16
; PRIOR APPLICATION NUMBER: 08/668,236
; PRIOR FILING DATE: 1996-06-14
; PRIOR APPLICATION NUMBER: 60/000,744
; PRIOR FILING DATE: 1995-06-30
; PRIOR APPLICATION NUMBER: 08/672,741
; PRIOR FILING DATE: 1996-06-28
; PRIOR APPLICATION NUMBER: 60/001,754
; PRIOR FILING DATE: 1995-08-01
; PRIOR APPLICATION NUMBER: 08/688,870
; PRIOR FILING DATE: 1996-07-31
; PRIOR APPLICATION NUMBER: 60/004,416
; PRIOR FILING DATE: 1995-09-28
; PRIOR APPLICATION NUMBER: 60/004,697
; PRIOR FILING DATE: 1995-10-03
; PRIOR APPLICATION NUMBER: 08/725,587
; PRIOR FILING DATE: 1996-10-03
; PRIOR APPLICATION NUMBER: 60/005,175
; PRIOR FILING DATE: 1995-10-02
; PRIOR APPLICATION NUMBER: 08/725,863
; PRIOR FILING DATE: 1996-10-04
; PRIOR APPLICATION NUMBER: 60/004,810
; PRIOR FILING DATE: 1995-10-02
; PRIOR APPLICATION NUMBER: 08/724,751
; PRIOR FILING DATE: 1996-10-02
; PRIOR APPLICATION NUMBER: 60/006,111
; PRIOR FILING DATE: 1995-10-24
; PRIOR APPLICATION NUMBER: 08/992,868
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 08/734,050
; PRIOR FILING DATE: 1996-10-18
; PRIOR APPLICATION NUMBER: 60/004,490
; PRIOR FILING DATE: 1995-09-29
; PRIOR APPLICATION NUMBER: 08/723,972
; PRIOR FILING DATE: 1996-09-27
; PRIOR APPLICATION NUMBER: 60/004,672
; PRIOR FILING DATE: 1995-10-02
; PRIOR APPLICATION NUMBER: 08/725,029
; PRIOR FILING DATE: 1996-10-02
; PRIOR APPLICATION NUMBER: 60/005,526
; PRIOR FILING DATE: 1995-09-29
; PRIOR APPLICATION NUMBER: 08/722,922
; PRIOR FILING DATE: 1996-09-27
; PRIOR APPLICATION NUMBER: 60/004,809

```
; PRIOR FILING DATE: 1995-10-02
; PRIOR APPLICATION NUMBER: 08/725,693
; PRIOR FILING DATE: 1996-09-30
; PRIOR APPLICATION NUMBER: 60/004,674
; PRIOR FILING DATE: 1995-10-02
; PRIOR APPLICATION NUMBER: 08/731,034
; PRIOR FILING DATE: 1996-10-02
; PRIOR APPLICATION NUMBER: 60/004,676
; PRIOR FILING DATE: 1995-10-02
; PRIOR APPLICATION NUMBER: 08/706,766
; PRIOR FILING DATE: 1996-09-27
; PRIOR APPLICATION NUMBER: 60/005,023
; PRIOR FILING DATE: 1995-10-10
; PRIOR APPLICATION NUMBER: 08/727,870
; PRIOR FILING DATE: 1996-10-09
; PRIOR APPLICATION NUMBER: 60/005,197
; PRIOR FILING DATE: 1995-10-10
; PRIOR APPLICATION NUMBER: 08/726,759
; PRIOR FILING DATE: 1996-10-09
; PRIOR APPLICATION NUMBER: 60/005,008
; PRIOR FILING DATE: 1995-10-10
; PRIOR APPLICATION NUMBER: 08/727,737
; PRIOR FILING DATE: 1996-10-08

Query Match 92.0%; Score 18.4; DB 20; Length 153;
Best Local Similarity 95.0%; Pred. No. 7.4e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGTGTGGGGCGCTGGTGCC 20
    ||||| ||||| ||||| |||||
DB 43 GGTGTCCGGGGCGCTGGTGCC 24

RESULT 14
US-09-533-806-823/c
; Sequence 823, Application US/09533806
; GENERAL INFORMATION:
; APPLICANT: Seilhamer, Jeffrey J.
; APPLICANT: Delegeane, Angelo M.
; APPLICANT: Stuart, Susan G.
; APPLICANT: Stuve, Laura L.
; APPLICANT: Mullahy, Sara J.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING OR REGULATING ISOMERASES
; FILE REFERENCE: PD-1005 CIP
; CURRENT APPLICATION NUMBER: US/09/533,806
; CURRENT FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: 07/916,491
; PRIOR FILING DATE: 1992-07-17
; PRIOR APPLICATION NUMBER: 07/977,780
; PRIOR FILING DATE: 1992-11-19
; PRIOR APPLICATION NUMBER: 08/100,523
; PRIOR FILING DATE: 1993-08-03
; PRIOR APPLICATION NUMBER: 09/008,119
; PRIOR FILING DATE: 1998-01-16
; PRIOR APPLICATION NUMBER: 08/196,364
; PRIOR FILING DATE: 1994-02-14
; PRIOR APPLICATION NUMBER: 08/282,991
; PRIOR FILING DATE: 1994-07-28
; PRIOR APPLICATION NUMBER: 08/438,571
; PRIOR FILING DATE: 1995-05-10
; PRIOR APPLICATION NUMBER: 08/179,873
; PRIOR FILING DATE: 1994-01-11
; PRIOR APPLICATION NUMBER: 08/504,732
; PRIOR FILING DATE: 1995-07-20
; PRIOR APPLICATION NUMBER: 08/137,951
; PRIOR FILING DATE: 1993-10-14
; PRIOR APPLICATION NUMBER: 08/197,801
; PRIOR FILING DATE: 1994-02-17
; PRIOR APPLICATION NUMBER: 08/237,491
; PRIOR FILING DATE: 1994-04-28
; PRIOR APPLICATION NUMBER: 08/296,757
; PRIOR FILING DATE: 1994-08-26
; PRIOR APPLICATION NUMBER: 08/221,531
; PRIOR FILING DATE: 1994-02-02
; PRIOR APPLICATION NUMBER: 08/435,761
; PRIOR FILING DATE: 1995-05-05
; PRIOR APPLICATION NUMBER: 08/194,317
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: 08/222,611
; PRIOR FILING DATE: 1994-03-31
; PRIOR APPLICATION NUMBER: 08/487,829
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/216,595
; PRIOR FILING DATE: 1994-03-22
; PRIOR APPLICATION NUMBER: 08/499,410
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: 08/271,217
; PRIOR FILING DATE: 1994-06-27
; PRIOR APPLICATION NUMBER: 08/521,383
; PRIOR FILING DATE: 1995-08-16
; PRIOR APPLICATION NUMBER: 08/274,621
; PRIOR FILING DATE: 1994-07-08
; PRIOR APPLICATION NUMBER: 08/413,150
; PRIOR FILING DATE: 1995-03-29
; PRIOR APPLICATION NUMBER: 08/270,638
; PRIOR FILING DATE: 1994-07-01
; PRIOR APPLICATION NUMBER: 08/412,033
; PRIOR FILING DATE: 1995-03-28
; PRIOR APPLICATION NUMBER: 08/276,164
; PRIOR FILING DATE: 1994-07-15
; PRIOR APPLICATION NUMBER: 08/293,347
; PRIOR FILING DATE: 1994-08-19
; PRIOR APPLICATION NUMBER: 08/413,793
; PRIOR FILING DATE: 1995-03-30
; PRIOR APPLICATION NUMBER: 08/303,241
; PRIOR FILING DATE: 1994-09-07
; PRIOR APPLICATION NUMBER: 08/323,523
; PRIOR FILING DATE: 1994-10-14
; PRIOR APPLICATION NUMBER: 08/489,200
; PRIOR FILING DATE: 1995-06-09
; PRIOR APPLICATION NUMBER: 08/320,011
; PRIOR FILING DATE: 1994-10-05
; PRIOR APPLICATION NUMBER: 08/440,743
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/334,881
; PRIOR FILING DATE: 1994-11-04
; PRIOR APPLICATION NUMBER: 08/369,881
; PRIOR FILING DATE: 1995-01-05
; PRIOR APPLICATION NUMBER: 08/373,361
; PRIOR FILING DATE: 1995-01-17
; PRIOR APPLICATION NUMBER: 08/393,220
; PRIOR FILING DATE: 1995-02-23
; PRIOR APPLICATION NUMBER: 08/494,619
; PRIOR FILING DATE: 1995-06-23
; PRIOR APPLICATION NUMBER: 08/972,819
; PRIOR FILING DATE: 1997-11-18
; PRIOR APPLICATION NUMBER: 08/385,268
; PRIOR FILING DATE: 1995-02-07
; PRIOR APPLICATION NUMBER: 08/964,263
; PRIOR FILING DATE: 1997-11-04
; PRIOR APPLICATION NUMBER: 08/392,180
; PRIOR FILING DATE: 1995-02-22
; PRIOR APPLICATION NUMBER: 08/964,265
; PRIOR FILING DATE: 1997-11-04
; PRIOR APPLICATION NUMBER: 08/395,244
; PRIOR FILING DATE: 1995-02-27
; PRIOR APPLICATION NUMBER: 08/972,899
; PRIOR FILING DATE: 1997-11-18
; PRIOR APPLICATION NUMBER: 08/451,242
; PRIOR FILING DATE: 1995-05-25
; PRIOR APPLICATION NUMBER: 08/392,715
; PRIOR FILING DATE: 1995-02-23
; PRIOR APPLICATION NUMBER: 08/963,650
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 08/416,401
```

1995-03-31
PRIOR FILING DATE: 08/404,891
PRIOR APPLICATION NUMBER: 1995-03-15
PRIOR FILING DATE: 08/406,219
PRIOR APPLICATION NUMBER: 1995-03-16
PRIOR FILING DATE: 08/497,967
PRIOR APPLICATION NUMBER: 1995-07-03
PRIOR FILING DATE: 08/408,872
PRIOR APPLICATION NUMBER: 1995-03-21
PRIOR FILING DATE: 08/413,151
PRIOR APPLICATION NUMBER: 1995-03-29
PRIOR FILING DATE: 08/502,242
PRIOR APPLICATION NUMBER: 1995-07-13
PRIOR FILING DATE: 08/421,124
PRIOR APPLICATION NUMBER: 1995-04-12
PRIOR FILING DATE: 08/446,910
PRIOR APPLICATION NUMBER: 1995-05-22
PRIOR FILING DATE: 08/429,361
PRIOR APPLICATION NUMBER: 1995-04-26
PRIOR FILING DATE: 08/440,817
PRIOR APPLICATION NUMBER: 1995-05-15
PRIOR FILING DATE: 60/000,275
PRIOR APPLICATION NUMBER: 1995-06-16
PRIOR FILING DATE: 08/658,236
PRIOR APPLICATION NUMBER: 1996-06-14
PRIOR FILING DATE: 60/000,744
PRIOR APPLICATION NUMBER: 1995-06-30
PRIOR FILING DATE: 08/672,741
PRIOR APPLICATION NUMBER: 1996-06-28
PRIOR FILING DATE: 60/001,754
PRIOR APPLICATION NUMBER: 1995-08-01
PRIOR FILING DATE: 08/688,870
PRIOR APPLICATION NUMBER: 1996-07-31
PRIOR FILING DATE: 60/004,416
PRIOR APPLICATION NUMBER: 1995-09-28
PRIOR FILING DATE: 60/004,697
PRIOR APPLICATION NUMBER: 1995-10-03
PRIOR FILING DATE: 08/725,587
PRIOR APPLICATION NUMBER: 1996-10-03
PRIOR FILING DATE: 60/005,175
PRIOR APPLICATION NUMBER: 1995-10-02
PRIOR FILING DATE: 08/725,863
PRIOR APPLICATION NUMBER: 1996-10-04
PRIOR FILING DATE: 60/004,810
PRIOR APPLICATION NUMBER: 1995-10-02
PRIOR FILING DATE: 08/724,751
PRIOR APPLICATION NUMBER: 1996-10-02
PRIOR FILING DATE: 60/006,111
PRIOR APPLICATION NUMBER: 1995-10-24
PRIOR FILING DATE: 08/992,868
PRIOR APPLICATION NUMBER: 1997-12-11
PRIOR FILING DATE: 08/734,050
PRIOR APPLICATION NUMBER: 1996-10-18
PRIOR FILING DATE: 60/004,490
PRIOR APPLICATION NUMBER: 1995-09-29
PRIOR FILING DATE: 08/723,972
PRIOR APPLICATION NUMBER: 1996-09-27
PRIOR FILING DATE: 60/004,672
PRIOR APPLICATION NUMBER: 1995-10-02
PRIOR FILING DATE: 08/725,029
PRIOR APPLICATION NUMBER: 1996-10-02
PRIOR FILING DATE: 60/005,526
PRIOR APPLICATION NUMBER: 1995-09-29
PRIOR FILING DATE: 08/722,922
PRIOR APPLICATION NUMBER: 1996-09-27
PRIOR FILING DATE: 60/004,809
PRIOR APPLICATION NUMBER: 1995-10-02
PRIOR FILING DATE: 08/725,693
PRIOR APPLICATION NUMBER: 1996-09-30
PRIOR FILING DATE: 60/004,674
PRIOR APPLICATION NUMBER: 1995-10-02
PRIOR FILING DATE: 08/731,034
PRIOR APPLICATION NUMBER: 1996-10-02

60/004,676
PRIOR APPLICATION NUMBER: 1995-10-02
PRIOR FILING DATE: 08/706,766
PRIOR APPLICATION NUMBER: 1996-09-27
PRIOR FILING DATE: 60/005,023
PRIOR APPLICATION NUMBER: 1995-10-10
PRIOR FILING DATE: 08/727,870
PRIOR APPLICATION NUMBER: 1996-10-09
PRIOR FILING DATE: 60/005,197
PRIOR APPLICATION NUMBER: 1995-10-10
PRIOR FILING DATE: 08/726,759
PRIOR APPLICATION NUMBER: 1996-10-09
PRIOR FILING DATE: 60/005,008
PRIOR APPLICATION NUMBER: 1995-10-10
PRIOR FILING DATE: 08/727,737
PRIOR APPLICATION NUMBER: 1996-10-08

Query Match 92.0%; Score 18.4; DB 20; Length 171;
Best Local Similarity 95.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGTGTGGGGGCTGTGTC 20
||||| |||||||||

Db 30 GGTGTGGGGGCTGTGTC 11
||||| |||||||||

RESULT 15
US-60-023-278-2937/c
Sequence 2937, Application US/60023278
GENERAL INFORMATION:
APPLICANT: Gooding, Douglas H.
APPLICANT: Stuve, Laura L.
APPLICANT: Stuart, Susan G.
APPLICANT: Ito, Laura Y.
APPLICANT: Akerblom, Ingrid E.
APPLICANT: Deleane, Angelo M.
APPLICANT: Naughton, Rebecca E.
APPLICANT: Klingler, Tod M.
TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM
TITLE OF INVENTION: HUMAN UTERUS
NUMBER OF SEQUENCES: 3768
CORRESPONDENCE ADDRESS:
ADDRESS: INCYTE PHARMACEUTICALS, INC.
STREET: 3174 PORTER DRIVE
CITY: PALO ALTO
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Word Perfect 6.1 for Windows/MS-DOS 6.2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/60/023,278
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: CERRONE, MICHAEL C., Ph.D.
REGISTRATION NUMBER: 39132
REFERENCE/DOCKET NUMBER: PD-0211P
TELEPHONE: (415) 855-0555
TELEFAX: (415) 845-4166
INFORMATION FOR SEQ ID NO: 2937:
SEQUENCE CHARACTERISTICS:
LENGTH: 171 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cdna
IMMEDIATE SOURCE:
CLONE: 1638235

US-60-023-278-2937

Query Match 92.0%; Score 18.4; DB 34; Length 171;
 Best Local Similarity 95.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 GGTGTGCGGGGCTGTGCC 20
 Db 30 GGTGTGCGGGGCTGTGCC 11

Search completed: April 20, 2001, 03:21:21
 Job time: 14168 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:15:28 ; Search time 101.94 Seconds
(without alignments)
27.149 Million cell updates/sec

Title: US-09-016-464-16

Perfect score: 20

Sequence: 1 GGTGTGGCGGCGCTGGTCC 20

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 46985 seqs, 69187998 residues

Total number of hits satisfying chosen parameters: 93970

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_NA_New:*

1: /cgn2_6/pdata1/pna/pct_NEW_COMB.seq:*

2: /cgn2_6/pdata1/pna/US06_NEW_COMB.seq:*

3: /cgn2_6/pdata1/pna/US07_NEW_COMB.seq:*

4: /cgn2_6/pdata1/pna/US08_NEW_COMB.seq:*

5: /cgn2_6/pdata1/pna/US09_NEW_COMB.seq:*

6: /cgn2_6/pdata1/pna/US60_NEW_COMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	ID	Description
1	20	100.0	20	5	US-09-543-679A-1046
2	20	100.0	180	5	US-09-543-679A-1046
3	20	100.0	827	5	US-09-543-679A-2970
4	20	100.0	6225	5	US-09-543-679A-2410
5	20	100.0	35459	5	US-09-543-679A-3003
6	15.8	79.0	480	5	US-09-739-449-7833
7	15.8	79.0	803	5	US-09-739-449-71
8	15.8	79.0	3750	6	US-60-248-505-1443
9	15.8	79.0	4069	6	US-60-248-505-1852
10	15.8	79.0	143551	5	US-09-739-449-203
11	15.8	79.0	144245	6	US-60-248-505-111
12	15.8	79.0	156975	6	US-60-248-505-520
13	15.4	77.0	493	4	US-08-276-163D-13715
14	15.2	76.0	317	4	US-08-276-163D-14916
15	15.2	76.0	494	4	US-08-276-163D-2027
16	15.2	76.0	497	4	US-08-276-163D-8557
17	15.2	76.0	501	4	US-08-276-163D-11669
18	15.2	76.0	1378	5	US-09-423-844-262
19	15.2	76.0	22081	6	US-60-248-505-38
20	15.2	76.0	30601	6	US-60-248-505-129
21	14.8	74.0	404	5	US-09-813-206-253
22	14.8	74.0	477	4	US-08-276-163D-2699
23	14.8	74.0	498	4	US-08-276-163D-14118
24	14.8	74.0	1089	5	US-09-739-449-875
25	14.8	74.0	1112	5	US-09-739-449-1516
26	14.8	74.0	19410	6	US-60-248-505-50
27	14.8	74.0	449171	6	US-60-248-505-42

28	14.4	72.0	504	4	US-08-276-163D-191	Sequence 191, App
29	14.2	71.0	229	5	US-09-442-384-134	Sequence 134, App
30	14.2	71.0	480	4	US-08-276-163D-8656	Sequence 8656, App
31	14.2	71.0	486	4	US-08-276-163D-7821	Sequence 7821, App
32	14.2	71.0	882	5	US-09-739-449-4672	Sequence 4672, App
33	14.2	71.0	921	5	US-09-739-449-1357	Sequence 1357, App
34	14.2	71.0	1671	1	PCT-US01-01351-340	Sequence 340, App
35	14.2	71.0	1671	1	PCT-US01-01351-341	Sequence 341, App
36	14.2	71.0	1671	1	PCT-US01-01351-342	Sequence 342, App
37	14.2	71.0	10046	1	PCT-US01-01351-458	Sequence 458, App
38	14.2	71.0	13491	6	US-60-248-505-337	Sequence 337, App
39	14.2	71.0	14780	6	US-60-248-505-130	Sequence 130, App
40	14.2	71.0	18676	6	US-60-248-505-428	Sequence 428, App
41	14.2	71.0	18772	1	PCT-US01-01315-63	Sequence 63, Appl
42	14.2	71.0	19650	5	US-09-819-989-3	Sequence 3, Appl
43	14.2	71.0	21287	6	US-60-248-505-415	Sequence 415, App
44	14.2	71.0	27355	6	US-60-248-505-643	Sequence 643, App
45	14.2	71.0	27785	6	US-60-248-505-284	Sequence 284, App

ALIGNMENTS

RESULT 1
US-09-543-679A-1046
; Sequence 1046, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRUCTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1046:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1046:
US-09-543-679A-1046

Query Match 100.0%; Score 20; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.9;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGCCTGGTGCC 20
|||||
Db 1 GGTGTGCGGGCCTGGTGCC 20

RESULT 2

US-09-543-679A-1725

Sequence 1725, Application US/09543679A

GENERAL INFORMATION:

APPLICANT: NYCE, Jonathan W.

TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
COMPOSITIONS, KIT & METHOD FOR TREATMENT
OF AIRWAY DISORDERS ASSOCIATED WITH
BRONCHOCONSTRICTION, LUNG INFLAMMATION,

NUMBER OF SEQUENCES: 3111

CORRESPONDENCE ADDRESS:

ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.

STREET: 7 Clarke Drive

CITY: Cranbury

STATE: NJ

COUNTRY: USA

ZIP: 08512

COMPUTER READABLE FORM:

MEDIUM TYPE: CD-R

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: N/A

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/543,679A

FILING DATE: 13-Apr-2000

CLASSIFICATION: UNKNOWN

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/127,958

FILING DATE: 1998-08-03

ATTORNEY/AGENT INFORMATION:

NAME: Anzel, Viviana

REGISTRATION NUMBER: 30,930

REFERENCE/DOCKET NUMBER: EPI-0067191b

TELECOMMUNICATION INFORMATION:

TELEPHONE: 609-409-3035

TELEFAX: 413-254-9245

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 1725:

SEQUENCE CHARACTERISTICS:

LENGTH: 180 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 1725:

US-09-543-679A-1725

Query Match 100.0%; Score 20; DB 5; Length 180;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGCCTGGTGCC 20
|||||
Db 1 GGTGTGCGGGCCTGGTGCC 20

RESULT 3

US-09-543-679A-2970/c

Sequence 2970, Application US/09543679A

GENERAL INFORMATION:

APPLICANT: NYCE, Jonathan W.

TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
COMPOSITIONS, KIT & METHOD FOR TREATMENT
OF AIRWAY DISORDERS ASSOCIATED WITH
BRONCHOCONSTRICTION, LUNG INFLAMMATION,

NUMBER OF SEQUENCES: 3111

CORRESPONDENCE ADDRESS:

ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.

STREET: 7 Clarke Drive

CITY: Cranbury

STATE: NJ

COUNTRY: USA

ZIP: 08512

COMPUTER READABLE FORM:

MEDIUM TYPE: CD-R

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: N/A

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/543,679A

FILING DATE: 13-Apr-2000

CLASSIFICATION: UNKNOWN

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/127,958

FILING DATE: 1998-08-03

ATTORNEY/AGENT INFORMATION:

NAME: Anzel, Viviana

REGISTRATION NUMBER: 30,930

REFERENCE/DOCKET NUMBER: EPI-0067191b

TELECOMMUNICATION INFORMATION:

TELEPHONE: 609-409-3035

TELEFAX: 413-254-9245

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 2970:

SEQUENCE CHARACTERISTICS:

LENGTH: 827 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 2970:

US-09-543-679A-2970

Query Match 100.0%; Score 20; DB 5; Length 827;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGCCTGGTGCC 20
|||||
Db 68 GGTGTGCGGGCCTGGTGCC 49

RESULT 4

US-09-543-679A-2410

Sequence 2410, Application US/09543679A

GENERAL INFORMATION:

APPLICANT: NYCE, Jonathan W.

TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
COMPOSITIONS, KIT & METHOD FOR TREATMENT
OF AIRWAY DISORDERS ASSOCIATED WITH
BRONCHOCONSTRICTION, LUNG INFLAMMATION,

NUMBER OF SEQUENCES: 3111

CORRESPONDENCE ADDRESS:

ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.

STREET: 7 Clarke Drive

CITY: Cranbury

STATE: NJ

COUNTRY: USA

ZIP: 08512

COMPUTER READABLE FORM:

MEDIUM TYPE: CD-R

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: N/A

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/543,679A

FILING DATE: 13-Apr-2000

CLASSIFICATION: UNKNOWN

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/127,958

```
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2410:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6225 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2410:
US-09-543-679A-2410

Query Match 100.0%; Score 20; DB 5; Length 6225;
Best Local Similarity 100.0%; Pred. No. 1.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGGCGCTGGTGCC 20
Db 133 GGTGTGCGGGGCGCTGGTGCC 152

RESULT 5
US-09-543-679A-3003
; Sequence 3003, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT,
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LONG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESS: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 3003:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35459 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 3003:
US-09-543-679A-3003
```

```
Query Match 100.0%; Score 20; DB 5; Length 35459;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGGCGCTGGTGCC 20
Db 133 GGTGTGCGGGGCGCTGGTGCC 152

RESULT 6
US-09-739-449-7833
; Sequence 7833, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Steven J.
; APPLICANT: Slater, Steven C.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 7833
; LENGTH: 480
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
US-09-739-449-7833
```

```
Query Match 79.0%; Score 15.8; DB 5; Length 480;
Best Local Similarity 89.5%; Pred. No. 97;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGGCGCTGGTGCC 19
Db 208 ggcgtgcggggccgggtgc 226
```

```
RESULT 7
US-09-739-449-71
; Sequence 71, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 71
; LENGTH: 803
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(803)
; OTHER INFORMATION: unsure at all n locations
US-09-739-449-71
```

```
Query Match 79.0%; Score 15.8; DB 5; Length 803;
Best Local Similarity 89.5%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGGCGCTGGTGCC 19
Db 105 ggggtgcggggcctggggc 123
```

```
RESULT 8
US-60-248-505-1443/c
; Sequence 1443, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1443
; LENGTH: 3750
; TYPE: DNA
; ORGANISM: Human
; US-60-248-505-1443

Query Match 79.0%; Score 15.8; DB 6; Length 3750;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 GTGTGCGGGCGCTGGTGC 20
   ||| ||||| ||||| |||
Db 1722 GTGGCGGGCGCTGGAGCC 1704

RESULT 9
US-60-248-505-1852
; Sequence 1852, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1852
; LENGTH: 4069
; TYPE: DNA
; ORGANISM: Human
; US-60-248-505-1852

Query Match 79.0%; Score 15.8; DB 6; Length 4069;
Best Local Similarity 89.5%; Pred. No. 77;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 GTGTGCGGGCGCTGGTGC 20
   ||| ||||| ||||| |||
Db 3345 gtggcggggcctggagcc 3363

RESULT 10
US-09-739-449-203
; Sequence 203, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)c
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 203
; LENGTH: 143551
```

```
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
; US-09-739-449-203

Query Match 79.0%; Score 15.8; DB 5; Length 143551;
Best Local Similarity 89.5%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGTGTGCGGGCGCTGGTGC 19
   ||| ||||| ||||| |||
Db 42073 ggcgtggggcgccgggtgc 42091

RESULT 11
US-60-248-505-111/c
; Sequence 111, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 111
; LENGTH: 144245
; TYPE: DNA
; ORGANISM: human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(144245)
; OTHER INFORMATION: n = A,T,C or G
; US-60-248-505-111

Query Match 79.0%; Score 15.8; DB 6; Length 144245;
Best Local Similarity 89.5%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 GTGTGCGGGCGCTGGTGC 20
   ||| ||||| ||||| |||
Db 91555 GTGGCGGGCGCTGGAGCC 91537

RESULT 12
US-60-248-505-520/c
; Sequence 520, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 520
; LENGTH: 156975
; TYPE: DNA
; ORGANISM: human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(156975)
; OTHER INFORMATION: n = A,T,C or G
; US-60-248-505-520

Query Match 79.0%; Score 15.8; DB 6; Length 156975;
Best Local Similarity 89.5%; Pred. No. 51;
```

```
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 GTGTGGGGGGCTGGTCC 20
   ||| ||||| ||||| |||
Db 55003 GTGGGGGGGGCTGGAGCC 54985

RESULT 13
US-08-276-163D-13715
; Sequence 13715, Application US/08276163D
; GENERAL INFORMATION:
; APPLICANT: Adams, et. al.
; TITLE OF INVENTION: Human Genes, Sequences, and Expression Products
; FILE REFERENCE: PO14
; CURRENT APPLICATION NUMBER: US/08/276.163D
; CURRENT FILING DATE: 1994-07-15
; NUMBER OF SEQ ID NOS: 15314
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13715
; LENGTH: 493
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (10)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (84)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (268)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (280)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (294)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (296)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (310)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (311)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (319)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (322)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (323)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (327)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (329)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (333)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (342)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (345)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (346)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (350)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (355)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (359)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (364)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (373)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (374)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (375)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (378)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (382)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (388)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (389)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (392)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (398)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (402)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (405)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (407)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (410)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (412)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (417)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (418)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (419)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (421)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (424)
; OTHER INFORMATION: n equals a,t,g, or c
```


THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:00:22 ; Search time 2028.86 Seconds
(without alignments)
57.668 Million cell updates/sec

Title: US-09-016-464-17
Perfect score: 19
Sequence: 1 GGGCGGGCGGAGCATCGC 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1283235 seqs, 3078962356 residues

Total number of hits satisfying chosen parameters: 2566470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl.*
1: gb_ba1.*
2: gb_ba2.*
3: gb_ba3.*
4: gb_in1.*
5: gb_in2.*
6: gb_in3.*
7: gb_on.*
8: gb_ov.*
9: gb_pat1.*
10: gb_pat2.*
11: gb_ph.*
12: gb_pl1.*
13: gb_pl2.*
14: gb_pl3.*
15: gb_pl4.*
16: em_ba1.*
17: em_ba2.*
18: em_fun.*
19: em_htgo_hum.*
20: em_htgo_inv.*
21: em_htgo_rod.*
22: em_htg_hum1.*
23: em_htg_hum2.*
24: em_htg_hum3.*
25: em_htg_hum4.*
26: em_htg_hum5.*
27: em_htg_hum6.*
28: em_htg_hum7.*
29: em_htg_hum8.*
30: em_htg_inv1.*
31: em_htg_inv2.*
32: em_htg_other.*
33: em_htg_rod.*
34: em_hum1.*
35: em_hum2.*
36: em_hum3.*
37: em_hum4.*
38: em_hum5.*
39: em_hum6.*
40: em_hum7.*
41: em_in.*
42: em_on.*
43: em_or.*

44: em_ov.*
45: em_pat.*
46: em_ph.*
47: em_pl.*
48: em_ro.*
49: em_sts.*
50: em_sy.*
51: em_un.*
52: em_vi.*
53: gb_sts1.*
54: gb_sts2.*
55: gb_sts3.*
56: gb_sy.*
57: gb_un.*
58: gb_vil.*
59: gb_v12.*
60: gb_htg1.*
61: gb_htg2.*
62: gb_htg3.*
63: gb_htg4.*
64: gb_htg5.*
65: gb_htg6.*
66: gb_htg7.*
67: gb_htg8.*
68: gb_htg9.*
69: gb_htg10.*
70: gb_htg11.*
71: gb_htg12.*
72: gb_htg13.*
73: gb_htg14.*
74: gb_htg15.*
75: gb_htg16.*
76: gb_htg17.*
77: gb_htg18.*
78: gb_htg19.*
79: gb_htg20.*
80: gb_htg21.*
81: gb_htg22.*
82: gb_htg23.*
83: gb_htg24.*
84: gb_htg25.*
85: gb_pr1.*
86: gb_pr2.*
87: gb_pr3.*
88: gb_pr4.*
89: gb_pr5.*
90: gb_pr6.*
91: gb_pr7.*
92: gb_pr8.*
93: gb_pr9.*
94: gb_ro1.*
95: gb_ro2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	19	100.0	23	9	AR106710	Sequence 8
C 2	19	100.0	23	10	124358	Sequence 8
C 3	19	100.0	340	54	G63807	Sequence 8
C 4	19	100.0	1400	88	AF276953	Sequence 8
C 5	19	100.0	1834	9	AR055229	Sequence 8
C 6	19	100.0	1834	9	AR055235	Sequence 8
C 7	19	100.0	3362	93	HUMENDOSYN	Sequence 8
C 8	19	100.0	3387	9	AR029278	Sequence 8
C 9	19	100.0	3387	10	124360	Sequence 11
C 10	19	100.0	3387	93	HUMCYCLOX	Sequence 11
C 11	19	100.0	10997	93	HUMPTGS2	Sequence 11

```

12 19 100.0 84412 92 HS973M2
c 13 17.4 91.6 654 45 E10546
c 14 17.4 91.6 654 45 E10547
c 15 17.4 91.6 2763 94 CPCOX2
c 16 17.4 91.6 3314 7 U97696
c 17 17.4 91.6 11702 1 AE001916
c 18 17.4 91.6 37931 3 SCD10
c 19 17.4 91.6 73934 1 AB039932
c 20 17.4 91.6 133965 88 AF064861
c 21 17.4 91.6 213732 1 AE001862
c 22 17.4 91.6 217594 2 AP002086
c 23 17.4 91.6 340000 91 HS21C079
c 24 17 89.5 18 9 AR029265
c 25 17 89.5 3387 9 AR106720
c 26 17 89.5 3398 7 AF027334
c 27 17 89.5 8479 7 AF027335
c 28 17 89.5 9453 93 HS004636
c 29 16.4 86.3 1825 7 AF047841
c 30 16.4 86.3 2948 3 RBRTXAB
c 31 16.4 86.3 3000 2 AVPTSP
c 32 16.4 86.3 3100 2 HS062676
c 33 16.4 86.3 5700 3 RCNRFABCD
c 34 16.4 86.3 10102 1 AE004712
c 35 16.4 86.3 10483 1 AE001887
c 36 16.4 86.3 10552 1 AE001989
c 37 16.4 86.3 10784 1 AE005080
c 38 16.4 86.3 12092 1 AE004571
c 39 16.4 86.3 12480 3 RCNRFNG
c 40 16.4 86.3 14377 3 SSP277295
c 41 16.4 86.3 22396 3 SCF43
c 42 16.4 86.3 34611 3 SCD63A
c 43 16.4 86.3 39228 2 MLCB1788
c 44 16.4 86.3 166753 13 AP002866
c 45 16 84.2 41 9 AR106716

```

ALIGNMENTS

```

RESULT 1
AR106710/c
LOCUS AR106710 23 bp DNA PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6107087.
ACCESSION AR106710
VERSION AR106710.1 GI:12821240
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
Unclassified.
O'Neill,G.P. and Mancini,J.A.
TITLE High level expression of human cyclooxygenase-2
JOURNAL Patent: US 6107087-A 8 22-AUG-2000;
FEATURES
Location/Qualifiers
source 1..23
BASE COUNT 1 a 11 c 7 g 4 t
ORIGIN

Query Match 100.0%; Score 19; DB 9; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Caps 0;

Qy 1 GGGCGCGGCGGAGCATGCG 19
| | | | | | | | | | | | | | | | | | | | |
Db 21 GGGCGCGGCGGAGCATGCG 3

RESULT 2
124358/c
LOCUS 124358 23 bp DNA PAT 07-OCT-1996
DEFINITION Sequence 8 from patent US 5543297.

```

```

ACCESSION I24358
VERSION I24358.1 GI:1604228
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
Unclassified.
1 (bases 1 to 23)
AUTHORS Cromlish,W.A., Kennedy,B.P., O'Neill,G., Vickers,P.J., Wong,E. and Mancini,J.A.
TITLE Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
JOURNAL Patent: US 5543297-A 8 06-AUG-1996;
FEATURES
Location/Qualifiers
source 1..23
BASE COUNT 1 a 11 c 7 g 4 t
ORIGIN

Query Match 100.0%; Score 19; DB 10; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGCGGAGCATGCG 19
| | | | | | | | | | | | | | | | | | | | |
Db 21 GGGCGCGGCGGAGCATGCG 3

RESULT 3
G63807/c
LOCUS G63807 340 bp DNA STS 20-DEC-1999
DEFINITION COX2 Exon1 Random genomic STS Homo sapiens STS genomic, sequence tagged site.
ACCESSION G63807
VERSION G63807.1 GI:6606624
KEYWORDS STS.
SOURCE Human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 (bases 1 to 340)
AUTHORS Oefner,P.J.
TITLE Human random genomic STS survey, unpublished data
JOURNAL Unpublished (1999)
COMMENT
Contact: Peter Oefner
Stanford Genome Center
Stanford University
855 California Ave., Palo Alto, CA 94304, USA
Tel.: 6508121926
Fax: 6508121975
Email: oefner@genome.stanford.edu
Primer A: TATAAAAGGAAGTTCTCTCGGT
Primer B: AGTCACGTAGTCTCTATTCGG
STS size: 340
PCR profile:
Initial denaturing step of 95 degrees C for 10 min to activate
Amplitaq Gold (1
min for AmpliTag);
14 cycles of touchdown: 94 degrees C for 20 sec, annealing for 1
min at 63
degrees C to
56 degrees C using decrements of 0.5 degrees C, extension at 72
degrees C for 1
min;
20 cycles at 94 degrees C for 20s, 56 degrees C for 45 sec, 72
degrees C for 1
min.
Protocol:
Template: 50 ng
Primer: each 0.2 uM
Taq Polymerase: 0.02 units/ul
Total Vol: 50 ul

```

Buffer: 1.5 mM
MgCl2: 50 mM
KCl: 10 mM
Tris-HCl: 8.3
pH: 10.3
DMSO: Location/Qualifiers
1..340

FEATURES

source
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="Random genomic STS"
/sex="Male and Female"

STS

primer_bind 1..24
primer_bind complement(318..340)

BASE COUNT 63 a 125 c 89 g 63 t
ORIGIN

Query Match 100.0%; Score 19; DB 54; Length 340;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGCGGAGCATCGC 19
|||||

Db 181 GGGCGCGCGGAGCATCGC 163

RESULT

AF276953/c AF276953 1400 bp DNA PRI 16-JUL-2000
LOCUS Homo sapiens cyclooxygenase-2 (PTGS2) gene, promoter region and
DEFINITION partial cds.
ACCESSION AF276953
VERSION AF276953.1 GI:9230774
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1400)
AUTHORS Lukiw,W.J., Pelaez,R.P., Martinez,J. and Bazan,N.G.
TITLE Budesonide epimer R or dexamethasone selectively inhibit platelet-activating factor-induced or interleukin 1beta-induced DNA binding activity of cis-acting transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes Proc. Natl. Acad. Sci. U.S.A. 95 (7), 3914-3919 (1998)

JOURNAL 98188304
MEDLINE 2 (bases 1 to 1400)
REFERENCE Lukiw,W.J. and Bazan,N.G.
AUTHORS Regulatory features of the human cyclooxygenase-2 (COX-2) promoter
TITLE Unpublished
JOURNAL 3 (bases 1 to 1400)
REFERENCE Lukiw,W.J. and Bazan,N.G.
AUTHORS Direct Submission
TITLE Submitted (10-JUN-2000) Neuroscience and Ophthalmology, Louisiana
JOURNAL State University School of Medicine, 2020 Gravier Street, New Orleans, LA 70112-2272, USA

FEATURES

source
1..1400
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/map="1q25.2"
/tissue_type="epidermal keratinocytes in primary culture"
misc_feature 1..50
/gene="PTGS2"
/note="potential scaffold/matrix attachment region; S/MAR"
promoter 1..1201
/gene="PTGS2"
gene 1..>1400
/gene="PTGS2"

protein_bind /note="COX2"
263..369
/gene="PTGS2"
/note="AP1-like site"
/bound_moiety="AP1"
359..365
/gene="PTGS2"
/note="AP1-like site"
/bound_moiety="AP1"
443..453
/gene="PTGS2"
/note="CAS-binding"
/bound_moiety="STAT1"
555..562
/gene="PTGS2"
/note="SIE-binding"
/bound_moiety="STAT3"
635..641
/gene="PTGS2"
/note="AP1-like site"
/bound_moiety="AP1"
748..768
/gene="PTGS2"
/bound_moiety="NF-kappaB"
939..952
/gene="PTGS2"
/note="AP2-like site"
/bound_moiety="AP2"
972..992
/gene="PTGS2"
/bound_moiety="NF-kappaB"
1056..1067
/gene="PTGS2"
/bound_moiety="AP2"
1069..1076
/gene="PTGS2"
/note="SIE-binding"
/bound_moiety="STAT3"
1078..1085
/gene="PTGS2"
/note="SIE-binding"
/bound_moiety="STAT3"
1168..1178
/gene="PTGS2"
/note="CAS-binding"
/bound_moiety="STAT1"
1170..1176
/gene="PTGS2"
1170..1173
/gene="PTGS2"
/note="TBP-binding"
/bound_moiety="TFIID"
1202..>1400
/gene="PTGS2"
/product="cyclooxygenase-2"
1335..>1400
/gene="PTGS2"
/EC_number="1.14.99.1"
/codon_start=1
/product="cyclooxygenase-2"
/protein_id="AAF85977.1"
/db_xref="GI:9230775"
/translation="MLARALLCAVLXLSHTGEYLA"
1358..1365
/gene="PTGS2"
/note="zif268-binding"
/bound_moiety="EGRI"
BASE COUNT 379 a 361 c 337 g 322 t 1 others
ORIGIN

Query Match 100.0%; Score 19; DB 88; Length 1400;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGCGGAGCATCGC 19
|||||
Db 1350 GGGCGCGGCGGAGCATCGC 1332

RESULT 5

AR055229/c LOCUS AR055229 1834 bp DNA PAT 29-SEP-1999
DEFINITION Sequence 3 from patent US 5837479.

ACCESSION AR055229
VERSION AR055229.1 GI:5980806
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

1 (bases 1 to 1834)
Young, D.A., O'Banion, M.K. and Winn, V.D.
AUTHORS Screening assays for inhibitors of mammalian prostaglandin H
TITLE synthase-2
JOURNAL Patent: US 5837479-A 3 17-NOV-1998;
FEATURES Location/Qualifiers
source 1. .1834

BASE COUNT 517 a 441 c 387 g 489 t

ORIGIN

Query Match 100.0%; Score 19; DB 9; Length 1834;

Best Local Similarity 100.0%; Pred. No. 3.7e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGCGGAGCATCGC 19

|||||

Db 24 GGGCGCGGCGGAGCATCGC 6

RESULT 6

AR055235/c LOCUS AR055235 1834 bp DNA PAT 29-SEP-1999
DEFINITION Sequence 14 from patent US 5837479.

ACCESSION AR055235
VERSION AR055235.1 GI:5980812
KEYWORDS
SOURCE Unknown.

ORGANISM

Unclassified.

1 (bases 1 to 1834)

Young, D.A., O'Banion, M.K. and Winn, V.D.

AUTHORS Screening assays for inhibitors of mammalian prostaglandin H

TITLE synthase-2

JOURNAL Patent: US 5837479-A 14 17-NOV-1998;

FEATURES Location/Qualifiers

source 1. .1834

BASE COUNT 517 a 441 c 387 g 489 t

ORIGIN

Query Match

Best Local Similarity 100.0%; Score 19; DB 9; Length 1834;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGCGGAGCATCGC 19

|||||

Db 24 GGGCGCGGCGGAGCATCGC 6

RESULT 7

HUMENDOSYN/c LOCUS HUMENDOSYN 3362 bp mRNA PRI 12-JUN-1993
DEFINITION Human endoperoxide synthase type II mRNA, complete cds.

ACCESSION

LI5326

LI5326.1 GI:291987

endoperoxide synthase type II.

KEYWORDS Homo sapiens (library: lambda gtl) prostaglandin cDNA to mRNA.

SOURCE

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

1 (bases 1 to 3362)

Jones, D.A., Carlton, D.P., McIntyre, T.M., Zimmerman, G.A. and

Prescott, S.M.

TITLE Molecular cloning of human prostaglandin endoperoxide synthase type

II and demonstration of expression in response to cytokines

JOURNAL J. Biol. Chem. 268, 9049-9054 (1993)

MEDLINE 93232069

FEATURES

Location/Qualifiers

source 1. .3362

/organism="Homo sapiens"

/db_xref="taxon:9606"

/cell_line="primary"

/cell_type="endothelial"

/tissue_type="prostaglandin"

/tissue_lib="lambda gtl"

/map="Chromosome 1"

93. .1907

/codon_start=1

/product="endoperoxide synthase type II"

/protein_id="AA335803.1"

/db_xref="GI:291988"

/translation="MLARALLCAVLALSHNTANPCSHPCQNRGVCMVGFQYKDC

TRTFYGCSTPEFLTRIKLFKPTPTVHYILTHFKGFVNVNIPFLRNATMSYV

LTSRHLIDSPPTYNADYGVKWEAFNSLSTYTRALPPVDDCTPLGVKKGQLPDS

NEVEKLRLRRKPIPDQGSNMFAFAQHFHQFQKTHKRGPAFTNGHGLGVDLNH

IYGETLARQKRLRFKDGKMKYQIIDGEMVPTVKDQAEIYPPQVPEHLRAVGQE

VFGSLGMLMYATWLREHNRVCDVLKQEHPEWDEQLFQTSRLILIGETIKIVIEDY

VQHLSGYFKLRFDELLFNKQFYQNRINAEFTLYHHPLLPDTFQIHQKYNVOQ

EYKNSILLHGITQVESFTQIAGRVAGRNVPAPVQVSOASTDQSKMYQSFN

FIYKRFMLKPYEFSELTGKMSAELEALYGDIDAVELYPALLVEKRPDAIFGETM

VEYGAPSLKGLMGNVICSPAYWKPTFGVEGVFOINTASIQSLICNNVKGCPFTSF

SVPDELKTVTINASSRSGLDDINPTLLKERSTEL"

BASE COUNT 1000 a 697 c 626 g 1039 t

ORIGIN

Query Match 100.0%; Score 19; DB 93; Length 3362;

Best Local Similarity 100.0%; Pred. No. 3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGCGGAGCATCGC 19

|||||

Db 108 GGGCGCGGCGGAGCATCGC 90

RESULT 8

AR029278/c LOCUS AR029278 3387 bp DNA PAT 29-SEP-1999

DEFINITION Sequence 29 from patent US 5859229.

ACCESSION AR029278

VERSION AR029278.1 GI:5941251

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 3387)

Kniiss, D.A.

TITLE Antisense oligonucleotides to suppress eicosanoid formation

JOURNAL Patent: US 5859229-A 29 12-JAN-1999;

FEATURES Location/Qualifiers

source 1. .3387

BASE COUNT 1011 a 712 c 633 g 1031 t

ORIGIN

```

Query Match      100.0%; Score 19; DB 9; Length 3387;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
|||||
Db 113 GGGCGCGGCGGAGCATCGC 95

RESULT 9
I24360/c
LOCUS      I24360      3387 bp      DNA      PAT      07-OCT-1996
DEFINITION Sequence 11 from patent US 5543297.
ACCESSION I24360
VERSION I24360.1 GI:1604230
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 3387)
AUTHORS Cromlish,W.A., Kennedy,B.P., O'Neill,G., Vickers,P.J., Wong,E. and Mancini,J.A.
TITLE Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
JOURNAL Patent: US 5543297-A 11 06-AUG-1996;
FEATURES
     Location/Qualifiers
         1..3387
            /organism="unknown"
BASE COUNT 1010 a 713 c 633 g 1031 t
ORIGIN

Query Match      100.0%; Score 19; DB 10; Length 3387;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
|||||
Db 113 GGGCGCGGCGGAGCATCGC 95

RESULT 10
HUMCYCLOX/c
LOCUS      HUMCYCLOX      3387 bp      mRNA      PRI      31-DEC-1994
DEFINITION Homo sapiens cyclooxygenase-2 (Cox-2) mRNA, complete cds.
ACCESSION M90100
VERSION M90100.1 GI:181253
KEYWORDS cyclooxygenase-2; prostaglandin synthase.
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 3387)
AUTHORS Hla,T. and Neilson,K.
TITLE Human cyclooxygenase-2 cDNA
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (16), 7384-7388 (1992)
MEDLINE 92356465
FEATURES
     Location/Qualifiers
         1..3387
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /cell_type="endothelial"
            /tissue_type="umbilical vein"
         1..97
            /gene="Cox-2"
         1..3387
            /gene="Cox-2"
         98..1912
            /gene="Cox-2"
            /EC_number="1.14.99.1"
            /codon_start=1
            /product="cyclooxygenase-2"
            /protein_id="AAA58433.1"

```

```

/db_xref="GI:181254"
/translation="MLARALLLCAVLASHTANPCSHPCQNRGVCMVSGVDQVKKDC
TRTFYGENCSTPEFLTRIKLFPTNTVHYILTHKGFVNVNNIPFLRNATSYV
LTSRSHLIDSPTYNADYGKSWFAFNSLYTRALPPVDDCPTPLGKGGKQLPDS
NEIVGKLLRRKFIPDQGSNMFAFAQHFTHOFTDKRKGPAFTNGLGHGVDLNH
IYGETLARORKLRLFKDGKMKYQIIDGEMYPPTYKDTQAEMLYPPQVPEHLRFVAGOE
VFGLVPGMLMTATLWLRHNRRVCDLVKQEHPEWGEQQLFQTSRLILIGETIKIVIEDY
VQHLGSHFKLKFDPPELLFNKQFYQNRKAAEFNTLYHHHLLPDPFOIHDQKYNQQ
FIYNSILLEGITQFVESPTROAGRVAGRNVPVAVQKYSQASIDGSRQMKYQSEN
EYKRKMLKPYESELGTGEKMSAEALYGDIDAVELYPALIVEKRPDAIFGETM
VEVGAPPSLKGMLGNVICSPAYWKPFSTFGGVGFQIINTASIQSLICNVKGCPTFSF
SVDPPELTKTVTINASSRSRLDLDINPTVLLKERSTEL"
98..148
/gene="Cox-2"
149..1909
/gene="Cox-2"
/EC_number="1.14.99.1"
/product="cyclooxygenase-2"
1913..3387
/gene="Cox-2"
3369..3374
/gene="Cox-2"
BASE COUNT 1010 a 712 c 633 g 1032 t
ORIGIN

Query Match      100.0%; Score 19; DB 93; Length 3387;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
|||||
Db 113 GGGCGCGGCGGAGCATCGC 95

RESULT 11
HUMPTGS2/c
LOCUS      HUMPTGS2      10997 bp      DNA      PRI      14-APR-2000
DEFINITION Human PTGS2 gene for prostaglandin endoperoxide synthase-2, complete cds.
ACCESSION D28235
VERSION D28235.1 GI:505116
KEYWORDS prostaglandin endoperoxide synthase-2.
SOURCE Homo sapiens Japanese peripheral blood DNA, clone_lib:EMBL3.
ORGANISM Homo sapiens
REFERENCE 1 (sites)
AUTHORS Hla,T. and Neilson,K.
TITLE Human cyclooxygenase-2 cDNA
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (16), 7384-7388 (1992)
MEDLINE 92366465
REFERENCE 2 (bases 1 to 10997)
AUTHORS Kosaka,T., Miyata,A., Ihara,H., Hara,S., Sugimoto,T., Takeda,O., Takahashi,E. and Tanabe,T.
TITLE Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2
JOURNAL Eur. J. Biochem. 221 (3), 889-897 (1994)
MEDLINE 94237153
REFERENCE 3 (bases 1 to 10997)
AUTHORS Tanabe,T.
TITLE Direct Submission
JOURNAL Submitted (19-FEB-1994) to the DDBJ/EMBL/GenBank databases. Tadashi Tanabe, National Cardiovascular Center Research Institute, Pharmacology; 5-7-1 Fujishiro-dai, Suita, Osaka 565, JAPAN (Tel:06-833-5012(ex.2514), Fax:06-872-7485)
MEDLINE 94237153
REFERENCE 3 (bases 1 to 10997)
AUTHORS Tanabe,T.
TITLE Direct Submission
JOURNAL Submitted (19-FEB-1994) to DDBJ by: Tadashi Tanabe, National Cardiovascular Center Research Institute 5-7-1 Fujishiro-dai, Suita Osaka 565 Japan
COMMENT 06-833-5012 x2514

```

Fax:

06-872-7485.

FEATURES

Location/Qualifiers

Source

1..10997
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="EMBL3"
 /tissue_type="Japanese peripheral blood"
 81..90
 /note="CARG box"

misc_signal

93..101

protein_bind

/bound_moiety="NF-IL6"

protein_bind

144..150

protein_bind

/bound_moiety="PEA-1"

protein_bind

328..333

misc_signal

/bound_moiety="myb"

protein_bind

460..465

misc_signal

/note="GATA-1"

protein_bind

584..589

misc_signal

/bound_moiety="myb"

protein_bind

734..739

misc_signal

/note="XRE (xenobiotic-response element)"

protein_bind

883..888

protein_bind

/bound_moiety="myb"

protein_bind

982..990

misc_signal

/bound_moiety="NF-IL6"

misc_signal

1005..1010

misc_signal

/note="GATA-1"

misc_signal

1121..1127

protein_bind

/note="CRE (cAMP-response element)"

protein_bind

1243..1252

protein_bind

/bound_moiety="NF-kappaB"

protein_bind

1291..1296

protein_bind

/bound_moiety="PEA-3"

protein_bind

1421..1426

protein_bind

/bound_moiety="Sp-1"

protein_bind

1468..1477

protein_bind

/bound_moiety="NF-kappaB"

protein_bind

1559..1567

misc_signal

/bound_moiety="NF-IL6"

TATA_signal

1632..1638

exon

/note="CRE"

1660..1666

1691..1876

/number=1

gene
 join(1825..1876,2677..2793,2914..3057,3711..3854,
 4570..4751,5484..5567,5687..5933,6215..6501,7003..7150,
 7637..8046)
 /gene="PTGS2"

CDS
 join(1825..1876,2677..2793,2914..3057,3711..3854,
 4570..4751,5484..5567,5687..5933,6215..6501,7003..7150,
 7637..8046)
 /gene="PTGS2"

join(1825..1876,2677..2793,2914..3057,3711..3854,
 4570..4751,5484..5567,5687..5933,6215..6501,7003..7150,
 7637..8046)
 /codon_start=1
 /product="prostaglandin endoperoxide synthase-2"
 /protein_id="BAA05698.1"
 /db_xref="GI:1020089"

translation="MLARALLCAVLASHTANPCSHPCONRCVMSVGFQYKDC
 TRTFYGENCSTPEFLTRIKLPTNTVHYILTHKFGMNVNNIPFLRNIMSYV
 LTRSHLIDSPPTNADYGYKWEAFSNLSYTRALPPVDDCTPLGVKGGKQLDPS
 NEIVKLLRRKFLPDQGSNMFAFAAQHTHQFFKTHKRGFAFTNGLGKGVDLNH
 YFTGLAROKRLFKDKMKYQIIDGEMYPPTVKDQAEMLYPPQVPEHLRAVGQEE
 VGLVPLGLMYATINLBEHRNVCVLDKQHPENGDEQLFQTSRLILGETIKVIEDY
 VOHLUGTHFLKFDPELFFNKFQYQNRKIAEFTLYHHPLLPDFTQIHDKRYNQYQ
 FYNNLSLLEHTGTFQVESETQTRAGVAGGRNVPVAVQVQSASIDQSRQMYQSPN
 EYRRFMKPYEPEETLGEKMSAELEALYGDIDAVELYPALIVKPRPDALFGETM
 VEVGAPFLSLGLGNVTCSPAYWKPTFGGEVGFQIINTASIQSLICNNKVGCPFTSF
 SVDPPELIKVTINASSRSGLDDINPTVLLKERSTEL"
 1825..1875
 /gene="PTGS2"

sig_peptide
 join(1876,2677..2793,2914..3057,3711..3854,4570..4751,
 5484..5567,5687..5933,6215..6501,7003..7150,7637..8043)
 /gene="PTGS2"

mat_peptide
 join(1876,2677..2793,2914..3057,3711..3854,4570..4751,
 5484..5567,5687..5933,6215..6501,7003..7150,7637..8043)
 /gene="PTGS2"

introns
 1877..2676
 /product="prostaglandin endoperoxide synthase-2"
 /number=1
 2596..2602
 /bound_moiety="AP-1"
 2677..2793
 /gene="PTGS2"
 /number=2
 2794..2913
 /number=2
 2914..3057
 /gene="PTGS2"
 /number=3
 3058..3710
 /number=3
 3711..3854
 /gene="PTGS2"
 /number=4
 3855..4569
 /number=4
 4570..4751
 /gene="PTGS2"
 /number=5
 4651
 /misc_difference
 /gene="PTGS2"
 /citation=[1]
 /replace="g"
 4752..5483
 /number=5
 5484..5567
 /gene="PTGS2"
 /number=6
 5568..5686
 /number=6
 5687..5933
 /gene="PTGS2"
 /number=7
 5840
 /misc_difference
 /gene="PTGS2"
 /citation=[1]
 /replace="a"
 5934..6214
 /number=7
 6215..6501
 /gene="PTGS2"
 /number=8
 6502..7002
 /number=8
 7003..7150
 /gene="PTGS2"
 /number=9
 7151..7636
 /number=9
 7637..>9979
 /number=10
 8062..8066
 /note="Shaw-Kamen's sequence (ATTTA)"
 8066..8070
 /note="Shaw-Kamen's sequence"
 8070..8074
 /note="Shaw-Kamen's sequence"
 8093..8097
 /note="Shaw-Kamen's sequence"
 8101..8105
 /note="Shaw-Kamen's sequence"
 8111..8115
 /note="Shaw-Kamen's sequence"
 8524..8528
 /note="Shaw-Kamen's sequence"
 8688..8692
 /note="Shaw-Kamen's sequence"
 8825..8829
 /note="Shaw-Kamen's sequence"

```

misc_signal      8993..8997
/Note="Shaw-Kamen's sequence"
misc_signal      9138..9142
/Note="Shaw-Kamen's sequence"
misc_signal      9468..9472
/Note="Shaw-Kamen's sequence"
misc_signal      9559..9563
/Note="Shaw-Kamen's sequence"
misc_signal      9684..9688
/Note="Shaw-Kamen's sequence"
misc_signal      9776..9780
/Note="Shaw-Kamen's sequence"
misc_signal      9801..9805
/Note="Shaw-Kamen's sequence"
misc_signal      9818..9822
/Note="Shaw-Kamen's sequence"
polyA_signal     9974..9979
misc_signal      10010..10014

Query Match      100.0%; Score 19; DB 93; Length 10997;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGCGCGGGGGGAGCATCGC 19
|||||
Db 1840 GGCGCGGGGGGAGCATCGC 1822

RESULT 12
HS973M2          84412 bp DNA PRI 23-NOV-1999
LOCUS            Human DNA sequence from clone 973M2 on chromosome 1q24.3-31.1
DEFINITION       Contains prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
                  synthase and cyclooxygenase) gene, ESTs, STS, GSSs, complete
                  sequence.
ACCESSION        AL035333
VERSION          AL035333.5 GI:4468336
KEYWORDS         HTG; PTC52.
SOURCE           human.
ORGANISM         Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 84412)
Coville,G.
Direct Submission
Submitted (20-APR-1999) Sanger Centre, Hinxton, Cambridgeshire,
CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk
requests: clonerequests@sanger.ac.uk
On Mar 22, 1999 this sequence version replaced gi:4464261.
During sequence assembly data is compared from overlapping clones.
Where differences are found these are annotated as variations
together with a note of the overlapping clone name. Note that the
variation annotation may not be found in the sequence submission
corresponding to the overlapping clone, as we submit sequences with
only a small overlap as described above.
IMPORTANT: This sequence is not the entire insert of clone 973M2.
It may be shorter because we only sequence overlapping sections
once, or longer because we arrange for a small overlap between
neighbouring submissions.
The true left end of clone dJ936p19 is at 84313 in this sequence.
This sequence has been finished according to sequence map criteria
as follows. An attempt is made to resolve all sequencing problems,
such as compressions and repeats, but not necessarily within known
annotated human repeat sequence elements (e.g. Alu). Where the
sequence is ambiguous, there is an annotation using the 'unsure'
feature key.
This sequence was generated from part of bacterial clone contigs of
human chromosome 1, constructed by the Sanger Centre Chromosome 1
Mapping Group. Further information can be found at
http://www.sanger.ac.uk/HGP/Chrl
973M2 is from the library RPC15 constructed at the Roswell Park
Cancer Institute by the group of Pieter de Jong. For further
details see http://bacpac.med.buffalo.edu/VECTOR: pcYPAC2.

Location/Qualifiers
1..84412
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/map="q24.3-31.1"
/clone_lib="RPC1-5"
/complement(28..>467)
/Note="match: GSS AQ109818 clone 2373H17"
1846..2203
/Note="179 copies 2 mer aa 59% conserved"
1849..2200
/Note="16 copies 22 mer 60% conserved"
1849..2055
/Note="69 copies 3 mer aag 85% conserved"
2217..2630
/Note="L2 repeat: matches 971..1393 of consensus"
2631..3236
/Note="MLT2D repeat: matches 1..553 of consensus"
3237..3384
/Note="L2 repeat: matches 826..971 of consensus"
3558..3687
/Note="MLTIC repeat: matches 344..466 of consensus"
3688..4392
/Note="LTR8 repeat: matches 1..691 of consensus"
4393..4699
/Note="MLTIC repeat: matches 7..344 of consensus"
4757..4848
/Note="MIR repeat: matches 164..257 of consensus"
5535..5677
/Note="MLT1I repeat: matches 129..276 of consensus"
5909..6211
/Note="AluSg repeat: matches 1..307 of consensus"
6521..6798
/Note="AluXs repeat: matches 1..297 of consensus"
7309..7593
/Note="L2 repeat: matches 2258..2525 of consensus"
7690..8469
/Note="L1PA2 repeat: matches 3..776 of consensus"
8465..13709
/Note="L1PA2 repeat: matches 900..6146 of consensus"
13912..14149
/Note="L2 repeat: matches 1592..1831 of consensus"
14537..14653
/Note="L1MC1 repeat: matches 6070..6187 of consensus"
14658..14797
/Note="L1MC1 repeat: matches 6183..6320 of consensus"
14822..15122
/Note="AluYb8 repeat: matches 1..308 of consensus"
15632..15782
/Note="LTR35 repeat: matches 454..613 of consensus"
16610..16900
/Note="AluJo repeat: matches 3..296 of consensus"
17460..17755
/Note="AluXs repeat: matches 1..298 of consensus"
complement(17729..>18136)
/Note="match: GSS AQ027623 clone 2322P16"
18539..18848
/Note="AluSg repeat: matches 1..307 of consensus"
19806..19905
/Note="MLTIC repeat: matches 1..103 of consensus"
19906..20214
/Note="AluSg repeat: matches 1..313 of consensus"
20215..20370
/Note="MLTIC repeat: matches 103..263 of consensus"
20371..20603
/Note="AluSg repeat: matches 43..283 of consensus"
20604..20828
/Note="MLTIC repeat: matches 263..466 of consensus"
21334..21461
/Note="L2 repeat: matches 1435..1567 of consensus"
22095..22621

```

```

repeat_region /note="LTR9 repeat: matches 12. .512 of consensus"
22640. .22769
repeat_region /note="65 copies 2 mer tt 69% conserved"
22658. .22745
repeat_region /note="4 copies 22 mer 78% conserved"
22772. .22824
repeat_region /note="LTR9 repeat: matches 450. .502 of consensus"
22825. .23133
repeat_region /note="AluSx repeat: matches 1. .312 of consensus"
23134. .23263
repeat_region /note="LTR9 repeat: matches 502. .625 of consensus"
23857. .24371
repeat_region /note="L2 repeat: matches 707. .1206 of consensus"
24372. .24493
repeat_region /note="FLAM.C repeat: matches 2. .123 of consensus"
24494. .24764
repeat_region /note="L2 repeat: matches 433. .707 of consensus"
24786. .25086
repeat_region /note="AluSx repeat: matches 3. .308 of consensus"
25087. .25154
repeat_region /note="34 copies 2 mer aa 74% conserved"
25175. .25369
repeat_region /note="L2 repeat: matches 173. .403 of consensus"
25391. .25673
repeat_region /note="AluSx repeat: matches 2. .309 of consensus"
25737. .25825
repeat_region /note="L2 repeat: matches 2571. .2644 of consensus"
26065. .26216
repeat_region /note="AluSg/x repeat: matches 177. .312 of consensus"
26650. .26946
repeat_region /note="AluY repeat: matches 1. .296 of consensus"
27162. .27764
repeat_region /note="L1MD2 repeat: matches 5731. .6333 of consensus"
28181. .28492
repeat_region /note="AluY repeat: matches 1. .311 of consensus"
28607. .28733
repeat_region /note="L2 repeat: matches 2553. .2676 of consensus"
28770. .29111
repeat_region /note="L2 repeat: matches 2089. .2411 of consensus"
complement(29157. .29553)
repeat_region /note="match: GSS AQ004513 clone 2294C15"
29185. .29333
repeat_region /note="MIR repeat: matches 10. .159 of consensus"
complement(29271. .29626)
repeat_region /note="match: GSS AQ005004 clone 2294D2"
complement(29291. .29581)
repeat_region /note="match: GSS AQ006900 clone 2294C20"
complement(29629. .29808)
repeat_region /note="match: AL009785 chromosome 1 HindIII fragment"
30165. .30466
repeat_region /note="L2 repeat: matches 2116. .2405 of consensus"
30467. .30888
repeat_region /note="MSTA repeat: matches 1. .426 of consensus"
30889. .31001
repeat_region /note="L2 repeat: matches 2405. .2553 of consensus"
31002. .31276
repeat_region /note="AluSp repeat: matches 37. .313 of consensus"
31277. .31303
repeat_region /note="L2 repeat: matches 2553. .2578 of consensus"
<31738. .32330
repeat_region /note="match: multiple ESTs; match: 3' EST T63799 clone
81383; Paired with EST T63823 matching this clone; match:
5' EST T63823 clone 81383; Paired with EST T63799 matching
this clone"
31847. .32100
repeat_region /note="L1MA9 repeat: matches 6028. .6292 of consensus"
32121. .32273
repeat_region /note="L1PA4 repeat: matches 5995. .6146 of consensus"
32281. .32356
repeat_region /note="38 copies 2 mer ta 68% conserved"
33919. .34214
repeat_region /note="L1MC1 repeat: matches 5926. .6243 of consensus"
34262. .34386

```

```

repeat_region /note="MLT2E repeat: matches 223. .347 of consensus"
34377. .34425
repeat_region /note="MLT2FB repeat: matches 267. .315 of consensus"
34426. .34741
repeat_region /note="AluSg repeat: matches 1. .310 of consensus"
34742. .34769
repeat_region /note="MLT2FB repeat: matches 240. .267 of consensus"
34770. .35121
repeat_region /note="MLT1A1 repeat: matches 1. .364 of consensus"
35122. .35357
repeat_region /note="MLT2FB repeat: matches 1. .380 of consensus"

Query Match 100.0%; Score 19; DB 92; Length 84412;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
DB 50633 GGGCGCGGCGGAGCATCGC 50651
|||||
RESULT 13
EI0546/c standard; DNA; UNC: 654 BP.
ID EI0546
XX AC EI0546;
XX AC EI0546.1
SV EI0546.1
XX 08-OCT-1997 (Rel. 52, Created)
DT 02-SEP-2000 (Rel. 65, Last updated, Version 2)
XX DE DNA encoding thiamin pyrophosphokinase from Paracoccus denitrificans.
XX KW JP 1996009985-A/1.
XX OS unidentified
XX OC unclassified.
XX RN [1]
XX RP 1-654
RA Iida A., Teshiba S.;
RT "PRODUCTION OF THIAMINE DIPHOSPHORIC ACID";
RL Patent number JP1996009985-A/1, 16-JAN-1996.
XX KYOWA HAKKO KOGYO CO LTD.
XX OS Paracoccus denitrificans
CC PN JP 1996009985-A/1
CC PD 16-JAN-1996
CC PF 01-JUL-1994 JP 1994150847
CC PI IIDA AKIHIRO, TESHIBA SADA0
CC PC C12P17/16, C12N1/21, C12N15/09, C12N9/12, (C12P17/16, C12R1/19),
CC PC (C12N1/21,
CC PC C12R1/19), (C12N15/09, C12R1/01);
CC CC strandedness: Double;
CC CC topology: Linear;
CC CC hypothetical: No;
CC CC anti-sense: No;
CC FH Key Location/Qualifiers
CC FH source 1. .654
CC FT /organism="Paracoccus denitrificans"
CC FT /strain="ATCC19367"
CC FT /clone="pAI213"
CC FT 1. .654
CC FT mat_peptide /product="Thiamin pyrophosphokinase from
CC FT Pracoccus
CC FT denitrificans"
XX key Location/Qualifiers
FH source 1. .654
FT /db_xref="taxon:32644"
FT

```


[illegible]

```
/codon_start=1
/product="cyclooxxygenase-2"
/protein_id="CAA69204.1"
/db_xref="GI:1556390"
/db_ref="SWISS-PROT:P70682"
/translation="MLARALLLCAALALGQAANPCSNPCQNGECLSVGFDKYKDCD
LTSRSHLIDSPPTNAHYGYSWEAFNSLSYTRALPPVADDCPTPMGVKKEKLPDS
NEVLEKVLRRKFTIPDQGTNNMFAPFAQHTHQFFKSDQKRGFAFTTGLAHGYDLSH
IYGETLDRHKLRLLFKDKMKYQIIDGEMYPPTVKETQVENMYPPIPEHARFVQGE
VFGLVPLMMYATLWREHNRVCVLDKOEHPEDDERLFTQSRLLILIGETIKIVIEDY
VQHLGSHFKLHFDPELIFNOQFYQNRVIASEFNTLYHWHPLLPDFTQIDQVYVFOQ
FLYNNLSILVEHGLTQFVESFTKQIAGRVAGGRNVPLAVORVAKASIEHSRKMKYOSLN
EYRRFLMKPVTSEELTGEKEMAAGLEALYGDIDAMELYPALLVEKPRPDATFGETM
VEMGAPSLKGLMGNPICSPPHYWKPSTFGGEVGFQIVNTASIQSLICNNVKGCPVTAF
NLPDPQLAKIVITINASASHSRLEDLSPTVLLKGRSTEL"
```

polyA_signal 2531..2536
BASE COUNT 798 a 635 c 589 g 741 t
ORIGIN

Query Match 91.6%; Score 17.4; DB 94; Length 2763;
Best Local Similarity 94.7%; Pred. No. 1.4e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GGGCGCGGGCGGAGCATCGC 19
Db 30 GCGCGCGGGCGGAGCATCGC 12

Search completed: April 20, 2001, 00:00:25
Job time: 9502 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:12:55 ; Search time 547.68 Seconds
(without alignments) .
20.252 Million cell updates/sec

Title: US-09-016-464-17

Perfect score:

Sequence: 1 GGGCGGGCGAGCATCGC 19

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 678276 seqs, 291890651 residues

Total number of hits satisfying chosen parameters: 1356552

Minimum DB seq length: 0

Minimum DB seq length:	0
Maximum DB seq length:	2000000000

post-processing: Minimum Match 0%

Post-processing: Minimum Match 0%
Maximum Match 100%

MAXIMUM MATCH 100%
Listing first 45 summaries

Database : N Genesq 0401:*

1:	/SID\$2/gcgdata/geneseq/geneseq/NA1980.DAT:*
2:	/SID\$2/gcgdata/geneseq/geneseq/NA1981.DAT:*
3:	/SID\$2/gcgdata/geneseq/geneseq/NA1982.DAT:*
4:	/SID\$2/gcgdata/geneseq/geneseq/NA1983.DAT:*
5:	/SID\$2/gcgdata/geneseq/geneseq/NA1984.DAT:*
6:	/SID\$2/gcgdata/geneseq/geneseq/NA1985.DAT:*
7:	/SID\$2/gcgdata/geneseq/geneseq/NA1986.DAT:*
8:	/SID\$2/gcgdata/geneseq/geneseq/NA1987.DAT:*
9:	/SID\$2/gcgdata/geneseq/geneseq/NA1988.DAT:*
10:	/SID\$2/gcgdata/geneseq/geneseq/NA1989.DAT:*
11:	/SID\$2/gcgdata/geneseq/geneseq/NA1990.DAT:*
12:	/SID\$2/gcgdata/geneseq/geneseq/NA1991.DAT:*
13:	/SID\$2/gcgdata/geneseq/geneseq/NA1992.DAT:*
14:	/SID\$2/gcgdata/geneseq/geneseq/NA1993.DAT:*
15:	/SID\$2/gcgdata/geneseq/geneseq/NA1994.DAT:*
16:	/SID\$2/gcgdata/geneseq/geneseq/NA1995.DAT:*
17:	/SID\$2/gcgdata/geneseq/geneseq/NA1996.DAT:*
18:	/SID\$2/gcgdata/geneseq/geneseq/NA1997.DAT:*
19:	/SID\$2/gcgdata/geneseq/geneseq/NA1998.DAT:*
20:	/SID\$2/gcgdata/geneseq/geneseq/NA1999.DAT:*
21:	/SID\$2/gcgdata/geneseq/geneseq/NA2000.DAT:*
22:	/SID\$2/gcgdata/geneseq/geneseq/NA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query %			ID	Description
	Score	Match	Length		
C 1	19	100.0	23	15 Q70997	Primer for 5' end
C 2	19	100.0	23	16 Q89384	COX-2 PCR 5' prime
C 3	19	100.0	429	21 Q57690	Arachidonic acid m
C 4	19	100.0	1834	15 Q61790	Sequence of human
C 5	19	100.0	1834	18 Q59635	Human prostaglandi
C 6	19	100.0	3387	15 Q71002	Cyclooxygenase-2 c
C 7	19	100.0	3387	16 Q89376	Human cyclooxygena
C 8	19	100.0	3387	21 F21115	Human low adenosin
C 9	19	100.0	3387	21 A34993	Human adenosine re
C 10	19	100.0	15240	21 F21117	Human low adenosin
C 11	19	100.0	15240	21 A34995	Human adenosine re

C 12	17.4	91.6	654	17	T08722	Paracoccus denitri
C 13	17.4	91.6	654	17	T08723	Paracoccus denitri
C 14	17	89.5	18	16	Q91482	Human cyclooxygena
C 15	17	89.5	9453	21	F21116	Human low adenosin
C 16	17	89.5	9453	21	A34994	Human adenosine re
C 17	16	84.2	41	16	Q89389	COX-2 oligonucleot
C 18	15.8	83.2	19	18	T76115	Human cyclooxygena
C 19	15.8	83.2	19	20	X53920	Human cyclooxygena
C 20	15.8	83.2	19	20	X53923	Eosinophil derived
C 21	15.8	83.2	19	21	F19485	Human prostaglandi
C 22	15.8	83.2	19	21	A33363	Low adenosine anti
C 23	15.8	83.2	60	18	T76114	Human cyclooxygena
C 24	15.8	83.2	60	20	X53922	Human cyclooxygena
C 25	15.8	83.2	60	20	X53925	Eosinophil derived
C 26	15.8	83.2	60	21	F19487	Human prostaglandi
C 27	15.8	83.2	60	21	A33365	Low adenosine anti
C 28	15.8	83.2	101	20	X54593	Human cyclooxygena
C 29	15.8	83.2	101	21	F20162	Human cyclooxygena
C 30	15.8	83.2	101	21	A34040	Human adenosine re
C 31	15.8	83.2	2206	15	Q74445	DNA located 3' of
C 32	15.8	83.2	6225	20	X55273	Human enzyme-relat
C 33	15.8	83.2	6225	21	F20843	Human multiple tar
C 34	15.8	83.2	6225	21	A34721	Human adenosine re
C 35	15.8	83.2	7742	18	T84745	Bordetella pertuss
C 36	15.8	83.2	11389	19	V34334	Human glycoengin-2
C 37	15.8	83.2	35384	20	F21436	Human enzyme-relat
C 38	15.8	83.2	114955	20	X53491	Human adenosine Al
C 39	15.4	81.1	764	20	Q97734	Extended human sec
C 40	15.4	81.1	65632	21	A81502	N. meningitidis pa
C 41	15.4	81.1	349980	21	F21544	Neisseria meningit
C 42	15.4	81.1	1437668	21	A81490	N. meningitidis B
C 43	15	78.9	15	16	Q91481	Human cyclooxygena
C 44	15	78.9	1312	15	Q73383	Human CCAAT/Enhanc
C 45	15	78.9	1312	17	T44325	DNA encoding CCAAT

ALIGNMENTS

RESULT	1
Q70997/c	
ID	Q70997 standard; cDNA; 23 BP.
AC	XX
CC	XX
XX	Q70997;
XX	
DT	27-FEB-1995 (first entry)
XX	
DE	Primer for 5' end of cyclooxygenase-2.
XX	
XX	Cyclooxygenase-2; primer; ss; polymerase chain reaction;
KW	osteosarcoma.
KW	XX
XX	
OS	Homo sapiens.
XX	
XX	
PN	W09414977-A.
XX	
XX	07-JUL-1994.
PD	
XX	
PF	17-DEC-1993; 93WO-CA00547.
XX	
XX	
PR	22-DEC-1992; 92US-0994760.
PR	06-MAY-1993; 93US-0064271.
XX	
XX	(MERI) MERCK FROSST CANADA INC.
PA	
PI	
XX	
PI	Cromlish WA, Kennedy BP, Mancini JA, O'Neill G, Vick
PI	Wong E;
XX	
XX	WPI; 1994-263635/32.
DR	

xx Assays for cyclo:oxygenase-1 and -2 - for identifying selective
PT antagonists, i.e. potential anti inflammatory etc., also new
PT human cyclo:oxygenase-2 and cDNA encoding it
PT

XX PS Example 43; Page 23; 55pp; English.

CC The primer corresponds to the 3' end of the cyclooxygenase-2 (COX2) cDNA sequence, and is used with Q70998 in a reverse transcription CC polymerase chain reaction analysis of osteosarcoma 143.98.2 CC cells. Results with this primer pair indicate that osteosarcoma CC cells express COX-2 mRNA. The COX-2 protein is used in assays to CC identify inhibitors which have antiinflammatory, antipyretic, analgesic and anticancer activity.

XX Sequence 23 BP; 1 A; 11 C; 7 G; 4 T; 0 other;

Query Match 100.0%; Score 19; DB 15; Length 23; Best Local Similarity 100.0%; Pred. No. 4.3; Mismatches 0; Indels 0; Gaps 0; Matches 19; Conservative 0;

Qy 1 GGGCGGGCGGAGCATCGC 19
 |||||||

Db 21 GGGCGGGCGGAGCATCGC 3

RESULT 2

ID Q89384 standard; cDNA; 23 BP.

XX Q89384;

AC Q89384;

XX 28-SEP-1995 (first entry)

XX COX-2 PCR 5' primer HCOX-1.

XX Cyclooxygenase-2; COX-2; COX-1; inhibitor; screening; osteosarcoma; glyceraldehyde-3-phosphate-dehydrogenase; G3PDH; primer; PCR; polymerase chain reaction; ss.

XX Synthetic.

OS WO9509238-A.

PN 06-APR-1995.

PD 13-SEP-1994; 94WO-CA00501.

PF 27-SEP-1993; 93US-0084033.

PR (MERI) MERCK FROSST CANADA INC.

PA Mancini JA, O'Neil GP;

PI WPI; 1995-147436/19.

DR High level expression of human cyclo:oxygenase (COX)-2 - using new 3' flanking region from COX-1, useful in assays for identifying potent, selective or preferential inhibitors of COX-2

XX Example 4; Page 24; 59pp; English.

XX The primers given in Q89384-85, corresp. to the 5' and 3' ends of COX-2 cDNA, were used in RT-PCR of human osteosarcoma 143 cell line total RNA to amplify COX-2 mRNA.

CC Sequence 23 BP; 1 A; 11 C; 7 G; 4 T; 0 other;

Query Match 100.0%; Score 19; DB 16; Length 23; Best Local Similarity 100.0%; Pred. No. 4.3; Mismatches 0; Indels 0; Gaps 0; Matches 19; Conservative 0;

Qy 1 GGGCGGGCGGAGCATCGC 19
 |||||||

Db 21 GGGCGGGCGGAGCATCGC 3

RESULT 3

C57690/c

ID C57690 standard; DNA; 429 BP.

XX C57690;

AC 25-JAN-2001 (first entry)

XX Arachidonic acid metabolism related genomic biallelic marker #324.

DE Human; biallelic marker; arachidonic acid metabolism; genotyping; detection; hybridisation; phenotype; haplotype; SNP; polymorphic base; single nucleotide polymorphism; hybridisation assay; sequencing assay; specific amplification assay; identification; ERMW; 12-LO-RBM; eicosanoid-related biallelic marker; 12-LO-related biallelic marker; ds.

XX Homo sapiens.

OS WO200047771-A2.

PN 17-AUG-2000.

PD 11-FEB-2000; 2000WO-IB00184.

PF 12-FEB-1999; 99US-0119917.

PR 23-MAR-1999; 99US-0275267.

PR 07-MAY-1999; 99US-0133200.

XX (GEST) GENSET.

XX Blumenfeld M, Bougueleret L, Chumakov I;

XX WPI; 2000-571881/53.

DR Novel biallelic markers useful for detecting conditions and genotypes associated with arachidonic acid metabolism -

XX Claim 13; Page 508; 802pp; English.

XX The present invention describes polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Methods from the present invention may be used to select individuals for clinical trials and predict responses to treatment with drugs. The polynucleotides may be used in hybridisation assays, sequencing assays and specific amplification assays for identifying an eicosanoid-related biallelic marker (ERBM) or 12-LO-related biallelic marker, and for amplifying a segment of nucleotides containing an ERMW. The polynucleotides are useful in diagnostic kits. The markers may be used to detect conditions and genotypes associated with arachidonic acid metabolism. C57367 to C58018 and B24019 and B24020 represent sequences used in the exemplification of the present invention.

XX N.B. Polymorphic bases (single nucleotide polymorphisms also known as SNPs) in the polynucleotide sequences from the present invention have been given as their corresponding degenerate bases e.g. a polymorphic base of C or T has been given as Y.

XX Sequence 429 BP; 84 A; 144 C; 113 G; 86 T; 2 other;

Query Match 100.0%; Score 19; DB 21; Length 429; Best Local Similarity 100.0%; Pred. No. 3.7; Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGGGCGGAGCATCGC 19
 |||||||

Db 200 GGGCGGGCGGAGCATCGC 182

RESULT 4

Q61790/c

KW	Prostaglandin H synthase-2; PGHS-2; cyclooxygenase; inflammation;
KW	pulmonary fibrosis; Alzheimer's disease; stroke; acute head injury;
KW	endometriosis; dysmenorrhea; pre-term labour; prostate cancer;
KW	colorectal cancer; squamous cell carcinoma; breast cancer;
KW	oral pharyngeal cancer; stomach cancer; fibrosarcoma; skin cancer;
KW	osteosarcoma; antiinflammatory; antisense; ribozyme; triple helix;
KW	gene therapy; diagnosis; ss.
XX	
XX	Homo sapiens.
OS	
FH	Key Location/Qualifiers
CDS	9..1823
FT	/*tag= a
FT	1375..1405
misc_feature	/*tag= b
FT	/note= "bases 1375-1405 show substantial divergence from the mouse PGHS-2 gene"
FT	
FT	misc_feature 1797..1827
FT	/*tag= c
FT	/note= "bases 1797-1827 show substantial divergence from the mouse PGHS-2 gene"
XX	
PN	WO9640720-A1.
PD	
XP	19-DEC-1996.
XX	
PE	03-JUN-1996; 95WO-US08311.
PR	07-JUN-1995; 95US-0487752.
XX	
PA	{UYRP } UNIV ROCHESTER.
P1	O'Banion MK, Winn VD, Young DA;
DR	WPI; 1997-052220/05.
XX	P-PSDB; W12698.
PT	Nucleic acid encoding human prostaglandin H synthase-2 - used in treating and detection of inflammation, pre-term labour, cancer, etc
PS	Example 9; Fig 6a-b; 126pp; English.
XX	
CC	A DNA clone (T59635) codes for human glucocorticoid-regulated
CC	prostaglandin H synthase 2 (PGHS-2) (W12698), an enzyme responsible
CC	for increased prostaglandin synthesis associated with inflamm-
CC	It was obtd. by PCR amplification of RNA isolated from serum- and
CC	cycloheximide-treated human fibroblast W138 cells, using PGHS-2-
CC	specific primers (see also T59638-39). The gene can be used to
CC	express recombinant PGHS-2 in transformed host cells for use in
CC	identifying cpds. that inhibit PGHS-2. It can also be used to
CC	detect expression of PGHS-2 as a means of diagnosing certain
CC	cancers. Antisense, ribozyme and triple helix constructs can be
CC	used to treat e.g. inflammation, pulmonary fibrosis, Alzheimer's
CC	disease, stroke, acute head injury, endometritis, dysmenorrhea,
CC	pre-term labour, cancer and radiation-induced injury.
XX	
SQ	Sequence 1834 BP; 517 A; 431 C; 397 G; 489 T; 0 other;
	Query Match 100.0%; Score 19; DB 18; Length 1834;
	Best Local Similarity 100.0%; Pred. No. 3.4;
	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps
QY	1 GGCGCGGGCGGAGCATCGC 19
Db	24 GGCGCGGGCGGAGCATCGC 6
RESULT	6
Q1002/c	Q1002 standard; cdna; 3387 BP.
ID	Q71002
XX	
AC	Q71002:

XX 27-FEB-1995 (first entry)
 XX DT
 XX DE
 XX KW Cyclooxygenase-2 cDNA.
 XX OS Cyclooxygenase-2; enzyme; osteosarcoma; assay; ss.
 XX FT
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 XX FT 97..1910
 XX FT /*tag= a
 XX FT /label= cyclooxygenase-2
 XX PN W09414977-A.
 XX PD 07-JUL-1994.
 XX PF 17-DEC-1993; 93WO-CA00547.
 XX PR 22-DEC-1992; 92US-0994760.
 XX PR 06-MAY-1993; 93US-0064271.
 XX PA (MERI) MERCK FROSST CANADA INC.
 XX PI Cromlish WA, Kennedy BP, Mancini JA, O'Neill G, Vickers PJ;
 XX PI Wong E;
 XX DR WPI; 1994-263635/32.
 XX DR P-PSDB; R56660.
 XX PT Assays for cyclo:oxygenase-1 and -2 - for identifying selective
 XX PT antagonists, i.e. potential anti inflammatory etc., also new
 XX PT human cyclo:oxygenase-2 and cDNA encoding it
 XX PS Disclosure; Fig 2A-2C; 55pp; English.
 XX CC The human cyclooxygenase-2 cDNA is isolated from osteosarcoma
 XX CC cells, and is expressed from a mammalian or eukaryotic vector. The
 XX CC COX-2 protein is used in assays to identify inhibitors which have
 XX CC antiinflammatory, antipyretic, analgesic and anticancer activity.
 XX SQ Sequence 3387 BP; 1010 A; 715 C; 631 G; 1031 T; 0 other;

Query Match 100.0%; Score 19; DB 15; Length 3387;
 Best Local Similarity 100.0%; Pred. No. 3.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGGCGGAGCATCGC 19
 Db 113 GGGCGCGGGCGGAGCATCGC 95

RESULT 7
 Q89376/c
 ID Q89376 standard; cDNA; 3387 BP.
 XX AC Q89376;
 XX DT 28-SEP-1995 (first entry)
 XX DE Human cyclooxygenase-2 cDNA.
 XX KW Cyclooxygenase-2; COX-2; inhibitor; screening;
 XX KW osteosarcoma; ss.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 XX FT 98..1912
 XX FT /*tag= a
 XX FT

PN W09509238-A.
 XX PD 06-APR-1995.
 XX PF 13-SEP-1994; 94WO-CA00501.
 XX PR 27-SEP-1993; 93US-0084033.
 XX PA (MERI) MERCK FROSST CANADA INC.
 XX PI Mancini JA, O'Neill GP;
 XX DR WPI; 1995-147436/19.
 XX DR P-PSDB; R72228.
 XX PT High level expression of human cyclo:oxygenase (COX)-2 - using
 XX PT new 3' flanking region from COX-1, useful in assays for
 XX PT identifying potent, selective or preferential inhibitors of COX-2
 XX PS Disclosure; Fig.2; 59pp; English.
 XX CC Full-length cDNA derived from human osteosarcoma cells (given in
 XX CC Q89376) encoded human COX-2 (R72228). High-level expression of COX-2
 XX CC in COS7 cells was achieved using a vaccinia or baculovirus vector and
 XX CC a construct in which COX-2 cDNA was attached at its 5' end to a 3'
 XX CC flanking sequence of human COX-1 cDNA (Q89377).
 XX SQ Sequence 3387 BP; 1010 A; 714 C; 632 G; 1031 T; 0 other;

Query Match 100.0%; Score 19; DB 16; Length 3387;
 Best Local Similarity 100.0%; Pred. No. 3.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGGCGGAGCATCGC 19
 Db 113 GGGCGCGGGCGGAGCATCGC 95

RESULT 8
 F21115/c
 ID F21115 standard; DNA; 3387 BP.
 XX AC F21115;
 XX DT 14-MAR-2001 (first entry)
 XX DE Human low adenosine antisense oligonucleotide related sequence #2682.
 XX KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 XX KW human; airway disorder; bronchoconstriction; lung inflammation;
 XX KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 XX KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 XX KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 XX KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 XX KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 XX KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 XX KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 XX KW cancer; ss.
 XX OS Homo sapiens.
 XX PN W0200062736-A2.
 XX PD 26-OCT-2000.
 XX PF 24-MAR-2000; 2000WO-US08020.
 XX PR 06-APR-1999; 99US-0127958.
 XX PA (UYEC-) UNIV EAST CAROLINA.
 XX PA (NYCE/) NYCE J W.
 XX FT

PI Nyce JW;
 XX WPI: 2000-679539/66.
 XX
 XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX
 XX Disclosure: Page 965-966; 1592pp; English.
 XX
 XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impaired respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.
 XX
 XX Sequence 3387 BP; 1010 A; 712 C; 633 G; 1032 T; 0 other;
 SQ
 Query Match 100.0%; Score 19; DB 21; Length 3387;
 Best Local Similarity 100.0%; Pred. No. 3.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GGGCGCGGCGGAGCATCGC 19
 Db 113 GGGCGCGGCGGAGCATCGC 95
 RESULT 9
 A34993/C
 ID A34993 standard; DNA: 3387 BP.
 XX
 XX A34993;
 XX
 XX 28-JUL-2000 (first entry)
 DT
 XX Human adenosine receptor related polynucleotide SEQ ID NO:2682.
 DE
 XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 XX Homo sapiens.
 OS
 XX

PN WO200009525-A2.
 XX 24-FEB-2000.
 PD
 XX 03-AUG-1999; 99WO-US17712.
 PF
 XX 03-AUG-1998; 98US-0095212.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Nyce JW;
 PI
 XX WPI: 2000-205971/18.
 DR
 XX
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX
 XX Disclosure: Page 890-891; 1343pp; English.
 PS
 XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A39992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.
 XX
 XX Sequence 3387 BP; 1010 A; 712 C; 633 G; 1032 T; 0 other;
 SQ
 Query Match 100.0%; Score 19; DB 21; Length 3387;
 Best Local Similarity 100.0%; Pred. No. 3.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GGGCGCGGCGGAGCATCGC 19
 Db 113 GGGCGCGGCGGAGCATCGC 95
 RESULT 10
 F21117/c
 ID F21117 standard; DNA: 15240 BP.
 XX
 XX F21117;
 AC
 XX 14-MAR-2001 (first entry)
 DT
 XX Human low adenosine antisense oligonucleotide related sequence #2684.
 DE
 XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW

KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.

XX WO200062736-A2.

XX 26-OCT-2000.

XX 24-MAR-2000; 2000WO-US08020.

XX 06-APR-1999; 99US-0127958.

XX (UYEC-) UNIV EAST CAROLINA.

XX (NYCE/) NYCE J W.

XX Nyce JW;

XX WPI; 2000-679539/66.

XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -

XX Disclosure; Page 968-972; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytosolic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with the
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors and
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. Fl8434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.

XX Sequence 15240 BP; 4672 A; 2944 C; 2804 G; 4820 T; 0 other;

Query Match 100.0%; Score 19; DB 21; Length 15240;
 Best Local Similarity 100.0%; Pred. No. 3.1;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GGGCGGGCGGCGATCC 19

|||||

DB 2513 GGGCGGGCGGCGATCC 2495

RESULT 11

A34995/c
 ID A34995 standard; DNA; 15240 BP.

XX A34995;

XX 28-JUL-2000 (first entry)

XX Human adenosine receptor related polynucleotide SEQ ID NO:2684.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytosolic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

XX WO200009525-A2.

XX 24-FEB-2000.

XX 03-AUG-1999; 99WO-US17712.

XX 03-AUG-1998; 98US-0095212.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -

XX Disclosure; Page 893-897; 1343pp; English.

XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytosolic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.

XX Sequence 15240 BP; 4672 A; 2944 C; 2804 G; 4820 T; 0 other;

Query Match 100.0%; Score 19; DB 21; Length 15240;
 Best Local Similarity 100.0%; Pred. No. 3.1;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
QY 1 GGGCGGGCGGAGCATCGC 19
    |||||
Db 2513 GGGCGGGCGGAGCATCGC 2495

RESULT 12
T08722/c
ID T08722 standard; DNA; 654 BP.
XX
AC T08722;
XX
DT 19-JUL-1996 (first entry)
XX
DE Paracoccus denitrificans thiamine pyrophosphokinase gene.
XX
KW Thiamine diphosphate biosynthesis; TPP; adenosine 5'-triphosphate;
KW tpk gene; ss.
XX
OS Paracoccus denitrificans (ATCC 19367).
XX
FH Key Location/Qualifiers
FT mat_peptide 1..654
FT /*tag= a
XX
PN JP08009985-A.
XX
PD 16-JAN-1996.
XX
PF 01-JUL-1994; 94JP-0150847.
XX
PR 01-JUL-1994; 94JP-0150847.
XX
PA (KYOW ) KYOWA HAKKO KOGYO KK.
XX
WPI; 1996-110279/12.
DR P-PSDB; R92223.
XX
PT Paracoccus sp. transformed with thiamine pyrophosphokinase gene -
PT useful for prodn. of thiamine di:phosphate from thiamine and
PT adenosine 5'-tri:phosphate
XX
PS Claim 8; Page 9; 1lpp; Japanese.
XX
CC The present sequence is one of the two sequences given in the
CC specification which each code for the same 218 amino acid sequence
CC of Paracoccus denitrificans thiamine pyrophosphokinase. The two
CC sequences differ by silent substitutions in codons 2-7 which were
CC introduced into T08723 by insertion of a synthetic linker.
CC Paracoccus bacteria transformed with the coding sequence are
CC increased production of thiamine diphosphate from thiamine and
CC adenosine 5'-triphosphate.
XX
SQ Sequence 654 BP; 83 A; 246 C; 218 G; 107 T; 0 other;

Query Match 91.6%; Score 17.4; DB 17; Length 654;
Best Local Similarity 94.7%; Pred. No. 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
    |||||
Db 652 GGGCGGGCGGAGCGTCGC 634

RESULT 13
T08723/c
ID T08723 standard; DNA; 654 BP.
XX
AC T08723;
XX
DT 19-JUL-1996 (first entry)
XX
DE Paracoccus denitrificans thiamine pyrophosphokinase gene.
XX
```

```
KW Thiamine diphosphate biosynthesis; TPP; adenosine 5'-triphosphate;
KW tpk gene; silent mutation; conservative codon replacement; ss.
XX
OS Paracoccus denitrificans (ATCC 19367).
XX
FH Key Location/Qualifiers
FT mat_peptide 1..654
FT /*tag= a
XX
PN JP08009985-A.
XX
PD 16-JAN-1996.
XX
PF 01-JUL-1994; 94JP-0150847.
XX
PR 01-JUL-1994; 94JP-0150847.
XX
PA (KYOW ) KYOWA HAKKO KOGYO KK.
XX
WPI; 1996-110279/12.
DR P-PSDB; R92223.
XX
PT Paracoccus sp. transformed with thiamine pyrophosphokinase gene -
PT useful for prodn. of thiamine di:phosphate from thiamine and
PT adenosine 5'-tri:phosphate
XX
PS Claim 9; Page 9-10; 1lpp; Japanese.
XX
CC The present sequence is one of the two sequences given in the
CC specification which each code for the same 218 amino acid sequence
CC of Paracoccus denitrificans thiamine pyrophosphokinase. The two
CC sequences differ by silent substitutions in codons 2-7 which were
CC introduced into T08723 by insertion of a synthetic linker.
CC Paracoccus bacteria transformed with the coding sequence are
CC useful for increased production of thiamine diphosphate from
CC thiamine and adenosine 5'-triphosphate.
XX
SQ Sequence 654 BP; 84 A; 246 C; 216 G; 108 T; 0 other;

Query Match 91.6%; Score 17.4; DB 17; Length 654;
Best Local Similarity 94.7%; Pred. No. 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
    |||||
Db 652 GGGCGGGCGGAGCGTCGC 634

RESULT 14
Q91482
ID Q91482 standard; DNA; 18 BP.
XX
AC Q91482;
XX
DT 08-FEB-1996 (first entry)
XX
DE Human cyclooxygenase-2 antisense oligonucleotide hCOX-2.7.
XX
KW human; cyclooxygenase-2; COX-2; prostaglandin; thromboxane;
KW inhibition; antisense therapy; premature labour; preeclampsia;
KW endometriosis; rheumatoid arthritis; glomerulitis; ARDS;
KW adult respiratory distress syndrome; ss.
XX
OS Synthetic.
XX
PN W09516466-A1.
XX
PD 22-JUN-1995.
XX
PF 16-DEC-1994; 94WO-US14508.
XX
PR 17-DEC-1993; 93US-0170089.
```

XX (OHIS) UNIV OHIO STATE.
PA Kniss DA;
XX WPI; 1995-231361/30.
XX
XX
XX Antisense oligo:nucleotide(s) binding cyclo:oxygenase and
PT thromboxane A2 synthase mRNA - used in treatment of diseases
PT involving prostaglandin(s) and thromboxane metabolism
XX
PS Claim 2; Page 36; 50pp; English.
XX
XX Antisense oligonucleotides were designed based on the 5'-UTR and
CC 3'-UTR sequences of mouse and human cyclooxygenase cDNAs. The
CC phosphorothioate derivs. ('S-oligonucleotides') of the different
CC antisense sequences were found to be effective for inhibiting
CC translation of cyclooxygenase and subsequent production of
CC prostaglandins and thromboxanes. The S-oligonucleotide derivs of O91475-
CC O91484 are based on the human cyclooxygenase-2 cDNA and are useful
CC for antisense therapy of ARDS, glomerulitis, rheumatoid arthritis,
CC premature labour, pre-eclampsia, endometriosis, etc.
XX
SQ Sequence 18 BP; 3 A; 5 C; 9 G; 1 T; 0 other;

Query Match 89.5%; Score 17; DB 16; Length 18;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATC 17
|||||
Db 2 gggcgcgggcgagcatc 18

RESULT 15
F21116/c
ID F21116 standard; DNA; 9453 BP.
XX
AC F21116;
XX
XX
DT 14-MAR-2001 (first entry)
XX
XX Human low adenosine antisense oligonucleotide related sequence #2683.
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
XX Homo sapiens.
OS
XX WO200062736-A2.
PN
XX 26-OCT-2000.
PD
XX
XX 24-MAR-2000; 2000WO-US08020.
PF
XX 06-APR-1999; 99US-0127958.
PR
XX (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
XX Nyce JW;
PI
XX WPI; 2000-679539/66.
XX

Low adenosine (A) content antisense oligonucleotides which do not trigger adenosine receptors during metabolism, useful e.g. for treating cancers and respiratory obstructions -
Disclosure; Page 966-968; 1592pp; English.
The present invention describes low adenosine (A) content antisense oligonucleotides and compositions (I) comprising them. In the antisense oligonucleotides the A is replaced by a 'Universal' or alternative base. (I) can have respiratory, bronchodilator, antiinflammatory, analgesic, immunosuppressive, antiasthmatic, hypotensive and cytostatic activities. The antisense oligonucleotides and (I) can be used to down-regulate the expression and/or activity of target polypeptides associated with lung/respiratory disorders and malignancies, such as stimulating and activating peptide factors and transmitters, transcription factors, immunoglobulins and antibodies, antibody receptors, cytokines and chemokines, endogenously produced specific and non-specific enzymes, binding proteins, adhesion molecules and their receptors, cytokine and chemokine receptors, adenosine receptors, bradykinin receptors, central nervous system (CNS) and peripheral nervous and non-nervous system receptors, CNS and peripheral nervous and non-nervous system peptide transmitters, defensins, growth factors, vasoactive peptides and receptors, binding proteins and malignancy associated proteins. The antisense oligonucleotides may be used in this way to treat disorders including respiratory obstruction (especially pulmonary obstruction and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or surfactant hypoproduction which are associated with a disease or condition selected from pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), pulmonary transplantation rejection, pulmonary infections, bronchitis, and/or cancer. F18434 to F21543 represent human polynucleotide fragments and antisense oligonucleotides used in the exemplification of the present invention.

Sequence 9453 BP; 2937 A; 1716 C; 1710 G; 3090 T; 0 other;

Query Match 89.5%; Score 17; DB 21; Length 9453;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATC 17
|||||
Db 981 GGGCGCGGCGGAGCATC 965

Search completed: April 20, 2001, 00:12:58
Job time: 10020 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 19, 2001, 23:24:55 ; Search time 7150.85 Seconds
(without alignments)
0.388 Million cell updates/sec

Title: US-09-016-464-17
Perfect score: 19
Sequence: 1 GGGCGGGCGGAGCATCGC 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 9623517 seqs, 73081774 residues

Total number of hits satisfying chosen parameters: 19247034

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: gb_estl1:*
2: gb_est2:*
3: gb_est3:*
4: gb_est4:*
5: gb_est5:*
6: gb_est6:*
7: gb_est7:*
8: gb_est8:*
9: gb_est9:*
10: gb_est10:*
11: gb_est11:*
12: gb_est12:*
13: gb_est13:*
14: gb_est14:*
15: gb_est15:*
16: gb_est16:*
17: gb_est17:*
18: gb_est18:*
19: gb_est19:*
20: gb_est20:*
21: gb_est21:*
22: gb_est22:*
23: gb_est23:*
24: gb_est24:*
25: gb_est33:*
26: gb_est34:*
27: gb_est35:*
28: gb_est36:*
29: gb_est37:*
30: gb_est38:*
31: gb_est39:*
32: gb_est40:*
33: em_estba:*
34: em_estfun:*
35: em_esthum1:*
36: em_esthum2:*
37: em_esthum3:*
38: em_esthum4:*
39: em_esthum5:*
40: em_esthum6:*
41: em_esthum7:*
42: em_esthum8:*
43: em_esthum9:*

44: em_esthum10:*
45: em_esthum11:*
46: em_esthum12:*
47: em_esthum13:*
48: em_esthum14:*
49: em_esthum15:*
50: em_esthum16:*
51: em_esthum17:*
52: em_esthum18:*
53: em_esthum19:*
54: em_esthum20:*
55: em_esthum21:*
56: em_esthum22:*
57: em_esthum23:*
58: em_esthum24:*
59: em_esthum25:*
60: em_esthum26:*
61: em_esthum27:*
62: em_esthum28:*
63: em_estin1:*
64: em_estin2:*
65: em_estin3:*
66: em_estin4:*
67: em_estin5:*
68: em_estom1:*
69: em_estov1:*
70: em_estov2:*
71: em_estpl1:*
72: em_estpl2:*
73: em_estpl3:*
74: em_estpl4:*
75: em_estpl5:*
76: em_estpl6:*
77: em_estpl7:*
78: em_estpl8:*
79: em_estpl9:*
80: em_estpl10:*
81: em_estro1:*
82: em_estro2:*
83: em_estro3:*
84: em_estro4:*
85: em_estro5:*
86: em_estro6:*
87: em_estro7:*
88: em_estro8:*
89: em_estro9:*
90: em_estro10:*
91: em_estro11:*
92: em_estro12:*
93: em_estro13:*
94: em_estro14:*
95: em_estro15:*
96: em_estro16:*
97: em_estro17:*
98: em_estro18:*
99: em_estro19:*
100: em_estro20:*
101: gb_est25:*
102: gb_est26:*
103: gb_est27:*
104: gb_est28:*
105: gb_est29:*
106: gb_est30:*
107: gb_est31:*
108: gb_est32:*
109: gb_est41:*
110: gb_est42:*
111: gb_est43:*
112: gb_est44:*
113: gb_est45:*
114: gb_est46:*
115: gb_est47:*

117: gb_est48:*
118: gb_est49:*
119: gb_est50:*
120: gb_est51:*
121: gb_est52:*
122: gb_est53:*
123: gb_est54:*
124: gb_est55:*
125: gb_est56:*
126: gb_est57:*
127: gb_est58:*
128: gb_est59:*
129: gb_est60:*
130: gb_est61:*
131: gb_est62:*
132: gb_est63:*
133: gb_est64:*
134: gb_est65:*
135: gb_est66:*
136: gb_est67:*
137: gb_est68:*
138: gb_est69:*
139: gb_est70:*
140: gb_est71:*
141: gb_est72:*
142: gb_est73:*
143: gb_est74:*
144: gb_est75:*
145: gb_est76:*
146: gb_est77:*
147: gb_est78:*
148: gb_est79:*
149: gb_est80:*
150: gb_est81:*
151: gb_est82:*
152: gb_est83:*
153: gb_est84:*
154: gb_est85:*
155: gb_est86:*
156: gb_est87:*
157: gb_est88:*
158: gb_est89:*
159: gb_est90:*
160: gb_est91:*
161: gb_est92:*
162: gb_est93:*
163: gb_est94:*
164: gb_est95:*
165: gb_est96:*
166: gb_est97:*
167: gb_est98:*
168: gb_est99:*
169: gb_est100:*
170: gb_est101:*
171: gb_est102:*
172: gb_est103:*
173: gb_est104:*
174: gb_est105:*
175: gb_est106:*
176: gb_est107:*
177: gb_est108:*
178: gb_est109:*
179: gb_est110:*
180: gb_est111:*
181: gb_est112:*
182: gb_est113:*
183: gb_est114:*
184: gb_est115:*
185: gb_est116:*
186: gb_est117:*
187: gb_est118:*
188: gb_est119:*
189: gb_est120:*

190: em_gss_pln1:*
191: em_gss_pln2:*
192: em_gss_pro1:*
193: em_gss_pro2:*
194: em_gss_rod1:*
195: em_gss_rod2:*
196: em_gss_rod3:*
197: em_gss_rod4:*
198: em_gss_rod5:*
199: em_gss_vrt1:*
200: em_gss_vrt2:*
201: em_gss_vrt3:*
202: gb_gss1:*
203: gb_gss2:*
204: gb_gss3:*
205: gb_gss4:*
206: gb_gss5:*
207: gb_gss6:*
208: gb_gss7:*
209: gb_gss8:*
210: gb_gss9:*
211: gb_gss10:*
212: gb_gss11:*
213: gb_gss12:*
214: gb_gss13:*
215: gb_gss14:*
216: gb_gss15:*
217: gb_gss16:*
218: gb_gss17:*
219: gb_gss18:*
220: gb_gss19:*
221: gb_gss20:*
222: gb_gss21:*
223: gb_gss22:*
224: gb_gss23:*
225: gb_gss24:*
226: gb_gss25:*
227: gb_gss26:*
228: gb_gss27:*
229: gb_gss28:*
230: gb_gss29:*
231: gb_gss30:*
232: gb_gss31:*
233: gb_gss32:*
234: gb_gss33:*
235: gb_gss34:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19	100.0	1040	139	BE785396
C 2	17.4	91.6	792	136	BE531093
C 3	17	89.5	435	232	FR0036546
C 4	16.4	86.3	346	213	AQ910758
C 5	16.4	86.3	595	165	BE336923
C 6	16.4	86.3	765	141	BE898809
C 7	16.4	86.3	803	104	AJ006537
C 8	16.4	86.3	805	146	BF259017
C 9	16.4	86.3	865	212	AQ858748
C 10	16.4	86.3	912	212	AQ872091
C 11	16	84.2	605	232	FR0036531
C 12	16	84.2	1582	145	BF255067
C 13	15.8	83.2	239	31	AV640162
C 14	15.8	83.2	264	161	BB595164
C 15	15.8	83.2	334	116	AW487153
C 16	15.8	83.2	348	137	BE587114
C 17	15.8	83.2	352	9	AA587234
C 18	15.8	83.2	369	20	AI414040

```

c 19 15.8 83.2 377 115 AW445941
c 20 15.8 83.2 379 167 BE484722
c 21 15.8 83.2 382 116 AW487170
c 22 15.8 83.2 399 116 AW489298
c 23 15.8 83.2 400 227 B07847
c 24 15.8 83.2 434 115 AW447389
c 25 15.8 83.2 444 115 AW456157
c 26 15.8 83.2 464 143 BF039865
c 27 15.8 83.2 473 137 BE604159
c 28 15.8 83.2 491 167 BE487654
c 29 15.8 83.2 509 30 AV594128
c 30 15.8 83.2 526 30 AV592535
c 31 15.8 83.2 534 167 BE484579
c 32 15.8 83.2 537 31 AV666430
c 33 15.8 83.2 544 30 AV597886
c 34 15.8 83.2 544 31 AV666454
c 35 15.8 83.2 545 137 BE588589
c 36 15.8 83.2 549 148 BF466887
c 37 15.8 83.2 556 30 AV597960
c 38 15.8 83.2 559 30 AV599540
c 39 15.8 83.2 562 30 AV607714
c 40 15.8 83.2 574 30 AV592392
c 41 15.8 83.2 582 30 AV594173
c 42 15.8 83.2 588 14 AB009110
c 43 15.8 83.2 595 212 AQ849708
c 44 15.8 83.2 596 30 AV595105
c 45 15.8 83.2 610 30 AV596710

```

ALIGNMENTS

```

RESULT 1
BE785396/c
LOCUS BE785396 1040 bp mRNA EST 20-OCT-2000
DEFINITION 6014781F1 NIH_MGC_68 Homo sapiens cDNA clone IMAGE:3880850 5',
mRNA sequence.
ACCESSION BE785396
VERSION BE785396.1 GI:10206594
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1040)
NIH-MGC http://mgc.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: DCTD/DPG/Gazdar
cDNA Library Arrayed by: Life Technologies, Inc.
cDNA Sequencing by: Incyte Genomics, Inc.
Clone Distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM9648 row: 1 column: 03
High quality sequence stop: 649.
Location/Qualifiers
1. .1040
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:3880850"
/clone_lib="NIH_MGC_68"
/tissue_type="large cell carcinoma"
/lab_host="DH10B (phage-resistant)"
/Note="Organ: lung; Vector: pCMV-SPORT6; Site: 1; NotI;
Site: 2; SalI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.8 kb. Library constructed by Life
Technologies."
307 a 314 c 231 g 188 t

```

FEATURES

```

source
Query Match 91.6%; Score 17.4; DB 136; Length 792;
Best Local Similarity 94.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
|||||
DB 599 GGGCGGGCGGAGCATCGC 581
|||||

RESULT 3
FR0036546
LOCUS FR0036546 435 bp DNA GSS
DEFINITION Fugu rubripes GSS sequence, clone 032A03ac3, genomic survey
22-OCT-1999

```

```

ORIGIN
Query Match 100.0%; Score 19; DB 139; Length 1040;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
|||||
DB 118 GGGCGGGCGGAGCATCGC 100
|||||

RESULT 2
BE531093/c
LOCUS BE531093 792 bp mRNA EST 09-AUG-2000
DEFINITION 601278455F1 NIH_MGC_39 Homo sapiens cDNA clone IMAGE:3610573 5',
mRNA sequence.
ACCESSION BE531093
VERSION BE531093.1 GI:9759738
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 792)
NIH-MGC http://mgc.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Ling Hong/Rubin Laboratory
cDNA Sequencing by: Incyte Genomics, Inc.
Clone Distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLCM266 row: n column: 14
High quality sequence stop: 606.
Location/Qualifiers
1. .792
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:3610573"
/clone_lib="NIH_MGC_39"
/tissue_type="adenocarcinoma"
/lab_host="DH10B (phage-resistant)"
/Note="Organ: pancreas; Vector: pONB7; Site: 1; XhoI;
Site: 2; EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(G). Library constructed
by Ling Hong in the laboratory of Gerald M. Rubin
(University of California, Berkeley) using ZAP-cDNA
synthesis kit (Stratagene) and Superscript II RT (Life
Technologies)."
105 a 290 c 284 g 113 t

```

FEATURES

```

source
Query Match 91.6%; Score 17.4; DB 136; Length 792;
Best Local Similarity 94.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
|||||
DB 599 GGGCGGGCGGAGCATCGC 581
|||||

RESULT 3
FR0036546
LOCUS FR0036546 435 bp DNA GSS
DEFINITION Fugu rubripes GSS sequence, clone 032A03ac3, genomic survey
22-OCT-1999

```



```

source
1. .805
/organism="Hordeum vulgare"
/cultivar="Morex"
/db_xref="taxon:4513"
/clone="HVSMEF0017G12f"
/clone_lib="Hordeum vulgare seedling root EST library
HVCN0007 (etiolated and unstressed)"
/tissue_type="Seedling root"
/lab_host="TJ121"
/notice="vector: lambdaZAP; Site_1: EcoRI; Site_2: XhoI"
BASE COUNT      202 a      212 c      195 g      196 t
ORIGIN

Query Match      86.3%; Score 16.4; DB 146; Length 805;
Best Local Similarity 94.4%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy  2  GCGCGGGCGGCGCATCGC 19
      ||||| ||||| ||||| |||
Db  266 GCGCGGGCGGCGCATCGC 283

RESULT 9
AQ858748/c      AQ858748      865 bp      DNA      GSS      03-NOV-1999
LOCUS
DEFINITION      clone nb0002D04r CUGI Rice BAC Library (EcoRI) Oryza sativa genomic
ACCESSION      AQ858748
VERSION        AQ858748.1 GI:6209205
KEYWORDS       GSS.
SOURCE         Oryza sativa.
ORGANISM       Oryza sativa
Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae;
Oryza.
REFERENCE
1 (bases 1 to 865)
Wing, R.A. and Dean, R.A.
A BAC End Sequencing Framework to Sequence the Rice Genome
JOURNAL
COMMENT
Contact: Wing RA
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: GGAACACGCTATGACCATG
Class: BAC ends
High quality sequence start: 19
High quality sequence stop: 501.
FEATURES
Location/Qualifiers
1. .865
/organism="Oryza sativa"
/strain="Japonica"
/cultivar="Nipponbare"
/db_xref="taxon:4530"
/clone="nb0002D04r"
/tissue_type="Leaf"
/lab_host="E. coli DH10B"
/notice="vector: pBACIndigo; Site_1: EcoRI; Site_2: EcoRI;
Rice is the most important food crop in the world. Half of
the world population, especially those inhabiting highly
populated areas of the humid tropics and subtropics, rely
on rice as their primary source of carbohydrate.
Monocotyledonous rice is a diploid plant (2n=24) with a
haploid genome equivalent of 431 Mbp (Arumuganathan and
Earle, 1991). The relatively small genome of rice, three
times larger than that of Arabidopsis, makes it suitable
for genomic studies. In order to facilitate positional
cloning, physical mapping and genome sequencing of rice,
we have constructed a BAC library from Oryza sativa,

```

```

Nipponbare variety using EcoRI as the cloning enzyme. The
library contains 55,296 clones with an average insert size
of 121 Kb providing approximately 15 haploid genome
equivalents. The deep coverage allows the isolation a
particular sequence with a probability of 99.9 %. Three
high density filters, each containing 18,432 clones
(doubly spotted), represent the whole library for colony
screening and can be requested from the Clemson University
BAC/EST Resource Center (www.genome.clemson.edu)."
BASE COUNT      145 a      250 c      215 g      250 t      5 others
ORIGIN

Query Match      86.3%; Score 16.4; DB 212; Length 865;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy  2  GCGCGGGCGGCGCATCGC 19
      ||||| ||||| ||||| |||
Db  695 GCGCGGGCGGCGCATCGC 678

RESULT 10
AQ872091/c      AQ872091      912 bp      DNA      GSS      03-NOV-1999
LOCUS
DEFINITION      clone nb0046H11f CUGI Rice BAC Library (EcoRI) Oryza sativa genomic
ACCESSION      AQ872091
VERSION        AQ872091.1 GI:6222542
KEYWORDS       GSS.
SOURCE         Oryza sativa.
ORGANISM       Oryza sativa
Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae;
Oryza.
REFERENCE
1 (bases 1 to 912)
Wing, R.A. and Dean, R.A.
A BAC End Sequencing Framework to Sequence the Rice Genome
JOURNAL
COMMENT
Contact: Wing RA
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: TAATACGACTCACTATAGG
Class: BAC ends
High quality sequence start: 174
High quality sequence stop: 310.
FEATURES
Location/Qualifiers
1. .912
/organism="Oryza sativa"
/strain="Japonica"
/cultivar="Nipponbare"
/db_xref="taxon:4530"
/clone="nb0046H11f"
/tissue_type="Leaf"
/lab_host="E. coli DH10B"
/notice="vector: pBACIndigo; Site_1: EcoRI; Site_2: EcoRI;
Rice is the most important food crop in the world. Half of
the world population, especially those inhabiting highly
populated areas of the humid tropics and subtropics, rely
on rice as their primary source of carbohydrate.
Monocotyledonous rice is a diploid plant (2n=24) with a
haploid genome equivalent of 431 Mbp (Arumuganathan and
Earle, 1991). The relatively small genome of rice, three
times larger than that of Arabidopsis, makes it suitable
for genomic studies. In order to facilitate positional
cloning, physical mapping and genome sequencing of rice,
we have constructed a BAC library from Oryza sativa,
Nipponbare variety using EcoRI as the cloning enzyme. The

```

library contains 55,296 clones with an average insert size of 121 Kb providing approximately 15 haploid genome equivalents. The deep coverage allows the isolation a particular sequence with a probability of 99.9 %. Three high density filters, each containing 18,432 clones (doubly spotted), represent the whole library for colony screening and can be requested from the Clemson University BAC/EST Resource Center (www.genome.clemson.edu)."

BASE COUNT 235 a 269 c 245 g 160 t 3 others

ORIGIN

Query Match 86.3%; Score 16.4; DB 212; Length 912;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCG 18
|||||
Db 123 GGGCGGGCGGAGCATCG 106

RESULT 11
FR0036531/c
LOCUS
DEFINITION Fugu rubripes GSS sequence, clone 032A03aH9, genomic survey sequence.
ACCESSION
VERSION AL124040.1 GI:6105655
KEYWORDS GSS; genome survey sequence.
SOURCE
ORGANISM Fugu rubripes

REFERENCE
AUTHORS Elgar,G., Clark,M.S., Smith,S., Meek,S., Warner,S., Edwards,Y.J.K., Umraniya,Y., Williams,G. and Brenner,S.
TITLE Direct Submission
JOURNAL Submitted (11-OCT-1999) MRC Human Genome Mapping Project Resource Centre, Hinxton, Cambridge, CB10 1SB. UK Email: biohelp@hmp.mrc.ac.uk
COMMENT Vector: pBluescript II KS
V_type: phagemid
PRIMER: KS

DESCR:
One pass dye-terminator sequencing of cosmid cloned genomic sequence.

FEATURES
source
1..605
/organism="Fugu rubripes"
/db_xref="taxon:31033"
/clone_lib="cosmid 032A03"
/clone="032A03aH9"

BASE COUNT 162 a 138 c 135 g 150 t 20 others

ORIGIN

Query Match 84.2%; Score 16; DB 232; Length 605;
Best Local Similarity 94.1%; Pred. No. 8.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATC 17
|||
Db 144 GGGCGGGCGGAGCATC 128

RESULT 12
BF255067
LOCUS
DEFINITION HVSMEf0005N17f Hordeum vulgare seedling root EST library HVCDNA0007 (etiolated and unstressed) Hordeum vulgare cDNA clone
HVSMEf0005N17f, mRNA sequence.
ACCESSION
BF255067

VERSION
KEYWORDS
SOURCE
ORGANISM

BF255067.1 GI:11184172
EST.
barley.
Hordeum vulgare
Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
Magnoliophyta; Liliopsida; Poales; Poaceae; Triticeae;
Hordeum.

REFERENCE
AUTHORS

1 (bases 1 to 1582)
Wing,R., Close,T.J., Kleinhofs,A., Wise,R., Begum,D., Frisch,D., Yu
,Y., Anderson,H., Dale,J., Henry,D., Kernodle,S., Palmer,M., Rambo
,T., Saski,C., Schwartzbeck,J., Simmons,J., Choi,D.W., Main,D. and
Wood,T.

TITLE

Development of a genetically and physically anchored EST resource
for barley genomics

JOURNAL

COMMENT

Unpublished (2000)
Contact: Wing RA
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: AATTAACCTCTACTAAAGGG
High quality sequence start: 414
High quality sequence stop: 1089.

FEATURES

source

1..1582
/organism="Hordeum vulgare"
/cultivar="Morex"
/db_xref="taxon:4513"
/clone="HVSMEf0005N17f"
/clone_lib="Hordeum vulgare seedling root EST library
HVCDNA0007 (etiolated and unstressed)"
/tissue_type="Seedling root"
/lab_host="TJC121"
/note="Vector: lambdaZAP; Site_1: EcoRI; Site_2: XhoI"

BASE COUNT 340 a 115 c 622 g 490 t 15 others

ORIGIN

Query Match 84.2%; Score 16; DB 145; Length 1582;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCAT 16

|||||

Db 1234 GGGCGGGCGGAGCAT 1249

RESULT 13
AV640162/c

LOCUS

DEFINITION AV640162 Chlamydomonas reinhardtii 5% CO2 Chlamydomonas reinhardtii
cDNA clone HCL011e01_r 5', mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Chlamydomonas reinhardtii.
Chlamydomonas reinhardtii
Eukaryota; Viridiplantae; Chlorophyta; Chlorophyceae; Volvocales;
Chlamydomonadales; Chlamydomonas.

REFERENCE

AUTHORS

1 (bases 1 to 239)
Asamizu,E., Miura,K., Kucho,K., Inoue,Y., Fukuzawa,H., Ohyama,K.,
Nakamura,Y. and Tabata,S.
Generation of expressed sequence tags from low-CO2 and high-CO2
adapted cells of Chlamydomonas reinhardtii

JOURNAL

MEDLINE

COMMENT

20539644
Contact: Erika Asamizu
The First Laboratory for Plant Gene Research
Kazusa DNA Research Institute
Yana 1532-3, Kisarazu, Chiba 292-0812, Japan
Email: asamizu@kazusa.or.jp, URL:<http://www.kazusa.or.jp/en/plant/>.

BACKWARD: GTTTTCCAGTCACGACG	
Plate: 44 row: F column: 10	
Seq primer: ATTTAGTGACACTATAG.	
Location/Qualifiers	
1. .334	
/organism="Bos taurus"	
/db_xref="taxon:9913"	
/clone_lib="MARC 1BOV"	
/tissue_type="pooled"	
/lab_host="DH10B"	
/notes="Vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;	
Library made from pooled tissue from lymph node, ovary,	
fat, hypothalamus, and pituitary."	
82 a 89 c 101 g 62 t	
BASE COUNT	
ORIGIN	

```
Query Match      83.2%; Score 15.8; DB 116; Length 334;
Best Local Similarity 89.5%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 1 GGCGCGGGCGAGCATCGC 19
|||
Db 283 GGCGCGGGCGACCATCGC 265

Search completed: April 19, 2001, 23:24:57
Job time: 8174 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:03:43 ; Search time 280.46 seconds
(without alignments)
11.829 Million cell updates/sec

Title: US-09-016-464-17

Perfect score: 19
Sequence: 1 GGGCGGCGGAGCATCGC 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 302621 seqs, 87301344 residues

Total number of hits satisfying chosen parameters: 605242

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_NA.*

- 1: /cgn2.6/ptodata/2/ina/5A_COMB.seq.*
- 2: /cgn2.6/ptodata/2/ina/5B_COMB.seq.*
- 3: /cgn2.6/ptodata/2/ina/6A_COMB.seq.*
- 4: /cgn2.6/ptodata/2/ina/6B_COMB.seq.*
- 5: /cgn2.6/ptodata/2/ina/PCTUS_COMB.seq.*
- 6: /cgn2.6/ptodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19	100.0	23	1	US-08-064-271-8
C 2	19	100.0	23	4	US-08-930-589A-8
C 3	19	100.0	1834	1	US-08-487-753-3
C 4	19	100.0	1834	1	US-08-487-753-14
C 5	19	100.0	1834	2	US-08-480-065-3
C 6	19	100.0	1834	2	US-08-480-065-14
C 7	19	100.0	1834	3	US-08-487-744-3
C 8	19	100.0	1834	3	US-08-487-744-14
C 9	19	100.0	1834	5	PCT-US93-09167-3
C 10	19	100.0	3387	1	US-08-064-271-11
C 11	19	100.0	3387	2	US-08-627-254C-29
C 12	17	89.5	18	2	US-08-627-254C-16
C 13	17	89.5	3387	4	US-08-930-589A-19
C 14	16	84.2	41	4	US-08-930-589A-14
C 15	15.8	83.2	2472	1	US-08-221-750A-2
C 16	15.8	83.2	7742	1	US-08-221-750A-1
C 17	15	78.9	15	2	US-08-627-254C-15
C 18	15	78.9	1312	1	US-08-205-506A-1
C 19	15	78.9	1312	5	PCT-US94-02389-1
C 20	14.8	77.9	1912	2	US-08-948-569A-11
C 21	14.8	77.9	1912	2	US-09-188-469-11
C 22	14.8	77.9	2312	1	US-07-736-178C-1
C 23	14.8	77.9	80161	4	US-09-036-987A-1
C 24	14.2	74.7	756	1	US-07-717-332D-1
C 25	14.2	74.7	1635	5	PCT-US94-05795-1
C 26	14.2	74.7	5970	4	US-09-320-878-21
C 27	14.2	74.7	6000	1	US-08-348-006B-6

C 28	14.2	74.7	6000	2	US-08-800-825A-6	Sequence 6, Appli
C 29	14.2	74.7	6000	5	PCT-US94-10166-6	Sequence 6, Appli
C 30	14.2	74.7	6250	1	US-08-729-214-23	Sequence 23, Appl
C 31	14.2	74.7	6250	4	US-09-028-934-23	Sequence 23, Appl
C 32	14.2	74.7	8931	4	US-09-028-934-28	Sequence 28, Appl
C 33	14.2	74.7	28804	2	US-08-592-874-1	Sequence 1, Appli
C 34	14.2	74.7	28804	3	US-09-096-942-2	Sequence 2, Appli
C 35	14.2	74.7	28804	3	US-09-096-867-2	Sequence 2, Appli
C 36	14.2	74.7	28958	1	US-08-258-261B-6	Sequence 6, Appli
C 37	14.2	74.7	28958	1	US-08-456-837-6	Sequence 6, Appli
C 38	14.2	74.7	28958	1	US-08-457-342-6	Sequence 6, Appli
C 39	14.2	74.7	28958	1	US-08-457-646A-6	Sequence 6, Appli
C 40	14.2	74.7	28958	1	US-08-458-076A-6	Sequence 6, Appli
C 41	14.2	74.7	28958	1	US-08-764-233A-4	Sequence 4, Appli
C 42	14.2	74.7	28958	1	US-08-457-335A-6	Sequence 6, Appli
C 43	14.2	74.7	28958	1	US-08-729-214-6	Sequence 6, Appli
C 44	14.2	74.7	28958	4	US-09-028-934-6	Sequence 6, Appli
C 45	14.2	74.7	38506	4	US-09-320-878-19	Sequence 19, Appli

ALIGNMENTS

RESULT 1
US-08-064-271-8/c
; Sequence 8, Application US/08064271
; Patent No. 5543297
; GENERAL INFORMATION:
; APPLICANT: Kennedy, Brian P.
; APPLICANT: Cromlish, Wanda A.
; APPLICANT: Mancini, Joseph A.
; APPLICANT: O'Neill, Gary
; APPLICANT: Vickers, Philip J.
; APPLICANT: Wong, Elizabeth
; TITLE OF INVENTION: HUMAN CYCLOOXYGENASE-2 CDNA AND
; TITLE OF INVENTION: ASSAY FOR EVALUATING CYCLOOXYGENASE ACTIVITY
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: 126 Lincoln Avenue
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.4kb
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: System 7
; SOFTWARE: Microsoft Word 5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/064,271
; FILING DATE: 19930506
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Panzer, Curtis C.
; REGISTRATION NUMBER: 33,752
; REFERENCE/DOCKET NUMBER: 189061A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908)594-3199
; TELEFAX: (908)594-4720
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-064-271-8

Query Match 100.0%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
; |
Db 21 GGGCGGGCGGAGCATCGC 3
; |
RESULT 2
US-08-930-589A-8/c
; Sequence 8, Application US/08930589A
; Patent No. 6107087
; GENERAL INFORMATION:
; APPLICANT: MERCK FROSST CANADA & CO.
; APPLICANT: O'NEILL, GARY P.
; APPLICANT: MANCINI, JOSEPH A.
; TITLE OF INVENTION: HIGH LEVEL EXPRESSION OF HUMAN
; TITLE OF INVENTION: CYCLOOXYGENASE-2
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O. Box 2000, 126 E. Lincoln Ave.
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065-0900
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/930.589A
; FILING DATE: 28-JUN-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coppola, Joseph A.
; REGISTRATION NUMBER: 38,413
; REFERENCE/DOCKET NUMBER: 19029PC
; TELEPHONE: 732-594-6734
; TELEFAX: 732-594-4720
; TELEX:
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-930-589A-8

Query Match 100.0%; Score 19; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
; |
Db 21 GGGCGGGCGGAGCATCGC 3
; |
RESULT 3
US-08-487-753-3/c
; Sequence 3, Application US/08487753
; Patent No. 5807733
; GENERAL INFORMATION:
; APPLICANT: Young, Donald A.
; APPLICANT: O'Banion, Michael K.
; APPLICANT: Winn, Virginia D.
; TITLE OF INVENTION: MAMMALIAN PROSTAGLANDIN H SYNTHASE-2

; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,753
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 3996-011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-9741/8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1834 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
US-08-487-753-3

Query Match 100.0%; Score 19; DB 1; Length 1834;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
; |
Db 24 GGGCGGGCGGAGCATCGC 6
; |
RESULT 4
US-08-487-753-14/c
; Sequence 14, Application US/08487753
; Patent No. 5807733
; GENERAL INFORMATION:
; APPLICANT: Young, Donald A.
; APPLICANT: O'Banion, Michael K.
; APPLICANT: Winn, Virginia D.
; TITLE OF INVENTION: MAMMALIAN PROSTAGLANDIN H SYNTHASE-2
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,753
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.

REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 3996-011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 1834 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-487-753-14

Query Match 100.0%; Score 19; DB 1; Length 1834;
Best Local Similarity 100.0%; Pred. No. 1.6; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 1 GGGCGCGGGCGAGCATCGC 19
|||||
DB 24 GGGCGCGGGCGAGCATCGC 6

RESULT 5
US-08-480-065-3/c
Sequence 3, Application US/08480065
Patent No. 5837479
GENERAL INFORMATION:
APPLICANT: Young, Donald A.
APPLICANT: O'Banion, Michael K.
APPLICANT: Winn, Virginia D.
TITLE OF INVENTION: SCREENING ASSAYS FOR INHIBITORS OF
TITLE OF INVENTION: MAMMALIAN PROSTAGLANDIN H SYNTHASE-2
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480,065
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A.
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 3996-012
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 1834 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-480-065-3

Query Match 100.0%; Score 19; DB 2; Length 1834;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGGCGAGCATCGC 19
|||||
DB 24 GGGCGCGGGCGAGCATCGC 6
RESULT 6
US-08-480-065-14/c
Sequence 14, Application US/08480065
Patent No. 5837479
GENERAL INFORMATION:
APPLICANT: Young, Donald A.
APPLICANT: O'Banion, Michael K.
APPLICANT: Winn, Virginia D.
TITLE OF INVENTION: SCREENING ASSAYS FOR INHIBITORS OF
TITLE OF INVENTION: MAMMALIAN PROSTAGLANDIN H SYNTHASE-2
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480,065
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A.
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 3996-012
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 1834 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-480-065-14

Query Match 100.0%; Score 19; DB 2; Length 1834;
Best Local Similarity 100.0%; Pred. No. 1.6; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 1 GGGCGCGGGCGAGCATCGC 19
|||||
DB 24 GGGCGCGGGCGAGCATCGC 6

RESULT 7
US-08-487-744-3/c
Sequence 3, Application US/08487744
Patent No. 6048850
GENERAL INFORMATION:
APPLICANT: Young, Donald A.
APPLICANT: O'Banion, Michael K.
APPLICANT: Winn, Virginia D.
TITLE OF INVENTION: METHODS FOR INHIBITING PROSTAGLANDIN
TITLE OF INVENTION: SYNTHESIS IN A MAMMALIAN HOST
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds

STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICANT: Young, Donald A.
FILING DATE:
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A.
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 3996-013
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 1834 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-487-744-3

Query Match 100.0%; Score 19; DB 3; Length 1834;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGGGCGGAGCATCGC 19
|||||
Db 24 GGGCGGGCGGAGCATCGC 6

RESULT 8
US-08-487-744-14/c
Sequence 14, Application US/08487744
Patent No. 6048850
GENERAL INFORMATION:
APPLICANT: Young, Donald A.
APPLICANT: O'Banion, Michael K.
APPLICANT: Winn, Virginia D.
TITLE OF INVENTION: METHODS FOR INHIBITING PROSTAGLANDIN
SYNTHESIS IN A MAMMALIAN HOST
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
FILING DATE:
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Coruzzi, Laura A.
REGISTRATION NUMBER: 30,742
REFERENCE/DOCKET NUMBER: 3996-013
TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 1834 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-487-744-14

Query Match 100.0%; Score 19; DB 3; Length 1834;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGGGCGGAGCATCGC 19
|||||
Db 24 GGGCGGGCGGAGCATCGC 6

RESULT 9
PCT-US93-09167-3/C
Sequence 3, Application PC/TUS9309167
GENERAL INFORMATION:
APPLICANT: Young, Donald A.
APPLICANT: O'Banion, M. Kerry
TITLE OF INVENTION: Stably-Transformed Mammalian Cells
TITLE OF INVENTION: Expressing a Regulated, Inflammatory Cyclooxygenase
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould
STREET: 3100 Norwest Center
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICANT: Young, Donald A.
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Woessner, Warren D.
REGISTRATION NUMBER: 30,440
REFERENCE/DOCKET NUMBER: 8840.20-US-01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 1834 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: Human PGHS-2
PCT-US93-09167-3

Query Match 100.0%; Score 19; DB 5; Length 1834;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGGGCGGAGCATCGC 19
|||||

```
Db      24 GGGCGGGCGGAGCATCGC 6

RESULT 10
US-08-064-271-11/c
; Sequence 11, Application US/08064271
; Patent No. 5543297
; GENERAL INFORMATION:
; APPLICANT: Kennedy, Brian P.
; APPLICANT: Cromlish, Wanda A.
; APPLICANT: Mancini, Joseph A.
; APPLICANT: O'Neil, Gary
; APPLICANT: Vickers, Philip J.
; APPLICANT: Wong, Elizabeth
; TITLE OF INVENTION: HUMAN CYCLOOXYGENASE-2 cDNA AND
; TITLE OF INVENTION: ASSAY FOR EVALUATING CYCLOOXYGENASE ACTIVITY.
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: 126 Lincoln Avenue
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.4kb
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: System 7
; SOFTWARE: Microsoft Word 5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/064,271
; FILING DATE: 19930506
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Panzer, Curtis C.
; REGISTRATION NUMBER: 33,752
; REFERENCE/DOCKET NUMBER: 189061A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908)594-3199
; TELEFAX: (908)594-4720
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3387 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-064-271-11

Query Match      100.0%; Score 19; DB 1; Length 3387;
Best Local Similarity 100.0%; Pred. No. 1.5;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 GGGCGGGCGGAGCATCGC 19
Db      113 GGGCGGGCGGAGCATCGC 95

RESULT 11
US-08-627-254C-29/c
; Sequence 29, Application US/08627254C
; Patent No. 5859229
; GENERAL INFORMATION:
; APPLICANT: Kniss, Douglas A.
; TITLE OF INVENTION: Eicosanoid Formation
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Calfee, Halter & Griwold LLP
; STREET: 800 Superior Avenue
; CITY: Cleveland
; STATE: Ohio
; COUNTRY: USA

Query Match      100.0%; Score 19; DB 1; Length 3387;
Best Local Similarity 100.0%; Pred. No. 1.5;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 GGGCGGGCGGAGCATCGC 19
Db      113 GGGCGGGCGGAGCATCGC 95

RESULT 12
US-08-627-254C-16
; Sequence 16, Application US/08627254C
; Patent No. 5859229
; GENERAL INFORMATION:
; APPLICANT: Kniss, Douglas A.
; TITLE OF INVENTION: Eicosanoid Formation
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Calfee, Halter & Griwold LLP
; STREET: 800 Superior Avenue
; CITY: Cleveland
; STATE: Ohio
; COUNTRY: USA
; ZIP: 44114
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/627,254C
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Golrick, Mary E.
; REGISTRATION NUMBER: 34,829
; REFERENCE/DOCKET NUMBER: 18525/00107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (216) 622-8200
; TELEFAX: (216) 241-0816
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
; ANTI-SENSE: YES
US-08-627-254C-16

Query Match 89.5%; Score 17; DB 2; Length 18;
Best Local Similarity 100.0%; Pred. No. 17; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0;

Qy 1 GGGCGGGCGGAGCATC 17
| | | | | | | | | | | | | | | | | | | | | |
Db 2 GGGCGGGCGGAGCATC 18

RESULT 13
US-08-930-589A-19/c
; Sequence 19, Application US/08930589A
; Patent No. 6107087
; GENERAL INFORMATION:
; APPLICANT: MERCK FROSST CANADA & CO.
; APPLICANT: O'NEILL, GARY P.
; APPLICANT: MANCINI, JOSEPH A.
; TITLE OF INVENTION: HIGH LEVEL EXPRESSION OF HUMAN
; TITLE OF INVENTION: CYCLOOXYGENASE-2
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O. Box 2000, 126 E. Lincoln Ave.
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065-0900
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/930,589A
; FILING DATE: 28-JUN-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coppola, Joseph A.
; REGISTRATION NUMBER: 38,413
; REFERENCE/DOCKET NUMBER: 19029PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 732-594-6734
; TELEFAX: 732-594-4720
; TELEX:
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 387 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-930-589A-19

Query Match 89.5%; Score 17; DB 4; Length 3387;
Best Local Similarity 100.0%; Pred. No. 11; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0;

Qy 1 GGGCGGGCGGAGCATC 17
| | | | | | | | | | | | | | | | | | | | | |
Db 113 GGGCGGGCGGAGCATC 97

RESULT 14
US-08-930-589A-14/c
; Sequence 14, Application US/08930589A
; Patent No. 6107087
; GENERAL INFORMATION:
; APPLICANT: MERCK FROSST CANADA & CO.
; APPLICANT: O'NEILL, GARY P.
; APPLICANT: MANCINI, JOSEPH A.
; TITLE OF INVENTION: HIGH LEVEL EXPRESSION OF HUMAN
; TITLE OF INVENTION: CYCLOOXYGENASE-2
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O. Box 2000, 126 E. Lincoln Ave.
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065-0900
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/930,589A
; FILING DATE: 28-JUN-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coppola, Joseph A.
; REGISTRATION NUMBER: 38,413
; REFERENCE/DOCKET NUMBER: 19029PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 732-594-6734
; TELEFAX: 732-594-4720
; TELEX:
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-930-589A-14

Query Match 84.2%; Score 16; DB 4; Length 41;
Best Local Similarity 100.0%; Pred. No. 43; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0;

Qy 1 GGGCGGGCGGAGCATC 16
| | | | | | | | | | | | | | | | | | | | | |
Db 17 GGGCGGGCGGAGCATC 2

RESULT 15
US-08-221-750A-2/c
; Sequence 2, Application US/08221750A
; Patent No. 5643747
; GENERAL INFORMATION:
; APPLICANT: Baker, Steven M.
; APPLICANT: Deitch, Robert A.
; TITLE OF INVENTION: Genes for the Export of Pertussis
; TITLE OF INVENTION: Holotoxin
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: USA

```
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/221,750A
; FILING DATE: 31-MAR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/031,619
; FILING DATE: 15-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Carroll, Alice O.
; REGISTRATION NUMBER: 33,542
; REFERENCE/DOCKET NUMBER: ACC93-01A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2472 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..2472
; US-08-221-750A-2
```

```
Query Match      83.2%; Score 15.8; DB 1; Length 2472;
Best Local Similarity 89.5%; Pred.No. 38;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 GGGCGCGCGCGAGCATCGC 19
        | | | | | | | | | | | | | | | |
Db      1627 GAGCGCGCGCGAGCATCGC 1609
```

Search completed: April 20, 2001, 00:03:44
Job time: 9681 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 03:21:21 ; Search time 11165 Seconds
(without alignments)
8.860 Million cell updates/sec

Title: US-09-016-464-17

Perfect score: 19

Sequence: 1 GGCGGGGGGAGCATCGC 19

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 13168883 seqs, 2603265903 residues

Total number of hits satisfying chosen parameters: 26337766

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_NA_Main:*

- 1: /cgn2_6/ptodata/2/pna/PCRTUS_COMB.seq.*
- 2: /cgn2_6/ptodata/2/pna/US06_COMB.seq.*
- 3: /cgn2_6/ptodata/2/pna/US07_COMB.seq.*
- 4: /cgn2_6/ptodata/2/pna/US080_COMB.seq.*
- 5: /cgn2_6/ptodata/2/pna/US081_COMB.seq.*
- 6: /cgn2_6/ptodata/2/pna/US082_COMB.seq.*
- 7: /cgn2_6/ptodata/2/pna/US083_COMB.seq.*
- 8: /cgn2_6/ptodata/2/pna/US084_COMB.seq.*
- 9: /cgn2_6/ptodata/2/pna/US085_COMB.seq.*
- 10: /cgn2_6/ptodata/2/pna/US086_COMB.seq.*
- 11: /cgn2_6/ptodata/2/pna/US087_COMB.seq.*
- 12: /cgn2_6/ptodata/2/pna/US088_COMB.seq.*
- 13: /cgn2_6/ptodata/2/pna/US089_COMB.seq.*
- 14: /cgn2_6/ptodata/2/pna/US090_COMB.seq.*
- 15: /cgn2_6/ptodata/2/pna/US091_COMB.seq.*
- 16: /cgn2_6/ptodata/2/pna/US092_COMB.seq.*
- 17: /cgn2_6/ptodata/2/pna/US093_COMB.seq.*
- 18: /cgn2_6/ptodata/2/pna/US094_COMB.seq.*
- 19: /cgn2_6/ptodata/2/pna/US095A_COMB.seq.*
- 20: /cgn2_6/ptodata/2/pna/US095B_COMB.seq.*
- 21: /cgn2_6/ptodata/2/pna/US095C_COMB.seq.*
- 22: /cgn2_6/ptodata/2/pna/US095D_COMB.seq.*
- 23: /cgn2_6/ptodata/2/pna/US096A_COMB.seq.*
- 24: /cgn2_6/ptodata/2/pna/US096B_COMB.seq.*
- 25: /cgn2_6/ptodata/2/pna/US096C_COMB.seq.*
- 26: /cgn2_6/ptodata/2/pna/US096D_COMB.seq.*
- 27: /cgn2_6/ptodata/2/pna/US096E_COMB.seq.*
- 28: /cgn2_6/ptodata/2/pna/US097A_COMB.seq.*
- 29: /cgn2_6/ptodata/2/pna/US097B_COMB.seq.*
- 30: /cgn2_6/ptodata/2/pna/US097C_COMB.seq.*
- 31: /cgn2_6/ptodata/2/pna/US098_COMB.seq.*
- 32: /cgn2_6/ptodata/2/pna/US099_COMB.seq.*
- 33: /cgn2_6/ptodata/2/pna/US099A_COMB.seq.*
- 34: /cgn2_6/ptodata/2/pna/US099B_COMB.seq.*
- 35: /cgn2_6/ptodata/2/pna/US099C_COMB.seq.*
- 36: /cgn2_6/ptodata/2/pna/US099D_COMB.seq.*
- 37: /cgn2_6/ptodata/2/pna/US099E_COMB.seq.*
- 38: /cgn2_6/ptodata/2/pna/US099F_COMB.seq.*
- 39: /cgn2_6/ptodata/2/pna/US099G_COMB.seq.*
- 40: /cgn2_6/ptodata/2/pna/US099H_COMB.seq.*
- 41: /cgn2_6/ptodata/2/pna/US099I_COMB.seq.*
- 42: /cgn2_6/ptodata/2/pna/US099J_COMB.seq.*
- 43: /cgn2_6/ptodata/2/pna/US099K_COMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	19	100.0	19	8	US-08-474-497-17 Sequence 17, Appl
2	19	100.0	19	14	US-09-016-464-17 Sequence 17, Appl
3	19	100.0	23	3	US-07-994-760-8 Sequence 8, Appli
4	19	100.0	23	4	US-08-084-033A-8 Sequence 8, Appli
5	19	100.0	23	13	US-08-930-589-8 Sequence 8, Appli
6	19	100.0	23	22	US-09-599-781-8 Sequence 8, Appli
7	19	100.0	159	1	PCT-US00-30888-11 Sequence 11, Appl
8	19	100.0	159	1	PCT-US00-30888-11 Sequence 11, Appl
9	19	100.0	159	18	US-09-437-457-11 Sequence 11, Appl
10	19	100.0	159	18	US-09-437-457-11 Sequence 11, Appl
11	19	100.0	159	29	US-09-729-447-11 Sequence 11, Appl
12	19	100.0	219	25	US-09-652-918-2902 Sequence 2902, Ap
13	19	100.0	227	25	US-09-652-816-6526 Sequence 6526, Ap
14	19	100.0	284	28	US-09-716-990-85 Sequence 85, Appl
15	19	100.0	346	17	US-09-396-087-2011 Sequence 2011, Ap
16	19	100.0	349	25	US-09-644-869-5749 Sequence 5749, Ap
17	19	100.0	374	29	US-09-726-809-2115 Sequence 2115, Ap
18	19	100.0	375	25	US-09-652-128-4892 Sequence 4892, Ap
19	19	100.0	381	29	US-09-726-809-1224 Sequence 1224, Ap
20	19	100.0	389	29	US-09-726-809-2204 Sequence 2204, Ap
21	19	100.0	390	25	US-09-652-915-6360 Sequence 6360, Ap
22	19	100.0	394	25	US-09-652-915-6254 Sequence 6254, Ap
23	19	100.0	403	25	US-09-652-816-6600 Sequence 6600, Ap
24	19	100.0	403	25	US-09-652-918-2324 Sequence 2324, Ap
25	19	100.0	403	29	US-09-726-810-516 Sequence 516, App
26	19	100.0	407	28	US-09-710-286-1462 Sequence 1462, Ap
27	19	100.0	421	29	US-09-721-588-2251 Sequence 2251, Ap
28	19	100.0	423	29	US-09-726-809-1444 Sequence 1444, Ap
29	19	100.0	424	29	US-09-726-810-1474 Sequence 1474, Ap
30	19	100.0	429	19	US-09-502-330-324 Sequence 324, App
31	19	100.0	429	25	US-09-641-638-324 Sequence 324, App
32	19	100.0	430	29	US-09-726-810-715 Sequence 715, App
33	19	100.0	431	28	US-09-716-990-210 Sequence 210, App
34	19	100.0	431	29	US-09-726-810-2251 Sequence 2251, Ap
35	19	100.0	445	25	US-09-644-869-7132 Sequence 7132, Ap
36	19	100.0	457	25	US-09-652-128-4340 Sequence 4340, Ap
37	19	100.0	462	29	US-09-726-809-1946 Sequence 1946, Ap
38	19	100.0	464	29	US-09-726-810-1436 Sequence 1436, Ap
39	19	100.0	467	17	US-09-396-087-985 Sequence 985, App
40	19	100.0	468	25	US-09-652-918-2292 Sequence 2292, Ap
41	19	100.0	469	28	US-09-710-286-1461 Sequence 1461, Ap
42	19	100.0	471	28	US-09-710-286-1903 Sequence 1903, Ap
43	19	100.0	472	28	US-09-716-990-483 Sequence 483, App
44	19	100.0	481	25	US-09-649-162-4790 Sequence 4790, Ap
45	19	100.0	482	18	US-09-432-241A-2676 Sequence 2676, Ap

- 44: /cgn2_6/ptodata/2/pna/US6012_COMB.seq.*
- 45: /cgn2_6/ptodata/2/pna/US6013_COMB.seq.*
- 46: /cgn2_6/ptodata/2/pna/US6014_COMB.seq.*
- 47: /cgn2_6/ptodata/2/pna/US6015_COMB.seq.*
- 48: /cgn2_6/ptodata/2/pna/US6016_COMB.seq.*
- 49: /cgn2_6/ptodata/2/pna/US6017_COMB.seq.*
- 50: /cgn2_6/ptodata/2/pna/US6018_COMB.seq.*
- 51: /cgn2_6/ptodata/2/pna/US6019_COMB.seq.*
- 52: /cgn2_6/ptodata/2/pna/US6020_COMB.seq.*
- 53: /cgn2_6/ptodata/2/pna/US6021_COMB.seq.*
- 54: /cgn2_6/ptodata/2/pna/US6022_COMB.seq.*
- 55: /cgn2_6/ptodata/2/pna/US6023_COMB.seq.*
- 56: /cgn2_6/ptodata/2/pna/US6024_COMB.seq.*
- 57: /cgn2_6/ptodata/2/pna/US6025_COMB.seq.*
- 58: /cgn2_6/ptodata/2/pna/US6026_COMB.seq.*
- 59: /cgn2_6/ptodata/2/pna/US6027_COMB.seq.*

ALIGNMENTS

```
RESULT 1
US-08-474-497-17
; Sequence 17, Application US/08474497
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; TITLE OF INVENTION: Using Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,497
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 12
; OTHER INFORMATION: /standard_name= "Reduced A"
;
;
; NAME/KEY: misc_feature
; LOCATION: 15
; OTHER INFORMATION: /standard_name= "Reduced A"
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-08-474-497-17

Query Match 100.0%; Score 19; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGGCGGAGCATCGC 19
   |||
Db 1 GGGCGCGGGCGGAGCATCGC 19

RESULT 2
US-09-016-464-17
; Sequence 17, Application US/09016464
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; TITLE OF INVENTION: Using Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,497
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 12
; OTHER INFORMATION: /standard_name= "Reduced A"
;
;
; NAME/KEY: misc_feature
; LOCATION: 15
; OTHER INFORMATION: /standard_name= "Reduced A"
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-016-464-17

Query Match 100.0%; Score 19; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGGCGGAGCATCGC 19
   |||
Db 1 GGGCGCGGGCGGAGCATCGC 19

RESULT 3
US-07-994-760-8/c
; Sequence 8, Application US/07994760
; GENERAL INFORMATION:
; APPLICANT: Kennedy, Brian P.
; APPLICANT: Cromlish, Wanda
; APPLICANT: O'Neill, Gary
; APPLICANT: Vickers, Philip J.
; APPLICANT: Wong, Elizabeth
; TITLE OF INVENTION: HUMAN CYCLOOXYGENASE-2 cDNA AND
; TITLE OF INVENTION: ASSAY FOR EVALUATING CYCLOOXYGENASE ACTIVITY
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: 126 Lincoln Avenue
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```
;
;
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/016,464
; FILING DATE: 30-Jan-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/474,497
; FILING DATE: <unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 12
; OTHER INFORMATION: /standard_name= "Reduced A"
;
;
; NAME/KEY: misc_feature
; LOCATION: 15
; OTHER INFORMATION: /standard_name= "Reduced A"
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-016-464-17

Query Match 100.0%; Score 19; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGGCGCGGGCGGAGCATCGC 19
   |||
Db 1 GGGCGCGGGCGGAGCATCGC 19

RESULT 3
US-07-994-760-8/c
; Sequence 8, Application US/07994760
; GENERAL INFORMATION:
; APPLICANT: Kennedy, Brian P.
; APPLICANT: Cromlish, Wanda
; APPLICANT: O'Neill, Gary
; APPLICANT: Vickers, Philip J.
; APPLICANT: Wong, Elizabeth
; TITLE OF INVENTION: HUMAN CYCLOOXYGENASE-2 cDNA AND
; TITLE OF INVENTION: ASSAY FOR EVALUATING CYCLOOXYGENASE ACTIVITY
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: 126 Lincoln Avenue
; CITY: Rahway
; STATE: NJ
; COUNTRY: USA
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```


COMPUTER: Macintosh IIfx
OPERATING SYSTEM: Macintosh
SOFTWARE: Microsoft Word 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/994,760
FILING DATE: 19921222
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Panzer, Curtis C.
REGISTRATION NUMBER: 33,752
REFERENCE/DOCKET NUMBER: 18906
TELECOMMUNICATION INFORMATION:
TELEPHONE: (908)594-3199
TELEFAX: (908)594-4720
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-07-994-760-8

Query Match 100.0%; Score 19; DB 3; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
Db 21 GGGCGGGCGGAGCATCGC 3

RESULT 4

US-08-033A-8/c
Sequence 8, Application US/08084033A
GENERAL INFORMATION:
APPLICANT: O'NEILL, GARY P
APPLICANT: MANCINI, JOSEPH A
TITLE OF INVENTION: HIGH LEVEL EXPRESSION OF HUMAN
CYCLOOXYGENASE-2
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: CHRISTINE E CARTY
STREET: P.O. BOX 2000, 126 E. LINCOLN AVE.
CITY: RAHWAY
STATE: NJ
COUNTRY: USA
ZIP: 07065
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/084,033A
FILING DATE: 28-JUN-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: CARTY, CHRISTINE E
REGISTRATION NUMBER: 36,099
REFERENCE/DOCKET NUMBER: 19029
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908-594-6734
TELEFAX: 908-594-4720
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-084-033A-8

Query Match 100.0%; Score 19; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
Db 21 GGGCGGGCGGAGCATCGC 3

RESULT 5

US-08-930-589-8/c
Sequence 8, Application US/08930589
GENERAL INFORMATION:
APPLICANT: MERCK FROSST CANADA & CO.
APPLICANT: O'NEILL, GARY P
APPLICANT: MANCINI, JOSEPH A
TITLE OF INVENTION: HIGH LEVEL EXPRESSION OF HUMAN
CYCLOOXYGENASE-2
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: MERCK & CO., INC.
STREET: P. O. BOX 2000 - 126 E. LINCOLN AVE.
CITY: RAHWAY
STATE: NJ
COUNTRY: USA
ZIP: 07065-0900
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/930,589
FILING DATE: 28-JUN-1998
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: COPPOLA, JOSEPH A.
REGISTRATION NUMBER: 38,413
REFERENCE/DOCKET NUMBER: 19029PC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 732-594-6734
TELEFAX: 732-594-4720
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-930-589-8

Query Match 100.0%; Score 19; DB 13; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
Db 21 GGGCGGGCGGAGCATCGC 3

RESULT 6

US-09-599-781-8/c
Sequence 8, Application US/09599781
GENERAL INFORMATION:
APPLICANT: MERCK FROSST CANADA & CO.
APPLICANT: O'NEILL, GARY P.
APPLICANT: MANCINI, JOSEPH A.
TITLE OF INVENTION: HIGH LEVEL EXPRESSION OF HUMAN
CYCLOOXYGENASE-2
NUMBER OF SEQUENCES: 23

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Metck & Co., Inc.
; STREET: P.O. Box 2000, 126 E. Lincoln Ave.
; CITY: Rahway
; STATE: NJ

; COUNTRY: USA
; ZIP: 07065-0900

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows

; SOFTWARE: FastSEQ for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/599,781

; FILING DATE: 21-Jun-2000

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/084,033

; FILING DATE: 27-Sep-1993

; ATTORNEY/AGENT INFORMATION:
; NAME: Coppola, Joseph A

; REGISTRATION NUMBER: 38,413

; REFERENCE/DOCKET NUMBER: 19029PC

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 732-594-6734

; TELEFAX: 732-594-4720

; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 8:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 23 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: cDNA

; SEQUENCE DESCRIPTION: SEQ ID NO: 8:

US-09-599-781-8

Query Match 100.0%; Score 19; DB 22; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GGGCGCGGGCAGCATCGC 19
|||||

Db 21 GGGCGCGGGCAGCATCGC 3
|||||

RESULT 7

PCT-US00-30888-11/c

; Sequence 11, Application PC/TUS0030888

; GENERAL INFORMATION:

; APPLICANT: Message Pharmaceuticals, Inc.

; TITLE OF INVENTION: NUCLEIC ACID SEQUENCES AND METHODS FOR

; IDENTIFYING COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN

; TITLE OF INVENTION: INTERACTIONS AND MRNA FUNCTIONALITY

; FILE REFERENCE: 50093/014W01

; CURRENT APPLICATION NUMBER: PCT/US00/30888

; CURRENT FILING DATE: 2000-11-09

; PRIOR APPLICATION NUMBER: 09/437,458

; PRIOR FILING DATE: 1999-11-10

; NUMBER OF SEQ ID NOS: 20

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 11

; LENGTH: 159

; TYPE: DNA

; ORGANISM: Homo sapiens

PCT-US00-30888-11

Query Match 100.0%; Score 19; DB 1; Length 159;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GGGCGCGGGCAGCATCGC 19
|||||

Db 113 GGGCGCGGGCAGCATCGC 95
|||||

RESULT 8

PCT-US00-30888A-11/c

; Sequence 11, Application PC/TUS0030888A

; GENERAL INFORMATION:

; APPLICANT: Message Pharmaceuticals, Inc.

; TITLE OF INVENTION: NUCLEIC ACID SEQUENCES AND METHODS FOR

; IDENTIFYING COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN

; TITLE OF INVENTION: INTERACTIONS AND MRNA FUNCTIONALITY

; FILE REFERENCE: 50093/014W01

; CURRENT APPLICATION NUMBER: PCT/US00/30888A

; CURRENT FILING DATE: 2000-11-09

; PRIOR APPLICATION NUMBER: 09/437,458

; PRIOR FILING DATE: 1999-11-10

; NUMBER OF SEQ ID NOS: 20

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 11

; LENGTH: 159

; TYPE: DNA

; ORGANISM: Homo sapiens

PCT-US00-30888A-11

Query Match 100.0%; Score 19; DB 1; Length 159;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GGGCGCGGGCAGCATCGC 19
|||||

Db 113 GGGCGCGGGCAGCATCGC 95
|||||

RESULT 9

US-09-437-457-11/c

; Sequence 11, Application US/09437457

; GENERAL INFORMATION:

; APPLICANT: Giordano, Anthony

; APPLICANT: Xavier, Ashish

; TITLE OF INVENTION: NUCLEIC ACID SEQUENCES AND METHODS FOR

; IDENTIFYING COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN

; TITLE OF INVENTION: INTERACTIONS AND MRNA FUNCTIONALITY

; FILE REFERENCE: 50093/014W01

; CURRENT APPLICATION NUMBER: US/09/437,457

; CURRENT FILING DATE: 1999-11-10

; NUMBER OF SEQ ID NOS: 20

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 11

; LENGTH: 159

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-437-457-11

Query Match 100.0%; Score 19; DB 18; Length 159;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GGGCGCGGGCAGCATCGC 19
|||||

Db 113 GGGCGCGGGCAGCATCGC 95
|||||

RESULT 10

US-09-437-458-11/c

; Sequence 11, Application US/09437458

; GENERAL INFORMATION:

; APPLICANT: Giordano, Anthony

; APPLICANT: Xavier, Ashish

; TITLE OF INVENTION: NUCLEIC ACID SEQUENCES AND METHODS FOR

; TITLE OF INVENTION: IDENTIFYING COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN
; FILE REFERENCE: 50093/014001
; CURRENT APPLICATION NUMBER: US/09/437,458
; CURRENT FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 159
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-437-458-11

Query Match 100.0%; Score 19; DB 18; Length 159;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
|||||

Db 113 GGGCGCGGCGGAGCATCGC 95

RESULT 11
US-09-729-447-11/c
; Sequence 11, Application US/09729447
; GENERAL INFORMATION:
; APPLICANT: Giordano, Anthony
; APPLICANT: Xavier, Ashish
; TITLE OF INVENTION: NUCLEIC ACID SEQUENCES AND METHODS FOR
; TITLE OF INVENTION: IDENTIFYING COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN
; FILE REFERENCE: 50093/014001
; CURRENT APPLICATION NUMBER: US/09/729,447
; CURRENT FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 09/437,458
; PRIOR FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 159
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-729-447-11

Query Match 100.0%; Score 19; DB 29; Length 159;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
|||||

Db 113 GGGCGCGGCGGAGCATCGC 95

RESULT 12
US-09-652-918-2902/c
; Sequence 2902, Application US/09652918
; GENERAL INFORMATION:
; APPLICANT: Galvin, Katherine
; APPLICANT: Holtzman, Douglas A.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID MOLECULES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 1600.1187-001
; CURRENT APPLICATION NUMBER: US/09/652,918
; CURRENT FILING DATE: 2000-08-30
; PRIOR APPLICATION NUMBER: 60/151,130
; PRIOR FILING DATE: 1999-08-30
; NUMBER OF SEQ ID NOS: 8985
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2902
; LENGTH: 219
; TYPE: DNA

; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(219)
; OTHER INFORMATION: n = A,T,C or G
US-09-652-918-2902

Query Match 100.0%; Score 19; DB 25; Length 219;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
|||||

Db 148 GGGCGCGGCGGAGCATCGC 130

RESULT 13
US-09-652-816-6526/c
; Sequence 6526, Application US/09652816
; GENERAL INFORMATION:
; APPLICANT: Gutierrez-Ramos, Jose-Carlos
; TITLE OF INVENTION: NOVEL NUCLEIC ACID MOLECULES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 1600.1177-001
; CURRENT APPLICATION NUMBER: US/09/652,816
; CURRENT FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/152,111
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 9647
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6526
; LENGTH: 227
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-652-816-6526

Query Match 100.0%; Score 19; DB 25; Length 227;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGCGGCGGAGCATCGC 19
|||||

Db 164 GGGCGCGGCGGAGCATCGC 146

RESULT 14
US-09-716-990-85/c
; Sequence 85, Application US/09716990
; GENERAL INFORMATION:
; APPLICANT: Gearing, David P.
; APPLICANT: Holtzman, Douglas A.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID MOLECULES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 1600.2039-001
; CURRENT APPLICATION NUMBER: US/09/716,990
; CURRENT FILING DATE: 2000-11-21
; PRIOR APPLICATION NUMBER: US 60/166,926
; PRIOR FILING DATE: 1999-11-22
; NUMBER OF SEQ ID NOS: 1691
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 85
; LENGTH: 284
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(284)
; OTHER INFORMATION: n = A,T,C or G
US-09-716-990-85

Query Match 100.0%; Score 19; DB 28; Length 284;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GGGCGCGGCGGAGCATCGC 19
 Db 147 GGGCGCGGCGGAGCATCGC 129

RESULT 15

US-09-396-087-2011/c
 ; Sequence 2011, Application US/09396087
 ; GENERAL INFORMATION:
 ; APPLICANT: Gearing, David P.
 ; APPLICANT: Holzman, Douglas A.
 ; TITLE OF INVENTION: NUCLEIC ACID MOLECULES DERIVED FROM A
 ; FILE REFERENCE: PULMONARY ARTERY SMOOTH MUSCLE LIBRARY
 ; CURRENT APPLICATION NUMBER: US/09/396.087
 ; CURRENT FILING DATE: 1999-09-14
 ; EARLIER APPLICATION NUMBER: 60/100,260
 ; EARLIER FILING DATE: 1998-09-14
 ; EARLIER APPLICATION NUMBER: 60/107,226
 ; EARLIER FILING DATE: 1998-11-05
 ; EARLIER APPLICATION NUMBER: 60/131,810
 ; EARLIER FILING DATE: 1999-04-30
 ; NUMBER OF SEQ ID NOS: 5220
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 2011
 ; LENGTH: 346
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: (1)...(346)
 ; OTHER INFORMATION: n = A,T,C or G
 US-09-396-087-2011

Query Match 100.0%; Score 19; DB 17; Length 346;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GGGCGCGGCGGAGCATCGC 19
 Db 139 GGGCGCGGCGGAGCATCGC 121

Search completed: April 20, 2001, 03:21:23
 Job time: 14170 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:15:36 ; Search time 101.94 Seconds
(without alignments)
25.791 Million cell updates/sec

Title: US-09-016-464-17
Perfect score: 19
Sequence: 1 GGCGCGGGCGAGCATGCG 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 46985 seqs, 69187998 residues

Total number of hits satisfying chosen parameters: 93970

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending_Patents_NA_New.*
1: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq.*
2: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq.*
3: /cgn2_6/ptodata/1/pna/US07_NEW_COMB.seq.*
4: /cgn2_6/ptodata/1/pna/US08_NEW_COMB.seq.*
5: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq.*
6: /cgn2_6/ptodata/1/pna/US60_NEW_COMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19	100.0	3387	5	US-09-543-679A-2682
C 2	19	100.0	13240	5	US-09-543-679A-2684
C 3	17	89.5	9453	5	US-09-543-679A-2683
C 4	15.8	83.2	19	5	US-09-543-679A-1052
C 5	15.8	83.2	60	5	US-09-543-679A-1054
C 6	15.8	83.2	101	5	US-09-543-679A-1054
C 7	15.8	83.2	1729	5	US-09-543-679A-1729
C 8	15.8	83.2	6225	5	US-09-543-679A-2410
C 9	14.8	77.9	267	5	US-09-543-679A-3003
C 10	14.8	77.9	267	5	US-09-739-449-6823
C 11	14.8	77.9	555	5	US-09-739-449-5546
C 12	14.8	77.9	3286	6	US-60-248-505-1976
C 13	14.8	77.9	26297	6	US-60-248-505-1617
C 14	14.8	77.9	68618	6	US-60-248-505-644
C 15	14.8	77.9	68619	6	US-60-248-505-35
C 16	14.8	77.9	124647	6	US-60-248-505-500
C 17	14.8	77.9	318095	5	US-60-248-505-285
C 18	14.8	77.9	506113	5	US-09-739-449-215
C 19	14.4	75.8	588	1	US-09-739-449-218
C 20	14.4	75.8	588	1	PCT-US01-09217-18
C 21	14.4	75.8	1479	5	US-09-816-523-18
C 22	14.4	75.8	17138	5	US-09-739-449-7339
C 23	14.4	75.8	20310	5	US-09-813-819-3
C 24	14.2	74.7	460	5	US-09-739-449-191
C 25	14.2	74.7	465	5	US-09-813-206-701
C 26	14.2	74.7	612	5	US-09-809-391-77
C 27	14.2	74.7	615	5	US-09-739-449-6998
C 28	14.2	74.7	615	5	US-09-739-449-6910

28	14.2	74.7	729	5	US-09-739-449-2486	Sequence 2486, Ap
29	14.2	74.7	774	5	US-09-739-449-6848	Sequence 6848, Ap
30	14.2	74.7	1033	5	US-09-813-206-700	Sequence 700, App
31	14.2	74.7	1068	5	US-09-813-206-18	Sequence 18, Appl
C 32	14.2	74.7	1074	5	US-09-739-449-5334	Sequence 5334, Ap
C 33	14.2	74.7	1158	5	US-09-739-449-4688	Sequence 4688, Ap
34	14.2	74.7	1159	5	US-09-813-206-20	Sequence 20, Appl
35	14.2	74.7	2223	1	PCT-US01-09226-28	Sequence 28, Appl
36	14.2	74.7	2265	5	US-09-739-449-4875	Sequence 4875, Ap
37	14.2	74.7	2343	5	US-09-739-449-7491	Sequence 7491, Ap
C 38	14.2	74.7	2467	5	US-09-739-449-5894	Sequence 5894, Ap
C 39	14.2	74.7	2664	5	US-09-739-449-4873	Sequence 4873, Ap
C 40	14.2	74.7	3008	1	PCT-US01-01350-298	Sequence 298, App
41	14.2	74.7	3296	5	US-09-423-844-309	Sequence 309, App
42	14.2	74.7	3753	1	PCT-US01-09226-29	Sequence 29, Appl
43	14.2	74.7	4629	5	US-09-739-449-7069	Sequence 7069, Ap
44	14.2	74.7	29171	6	US-60-248-505-258	Sequence 258, App
45	14.2	74.7	29172	6	US-60-248-505-462	Sequence 462, App

ALIGNMENTS

RESULT 1
US-09-543-679A-2682/c
; Sequence 2682, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2682:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3387 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2682
US-09-543-679A-2682

Query Match 100.0%; Score 19; DB 5; Length 3387;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
|||||
Db 113 GGGCGGGCGGAGCATCGC 95

RESULT 2

US-09-543-679A-2684/c
; Sequence 2684, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512

COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A

CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543.679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03

ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 2684:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15240 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2684
US-09-543-679A-2684

Query Match 100.0%; Score 19; DB 5; Length 15240;
Best Local Similarity 100.0%; Pred. No. 0.25;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATCGC 19
|||||
Db 2513 GGGCGGGCGGAGCATCGC 2495

RESULT 3

US-09-543-679A-2683/c
; Sequence 2683, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A

CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543.679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03

ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 2683:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9453 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2683
US-09-543-679A-2683

Query Match 89.5%; Score 17; DB 5; Length 9453;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGGCGGGCGGAGCATC 17
|||||
Db 981 GGGCGGGCGGAGCATC 965

RESULT 4

US-09-543-679A-1052
; Sequence 1052, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512

COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A

CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543.679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958

[illegible]

```
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
;
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
;
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Anzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 2410:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6225 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2410:
US-09-543-679A-2410

Query Match      83.2%; Score 15.8; DB 5; Length 6225;
Best Local Similarity 89.5%; Pred. No. 8.8;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGGCGCGGGCGGAGCATCGC 19
   ||||| ||||| || |||||
Db 313 GGGCGCGGGCGGCBGCBTCGC 331

RESULT 8
US-09-543-679A-3003
; Sequence 3003, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
;
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
;
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
```

```
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Anzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 3003:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35459 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 3003:
US-09-543-679A-3003

Query Match      83.2%; Score 15.8; DB 5; Length 35459;
Best Local Similarity 89.5%; Pred. No. 6.8;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GGGCGCGGGCGGAGCATCGC 19
   ||||| ||||| || |||||
Db 313 GGGCGCGGGCGGCBGCBTCGC 331

RESULT 9
US-09-739-449-6823/c
; Sequence 6823, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 6823
; LENGTH: 267
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
US-09-739-449-6823

Query Match      77.9%; Score 14.8; DB 5; Length 267;
Best Local Similarity 88.9%; Pred. No. 40;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 GGGCGGGCGGAGCATCGC 19
   ||||| ||||| || |||||
Db 264 GGGCGGGCGGCGGATCGC 247

RESULT 10
US-09-739-449-5546/c
; Sequence 5546, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
```


[illegible]

```

; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 500
; LENGTH: 68619
; TYPE: DNA
; ORGANISM: human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(68619)
; OTHER INFORMATION: n = A,T,C or G
US-60-248-505-500

```

```

Query Match          77.9%; Score 14.8; DB 6; Length 68619;
Best Local Similarity 88.9%; Pred. No. 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 GGGCGCGGGCGGAGCATCG 18
        || ||||| |||||
Db 53761 ggccgcgggcgcgcatcg 53778

```

Search completed: April 20, 2001, 00:15:40
Job time: 9477 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:00:25 ; Search time 2028.86 seconds
(without alignments)
63.738 Million cell updates/sec

Title: US-09-016-464-18

Perfect score: 21

Sequence: 1 CCTCCTTCCTGGTCTGTCTGC 21

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 1283235 seqs, 3078962356 residues

Total number of hits satisfying chosen parameters: 2566470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:*

- 1: gb_ba1:*
- 2: gb_ba2:*
- 3: gb_ba3:*
- 4: gb_in1:*
- 5: gb_in2:*
- 6: gb_in3:*
- 7: gb_om:*
- 8: gb_ov:*
- 9: gb_pat1:*
- 10: gb_pat2:*
- 11: gb_ph:*
- 12: gb_pl1:*
- 13: gb_pl2:*
- 14: gb_pl3:*
- 15: gb_pl4:*
- 16: em_ba1:*
- 17: em_ba2:*
- 18: em_fun:*
- 19: em_htgo_hum:*
- 20: em_htgo_inv:*
- 21: em_htgo_rod:*
- 22: em_htg_hum1:*
- 23: em_htg_hum2:*
- 24: em_htg_hum3:*
- 25: em_htg_hum4:*
- 26: em_htg_hum5:*
- 27: em_htg_hum6:*
- 28: em_htg_hum7:*
- 29: em_htg_hum8:*
- 30: em_htg_inv1:*
- 31: em_htg_inv2:*
- 32: em_htg_other:*
- 33: em_htg_rod:*
- 34: em_hum1:*
- 35: em_hum2:*
- 36: em_hum3:*
- 37: em_hum4:*
- 38: em_hum5:*
- 39: em_hum6:*
- 40: em_hum7:*
- 41: em_in:*
- 42: em_om:*
- 43: em_or:*

- 44: em_ov:*
- 45: em_pat:*
- 46: em_ph:*
- 47: em_pl:*
- 48: em_ro:*
- 49: em_sts:*
- 50: em_sy:*
- 51: em_un:*
- 52: em_vi:*
- 53: gb_sts1:*
- 54: gb_sts2:*
- 55: gb_sts3:*
- 56: gb_sy:*
- 57: gb_un:*
- 58: gb_vil:*
- 59: gb_vil2:*
- 60: gb_vil3:*
- 61: gb_vil4:*
- 62: gb_vil5:*
- 63: gb_vil6:*
- 64: gb_vil7:*
- 65: gb_vil8:*
- 66: gb_vil9:*
- 67: gb_vil10:*
- 68: gb_vil11:*
- 69: gb_vil12:*
- 70: gb_vil13:*
- 71: gb_vil14:*
- 72: gb_vil15:*
- 73: gb_vil16:*
- 74: gb_vil17:*
- 75: gb_vil18:*
- 76: gb_vil19:*
- 77: gb_vil20:*
- 78: gb_vil21:*
- 79: gb_vil22:*
- 80: gb_vil23:*
- 81: gb_vil24:*
- 82: gb_vil25:*
- 83: gb_vil26:*
- 84: gb_vil27:*
- 85: gb_vil28:*
- 86: gb_vil29:*
- 87: gb_vil30:*
- 88: gb_vil31:*
- 89: gb_vil32:*
- 90: gb_vil33:*
- 91: gb_vil34:*
- 92: gb_vil35:*
- 93: gb_vil36:*
- 94: gb_vil37:*
- 95: gb_vil38:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	21	100.0	483	91	GGU24097
C 2	21	100.0	483	93	PTU24103
C 3	21	100.0	715	92	HSECP
C 4	21	100.0	718	93	HUMCPA
C 5	21	100.0	1199	88	AF294027
C 6	21	100.0	1199	88	AF294028
C 7	21	100.0	1203	88	AF294019
C 8	21	100.0	1203	88	AF294020
C 9	21	100.0	1203	88	AF294021
C 10	21	100.0	1203	88	AF294022
C 11	21	100.0	1203	88	AF294023

```
c 12 21 100.0 1203 88 AF294024
c 13 21 100.0 1203 88 AF294025
c 14 21 100.0 1203 88 AF294026
c 15 21 100.0 1452 92 HSECP1
c 16 21 100.0 1669 92 HSECPG
c 17 21 100.0 157981 83 CNS05T04
c 18 21 100.0 162472 83 CNS01DUW
c 19 19.4 92.4 483 93 MFU24098
c 20 19.4 92.4 152689 77 AC087102
c 21 18.4 87.6 618 54 G56653
c 22 18.4 87.6 98070 88 AC025463
c 23 18.4 87.6 151104 61 AC010250
c 24 18.4 87.6 151408 61 AC010397
c 25 18.4 87.6 153170 91 HS1103G7
c 26 18.4 87.6 159920 86 AC008447
c 27 18.4 87.6 174788 83 CNS01DUW
c 28 18.4 87.6 200078 63 AC012181
c 29 18.4 87.6 204405 66 AC021183
c 30 18 85.7 138941 89 AL136528
c 31 18 85.7 140084 81 AL1390963
c 32 18 85.7 150829 61 AC009092
c 33 18 85.7 164919 69 AC024903
c 34 18 85.7 168951 65 AC016927
c 35 18 85.7 169391 66 AC021021
c 36 18 85.7 181104 61 AC009162
c 37 18 85.7 202872 62 AC016160
c 38 18 85.7 207882 62 AC010674
c 39 17.8 84.8 482 53 AF192011
c 40 17.8 84.8 483 53 PP024101
c 41 17.8 84.8 1032 53 AC006LFE
c 42 17.8 84.8 3583 93 HUMUBILP
c 43 17.8 84.8 3653 98 AF009356
c 44 17.8 84.8 14180 94 MM067065
c 45 17.8 84.8 36687 90 AL391690
```

ALIGNMENTS

```
RESULT 1
GGU24097/c 483 bp DNA 17-JUN-1995
LOCUS Gorilla gorilla eosinophil cationic protein gene, complete cds.
DEFINITION U24097
ACCESSION U24097
VERSION U24097.1 GI:790263
KEYWORDS ribonuclease.
SOURCE gorilla.
ORGANISM Gorilla gorilla
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.
REFERENCE 1 (bases 1 to 483)
AUTHORS Rosenberg,H.F., Dyer,K.D., Tiffany,H.L. and Gonzalez,M.
TITLE Rapid evolution of a unique family of primate ribonuclease genes
JOURNAL Nature Genet. 10 (2), 219-223 (1995)
MEDLINE 95392576
REFERENCE 2 (bases 1 to 483)
AUTHORS Rosenberg,H.F.
TITLE Direct Submission
JOURNAL Submitted (04-APR-1995) Helene F. Rosenberg, Laboratory of Host
Defenses, NIAID, National Institutes of Health, Building 10, Room
11N104, 9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
Location/Qualifiers
1..483
/db_xref="taxon:9593"
1..81
1..483
/notes="ribonuclease"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAC50143.1"
/db_xref="GI:790264"
/translation="MVPKLFTSQICLLLLGLMGVEGSLHARPPQFTFAQWFAIQHIS
```

```
LNPPRCTIAMRVINNYRWCKNQNTFLRTTFANVNVCGNOSIRCLNHRNLNCHRSR
FRVPLLHCDDLINFGAQNISCRYADRGRRFYVVACDNRDPQDSRPYPVPVHLDTTI
"
mat_peptide 82..480
/notes="ribonuclease"
/product="eosinophil cationic protein"
BASE COUNT 126 a 120 c 101 g 136 t
ORIGIN

Query Match 100.0%; Score 21; DB 91; Length 483;
Best Local Similarity 100.0%; Pred. No. 4.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGCTGTCG 21
Db 396 CCTCCTTCCTGGTCTGCTGTCG 376

RESULT 2
PTU24103/c 483 bp DNA 17-JUN-1995
LOCUS Pan troglodytes eosinophil cationic protein gene, complete cds.
DEFINITION PTU24103
ACCESSION U24103
VERSION U24103.1 GI:790277
KEYWORDS ribonuclease.
SOURCE chimpanzee.
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE 1 (bases 1 to 483)
AUTHORS Rosenberg,H.F., Dyer,K.D., Tiffany,H.L. and Gonzalez,M.
TITLE Rapid evolution of a unique family of primate ribonuclease genes
JOURNAL Nature Genet. 10 (2), 219-223 (1995)
MEDLINE 95392576
REFERENCE 2 (bases 1 to 483)
AUTHORS Rosenberg,H.F.
TITLE Direct Submission
JOURNAL Submitted (04-APR-1995) Helene F. Rosenberg, Laboratory of Host
Defenses, NIAID, National Institutes of Health, Building 10 Room
11N104, 9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
Location/Qualifiers
1..483
/db_xref="taxon:9598"
1..81
1..483
/notes="ribonuclease"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAC50150.1"
/db_xref="GI:790278"
/translation="MVPKLFTSQICLLLLGLMGVEGSLHARPPQFTFAQWFAIQHIS
LNPPRCTIAMRVINNYRWCKNQNTFLRTTFANVNVCGNOSIRCPHNRRLNCHQSR
FRVPLLHCDDLINFGAQNISCRYADRGRRFYVVACDNRDPQDSRPYPVPVHLDTTI
"
mat_peptide 82..480
/notes="ribonuclease"
/product="eosinophil cationic protein"
BASE COUNT 126 a 122 c 102 g 133 t
ORIGIN

Query Match 100.0%; Score 21; DB 93; Length 483;
Best Local Similarity 100.0%; Pred. No. 4.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGCTGTCG 21
Db 396 CCTCCTTCCTGGTCTGCTGTCG 376

RESULT 3
```

HSECP/c
LOCUS Human mRNA for eosinophil cationic protein ECP. 715 bp mRNA PRI 22-MAR-1995
DEFINITION X15161
ACCESSION X15161
VERSION 1
KEYWORDS cytotoxin; eosinophil cationic protein; glycoprotein; neurotoxin; matrix protein; neurotoxin; perforin; ribonuclease.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 715)
AUTHORS Rosenber, H.F.
TITLE Direct Submission
JOURNAL Submitted (29-APR-1989) Rosenberg H.F., Beth Israel Hospital, 330 Brookline Avenue, Boston MA 02215, USA
REFERENCE 2 (bases 1 to 715)
AUTHORS Rosenber, H.F., Ackerman, S.J. and Tenen, D.G.
TITLE Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity
JOURNAL J. Exp. Med. 170 (1), 163-176 (1989)
MEDLINE 89310354
FEATURES Location/Qualifiers
source 1..715
/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="peripheral blood granulocytes"
/cell_type="eosinophil"
/cell_line="HL-60"
/clone_lib="lambda gt11"
<1..715
/note="ECP mRNA"
55..135
/product="signal peptide ((AA -27 to -1))"
55..537
/note="ECP preprotein"
/codon_start=1
/protein_id="CAA33251.1"
/db_xref="GI:31077"
/db_xref="SWISS-PROT:P12724"
/translation="MVPKLTFSQICLLLLGLMGVSGSLHARPPQFTRAQWFAIOHIS LNPFRCTIAMRAINRYRWCKNQNTFLRTTFANVYVCGNOSIRCPHNTLNCHRS FRVPLLLHCDLINPGAQNTISNCRYADPRGRFYVACDNRDPRDSPRYPVVPVHLDTTI"
mat_peptide 136..534
/product="mature ECP (AA 1-133)"
polyA_site 715
/note="polyA site"
BASE COUNT 185 a 199 c 141 g 190 t
ORIGIN
Query Match 100.0%; Score 21; DB 92; Length 715;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CCTCCTTCCTGGTCTGCTGC 21
|||||
Db 450 CCTCCTTCCTGGTCTGCTGC 430
RESULT 4
HUMCEPA 718 bp mRNA PRI 06-OCT-1994
LOCUS Homo sapiens eosinophil cationic protein (ECP) mRNA, complete cds.
DEFINITION M28128
ACCESSION M28128
VERSION 1
KEYWORDS ECP gene; eosinophil cationic protein; neurotoxin.
SOURCE Homo sapiens cdna to mRNA.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 718)

Barker, R.L., Loegering, D.A., Ten, R.M., Hamann, K.J., Pease, L.R. and Gleich, G.J.
Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases
J. Immunol. 143 (3), 952-955 (1989)
MEDLINE 89309773
COMMENT On Oct 8, 1994 this sequence version replaced gi:341832.
FEATURES Location/Qualifiers
source 1..718
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_line="mononuclear cord blood cells stimulated with EL4 supernatants"
/cell_type="eosinophil"
/note="vector lambda ZAP"
1..52
53..535
/note="bp 302..310, 326..334, 407..414 glycosylation site; preprotein"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAA50283.1"
/db_xref="GI:556200"
/translation="MVPKLTFSQICLLLLGLMGVSGSLHARPPQFTRAQWFAIOHIS LNPFRCTIAMRAINRYRWCKNQNTFLRTTFANVYVCGNOSIRCPHNTLNCHRS FRVPLLLHCDLINPGAQNTISNCRYADPRGRFYVACDNRDPRDSPRYPVVPVHLDTTI"
sig_peptide 53..133
mat_peptide 134..532
/product="eosinophil cationic protein"
3'UTR 536..713
polyA_signal 187 a 197 c 144 g 190 t
BASE COUNT
ORIGIN
Query Match 100.0%; Score 21; DB 93; Length 718;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CCTCCTTCCTGGTCTGCTGC 21
|||||
Db 448 CCTCCTTCCTGGTCTGCTGC 428
RESULT 5
AF294027/c 1199 bp DNA PRI 19-DEC-2000
LOCUS Pan troglodytes haplotype 1 eosinophil cationic protein (ECP) gene, complete cds.
DEFINITION AF294027
ACCESSION AF294027.1 GI:9954419
VERSION
KEYWORDS chimpanzee.
SOURCE Pan troglodytes
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE 1 (bases 1 to 1199)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE 2 (bases 1 to 1199)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104, 9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES Location/Qualifiers
source 1..1199
/organism="Pan troglodytes"
/db_xref="taxon:9598"
/haplotype="1"

```

mRNA      join(<209..276,503..1169)
/gene="ECP"
/product="eosinophil cationic protein"
<209..1169
/gene="ECP"
508..990
/gene="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG09050.1"
/db_xref="GI:9954420"
/translation="MVPKLFSTQICLLLLGLMGVEGSLHARPPQFTRAQWFAIQHIS
LNPPRCTIAMRVINNYRWCKNONTFLRTTFANVNVCGNQSIRCPNRTLNCHQSR
FRVPLHCDLNPQAQINISCRYADRGRRFYVACDNRDPRSPRYVPVPHLDATI"
BASE COUNT 308 a 305 c 292 g 294 t
ORIGIN

Query Match      100.0%; Score 21; DB 88; Length 1199;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTCCTTCCTGCTGCTGCTGC 21
|||||
Db 903 CCTCCTTCCTGCTGCTGCTGC 883

RESULT 6
AF294028/c
LOCUS      AF294028      1199 bp      DNA      PRI      19-DEC-2000
DEFINITION Pan troglodytes haplotype 2 eosinophil cationic protein (ECP) gene,
complete cds.
ACCESSION  AF294028
VERSION     AF294028.1 GI:9954421
KEYWORDS   chimpanzee.
SOURCE     Pan troglodytes
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
REFERENCE  1 (bases 1 to 1199)
AUTHORS   Zhang,J. and Rosenberg,H.F.
TITLE     Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL   Genetics 156 (4), 1949-1958 (2000)
PUBMED   11102386
REFERENCE  2 (bases 1 to 1199)
AUTHORS   Zhang,J. and Rosenberg,H.F.
TITLE     Direct Submission
JOURNAL   Submitted (08-AUG-2000) LHD/NIH/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES   Location/Qualifiers
            source
            1..1199
            /organism="Pan troglodytes"
            /db_xref="taxon:9598"
            /haplotype="2"
mRNA      join(<209..276,503..1169)
/gene="ECP"
/product="eosinophil cationic protein"
<209..1169
/gene="ECP"
508..990
/gene="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG09051.1"
/db_xref="GI:9954422"
/translation="MVPKLFSTQICLLLLGLMGVEGSLHARPPQFTRAQWFAIQHIS
LNPPRCTIAMRVINNYRWCKNONTFLRTTFANVNVCGNQSIRCPNRTLNCHQSR
FRVPLHCDLNPQAQINISCRYADRGRRFYVACDNRDPRSPRYVPVPHLDATI"
BASE COUNT 308 a 306 c 292 g 293 t
ORIGIN
```

```

Query Match      100.0%; Score 21; DB 88; Length 1199;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTCCTTCCTGCTGCTGCTGC 21
|||||
Db 903 CCTCCTTCCTGCTGCTGCTGC 883

RESULT 7
AF294019/c
LOCUS      AF294019      1203 bp      DNA      PRI      19-DEC-2000
DEFINITION Homo sapiens haplotype 1 eosinophil cationic protein gene, complete
cds.
ACCESSION  AF294019
VERSION     AF294019.1 GI:11139039
KEYWORDS   human.
SOURCE     Homo sapiens
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1203)
AUTHORS   Zhang,J. and Rosenberg,H.F.
TITLE     Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL   Genetics 156 (4), 1949-1958 (2000)
PUBMED   11102386
REFERENCE  2 (bases 1 to 1203)
AUTHORS   Zhang,J. and Rosenberg,H.F.
TITLE     Direct Submission
JOURNAL   Submitted (08-AUG-2000) LHD/NIH/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES   Location/Qualifiers
            source
            1..1203
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /haplotype="1"
mRNA      join(209..276,507..1173)
            /product="eosinophil cationic protein"
            209..276
            /number=1
            join(209..276,507..511)
            277..506
            /number=1
            507..1173
            /number=2
            512..994
            /note="ECP"
            /codon_start=1
            /product="eosinophil cationic protein"
            /protein_id="AAG31589.1"
            /db_xref="GI:11139040"
            /translation="MVPKLFSTQICLLLLGLMGVEGSLHARPPQFTRAQWFAIQHIS
LNPPRCTIAMRVINNYRWCKNONTFLRTTFANVNVCGNQSIRCPNRTLNCHQSR
FRVPLHCDLNPQAQINISCTYADRGRRFYVACDNRDPRSPRYVPVPHLDTTI"
            "
3'UTR      995..1173
BASE COUNT 317 a 306 c 285 g 295 t
ORIGIN

Query Match      100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTCCTTCCTGCTGCTGCTGC 21
|||||
Db 907 CCTCCTTCCTGCTGCTGCTGC 887

RESULT 8
```

AF294020/c
LOCUS Homo sapiens haplotype 2 eosinophil cationic protein gene, complete 1203 bp DNA PRI 19-DEC-2000
DEFINITION cds.
ACCESSION AF294020
VERSION AF294020.1 GI:11139041
KEYWORDS human.
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE 2 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
Location/Qualifiers
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="2"
mRNA join(209..276,507..1173)
exon /product="eosinophil cationic protein"
209..276
/number=1
5'UTR join(209..276,507..511)
intron 277..506
/number=1
exon 507..1173
CDS /number=2
512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG31590.1"
/db_xref="GI:11139042"
/translation="MVPKLTFSQICLLLLGLMGVSGSLHARPPQFTRAQWFAIQHIS
LNPPRTIAMRAINNYRWCKNQNTFLRTTFANVYVNCNQSIRCPHNRLNCHRSR
FRVPLHCDLNPQAQINISCTYADPGRFRVYVACDNRDRSPRYVPVPHLDTTI
"
3'UTR 995..1173
BASE COUNT 318 a 303 c 287 g 295 t
ORIGIN
Query Match 100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CCTCCTTCCTGGTCTGCTGC 21
|||||
Db 907 CCTCCTTCCTGGTCTGCTGC 887
RESULT 9
AF294021/c
LOCUS Homo sapiens haplotype 3 eosinophil cationic protein gene, complete 1203 bp DNA PRI 19-DEC-2000
DEFINITION cds.
ACCESSION AF294021
VERSION AF294021.1 GI:11139043
KEYWORDS human.
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1203)

AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE 2 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
Location/Qualifiers
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="3"
mRNA join(209..276,507..1173)
exon /product="eosinophil cationic protein"
209..276
/number=1
5'UTR join(209..276,507..511)
intron 277..506
/number=1
exon 507..1173
CDS /number=2
512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG31591.1"
/db_xref="GI:11139044"
/translation="MVPKLTFSQICLLLLGLMGVSGSLHARPPQFTRAQWFAIQHIS
LNPPRTIAMRAINNYRWCKNQNTFLRTTFANVYVNCNQSIRCPHNRLNCHRSR
FRVPLHCDLNPQAQINISCTYADPGRFRVYVACDNRDRSPRYVPVPHLDTTI
"
3'UTR 995..1173
BASE COUNT 317 a 305 c 286 g 295 t
ORIGIN
Query Match 100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CCTCCTTCCTGGTCTGCTGC 21
|||||
Db 907 CCTCCTTCCTGGTCTGCTGC 887
RESULT 10
AF294022/c
LOCUS Homo sapiens haplotype 4 eosinophil cationic protein gene, complete 1203 bp DNA PRI 19-DEC-2000
DEFINITION cds.
ACCESSION AF294022
VERSION AF294022.1 GI:11139045
KEYWORDS human.
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE 2 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
Location/Qualifiers
1..1203

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="4"
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
join(209..276,507..511)
277..506
/number=1
507..1173
/number=2
512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/db_xref="AAG31593.1"
/db_xref="GI:11139046"
/translation="MVPKLTFSQICLLLLGLMGVEGSLHARPPQFTRAOWFAIQHIS
LNPPRCTIAMRAINNYWRCKNQNTFLRTTFANVVNCGNOSIRCPHNRITLNNCHRSR
FRVPLHCDLLNPGAQNISCRYADRGRRFYVVACDNRDRDPSRIPYVPVHLDTTI
"
3'UTR 995..1173
BASE COUNT 317 a 304 c 287 g 295 t
ORIGIN

Query Match 100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCTTCTCTGCTGCTGTCG 21
|||||
Db 907 CCTCTTCTCTGCTGCTGTCG 887

RESULT 11
AF294023/c
LOCUS AF294023 1203 bp DNA PRI 19-DEC-2000
DEFINITION Homo sapiens haplotype 5 eosinophil cationic protein gene, complete
cds.
ACCESSION AF294023
VERSION AF294023.1 GI:11139047
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1203)
Zhang, J. and Rosenberg, H.F.
Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
AUTHORS Zhang, J. and Rosenberg, H.F.
DIRECT SUBMISSION
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
Location/Qualifiers
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="5"
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
join(209..276,507..511)
277..506
/number=1
507..1173
/number=2
512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/db_xref="AAG31594.1"
/db_xref="GI:11139050"
/translation="MVPKLTFSQICLLLLGLMGVEGSLHARPPQFTRAOWFAIQHIS
LNPPRCTIAMRAINNYWRCKNQNTFLRTTFANVVNCGNOSIRCPHNRITLNNCHRSR
FRVPLHCDLLNPGAQNISCRYADRGRRFYVVACDNRDRDPSRIPYVPVHLDTTI
"
3'UTR 995..1173
BASE COUNT 317 a 303 c 287 g 296 t
ORIGIN

```

```

512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/db_xref="AAG31593.1"
/db_xref="GI:11139048"
/translation="MVPKLTFSQICLLLLGLMGVEGSLHARPPQFTRAOWFAIQHIS
LNPPRCTIAMRAINNYWRCKNQNTFLRTTFANVVNCGNOSIRCPHNRITLNNCHRSR
FRVPLHCDLLNPGAQNISCRYADRGRRFYVVACDNRDRDPSRIPYVPVHLDTTI
"
3'UTR 995..1173
BASE COUNT 316 a 304 c 287 g 296 t
ORIGIN

Query Match 100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCTTCTCTGCTGCTGTCG 21
|||||
Db 907 CCTCTTCTCTGCTGCTGTCG 887

RESULT 12
AF294024/c
LOCUS AF294024 1203 bp DNA PRI 19-DEC-2000
DEFINITION Homo sapiens haplotype 6 eosinophil cationic protein gene, complete
cds.
ACCESSION AF294024
VERSION AF294024.1 GI:11139049
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1203)
Zhang, J. and Rosenberg, H.F.
Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
AUTHORS Zhang, J. and Rosenberg, H.F.
DIRECT SUBMISSION
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
Location/Qualifiers
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="6"
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
join(209..276,507..511)
277..506
/number=1
507..1173
/number=2
512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/db_xref="AAG31594.1"
/db_xref="GI:11139050"
/translation="MVPKLTFSQICLLLLGLMGVEGSLHARPPQFTRAOWFAIQHIS
LNPPRCTIAMRAINNYWRCKNQNTFLRTTFANVVNCGNOSIRCPHNRITLNNCHRSR
FRVPLHCDLLNPGAQNISCRYADRGRRFYVVACDNRDRDPSRIPYVPVHLDTTI
"
3'UTR 995..1173
BASE COUNT 317 a 303 c 287 g 296 t
ORIGIN

```


ORIGIN

Query Match 100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGCTGC 21
|||||
Db 907 CCTCCTTCCTGGTCTGCTGC 887

RESULT 13

AF294025/c
LOCUS
DEFINITION Homo sapiens haplotype 7 eosinophil cationic protein gene, complete cds.
ACCESSION AF294025
VERSION AF294025.1 GI:11139051
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE 2 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104, 9000 Rockville Pike, Bethesda, MD 20892, USA

FEATURES

source
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="7"
mRNA
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
exon
join(209..276,507..511)
5'UTR
intron
277..506
/number=1
exon
507..1173
/number=2
CDS
512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG31595.1"
/db_xref="GI:11139052"
/translation="MVPKLFSTQICLLLLGLMGVSGSLHARPPQFTRAQWFAIQHIS
LNPRCTIAMRAINNYRWCKNONTFLRTTFANVYVNCNQSIGRCPHNRTLNNCHRSR
FRVPLHCDLINPGAQINISCTYADRGRRFYVACDNRDPRDSPRYVPVPHLDTTI
"

BASE COUNT

3'UTR 995..1173
BASE COUNT 317 a 304 c 286 g 296 t
ORIGIN

Query Match 100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGCTGC 21
|||||
Db 907 CCTCCTTCCTGGTCTGCTGC 887

RESULT 14

AF294026/c
LOCUS
DEFINITION Homo sapiens haplotype 8 eosinophil cationic protein gene, complete cds.
ACCESSION AF294026
VERSION AF294026.1 GI:11139053
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE 2 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104, 9000 Rockville Pike, Bethesda, MD 20892, USA

FEATURES

source
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="8"
mRNA
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
exon
join(209..276,507..511)
5'UTR
intron
277..506
/number=1
exon
507..1173
/number=2
CDS
512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG31596.1"
/db_xref="GI:11139054"
/translation="MVPKLFSTQICLLLLGLMGVSGSLHARPPQFTRAQWFAIQHIS
LNPRCTIAMRAINNYRWCKNONTFLRTTFANVYVNCNQSIGRCPHNRTLNNCHRSR
FRVPLHCDLINPGAQINISCRYADRGRRFYVACDNRDPRDSPRYVPVPHLDTTI
"

3'UTR 995..1173
BASE COUNT 316 a 305 c 287 g 295 t
ORIGIN

Query Match 100.0%; Score 21; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGCTGC 21
|||||
Db 907 CCTCCTTCCTGGTCTGCTGC 887

RESULT 15

HSECPI/c
LOCUS
DEFINITION Human DNA for eosinophil cationic protein ECP.
ACCESSION X16545
VERSION X16545.1 GI:31080
KEYWORDS cytotoxin; eosinophil cationic protein; helminthotoxin; neurotoxin.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1452)

AUTHORS Barker,R.L.
TITLE Direct Submission
JOURNAL Submitted (18-SEP-1989) Barker R.L., Mayo Clinic and Foundation,
401 Guggenheim, Rochester Minnesota 55905, U S A
REFERENCE 2 (bases 1 to 1452)
AUTHORS Hamann,K.J., Ten,R.M., Loegering,D.A., Jenkins,R.B., Heise,M.T.,
Schad,C.R., Pease,L.R., Gleich,G.J. and Barker,R.L.
TITLE Structure and chromosome localization of the human
eosinophil-derived neurotoxin and eosinophil cationic protein
genes: evidence for intronless coding sequences in the ribonuclease
gene superfamily
JOURNAL Genomics 7 (4), 535-546 (1990)
MEDLINE 90353951
COMMENT see X15161 for human ECP cDNA seq.
FEATURES
 source
 1..1452
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="eosinophil"
 /cell_line="human fetal liver charon 4A."
 /clone_lib="ATCC 37333"
 225..231
 279..320
 /number=1
 join(279..320,551..1217)
 321..550
 /number=1
 551..1217
 /number=2
 556..636
 /product="signal peptide (AA -27 to -1)"
 556..1038
 /note="eosinophil cationic protein precursor"
 /codon_start=1
 /protein_id="CAA34545.1"
 /db_xref="GI:31081"
 /db_xref="SWISS-PROT:P12724"
 /translation="MVPKLETSOICLLLLGLMGVGLHARPPQFTRAQWFAIQHIS
 LNPPRCTAMRAINNYWRCKNONTLETTTFANVYVCGNOSIRCPHNRITLNNCHRSR
 FRVPLLLHCDLINPGAQNISNCRYADRPGRFYVACDNRDPRDSFRYPVPVPHLDTTI
 "
 637..1035
 /product="mat. eosinophil cationic protein (AA 1 - 133)"
 1196..1201
mat_peptide 637..1035
polyA_signal 1196..1201
BASE COUNT 380 a 376 c 323 g 373 t
ORIGIN

Query Match 100.0%; Score 21; DB 92; Length 1452;
Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCTGCTGCTGTCG 21 -
 |||||
Db 951 CCTCCTTCTGCTGCTGTCG 931

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:12:58 ; Search time 547.68 Seconds
(without alignments)
22.384 Million cell updates/sec

Title: US-09-016-464-18
Perfect score: 21
Sequence: 1 CCTCCCTCGTGTGTGTGC 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 678276 seqs, 291890651 residues

Total number of hits satisfying chosen parameters: 1356552

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_0401.*
1: /SIDS2/gcgdata/geneseq/geneseq/NA1980.DAT.*
2: /SIDS2/gcgdata/geneseq/geneseq/NA1981.DAT.*
3: /SIDS2/gcgdata/geneseq/geneseq/NA1982.DAT.*
4: /SIDS2/gcgdata/geneseq/geneseq/NA1983.DAT.*
5: /SIDS2/gcgdata/geneseq/geneseq/NA1984.DAT.*
6: /SIDS2/gcgdata/geneseq/geneseq/NA1985.DAT.*
7: /SIDS2/gcgdata/geneseq/geneseq/NA1986.DAT.*
8: /SIDS2/gcgdata/geneseq/geneseq/NA1987.DAT.*
9: /SIDS2/gcgdata/geneseq/geneseq/NA1988.DAT.*
10: /SIDS2/gcgdata/geneseq/geneseq/NA1989.DAT.*
11: /SIDS2/gcgdata/geneseq/geneseq/NA1990.DAT.*
12: /SIDS2/gcgdata/geneseq/geneseq/NA1991.DAT.*
13: /SIDS2/gcgdata/geneseq/geneseq/NA1992.DAT.*
14: /SIDS2/gcgdata/geneseq/geneseq/NA1993.DAT.*
15: /SIDS2/gcgdata/geneseq/geneseq/NA1994.DAT.*
16: /SIDS2/gcgdata/geneseq/geneseq/NA1995.DAT.*
17: /SIDS2/gcgdata/geneseq/geneseq/NA1996.DAT.*
18: /SIDS2/gcgdata/geneseq/geneseq/NA1997.DAT.*
19: /SIDS2/gcgdata/geneseq/geneseq/NA1998.DAT.*
20: /SIDS2/gcgdata/geneseq/geneseq/NA1999.DAT.*
21: /SIDS2/gcgdata/geneseq/geneseq/NA2000.DAT.*
22: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	21	100.0	21	T76118	Human eosinophil c
2	21	100.0	81	X54596	Eosinophil cationi
3	21	100.0	81	F20165	Human eosinophil c
4	21	100.0	81	A34043	Human adenosine re
5	21	100.0	715	F21294	Human low adenosin
6	21	100.0	715	A35172	Human adenosine re
7	21	100.0	718	F21293	Human low adenosin
8	21	100.0	718	A35171	Human adenosine re
9	21	100.0	1452	F21295	Human low adenosin
10	21	100.0	1452	A35173	Human adenosine re
11	21	100.0	2885	F21296	Human low adenosin

c	12	21	100.0	2885	21	A35174	Human adenosine re
	13	21	100.0	7033	21	F20844	Human low adenosin
	14	21	100.0	7033	21	A34722	Human adenosine re
	15	21	100.0	7036	20	X55274	Human factor-relat
	16	21	100.0	114955	20	X53491	Human adenosine A1
	17	21	100.0	209273	21	F21437	Human factor-relat
	18	17.8	84.8	14180	19	V05159	Mouse butyrophilin
	19	17.4	82.9	262	18	X83217	Breast cancer tumo
	20	17.4	82.9	262	19	V68816	DNA molecule encod
	21	17.4	82.9	262	21	C80740	Human breast tumou
	22	16.8	80.0	585	20	X97764	Extended human sec
	23	16.8	80.0	1446	21	C73870	Human secreted pro
	24	16.8	80.0	2088	20	V68453	Human guanine nucl
	25	16.8	80.0	2178	20	V68451	Human guanine nucl
	26	16.8	80.0	2335	21	A47618	KCNQ4 Potassium ch
c	27	16.2	77.1	328	21	A93845	TADG-12V (truncate
	28	16.2	77.1	467	21	C28112	Human secreted pro
	29	16.2	77.1	735	21	C75784	Human ORF1339
c	30	16.2	77.1	775	18	T95759	Arabidopsis SCAREC
c	31	16.2	77.1	775	21	C65292	Arabidopsis thalia
c	32	16.2	77.1	2096	21	C50354	Arabidopsis thalia
c	33	16.2	77.1	2313	21	C294095	Haematopoietic ste
c	34	16.2	77.1	2394	21	C64285	Human membrane-ass
c	35	16.2	77.1	2544	21	A93843	Tumour associated
c	36	16.2	77.1	3517	17	T31287	Rabbit poly-immuno
c	37	16.2	77.1	3857	21	C294129	Haematopoietic ste
c	38	16	76.2	2007	13	Q27287	DNA encoding TAP.
c	39	16	76.2	7686	21	C29335	Human acrosome rea
c	40	15.8	75.2	775	21	F14522	Aspergillus oryzae
c	41	15.4	73.3	784	21	F11868	Aspergillus oryzae
c	42	15.4	73.3	5278	18	V04446	Rat programmed cel
c	43	15.2	72.4	251	19	X12564	Human biallelic po
c	44	15.2	72.4	300	20	C214540	Human gene express
c	45	15.2	72.4	485	21	A15088	Gene fragment homo

ALIGNMENTS

RESULT 1
T76118
ID T76118 standard; DNA; 21 BP.
XX
AC T76118;
XX
DT 12-SEP-1997 (first entry)
XX
DE Human eosinophil cationic protein antisense oligonucleotide HSECPAS1.
XX
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW chronic obstructive pulmonary disease; bronchitis; ss.
XX
OS Synthetic.
XX
PN WO9640162-A1.
XX
PD 19-DEC-1996.
XX
PF 06-JUN-1996; 96WO-US09306.
XX
PR 07-JUN-1995; 95US-0474497.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Metzger WJ, Nyce JW;
XX
DR WPI; 1997-051871/05.
XX
PT Treatment of airway diseases such as asthma - by topically applying
PT adenosine-free antisense oligo:nucleotide to airway epithelium of
PT subject
XX
PS Claim 5; Page 26; 71pp; English.

XX A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide
 CC HSECPAS1 specific for the human eosinophil cationic protein. The method
 CC can be used to treat airway diseases such as cystic fibrosis, asthma,
 CC chronic obstructive pulmonary disease, bronchitis and other
 CC airway diseases characterised by an inflammatory response. By
 CC eliminating adenosine from the antisense ON, its liberation upon
 CC antisense degradation is prevented, thereby preventing adenosine-
 CC induced bronchoconstriction in patients with hyper-reactive airways.
 XX
 SQ Sequence 21 BP; 0 A; 9 C; 4 G; 8 T; 0 other;

Query Match 100.0%; Score 21; DB 18; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTCTCTGCTGCTGTC 21
 Db 1 cctcctctctgctgctgtcgc 21

RESULT 2

XX54596
 ID X54596 standard; DNA; 81 BP.

XX X54596;

DT 05-JUL-1999 (first entry)

DE Eosinophil cationic protein antisense oligonucleotide fragment.

XX Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.

XX Synthetic.

XX WO9913886-A1.

XX 25-MAR-1999.

XX 17-SEP-1998; 98WO-US19419.

XX 09-JUN-1998; 98US-0093972.

XX 17-SEP-1997; 97US-0059160.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX WPI; 1999-229400/19.

XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction

XX Disclosure; Page 46; 120pp; English.

XX The specification describes antisense oligonucleotides (X52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding

CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences X55272-74. These multiple target
 CC oligonucleotides (specifically X55180-271) can be used for the antisense
 CC treatment of diseases and conditions. Typical diseases and conditions
 CC are those associated with impaired respiration and inflammation,
 CC including lung diseases, pulmonary vasoconstriction, inflammation,
 CC allergic rhinitis, acute asthma, allergies, asthma, impeded respiration,
 CC respiratory distress syndrome, pain, cystic fibrosis, pulmonary
 CC hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic
 CC cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic
 CC metastases, as well as all types of cancers which may metastasize or have
 CC metastasized to the lungs, including breast and prostate cancer.

XX Sequence 81 BP; 0 A; 21 C; 20 G; 25 T; 15 other;

Query Match 100.0%; Score 21; DB 20; Length 81;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTCTCTGCTGCTGTC 21
 Db 1 cctcctctctgctgctgtcgc 21

RESULT 3

XX F20165

ID F20165 standard; DNA; 81 BP.

XX F20165;

DT 14-MAR-2001 (first entry)

DE Human eosinophil cationic protein polynucleotide fragment #1732.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antilasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.

XX WO200062736-A2.

XX 26-OCT-2000.

XX 24-MAR-2000; 2000WO-US08020.

XX 06-APR-1999; 99US-0127958.

XX (UYEC-) UNIV EAST CAROLINA.

XX (NYCE/) NYCE J W.

XX Nyce JW;

XX WPI; 2000-679539/66.

XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX Claim 14; Page 142; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense

CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.

SQ Sequence 81 BP; 0 A; 21 C; 20 G; 25 T; 15 other;

Query Match 100.0%; Score 21; DB 21; Length 81;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTCTCTGGTCTGTCG 21
 Db 1 cctcctctctggtctgtctgc 21

RESULT 4
 ID A34043 standard; DNA; 81 BP.

XX A34043;

XX 28-JUL-2000 (first entry)

XX Human adenosine receptor related polynucleotide SEQ ID NO:1732.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

OS WO200009525-A2.

PN 24-FEB-2000.

XX 03-AUG-1999; 99WO-US17712.

XX 03-AUG-1998; 98US-0095212.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary
 DR vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers

XX Disclosure; Page 480; 1343pp; English.

XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.

SQ Sequence 81 BP; 0 A; 21 C; 20 G; 25 T; 15 other;

Query Match 100.0%; Score 21; DB 21; Length 81;
 Best Local Similarity 100.0%; Pred. No. 1.2;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTCTCTGGTCTGTCG 21
 Db 1 cctcctctctggtctgtctgc 21

RESULT 5
 F21294/c

ID F21294 standard; DNA; 715 BP.

XX F21294;

XX 14-MAR-2001 (first entry)

XX Human low adenosine antisense oligonucleotide related sequence #2861.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.

XX WO200062736-A2.

PN

PD 26-OCT-2000.
 XX
 PF 24-MAR-2000; 2000WO-US08020.
 XX
 PR 06-APR-1999; 99US-0127958.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE-) NYCE J W.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-679539/66.
 XX
 XX
 PT Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating;
 PT cancers and respiratory obstructions -
 PS
 PS Disclosure; Page 1288; 1592pp; English.
 XX
 CC The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense.
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impaired respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.
 XX
 SQ Sequence 715 BP; 185 A; 199 C; 141 G; 190 T; 0 other;

 Query Match 100.0%; Score 21; DB 21; Length 715;
 Best Local Similarity 100.0%; Pred. No. 1.4;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 CCTCCTTCCTGGTCGTCTGC 21
 |||
 DB 450 CCTCCTTCCTGGTCGTCTGC 430

 RESULT 6
 A35172/c
 ID A35172 standard; DNA; 715 BP.
 XX
 AC A35172;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Human adenosine receptor related polynucleotide 2nd SEQ ID NO:46.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;

KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200009525-A2.
 PN
 XX 24-FEB-2000.
 PD
 XX
 XX 03-AUG-1999; 99WO-US17712.
 PF
 XX 03-AUG-1998; 98US-0095212.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 XX
 PA
 XX
 XX Nyce JW;
 PI
 XX WPI; 2000-205971/18.
 DR
 XX
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 PT
 XX
 XX Disclosure; Page 1205; 1343pp; English.
 XX
 CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.
 XX
 SQ Sequence 715 BP; 185 A; 199 C; 141 G; 190 T; 0 other;

 Query Match 100.0%; Score 21; DB 21; Length 715;
 Best Local Similarity 100.0%; Pred. No. 1.4;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 CCTCCTTCCTGGTCGTCTGC 21
 |||
 DB 450 CCTCCTTCCTGGTCGTCTGC 430

 RESULT 7
 F21293/c
 ID F21293 standard; DNA; 718 BP.
 XX
 XX F21293;
 AC

XX 14-MAR-2001 (first entry)
XX Human low adenosine antisense oligonucleotide related sequence #2860.
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
XX human; airway disorder; bronchoconstriction; lung inflammation;
XX surfactant depletion; respiratory; bronchodilator; antiinflammatory;
XX immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
XX respiratory obstruction; pulmonary obstruction; impeded respiration;
XX surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
XX respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
XX pulmonary hypertension; emphysema; pulmonary transplantation rejection;
XX chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
XX cancer; ss.
XX
XX Homo sapiens.
XX
XX WO200062736-A2.
XX
XX 26-OCT-2000.
XX
XX 24-MAR-2000; 2000WO-US08020.
XX
XX 06-APR-1999; 99US-0127958.
XX
XX (UYEC-) UNIV EAST CAROLINA.
XX (NYCE/) NYCE J W.
XX
XX Nyce JW;
XX
XX WPI; 2000-679539/66.
XX
XX Low adenosine (A) content antisense oligonucleotides which do not
XX trigger adenosine receptors during metabolism, useful e.g. for treating
XX cancers and respiratory obstructions -
XX
XX Disclosure; Page 1288; 1592pp; English.
XX
XX The present invention describes low adenosine (A) content antisense
XX oligonucleotides and compositions (I) comprising them. In the antisense
XX oligonucleotides the A is replaced by a 'universal' or alternative base.
XX (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
XX immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
XX The antisense oligonucleotides and (I) can be used to down-regulate the
XX expression and/or activity of target polypeptides associated with
XX lung/respiratory disorders and malignancies, such as stimulating and
XX activating peptide factors and transmitters, transcription factors,
XX immunoglobulins and antibodies, antibody receptors, cytokines and
XX chemokines, endogenously produced specific and non-specific enzymes,
XX binding proteins, adhesion molecules and their receptors, cytokine and
XX chemokine receptors, adenosine receptors, bradykinin receptors, central
XX nervous system (CNS) and peripheral nervous and non-nervous system
XX receptors, CNS and peripheral nervous and non-nervous system peptide
XX transmitters, defensins, growth factors, vasoactive peptides and
XX receptors, binding proteins and malignancy associated proteins. The
XX antisense oligonucleotides may be used in this way to treat disorders
XX including respiratory obstruction (especially pulmonary obstruction
XX and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
XX and/or surfactant hypoproduction which are associated with a disease or
XX condition selected from pulmonary vasoconstriction, inflammation,
XX allergies, asthma, impeded respiration, respiratory distress syndrome
XX (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
XX pulmonary transplantation rejection, pulmonary infections, bronchitis,
XX and/or cancer. F18434 to F21543 represent human polynucleotide fragments
XX and antisense oligonucleotides used in the exemplification of the
XX present invention.
XX
XX Sequence 718 BP; 187 A; 197 C; 144 G; 190 T; 0 other;
SQ

Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CCTCCTTCTGCTGCTGTCG 21
DB 448 CCTCCTTCTGCTGCTGTCG 428
RESULT 8
A35171/c
ID A35171 standard; DNA; 718 BP.
XX A35171;
XX
XX 28-JUL-2000 (first entry)
XX Human adenosine receptor related polynucleotide 2nd SEQ ID NO:45.
XX
XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
XX phosphorothioate; impaired respiration; inflammation; allergy;
XX allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
XX antiasthmatic; cytostatic; analgesic; impaired airway;
XX lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
XX respiratory distress syndrome; pain; cystic fibrosis; emphysema;
XX pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
XX cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
XX Homo sapiens.
XX
XX WO200009525-A2.
XX
XX 24-FEB-2000.
XX
XX 03-AUG-1999; 99WO-US17712.
XX
XX 03-AUG-1998; 98US-0095212.
XX
XX (UYEC-) UNIV EAST CAROLINA.
XX
XX Nyce JW;
XX
XX WPI; 2000-205971/18.
XX
XX New antisense oligonucleotides useful for treating e.g. pulmonary
XX vasoconstriction, inflammation, allergies, asthma, hypertension,
XX bronchitis, emphysema, respiratory distress syndrome, ischemia or
XX cancers -
XX
XX Disclosure; Page 1205; 1343pp; English.
XX
XX The present invention describes a new composition comprising an antisense
XX oligonucleotide (ON) with low adenosine (up to 15%), which targets
XX nucleic acids involved in bronchoconstriction, allergies, and/or
XX inflammation. The ON can have antiinflammatory, antiallergic,
XX antiasthmatic, cytostatic and analgesic activities. The compositions are
XX useful for the treatment of diseases associated with inflammation,
XX impaired airways, including lung disease and diseases whose secondary
XX effects afflict the lungs of a subject. They can be used for treating
XX e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
XX impeded respiration, respiratory distress syndrome, pain, cystic
XX fibrosis, pulmonary hypertension, emphysema, chronic obstructive
XX pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
XX carcinomas, and cancers which may metastasize to the lungs, including
XX breast and prostate cancer. The reduction of the adenosine content of the
XX ONs reduces side effects. The A-containing ONs break down with the
XX release of deoxyadenosine which activates adenosine receptors causing
XX bronchoconstriction and inflammation. A32313 to A35312 represent the
XX nucleotide sequences given in the sequence listing from the present
XX invention, which correspond to SEQ ID NO:1 to 2815, and then the last
XX 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
XX differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
XX to A33992) are specifically claimed ONs from the present invention.
XX N.B. Sequences given in the disclosure of the present invention do not

CC match up with their corresponding SEQ ID NO: sequences given in the
CC sequence listing.
XX
SQ Sequence 718 BP; 187 A; 197 C; 144 G; 190 T; 0 other;

Query Match 100.0%; Score 21; DB 21; Length 718;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCTGCTGCTGTC 21
|||||
Db 448 CCTCCTTCTGCTGCTGTC 428

RESULT 9
F21295/c
ID F21295 standard; DNA; 1452 BP.
XX
AC F21295;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human low adenosine antisense oligonucleotide related sequence #2862.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US08020.
XX
PR 06-APR-1999; 99US-0127958.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PA (NYCE/) NYCE J W.
XX
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX
PS Disclosure; Page 1288-1289; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC oligonucleotides (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and/or activity of target polypeptides associated with the
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system

CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
CC and antisense oligonucleotides used in the exemplification of the
CC present invention.
XX
SQ Sequence 1452 BP; 380 A; 376 C; 323 G; 373 T; 0 other;

Query Match 100.0%; Score 21; DB 21; Length 1452;
Best Local Similarity 100.0%; Pred. No. 1.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCTGCTGCTGTC 21
|||||
Db 951 CCTCCTTCTGCTGCTGTC 931

RESULT 10
A35173/c
ID A35173 standard; DNA; 1452 BP.
XX
AC A35173;
XX
DT 28-JUL-2000 (first entry)
XX
DE Human adenosine receptor related polynucleotide 2nd SEQ ID NO:47.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US17712.
XX
PR 03-AUG-1998; 98US-0095212.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers -
XX
PS Disclosure; Page 1205-1206; 1343pp; English.
XX
CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or

CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiallergic, cytotatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects affect the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A3313 to A3512 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.
 XX
 SQ Sequence 1452 BP; 380 A; 376 C; 323 G; 373 T; 0 other;

Query Match 100.0%; Score 21; DB 21; Length 1452;

Best Local Similarity 100.0%; Pred. No. 1.5;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGCTGC 21

DB 951 CCTCCTTCCTGGTCTGCTGC 931

RESULT 11

F21296/c

ID F21296 standard; DNA; 2885 BP.

AC F21296;

DT 14-MAR-2001 (first entry)

XX Human low adenosine antisense oligonucleotide related sequence #2863.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiallergic; analgesic; hypotensive; cytotatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.

OS

XX WO2000062736-A2.

PN

XX 26-OCT-2000.

PD

XX 24-MAR-2000; 2000WO-US08020.

XX

XX 06-APR-1999; 99US-0127958.

XX (UYEC-) UNIV EAST CAROLINA.

XX (NYCE/) NYCE J W.

XX Nyce JW;

XX WPI; 2000-679539/66.

XX

XX

XX

XX

XX

XX

XX

PT Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX Disclosure; Page 1289; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiallergic, hypotensive and cytotatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.

XX Sequence 2885 BP; 752 A; 772 C; 608 G; 753 T; 0 other;

Query Match 100.0%; Score 21; DB 21; Length 2885;

Best Local Similarity 100.0%; Pred. No. 1.6;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGCTGC 21

DB 2384 CCTCCTTCCTGGTCTGCTGC 2364

RESULT 12

A35174/c

ID A35174 standard; DNA; 2885 BP.

XX A35174;

XX A35174;

XX 28-JUL-2000 (first entry)

XX Human adenosine receptor related polynucleotide 2nd SEQ ID NO:48.

XX

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;

XX phosphorothioate; impaired respiration; inflammation; allergy;

XX allergic disease; bronchoconstriction; inhibitor; antiinflammatory;

XX antiallergic; antiallergic; cytotatic; analgesic; impaired airway;

XX lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;

XX respiratory distress syndrome; pain; cystic fibrosis; emphysema;

XX pulmonary hypertension; chronic obstructive pulmonary disease; COPD;

XX cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

XX WO200009525-A2.

XX 24-FEB-2000.

XX

XX

XX

XX

XX

XX

XX

XX

PF 03-AUG-1999; 99WO-US17712.
 XX
 PR 03-AUG-1998; 98US-0095212.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-205971/18.
 XX
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX
 XX Disclosure: Page 1206; 1343pp; English.
 PS
 XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antisthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.
 XX
 SQ Sequence 2885 BP; 752 A; 772 C; 608 G; 753 T; 0 other;

Query Match 100.0%; Score 21; DB 21; Length 2885;
 Best Local Similarity 100.0%; Pred. No. 1.6;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGCTGCTGTC 21
 Db 2384 CCTCCTTCCTGCTGCTGTC 2364

RESULT 13
 F20844
 ID F20844 standard; DNA; 7033 BP.
 XX
 AC F20844;
 XX
 XX 14-MAR-2001 (first entry)
 XX
 DE Human low adenosine antisense oligonucleotide #2411.
 XX
 XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antisthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; Impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;

KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 XX cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200062736-A2.
 XX
 PD 26-OCT-2000.
 XX
 XX 24-MAR-2000; 2000WO-US08020.
 PF
 XX 06-APR-1999; 99US-0127958.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX (NYCE/) NYCE J W.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-679539/66.
 XX
 XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX
 PS Claim 14; Page 637-639; 1592pp; English.
 XX
 XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antisthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.
 XX
 SQ Sequence 7033 BP; 82 A; 2193 C; 2184 G; 2057 T; 517 other;

Query Match 100.0%; Score 21; DB 21; Length 7033;
 Best Local Similarity 100.0%; Pred. No. 1.7;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGCTGCTGTC 21
 Db 1 cctccttcctgctgctgctgc 21

RESULT 14
 A34722
 ID A34722 standard; DNA; 7033 BP.
 XX
 AC A34722;

XX DT 28-JUL-2000 (first entry)

XX DE Human adenosine receptor related polynucleotide SEQ ID NO:2411.

XX XX

XX KW Human; adenosine receptor; low adenosine antisense oligonucleotide; phosphorothioate; impaired respiration; inflammation; allergy; allergic disease; bronchoconstriction; inhibitor; antiinflammatory; antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway; lung disease; ischaemic condition; pulmonary vasoconstriction; asthma; respiratory distress syndrome; pain; cystic fibrosis; emphysema; pulmonary hypertension; chronic obstructive pulmonary disease; COPD; cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX OS Homo sapiens.

XX XX

XX PN WO200009525-A2.

XX XX

XX PD 24-FEB-2000.

XX PF 03-AUG-1999; 99WO-US17712.

XX PR 03-AUG-1998; 98US-0095212.

XX PA (UYEC-) UNIV EAST CAROLINA.

XX PI Nyce JW;

XX DR WPI: 2000-205971/18.

XX XX

XX PT New antisense oligonucleotides useful for treating e.g. pulmonary vasoconstriction, inflammation, allergies, asthma, hypertension, bronchitis, emphysema, respiratory distress syndrome, ischemia or cancers

XX PS Disclosure; Page 569-571; 1343pp; English.

XX CC The present invention describes a new composition comprising an antisense oligonucleotide (ON) with low adenosine (up to 15%), which targets nucleic acids involved in bronchoconstriction, allergies, and/or inflammation. The ON can have antiinflammatory, antiallergic, antiasthmatic, cytostatic and analgesic activities. The compositions are useful for the treatment of diseases associated with inflammation, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject. They can be used for treating e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma, impaired respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukaemias, lymphomas, carcinomas, and cancers which may metastasize to the lungs, including breast and prostate cancer. The reduction of the adenosine content of the ONs reduces side effects. The A-containing ONs break down with the release of deoxyadenosine which activates adenosine receptors causing bronchoconstriction and inflammation. A32313 to A3312 represent the nucleotide sequences given in the sequence listing from the present invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185 sequences are also called SEQ ID NO:1 to 185, but the sequences differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323 to A33922) are specifically claimed ONs from the present invention. CC N.B. Sequences given in the disclosure of the present invention do not match up with their corresponding SEQ ID NO: sequences given in the sequence listing.

XX SQ Sequence 7033 BP; 82 A; 2193 C; 2184 G; 2057 T; 517 other;

Query Match 100.0%; Score 21; DB 21; Length 7033;

Best Local Similarity 100.0%; Pred. No. 1.7;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCCTCTGCTGCTGCTGC 21

DB 1 cctccctctgctgctgctgc 21

RESULT 15

XX X55274

XX ID X55274 standard; DNA; 7036 BP.

XX AC X55274;

XX DT 05-JUL-1999 (first entry)

XX DE Human factor-related antisense polynucleotide.

XX KW Antisense oligonucleotide; multiple target; antisense treatment; impaired respiration; inflammation; lung disease; pulmonary vasoconstriction; inflammation; allergic rhinitis; acute asthma; allergy; asthma; impeded respiration; respiratory distress syndrome; pain; cystic fibrosis; pulmonary hypertension; pulmonary vasoconstriction; emphysema; chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma; colon cancer; breast cancer; lung cancer; pancreatic cancer; hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis; prostate cancer; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO9913886-A1.

XX PD 25-MAR-1999.

XX PF 17-SEP-1998; 98WO-US19419.

XX PR 09-JUN-1998; 98US-0093972.

XX PR 17-SEP-1997; 97US-0059160.

XX PA (UYEC-) UNIV EAST CAROLINA.

XX PI Nyce JW;

XX DR WPI: 1999-229400/19.

XX PT New antisense oligonucleotides used in treatment of, e.g. pulmonary vasoconstriction

XX PS Disclosure; Page 25-27; 120pp; English.

XX CC The specification describes antisense oligonucleotides (X52869-X55271) directed against at least 2 mRNAs selected from target genes, coding and non-coding regions of RNAs corresponding to target genes, gene initiation codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-end and the juxta-section between coding and non-coding regions and all segments of RNAs encoding proteins associated with one or more diseases, conditions or mixtures. The antisense oligonucleotides may be derived from sequences X55272-74. These multiple target oligonucleotides (specifically X55180-271) can be used for the antisense treatment of diseases and conditions. Typical diseases and conditions are those associated with impaired respiration and inflammation, including lung diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis, acute asthma, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as well as all types of cancers which may metastasize or have metastasized to the lungs, including breast and prostate cancer.

XX SQ Sequence 7036 BP; 82 A; 2194 C; 2185 G; 2058 T; 517 other;

Query Match 100.0%; Score 21; DB 20; Length 7036;

Best Local Similarity 100.0%; Pred. No. 1.7;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Search completed: April 20, 2001, 00:12:59
Job time: 10021 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 19, 2001, 23:24:57 ; Search time 7150.85 Seconds
(without alignments) ,
0.429 Million cell updates/sec

Title: US-09-016-464-18
Perfect score: 21
Sequence: 1 CCTCCTTCCTGGTCTGTCTGC 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 9623517 seqs, 73081774 residues

Total number of hits satisfying chosen parameters: 19247034

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*

- 1: gb_estl1:*
- 2: gb_estl2:*
- 3: gb_estl3:*
- 4: gb_estl4:*
- 5: gb_estl5:*
- 6: gb_estl6:*
- 7: gb_estl7:*
- 8: gb_estl8:*
- 9: gb_estl9:*
- 10: gb_estl10:*
- 11: gb_estl11:*
- 12: gb_estl12:*
- 13: gb_estl13:*
- 14: gb_estl14:*
- 15: gb_estl15:*
- 16: gb_estl16:*
- 17: gb_estl17:*
- 18: gb_estl18:*
- 19: gb_estl19:*
- 20: gb_estl20:*
- 21: gb_estl21:*
- 22: gb_estl22:*
- 23: gb_estl23:*
- 24: gb_estl24:*
- 25: gb_estl33:*
- 26: gb_estl34:*
- 27: gb_estl35:*
- 28: gb_estl36:*
- 29: gb_estl37:*
- 30: gb_estl38:*
- 31: gb_estl39:*
- 32: gb_estl40:*
- 33: em_estba:*
- 34: em_estfun:*
- 35: em_esthum1:*
- 36: em_esthum2:*
- 37: em_esthum3:*
- 38: em_esthum4:*
- 39: em_esthum5:*
- 40: em_esthum6:*
- 41: em_esthum7:*
- 42: em_esthum8:*
- 43: em_esthum9:*

- 44: em_esthum10:*
- 45: em_esthum11:*
- 46: em_esthum12:*
- 47: em_esthum13:*
- 48: em_esthum14:*
- 49: em_esthum15:*
- 50: em_esthum16:*
- 51: em_esthum17:*
- 52: em_esthum18:*
- 53: em_esthum19:*
- 54: em_esthum20:*
- 55: em_esthum21:*
- 56: em_esthum22:*
- 57: em_esthum23:*
- 58: em_esthum24:*
- 59: em_esthum25:*
- 60: em_esthum26:*
- 61: em_esthum27:*
- 62: em_esthum28:*
- 63: em_estin1:*
- 64: em_estin2:*
- 65: em_estin3:*
- 66: em_estin4:*
- 67: em_estin5:*
- 68: em_estom1:*
- 69: em_estom2:*
- 70: em_estov1:*
- 71: em_estov2:*
- 72: em_estpl1:*
- 73: em_estpl2:*
- 74: em_estpl3:*
- 75: em_estpl4:*
- 76: em_estpl5:*
- 77: em_estpl6:*
- 78: em_estpl7:*
- 79: em_estpl8:*
- 80: em_estpl9:*
- 81: em_estpl10:*
- 82: em_estro1:*
- 83: em_estro2:*
- 84: em_estro3:*
- 85: em_estro4:*
- 86: em_estro5:*
- 87: em_estro6:*
- 88: em_estro7:*
- 89: em_estro8:*
- 90: em_estro9:*
- 91: em_estro10:*
- 92: em_estro11:*
- 93: em_estro12:*
- 94: em_estro13:*
- 95: em_estro14:*
- 96: em_estro15:*
- 97: em_estro16:*
- 98: em_estro17:*
- 99: em_estro18:*
- 100: em_estro19:*
- 101: em_estro20:*
- 102: gb_est25:*
- 103: gb_est26:*
- 104: gb_est27:*
- 105: gb_est28:*
- 106: gb_est29:*
- 107: gb_est30:*
- 108: gb_est31:*
- 109: gb_est32:*
- 110: gb_est41:*
- 111: gb_est42:*
- 112: gb_est43:*
- 113: gb_est44:*
- 114: gb_est45:*
- 115: gb_est46:*
- 116: gb_est47:*

```

117: gb_est48:*
118: gb_est49:*
119: gb_est50:*
120: gb_est51:*
121: gb_est52:*
122: gb_est53:*
123: gb_est54:*
124: gb_est55:*
125: gb_est56:*
126: gb_est57:*
127: gb_est58:*
128: gb_est59:*
129: gb_est60:*
130: gb_est61:*
131: gb_est62:*
132: gb_est63:*
133: gb_est64:*
134: gb_est65:*
135: gb_est66:*
136: gb_est67:*
137: gb_est68:*
138: gb_est69:*
139: gb_est70:*
140: gb_est71:*
141: gb_est72:*
142: gb_est73:*
143: gb_est74:*
144: gb_est75:*
145: gb_est76:*
146: gb_est77:*
147: gb_est78:*
148: gb_est79:*
149: gb_est80:*
150: gb_est81:*
151: gb_est82:*
152: gb_est83:*
153: gb_est84:*
154: gb_est85:*
155: gb_est86:*
156: gb_est87:*
157: gb_est88:*
158: gb_est89:*
159: gb_est90:*
160: gb_est91:*
161: gb_est92:*
162: gb_est93:*
163: gb_est94:*
164: gb_est95:*
165: gb_est96:*
166: gb_est97:*
167: gb_est98:*
168: gb_est99:*
169: gb_est100:*
170: gb_est101:*
171: gb_est102:*
172: gb_est103:*
173: gb_est104:*
174: gb_est105:*
175: gb_est106:*
176: gb_est107:*
177: gb_est108:*
178: gb_est109:*
179: gb_est110:*
180: gb_est111:*
181: gb_est112:*
182: gb_est113:*
183: gb_est114:*
184: gb_est115:*
185: gb_est116:*
186: gb_est117:*
187: gb_est118:*
188: gb_est119:*
189: gb_est120:*

```

```

190: em_gss_pln1:*
191: em_gss_pln2:*
192: em_gss_pro:*
193: em_gss_rod1:*
194: em_gss_rod2:*
195: em_gss_rod3:*
196: em_gss_rod4:*
197: em_gss_rod5:*
198: em_gss_vrt1:*
199: em_gss_vrt2:*
200: em_gss_vrt3:*
201: gb_gss1:*
202: gb_gss2:*
203: gb_gss3:*
204: gb_gss4:*
205: gb_gss5:*
206: gb_gss6:*
207: gb_gss7:*
208: gb_gss8:*
209: gb_gss9:*
210: gb_gss10:*
211: gb_gss11:*
212: gb_gss12:*
213: gb_gss13:*
214: gb_gss14:*
215: gb_gss15:*
216: gb_gss16:*
217: gb_gss17:*
218: gb_gss18:*
219: gb_gss19:*
220: gb_gss20:*
221: gb_gss21:*
222: gb_gss22:*
223: gb_gss23:*
224: gb_gss24:*
225: gb_gss25:*
226: gb_gss26:*
227: gb_gss27:*
228: gb_gss28:*
229: gb_gss29:*
230: gb_gss30:*
231: gb_gss31:*
232: gb_gss32:*
233: gb_gss33:*
234: gb_gss34:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
c 1	21	100.0	231	170	BF895434 CM0-MT015
c 2	21	100.0	285	172	BG014139 IL5-CN023
c 3	21	100.0	302	170	BF902198 IL5-MT020
c 4	21	100.0	323	9	AA587166 nn74c10.s
c 5	21	100.0	597	110	AW075940 xa82a02.x
c 6	19	90.5	1569	150	BF570099 602185939
c 7	18.4	87.6	96	11	AA716588 z966d04.s
c 8	18.4	87.6	137	215	AZ071781 RPCI-23-4
c 9	18.4	87.6	273	115	AW468752 hd27e07.x
10	18.4	87.6	482	148	BF441931 258400 MA
11	18.4	87.6	492	207	AQ482290 RPCI-11-2
12	18.4	87.6	618	204	AQ315451 RPCI11-10
13	18.4	87.6	1002	231	CNS031BT AL249266 Tetraodon
14	17.8	84.8	220	173	BG092228 mac06f10.
c 15	17.8	84.8	222	9	AA562957 v157c06.f
c 16	17.8	84.8	230	120	AW812057 RCS-ST017
17	17.8	84.8	237	173	BG090438 mac06f10.
18	17.8	84.8	268	121	AW878939 MRI-OT001

```

19 17.8 84.8 275 163 BE133367
20 17.8 84.8 277 148 BF455872
21 17.8 84.8 295 3 AA172447
22 17.8 84.8 303 226 AZ698812
23 17.8 84.8 337 138 BE692014
24 17.8 84.8 367 117 AW551216
25 17.8 84.8 383 137 BE634214
26 17.8 84.8 401 4 AA221180
27 17.8 84.8 401 146 BF329952
28 17.8 84.8 407 138 BE690759
29 17.8 84.8 419 13 AA870628
30 17.8 84.8 429 3 AA184116
31 17.8 84.8 447 3 AA175320
32 17.8 84.8 448 142 BE990692
33 17.8 84.8 449 12 AA832759
34 17.8 84.8 462 10 AA700071
35 17.8 84.8 463 175 C77473
36 17.8 84.8 470 4 AA273661
37 17.8 84.8 480 122 AW990166
38 17.8 84.8 483 172 BG065930
39 17.8 84.8 488 14 AF006694
40 17.8 84.8 502 173 BG079197
41 17.8 84.8 519 140 BE853286
42 17.8 84.8 545 138 BE688759
43 17.8 84.8 690 166 BE375439
44 17.8 84.8 796 141 BE916162
45 17.4 82.9 298 125 BB130738

ALIGNMENTS

RESULT 1
BF895434/C
LOCUS BF895434 231 bp mRNA EST 18-JAN-2001
DEFINITION CM0-MT0151-211100-690-g08 MT0151 Homo sapiens cDNA, mRNA sequence.
ACCESSION BF895434
VERSION BF895434.1 GI:12286893
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 231)
AUTHORS Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
TITLE Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=CM0&t2=CM0-MT0151-211100-690-g08&t3=2000-11-21&t4=1)
Seq primer: puc 18 forward
High quality sequence start: 14
High quality sequence stop: 231.
Location/Qualifiers
1. .231
/organism="Homo sapiens"
/db_xref="taxon:9606"

FEATURES
source
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=CM0&t2=CM0-MT0151-211100-690-g08&t3=2000-11-21&t4=1)
Seq primer: puc 18 forward
High quality sequence stop: 231.
Location/Qualifiers
1. .231
/organism="Homo sapiens"
/db_xref="taxon:9606"

BASE COUNT 77 a 55 c 68 g 85 t
ORIGIN

/clone_lib="MT0151"
/dev_stage="Adult"
/Note="Organ: marrow; Vector: puc18; Site_1: SmaI; Site_2:
SmaI; A mini-library was made by cloning products derived
from ORESTES PCR (U.S. Letters Patent application No. 196
,716 - Ludwig Institute for Cancer Research) profiles
into the puc 18 vector. Reverse transcription of tissue
mRNA and cDNA amplification were performed under low
stringency conditions."
BASE COUNT 62 a 60 c 49 g 60 t
ORIGIN

Query Match 100.0%; Score 21; DB 170; Length 231;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGCTGCTGCTGCTGC 21
|||||
DB 129 CCTCCTTCCTGCTGCTGCTGCTGC 109

RESULT 2
BG014139 285 bp mRNA EST 24-JAN-2001
LOCUS IL5-GN0238-201200-362-c05 GN0238 Homo sapiens cDNA, mRNA sequence.
DEFINITION BG014139
ACCESSION BG014139
VERSION BG014139.1 GI:12465039
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 285)
AUTHORS Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
TITLE Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=IL5&t2=IL5-GN0238-201200-362-c05&t3=2000-12-20&t4=1)
Seq primer: puc 18 forward
High quality sequence stop: 285.
Location/Qualifiers
1. .285
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="GN0238"
/dev_stage="Adult"
/Note="Organ: placenta_normal; Vector: puc18; Site_1: SmaI
; Site_2: SmaI; A mini-library was made by cloning
products derived from ORESTES PCR (U.S. Letters Patent
application No. 196,716 - Ludwig Institute for Cancer
Research) profiles into the puc 18 vector. Reverse
transcription of tissue mRNA and cDNA amplification were
performed under low stringency conditions."
BASE COUNT 77 a 55 c 68 g 85 t
ORIGIN

```

```

Query Match      100.0%; Score 21; DB 172; Length 285;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCTGCTGCTGCTGC 21
    |||||||||||||||||||
Db 12 CCTCCTTCTGCTGCTGCTGC 32

RESULT 3
BF902198/c      302 bp      mRNA      EST      18-JAN-2001
DEFINITION      IL5-MT0207-121200-339-e11 MT0207 Homo sapiens cDNA, mRNA sequence.
ACCESSION      BF902198
VERSION        BF902198.1 GI:12293657
KEYWORDS       EST.
SOURCE         human.
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 302)
AUTHORS        Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
                Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
                Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
                Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
                ,M.J., Soares,F., Brencani,R.R., Reis,L.F., de Souza,S.J. and
                Simpson,A.J.
TITLE          Shotgun sequencing of the human transcriptome with ORF expressed
                sequence tags
JOURNAL        Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE        20202663
COMMENT        Contact: Simpson A.J.G.
                Laboratory of Cancer Genetics
                Ludwig Institute for Cancer Research
                Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
                Brazil
                Tel: +55-11-2704922
                Fax: +55-11-2707001
                Email: asimpson@ludwig.org.br
                This sequence was derived from the FAPESP/LICR Human Cancer Genome
                Project. This entry can be seen in the following URL
                (http://www.ludwig.org.br/scripts/gethtml2.pl?tl=IL5t2-IL5-MT0207-
                121200-339-e11&t3=2000-12-12&t4=1)
                Seq primer: puc 18 forward
                High quality sequence stop: 301.
FEATURES       Location/Qualifiers
                source          1..302
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone_lib="WT0207"
                /dev_stage="Adult"
                /note="Organ: marrow; Vector: puc18; Site_1: SmaI; Site_2:
                SmaI; A mini-library was made by cloning products derived
                from ORESTES PCR (U.S. Letters Patent application No. 196
                716 - Ludwig Institute for Cancer Research) profiles
                into the puc 18 vector. Reverse transcription of tissue
                mRNA and cDNA amplification were performed under low
                stringency conditions."
BASE COUNT     91 a 71 c 60 g 80 t

Query Match      100.0%; Score 21; DB 170; Length 302;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCTGCTGCTGCTGC 21
    |||||||||||||||||||
Db 274 CCTCCTTCTGCTGCTGCTGC 254

RESULT 5
AM075940        597 bp      mRNA      EST      13-OCT-1999
LOCUS           xa82a02.x1 NCI_CGAP_CML1 Homo sapiens cDNA clone IMAGE:2573258 3'
DEFINITION      similar to gb:X55990_rnal EOSINOPHIL CATIONIC PROTEIN PRECURSOR
                (HUMAN);, mRNA sequence.
ACCESSION      AM075940
VERSION        AM075940.1 GI:6030938
KEYWORDS       EST.
SOURCE         human.
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 597)
AUTHORS        NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE          National Cancer Institute, Cancer Genome Anatomy Project (CGAP),

Query Match      100.0%; Score 21; DB 9; Length 323;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCTGCTGCTGCTGC 21
    |||||||||||||||||||
Db 266 CCTCCTTCTGCTGCTGCTGC 286

RESULT 4
AA587166        323 bp      mRNA      EST      26-SEP-1997
LOCUS           nn74C10.s1 NCI_CGAP_Lar1 Homo sapiens cDNA clone IMAGE:1089618 3'
DEFINITION      similar to gb:X55990_rnal EOSINOPHIL CATIONIC PROTEIN PRECURSOR
                (HUMAN);, mRNA sequence.
ACCESSION      AA587166
VERSION        AA587166.1 GI:2397980
KEYWORDS       EST.
SOURCE         human.
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 323)
AUTHORS        NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE          National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
                Tumor Gene Index
                Unpublished (1997)
                Contact: Robert Strausberg, Ph.D.
                Tel: (301) 496-1550
                Email: Robert_Strausberg@nih.gov
                Tissue Procurement: L. Jeffrey Medeiros, M.D., Michael R.
                Emmert-Buck, M.D., Ph.D.
                CDNA Library Preparation: Stratagene, Inc.
                CDNA Library Arrayed by: Greg Lennon, Ph.D.
                DNA Sequencing by: Washington University Genome Sequencing Center
                Clone distributing by: NCI-CGAP clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                www-bio.llnl.gov/bbrp/image/image.html
                Insert Length: 439 Std Error: 0.00
                Seq primer: -40m13 fwd, ET from Amersham.
FEATURES       Location/Qualifiers
                source          1..323
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone_lib="NCI_CGAP_Lar1"
                /tissue_type="larynx"
                /lab_host="SOLR (kanamycin resistant)"
                /note="Organ: larynx; Vector: Bluescript SK-; Site_1:
                EcoRI; Site_2: XhoI; Cloned unidirectionally. Primer:
                Oligo dt. Larynx. 5' adaptor sequence: 5' GAATTCGGCAGG
                3' 3' adaptor sequence: 5' CTCAGTTTTTTTTTTTTTTT 3'
                Average insert size: 0.9 kb."
BASE COUNT     84 a 59 c 96 g 84 t

```


JOURNAL
COMMENT

Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: Elisabeth Paletta, Jonathan D. Licht, M.D.,
Michael R. Emmert-Buck, M.D., Ph.D. cDNA Library Preparation: Life
Technologies, Inc. cDNA Library Arrayed by: Christa Prange, The
I.M.A.G.E. Consortium DNA Sequencing by: Washington University
Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/dbp/image/image.html
Seq primer: -400P from Gibco
High quality sequence stop: 328.

FEATURES
source

1. .597
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2573258"
/tissue_type="myeloid cells, 18 pooled CML cases, BCR/ABL
rearrangement positive, includes both chronic phase and
myeloid blast crisis"
/lab_host="DH10B"
/note="Organ: whole blood; Vector: pCMV-SPORT6; Site_1:
SalI; Site_2: NotI; Cloned unidirectionally. Primer:
Oligo dr. Library constructed by Life Technologies."
BASE COUNT 157 a 111 c 174 g 155 t
ORIGIN

Query Match 100.0%; Score 21; DB 110; Length 597;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTCCTTCCTGGTCTGCTGC 21
|||||
Db 267 CCCTTCCTGGTCTGCTGC 287

RESULT 6
BF570099/c
LOCUS
DEFINITION BF570099 1569 bp mRNA EST 12-DEC-2000
602185939T1 NIH_MGC_45 Homo sapiens cDNA clone IMAGE:4310576 3',
mRNA sequence.

ACCESSION BF570099.1 GI:11643811
VERSION
KEYWORDS
SOURCE human.
ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1569)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550

Email: Robert.Strausberg@nih.gov
Tissue Procurement: Linehan
cDNA Library Preparation: Ling Hong/Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLC1185 row: m column: 09
High quality sequence start: 10
High quality sequence stop: 642.
Location/Qualifiers
1. .1569
/organism="Homo sapiens"

/db_xref="taxon:9606"
/clone="IMAGE:4310576"
/tissue_type="renal carcinoma (ascites)"
/lab_host="DH10B (phage-resistant)"
/note="Organ: kidney; Vector: pOTB7; Site_1: XhoI; Site_2:
EcoRI; cDNA made by oligo-dr priming. Directionally cloned
into EcoRI/XhoI sites using the following 5' adaptor:
GGCAGCAG(G). Library constructed by Ling Hong in the
Laboratory of Gerald M. Rubin (University of California,
Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and
Superscript II RT (Life Technologies). Note: this is a
NIH_MGC Library."
BASE COUNT 584 a 375 c 399 g 211 t
ORIGIN

Query Match 90.5%; Score 19; DB 150; Length 1569;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 CTCCTTCCTGGTCTGCTG 20
|||||
Db 1546 CTCCTTCCTGGTCTGCTG 1528

RESULT 7
AA716588/c

LOCUS
DEFINITION AA716588 96 bp mRNA EST 29-DEC-1997
z966d04.sl Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone
IMAGE:398311 3' similar to gb:J04794 ALCOHOL DEHYDROGENASE (HUMAN
);, mRNA sequence.

ACCESSION AA716588
VERSION AA716588.1 GI:2728862
KEYWORDS
SOURCE EST.
ORGANISM human.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 96)
AUTHORS Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,
Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin
J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B.,
White, Y., Wylie, T., Waterston, R. and Wilson, R.
WashU-NCI human EST Project
Unpublished (1997)
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu

This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Seq primer: -40m13 fwd. ET from Amersham
High quality sequence stop: 1.
Location/Qualifiers
1. .96

FEATURES
source

/organism="Homo sapiens"
/db_xref="GDB:1306134"
/db_xref="taxon:9606"
/clone="IMAGE:398311"
/tissue_type="Soares_fetal_heart_NbHH19W"
/sex="unknown"
/dev_stage="19 weeks"
/lab_host="DH10B (ampicillin resistant)"
/note="Organ: heart; Vector: pT7T3D (Pharmacia) with a
modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
strand cDNA was primed with a Not I -oligo(dT) primer [5'
TGTACCATCTGAAGTGGGAGCGGCATCTTTTTTTTTTTT 3'],
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacia), digested with Not I and cloned into

the Not I and Eco RI sites of a modified pT73 vector (Pharmacia). Library went through one round of normalization to a Cot = 5. Library constructed by M.Fatima Bonaldo. This library was constructed from the same fecus as the fetal lung library, Soares fetal lung NBHL19W.

BASE COUNT 33 a 20 c 24 g 19 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 11; Length 96;
Best Local Similarity 95.0%; Pred. No. 3.6e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CTCCTTCCTGGTCTGTCTGC 21

Db 76 CTCCTTCCTAGTCTGTCTGC 57

RESULT 8
AZ071781/c
LOCUS
DEFINITION AZ071781 DNA GSS 31-MAR-2000
PCIC-23-435M13.TV PCIC-23 Mus musculus genomic clone PCIC-23-435M13
, DNA sequence.
ACCESSION AZ071781
VERSION
KEYWORDS
SOURCE
ORGANISM Mus musculus
house mouse.

REFERENCE
AUTHORS
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 137)
Zhao,S., Nierman,W., Feldblyum,T., Malek,J., Shatsman,S., Akinret
B., Levis,M., McGann,S., Tsegaye,G., Geer,K., Krol,M., de Jong,P.
and Fraser,C.M.
Mouse BAC End Sequences from Library PCIC-23
Unpublished (1999)
Other GSSs: PCIC-23-435M13.TJ

TITLE
JOURNAL
COMMENT

Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org
Clones are derived from the mouse BAC library PCIC-23. For BAC
library availability, please contact Pieter de Jong
(pieter@dejong.med.buffalo.edu). Clones may be purchased from
BACPAC Resources (<http://bacpac.med.buffalo.edu/orderingframe.htm>)
or from Resea ch Genetics (info@resgen.com). BAC end page:
http://www.tigr.org/tldb/bac_ends/mouse/bac_end_intro.html
Plate: 435 Row: M Column: 13
Seq primer: 17
Class: BAC ends.
Location/Qualifiers
1. 137
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="PCIC-23-435M13"
/clone_lib="PCIC-23"
/sex="Female"
/lab_host="DH10B"
/note="Organ: Kidney/Brain; Vector: pBACe3.6; Site:1;
EcoRI; Site:2; EcoRI; Female C57BL/6J mouse kidney and/or
brain genomic DNA was isolated and partially digested
with a combination of EcoRI and EcoRI Methylase. Size
selected DNA was cloned into the pBACe3.6 vector at the
EcoRI sites. The ligation products were transformed into
DH10B electrocompetent cells (BRL Life Technologies)."
48 a 55 c 34 g 0 t

BASE COUNT
ORIGIN

Query Match 87.6%; Score 18.4; DB 215; Length 137;
Best Local Similarity 95.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTGC 20

Db 36 CCTCCTTCCTGGCTGTCTGC 17

RESULT 9
AW468752
LOCUS
DEFINITION hd27e07.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone
IMAGE:2910756 3', mRNA sequence.
ACCESSION AW468752
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens
human.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

1 (bases 1 to 273)
NCI-CCGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP).
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert_Strausberg@nih.gov
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Seq primer: -40UP from Gibco.
Location/Qualifiers
1. 273
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2910756"
/clone_lib="Soares_NFL_T_GBC_S1"
/lab_host="DH10B"

/note="Organ: pooled; Vector: pT73D-Pac (Pharmacia) with
a modified polylinker; Site:1: Not I; Site:2: Eco RI;
Equal amounts of plasmid DNA from three normalized
libraries (fetal lung NBHL19W, testis NHT, and B-cell
NCI_CGAP_GCB1) were mixed, and ss circles were made in
vitro. Following HAP purification, this DNA was used as
tracer in a subtractive hybridization reaction. The driver
was PCR-amplified cDNAs from pools of 5,000 clones made
from the same 3 libraries. The pools consisted of
I.M.A.G.E. clones 297480-302087, 682632-687239,
726408-728711, and 729096-731399. Subtraction by Bento
Soares and M. Fatima Bonaldo."
BASE COUNT 55 a 64 c 61 g 93 t
ORIGIN

Query Match 87.6%; Score 18.4; DB 115; Length 273;
Best Local Similarity 95.0%; Pred. No. 4.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CTCCTTCCTGGTCTGTCTGC 21

Db 141 CTCCTTCCTGGCTGTCTGC 160

RESULT 10
BF441931
LOCUS
DEFINITION BF441931 482 bp mRNA EST
258400 MARC 2P1G Sus scrofa cDNA 5', mRNA sequence.
ACCESSION BF441931
VERSION BF441931.1 GI:11502023
KEYWORDS EST.
SOURCE
pig.

Clones are derived from the human BAC library RPCI-11. For BAC library availability, please contact pieter de Jong (pieter@dejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering>) or from Research Genet cs (info@resgen.com). BAC end search page: http://www.tigr.org/tdb/humgen/bac_end_search/bac_end_search.html.

	144 a	94 c	104 g	150 t
ch				
l Similarity		87.6%	Score 18.4;	DB 207; Length 492;
		95.0%;	Pred. No. 4.4e+02;	

Similarity 95.0%; Pred. No. 4.4e+02; Indels 0; Gaps 0;
19; Conservative 0; Mismatches 1;

RPCT11-10A3.TV RPCT-11 Homo sapiens genomic clone RPCT-11-10A3,
 DNA sequence.
 AQ315451
 AQ315451.1 GI:4046914
 GSS.
 human.

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 618)
Adams, M.D., Rounsley, S.D., Zhao, S., Bass, S., Linher, K., Golden, K.,
Berry, K., Granger, D., Suh, E., Wibte, C., de Jong, P. and Venter, J.C.

Adams, M.D., Rounsley, S.D., Zhao, S., Bass, S., Linher, K., Golden, K., Berry, K., Granger, D., Suh, E., Wible, C., de Jong, P. and Venter, J.C.: Use of human BAC End Sequences for Sequence-Ready Map Building Unpublished (1998)

Other_GSSs: RPC11-104A3.TJ

Contact: Shaying zhao, William Nierman, Mark Adams

The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850
Tel: 301 838 0200
Fax: 301 838 0208
Email: hbest@ig.org
Clones are derived from the human BAC library RPT1-11. For BAC

(pieter@edejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/ordering>) or from Research Genetics (info@resgen.com). BAC end search page: http://www.tigr.org/tdb/hungen/bac_end_search/bac_end_search.html
Seq primer: T7
Class: BAC ends.

```
1. 618
/organism="Homo sapiens"
/db_xref="GDB:753954"
/db_xref="taxon:9606"
/clone="RPC1-11-I04A3"
/clone_lib="RPC1-11"
/sex="Male"
```

```

/cell_type="Lymphocytes"
/note="Vector: pBACe3.6; Site_1: EcoRI; Site_2: EcoRI;
RPC111 Human Male BAC Library"
BASE COUNT      126 a   163 c   173 g   156 t
ORIGIN

Query Match      87.6%; Score 18.4; DB 204; Length 618;
Best Local Similarity 95.0%; Pred. No. 4.6e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 CTCCTTCCTGGTCTGCTGTC 21
   || ||||| ||||| |||||
Db 9 CTCCTTCCTGGTCTGCTGTC 28

RESULT 13
CNS03LBT      1002 bp      DNA      GSS      17-MAY-2000
LOCUS      Tetraodon nigroviridis genome survey sequence PUC-Ori end of clone
DEFINITION      035124 of library G from Tetraodon nigroviridis, genomic survey
sequence.
ACCESSION      AL249266
VERSION      AL249266.1 GI:7970278
KEYWORDS      GSS; genome survey sequence.
SOURCE      Tetraodon nigroviridis.
ORGANISM      Tetraodon nigroviridis.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Eurypterygii; Ctenosquamata; Acanthomorpha; Euacanthomorpha;
Holacanthopterygii; Acanthopterygii; Percomorpha;
Tetraodontiformes; Tetraodontidae; Tetraodontidae; Tetraodon.
REFERENCE      1 (bases 1 to 1002)
AUTHORS      Roest-Crollius,H., Jaillon,O., Dasilva,C., Fzames,C., Fisher,C.,
Bouneau,L., Billault,A., Quetier,F., Saurin,W., Bernot,A. and
Weissenbach,J.
TITLE      Characterization and repeat analysis of the compact genome of the
freshwater pufferfish Tetraodon nigroviridis
JOURNAL      Unpublished
REFERENCE      2 (bases 1 to 1002)
AUTHORS      Roest-Crollius,H., Jaillon,O., Dasilva,C., Bouneau,L., Fisher,C.,
Bernot,A., Fzames,C., Wincker,P., Brottier,P., Quetier,F.,
Saurin,W. and Weissenbach,J.
TITLE      Human gene number estimate provided by genome wide analysis using
Tetraodon nigroviridis DNA sequence
JOURNAL      Unpublished
REFERENCE      3 (bases 1 to 1002)
AUTHORS      Genoscope.
TITLE      Direct Submission
JOURNAL      Submitted (12-APR-2000) to the EMBL/GenBank/DBJ databases
COMMENT      This sequence is a single read and was generated as part of a large
scale clone-end sequencing project of the Tetraodon nigroviridis
genome. For more information, please take a look at
http://www.genoscope.cns.fr/tetraodon.
FEATURES
    Location/Qualifiers
        1..1002
            /organism="Tetraodon nigroviridis"
            /db_xref="taxon:99883"
            /clone="035124"
            /clone_lib="G"
            /note="Genoscope sequence ID : COBG035BE12SP1-end :
PUC-Ori"
BASE COUNT      228 a   273 c   253 g   243 t      5 others
ORIGIN

Query Match      87.6%; Score 18.4; DB 231; Length 1002;
Best Local Similarity 95.0%; Pred. No. 4.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGCTGTC 20
   ||||| ||||| ||||| ||
Db 614 CTCCTTCCTGGTCTGCTGTC 633

```

```

RESULT 14
BG092228/c
LOCUS      mac06f10.x1 Soares mouse 3NbMS Mus musculus cDNA clone
DEFINITION      IMAGE:3999115 3', mRNA sequence.
ACCESSION      BG092228
VERSION      BG092228.1 GI:12574780
KEYWORDS      EST.
SOURCE      house mouse.
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      1 (bases 1 to 220)
AUTHORS      NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE      National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL      Unpublished (1997)
COMMENT      Other ESTs: mac06f10.y1
Contact: Robert Strausberg, Ph.D.
Tel.: (301) 496-1550
Email: Robert.Strausberg@nih.gov
This clone is available royalty-free through LLNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:1496843.
FEATURES
    Location/Qualifiers
        1..220
            /organism="Mus musculus"
            /strain="C57BL/6J"
            /db_xref="taxon:10090"
            /clone="IMAGE:3999115"
            /clone_lib="Soares mouse 3NbMS"
            /sex="male"
            /tissue_type="Spleen"
            /dev_stage="4 weeks"
            /lab_host="DH10B"
            /note="Vector: pT7T3D-Pac (Pharmacia) with a modified
polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
was primed with a Not I - oligo(dT) primer [5',
TGTTACCAATCTGAAGTGGAGCGCGCTGTTTTTTTTTTTTTTTTTTTTT
3']; double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT7T3 vector. RNA
provided by Dr. Bertrand Jordan. Library went through
three rounds of normalization, and was constructed by
Bento Soares and M.Patima Bonaldo."
BASE COUNT      80 a    44 c    41 g    55 t
ORIGIN

Query Match      84.8%; Score 17.8; DB 173; Length 220;
Best Local Similarity 90.5%; Pred. No. 7.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGCTGTC 21
   ||||| ||||| ||||| ||
Db 160 CCTCCTACCTGTTCTGCTGTC 140

RESULT 15
AA562957/c
LOCUS      AA562957 222 bp      mRNA      EST      18-AUG-1997
DEFINITION      v157c06.r1 Stratagene mouse skin (#937313) Mus musculus cDNA clone
IMAGE:976330 5', mRNA sequence.
ACCESSION      AA562957
VERSION      AA562957.1 GI:2334422
KEYWORDS      EST.
SOURCE      house mouse.
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE      1 (bases 1 to 222)

```

AUTHORS

Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.

TITLE

The WashU-HHMI Mouse EST Project

JOURNAL

Unpublished (1996)

COMMENT

Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:557058

Seq primer: -28ml3 rev1 ET from Amersham.

FEATURES

source

Location/Qualifiers

1..222
/organism="Mus musculus"
/strain="C57BL/6"
/db_xref="taxon:10090"
/clone="IMAGE:976330"
/clone_lib="Stratagene mouse skin (#937313)"
/sex="females"
/tissue.type="whole skin"
/dev_stage="11 weeks old"
/lab_host="SOLR (kanamycin resistant)"
/note="Organ: skin; Vector: pBluescript SK-; Site_1: EcoRI
; Site_2: XhoI; Cloned unidirectionally. Primer: Oligo
dt. Whole skin from 11 week old C57BL/6 female mice.
Average insert size: 1.0 kb; Uni-ZAP XR Vector: -5'
adaptor sequence: 5' GAATTCGCGACGAG 3' -3' adaptor
sequence: 5' CTCGAGTTTTTTTTTTTTTTTTT 3'"
84 a 43 c 43 g 52 t

BASE COUNT

ORIGIN

Query Match 84.8%; Score 17.8; DB 9; Length 222;
Best Local Similarity 90.5%; Pred. No. 7.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 CCTCCTCTCGTCTGCTGTC 21
||||| ||||| ||||| |||||
Db 174 CCTCCTACCTGTTCTGCTGTC 154

Search completed: April 19, 2001, 23:25:00
Job time: 8177 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:03:44 ; Search time 280.46 seconds
(without alignments)
13.074 Million cell updates/sec

Title: US-09-016-464-18
Perfect score: 21
Sequence: 1 CCTCCTTCCTGCTGCTGCTGC 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 302621 seqs, 87301344 residues

Total number of hits satisfying chosen parameters: 605242

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA: *
1: /cgn2_6/ptodata/2/ina/5A_COMB.seq: *
2: /cgn2_6/ptodata/2/ina/5B_COMB.seq: *
3: /cgn2_6/ptodata/2/ina/6A_COMB.seq: *
4: /cgn2_6/ptodata/2/ina/6B_COMB.seq: *
5: /cgn2_6/ptodata/2/ina/FCUS_COMB.seq: *
6: /cgn2_6/ptodata/2/ina/backfiles1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	16.2	77.1	3517	2	US-08-642-406A-20
C 2	16.2	77.1	3517	3	US-08-434-000A-1
C 3	15.2	72.4	591	3	US-08-545-809A-17
C 4	15.2	72.4	868	2	US-08-993-228-15
C 5	15.2	72.4	1269	1	US-08-396-218-1
C 6	15.2	72.4	1269	1	US-08-760-116-1
C 7	15.2	72.4	2842	1	US-08-175-388-3
C 8	15.2	72.4	2842	2	US-08-779-620-3
C 9	15.2	72.4	2842	4	US-08-818-726-3
C 10	15.2	72.4	12311	4	US-08-750-717-1
C 11	14.8	70.5	1574	3	US-08-845-546-1
C 12	14.8	70.5	1736	1	US-08-518-474-7
C 13	14.8	70.5	3266	1	US-08-369-043-3
C 14	14.6	69.5	41	2	US-08-343-443B-24
C 15	14.6	69.5	648	1	US-08-681-812-1
C 16	14.6	69.5	658	4	US-08-792-013-5
C 17	14.6	69.5	1250	1	US-08-331-657-5
C 18	14.6	69.5	1894	3	US-07-728-220C-1
C 19	14.6	69.5	1953	3	US-08-826-246-1
C 20	14.6	69.5	1953	3	US-08-944-495-1
C 21	14.6	69.5	1953	3	US-09-126-640-1
C 22	14.6	69.5	3066	1	US-08-142-439A-1
C 23	14.6	69.5	3066	2	US-08-869-477-1
C 24	14.6	69.5	3403	4	US-08-448-489-2
C 25	14.6	69.5	3437	4	US-08-704-711A-9
C 26	14.6	69.5	3456	4	US-08-704-711A-8
C 27	14.6	69.5	3777	3	US-09-121-321-15

28	14.6	69.5	3907	4	US-08-475-742-1	Sequence 1, Appl
29	14.6	69.5	4406	1	US-08-369-043-1	Sequence 1, Appl
C 30	14.6	69.5	87350	3	US-08-781-891-79	Sequence 79, Appl
C 31	14.4	68.6	297	3	US-08-894-699-3	Sequence 3, Appl
C 32	14.4	68.6	358	2	US-08-713-052-1	Sequence 1, Appl
33	14.4	68.6	1371	2	US-08-428-713-1	Sequence 1, Appl
34	14.4	68.6	1371	3	US-08-904-179-1	Sequence 9, Appl
35	14.4	68.6	1374	2	US-08-428-713-9	Sequence 9, Appl
36	14.4	68.6	1374	3	US-08-904-179-9	Sequence 9, Appl
C 37	14.4	68.6	2474	2	US-08-666-392A-2	Sequence 2, Appl
C 38	14.4	68.6	2550	6	5258287-23	Patent No. 5258287
39	14.4	68.6	4157	2	US-08-162-146-2	Sequence 2, Appl
40	14.2	67.6	109	4	US-08-961-810-38	Sequence 38, Appl
41	14.2	67.6	109	4	US-08-352-902D-38	Sequence 38, Appl
C 42	14.2	67.6	152	1	US-08-136-277-15	Sequence 15, Appl
C 43	14.2	67.6	152	2	US-08-479-403-15	Sequence 15, Appl
C 44	14.2	67.6	152	3	US-08-835-734-15	Sequence 15, Appl
45	14.2	67.6	377	4	US-08-961-810-19	Sequence 19, Appl

ALIGNMENTS

RESULT 1
US-08-642-406A-20/c
; Sequence 20, Application US/08642406A
; Patent No. 5959177
; GENERAL INFORMATION:
; APPLICANT: Hein, Mich B.
; APPLICANT: Hiatt, Andrew C.
; APPLICANT: Ma, Julian K. C.
; TITLE OF INVENTION: TRANSGENIC PLANTS EXPRESSING ASSEMBLED
; TITLE OF INVENTION: SECRETORY ANTIBODIES
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: THE SCRIPPS RESEARCH INSTITUTE
; STREET: 10666 No. 5959177th Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: US
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/642,406A
; FILING DATE: 03-MAY-1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/591,823
; FILING DATE: 02-OCT-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/427,765
; FILING DATE: 27-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Logan, April C.
; REGISTRATION NUMBER: 33,950
; REFERENCE/DOCKET NUMBER: 184.2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 554-2937
; TELEFAX: (619) 554-6312
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3517 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-642-406A-20

APPLICANT: Agostino, Michael J.
TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genetics Institute, Inc.
STREET: 87 Cambridgepark Drive
CITY: Cambridge
STATE: MA
COUNTRY: U.S.A.
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/993,228
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Sprunger, Suzanne A.
REGISTRATION NUMBER: 41,323
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 498-8284
TELEFAX: (617) 876-5851
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 868 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-993-228-15

Query Match 72.4%; Score 15.2; DB 2; Length 868;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CCTCCTCTCTGGTCTGTCG 20
||||| |||| |||| ||||
DB 702 CCTCCTCTCTGGTCTGTCG 721

RESULT 5
US-08-396-218-1
Sequence 1, Application US/08396218
Patent No. 5695966
GENERAL INFORMATION:
APPLICANT: INVENTI, Augusto
APPLICANT: BREME, Umberto
APPLICANT: COLOMBO, Anna L
APPLICANT: HUTCHINSON, Charles R
APPLICANT: OTTEN, Sharee
APPLICANT: SCOTTI, Claudio
TITLE OF INVENTION: PROCESS FOR PREPARING DOXORUBICIN
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIKAIDO, MARMELSTEIN, MURRAY & ORAM
STREET: 655 Fifteenth Street, N. W., Suite 330 - G
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005-5701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/396,218

FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: KITTS, Monica C
REGISTRATION NUMBER: 36,105
REFERENCE/DOCKET NUMBER: P1615-5002
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202/638-5000
TELEFAX: 202/638-4810
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1269 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Streptomyces peucetius
FEATURE:
NAME/KEY: CDS
LOCATION: 1..1269
US-08-396-218-1

Query Match 72.4%; Score 15.2; DB 1; Length 1269;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 CTCCTTCCTGGTCTGTCGC 21
||||| |||| |||| ||||
DB 801 CTCCTTCCTGGTCTGTCGC 820

RESULT 6
US-08-760-116-1
Sequence 1, Application US/08760116
Patent No. 5786190
GENERAL INFORMATION:
APPLICANT: INVENTI, Augusto
APPLICANT: BREME, Umberto
APPLICANT: COLOMBO, Anna L
APPLICANT: HUTCHINSON, Charles R
APPLICANT: OTTEN, Sharee
APPLICANT: SCOTTI, Claudio
TITLE OF INVENTION: PROCESS FOR PREPARING DOXORUBICIN
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIKAIDO, MARMELSTEIN, MURRAY & ORAM LLP
STREET: 655 Fifteenth Street, N. W., Suite 330 - G
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005-5701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/760,116
FILING DATE: 3-DEC-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/396,218
FILING DATE: 27-FEB-1995
ATTORNEY/AGENT INFORMATION:
NAME: KITTS, Monica C
REGISTRATION NUMBER: 36,105
REFERENCE/DOCKET NUMBER: P1615-6007
TELECOMMUNICATION INFORMATION:

```
;
; TELEPHONE: 202/638-5000
; TELEFAX: 202/638-4810
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1269 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORGANISM: Streptomyces peucetius
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..1269
;
US-08-760-116-1

Query Match 72.4%; Score 15.2; DB 1; Length 1269;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 CTCCTTCCTGGTCTCTGCG 21
|||||
Db 801 CTCCTTCCTGGGCTCTCTGCG 820

RESULT 7
US-08-175-388-3
; Sequence 3, Application US/08175388
; Patent No. 5641674
; GENERAL INFORMATION:
; APPLICANT: DEHOUX, PIERRE
; TITLE OF INVENTION: Nucleotide Sequences and Proteins
; TITLE OF INVENTION: Conferring Cycloheximide Resistance
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 15-JUL-1991
; PRIOR APPLICATION NUMBER: FR 9108906
; FILING DATE: 09-JUN-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/FR92/00685
; FILING DATE: 15-JUL-1992
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1269 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORGANISM: Streptomyces peucetius
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..1269
;
US-08-760-116-1
```

```
;
; STRANDEDNESS: double
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-08-175-388-3

Query Match 72.4%; Score 15.2; DB 1; Length 2842;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTG 20
|||||
Db 259 CCTCCTTCCTGGTCTGTCTG 278

RESULT 8
US-08-779-620-3
; Sequence 3, Application US/08779620
; Patent No. 5830997
; GENERAL INFORMATION:
; APPLICANT: DEHOUX, PIERRE
; TITLE OF INVENTION: Nucleotide Sequences and Proteins
; TITLE OF INVENTION: Conferring Cycloheximide Resistance
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 15-JUL-1991
; PRIOR APPLICATION NUMBER: US/08/779,620
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/175,388
; FILING DATE: 09-JUN-1994
; APPLICATION NUMBER: PCT/FR92/00685
; FILING DATE: 15-JUL-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: FR 9108906
; FILING DATE: 15-JUL-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Oblon, No. 5830997man F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 660-071-0 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 413-3000
; TELEFAX: (703) 413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2842 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-08-779-620-3

Query Match 72.4%; Score 15.2; DB 2; Length 2842;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTG 20
```

```

Query Match      72.4%; Score 15.2; DB 2; Length 2842;
Best Local Similarity 85.0%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1 CCTCCTCTCGTCTGCTG 20
      ||| | ||||| |||||
Db      259 CCTTCTCTCGTCTGCTG 278

RESULT 10
US-08-750-717-1/c
; Sequence 1, Application US/08750717
; Patent No. 6180109
; GENERAL INFORMATION:
; APPLICANT: MOORMANN, Robertus J. M.
; APPLICANT: VAN RIJN, Petrus A.

```

CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/845,546
FILING DATE: 24-APR-1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Friebe, Thomas E.
REGISTRATION NUMBER: 29,258
REFERENCE/DOCKET NUMBER: 8607-018
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-790-9090
TELEFAX: 212-869-8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1574 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cdna
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 17...1543
OTHER INFORMATION:
US-08-845-546-1

Query Match 70.5%; Score 14.8; DB 3; Length 1574;
Best Local Similarity 88.9%; Pred. No. 2.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CCTTCTGGTCTGCTGC 21
||||||| |||||
Db 289 CCTTCTGGTCTGCTGC 272

RESULT 12
US-08-518-474-7
Sequence 7, Application US/08518474
Patent No. 5599920
GENERAL INFORMATION:
APPLICANT: Patel, Pragna I.
APPLICANT: Suter, Ueli
APPLICANT: Snipes, G. J.
APPLICANT: Welcher, Andrew
APPLICANT: DeLeon, Marino
APPLICANT: Lupski, James R.
APPLICANT: Shooter, Eric M.
TITLE OF INVENTION: PERIPHERAL MYELIN PROTEIN CODING
TITLE OF INVENTION: SEQUENCE AND METHOD
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77010-3095
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/518,474

FILING DATE: 21-AUG-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/308,488
FILING DATE: 19-SEP-1994
APPLICATION NUMBER: US 07/879,623
FILING DATE: 06-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5331-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 1736 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-518-474-7

Query Match 70.5%; Score 14.8; DB 1; Length 1736;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3 TCCTTCTGGTCTGCTG 20
||||| ||||| |||||
Db 434 TCCTTCTGGTCTGCTG 451

RESULT 13
US-08-369-043-3
Sequence 3, Application US/08369043
Patent No. 5491064
GENERAL INFORMATION:
APPLICANT: Lichy, Jack H
APPLICANT: Howley, Peter M
TITLE OF INVENTION: HTS1-Gene, A Human Tumor Suppressor Gene
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend
STREET: 1 Market Plaza, Steuart Tower, Suite 2000
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/369,043
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/916,762
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Weber, Kenneth A
REGISTRATION NUMBER: 31,677
REFERENCE/DOCKET NUMBER: 15280-65
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-543-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 3266 base pairs
TYPE: nucleic acid

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-369-043-3

Query Match 70.5%; Score 14.8; DB 1; Length 3266;

Best Local Similarity 88.9%; Pred. No. 2.5e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3 TCCTTCCTGCTGCTGCTG 20

Db 1074 TCCTTCCTGCTGCTGCTG 1091

RESULT 14

US-08-343-443B-24

; Sequence 24, Application US/08343443B

; Patent No. 5968734

; GENERAL INFORMATION:

; APPLICANT: Aurias, Alain

; APPLICANT: Delattre, Olivier

; APPLICANT: Desmaze, Chantal

; APPLICANT: Melot, Thomas

; APPLICANT: Peter, Martine

; APPLICANT: Ploougastel, Beatrice

; APPLICANT: Thomas, Gilles

; APPLICANT: Zucman, Jessica

; TITLE OF INVENTION: NUCLEIC ACID CORRESPONDING TO A GENE OF

; TITLE OF INVENTION: CHROMOSOME 22 INVOLVED IN RECURRENT CHROMOSOMAL

; TITLE OF INVENTION: TRANSLOCATIONS ASSOCIATED WITH THE DEVELOPMENT OF CANCEROUS

; TITLE OF INVENTION: TUMORS, AND NUCLEIC ACIDS OF FUSION RESULTING FROM SAID

; NUMBER OF SEQUENCES: 129

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Weiser & Associates

; STREET: 230 South Fifteenth Street

; CITY: Philadelphia

; STATE: PA

; COUNTRY: USA

; ZIP: 19102

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: AEDIT 1.0 DOS text editor

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/343,443B

; FILING DATE: 18-NOV-1994

; CLASSIFICATION: 514

; PRIOR APPLICATION NUMBER: PCT/FR93/00494

; FILING DATE: 19-MAY-1993

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: FR 92/06123

; FILING DATE: 20-MAY-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Weiser, Gerard J.

; REGISTRATION NUMBER: 19,763

; REFERENCE/DOCKET NUMBER: 989.6121P

; TELEPHONE: 215-875-8383

; TELEFAX: 215-875-8394

; INFORMATION FOR SEQ ID NO: 24:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 41 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

US-08-343-443B-24

Query Match 69.5%; Score 14.6; DB 2; Length 41;

Best Local Similarity 81.0%; Pred. No. 2.1e+02;

Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGCTGCTGCTG 21

Db 1 CCTCCTACCAAGTCAGTCTAC 21

RESULT 15

US-08-681-812-1/c

; Sequence 1, Application US/08681812

; Patent No. 5763593

; GENERAL INFORMATION:

; APPLICANT: Young, Richard A.

; APPLICANT: Gadbois, Ellen L.

; APPLICANT: Chao, David M.

; TITLE OF INVENTION: TBP-Associated Global Negative Regulator

; TITLE OF INVENTION: and Methods of Use Thereof

; NUMBER OF SEQUENCES: 7

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.

; STREET: Two Militia Drive

; CITY: Lexington

; STATE: Massachusetts

; COUNTRY: USA

; ZIP: 02173

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/681,812

; FILING DATE: 29-JUL-1996

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Granahan, Patricia

; REGISTRATION NUMBER: 32,227

; REFERENCE/DOCKET NUMBER: WH196-07

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 617-861-6240

; TELEFAX: 617-861-9540

; INFORMATION FOR SEQ ID NO: 1:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 648 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; MOLECULE TYPE: protein

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 109..534

US-08-681-812-1

Query Match 69.5%; Score 14.6; DB 1; Length 648;

Best Local Similarity 81.0%; Pred. No. 2.7e+02;

Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGCTGCTGCTG 21

Db 314 CCTATATCCTGCTGCTGCTG 294

Search completed: April 20, 2001, 00:03:45

Job time: 9682 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 03:21:23 ; Search time 11165 seconds.
(without alignments)
9.793 Million cell updates/sec

Title: US-09-016-464-18

Perfect score: 21

Sequence: 1 CCTCCTTCCTGGTCTGCTGC 21

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 13168883 seqs, 2603265903 residues

Total number of hits satisfying chosen parameters: 26337766

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_NA_Main.*

- 1: /cgn2_6/ptodata/2/pna/pctus_COMB.seq.*
- 2: /cgn2_6/ptodata/2/pna/US06_COMB.seq.*
- 3: /cgn2_6/ptodata/2/pna/US07_COMB.seq.*
- 4: /cgn2_6/ptodata/2/pna/US080_COMB.seq.*
- 5: /cgn2_6/ptodata/2/pna/US081_COMB.seq.*
- 6: /cgn2_6/ptodata/2/pna/US082_COMB.seq.*
- 7: /cgn2_6/ptodata/2/pna/US083_COMB.seq.*
- 8: /cgn2_6/ptodata/2/pna/US084_COMB.seq.*
- 9: /cgn2_6/ptodata/2/pna/US085_COMB.seq.*
- 10: /cgn2_6/ptodata/2/pna/US086_COMB.seq.*
- 11: /cgn2_6/ptodata/2/pna/US087_COMB.seq.*
- 12: /cgn2_6/ptodata/2/pna/US088_COMB.seq.*
- 13: /cgn2_6/ptodata/2/pna/US089_COMB.seq.*
- 14: /cgn2_6/ptodata/2/pna/US090_COMB.seq.*
- 15: /cgn2_6/ptodata/2/pna/US091_COMB.seq.*
- 16: /cgn2_6/ptodata/2/pna/US092_COMB.seq.*
- 17: /cgn2_6/ptodata/2/pna/US093_COMB.seq.*
- 18: /cgn2_6/ptodata/2/pna/US094_COMB.seq.*
- 19: /cgn2_6/ptodata/2/pna/US095A_COMB.seq.*
- 20: /cgn2_6/ptodata/2/pna/US095B_COMB.seq.*
- 21: /cgn2_6/ptodata/2/pna/US095C_COMB.seq.*
- 22: /cgn2_6/ptodata/2/pna/US095D_COMB.seq.*
- 23: /cgn2_6/ptodata/2/pna/US096A_COMB.seq.*
- 24: /cgn2_6/ptodata/2/pna/US096B_COMB.seq.*
- 25: /cgn2_6/ptodata/2/pna/US096C_COMB.seq.*
- 26: /cgn2_6/ptodata/2/pna/US096D_COMB.seq.*
- 27: /cgn2_6/ptodata/2/pna/US096E_COMB.seq.*
- 28: /cgn2_6/ptodata/2/pna/US097A_COMB.seq.*
- 29: /cgn2_6/ptodata/2/pna/US097B_COMB.seq.*
- 30: /cgn2_6/ptodata/2/pna/US097C_COMB.seq.*
- 31: /cgn2_6/ptodata/2/pna/US098_COMB.seq.*
- 32: /cgn2_6/ptodata/2/pna/US099_COMB.seq.*
- 33: /cgn2_6/ptodata/2/pna/US0001_COMB.seq.*
- 34: /cgn2_6/ptodata/2/pna/US0002_COMB.seq.*
- 35: /cgn2_6/ptodata/2/pna/US0003_COMB.seq.*
- 36: /cgn2_6/ptodata/2/pna/US0004_COMB.seq.*
- 37: /cgn2_6/ptodata/2/pna/US0005_COMB.seq.*
- 38: /cgn2_6/ptodata/2/pna/US0006_COMB.seq.*
- 39: /cgn2_6/ptodata/2/pna/US0007_COMB.seq.*
- 40: /cgn2_6/ptodata/2/pna/US0008_COMB.seq.*
- 41: /cgn2_6/ptodata/2/pna/US0009_COMB.seq.*
- 42: /cgn2_6/ptodata/2/pna/US0010_COMB.seq.*
- 43: /cgn2_6/ptodata/2/pna/US0011_COMB.seq.*

- 44: /cgn2_6/ptodata/2/pna/US0012_COMB.seq.*
- 45: /cgn2_6/ptodata/2/pna/US0013_COMB.seq.*
- 46: /cgn2_6/ptodata/2/pna/US0014_COMB.seq.*
- 47: /cgn2_6/ptodata/2/pna/US0015_COMB.seq.*
- 48: /cgn2_6/ptodata/2/pna/US0016_COMB.seq.*
- 49: /cgn2_6/ptodata/2/pna/US0017_COMB.seq.*
- 50: /cgn2_6/ptodata/2/pna/US0018_COMB.seq.*
- 51: /cgn2_6/ptodata/2/pna/US0019_COMB.seq.*
- 52: /cgn2_6/ptodata/2/pna/US0020_COMB.seq.*
- 53: /cgn2_6/ptodata/2/pna/US0021_COMB.seq.*
- 54: /cgn2_6/ptodata/2/pna/US0022_COMB.seq.*
- 55: /cgn2_6/ptodata/2/pna/US0023_COMB.seq.*
- 56: /cgn2_6/ptodata/2/pna/US0024_COMB.seq.*
- 57: /cgn2_6/ptodata/2/pna/US0025_COMB.seq.*
- 58: /cgn2_6/ptodata/2/pna/US0026_COMB.seq.*
- 59: /cgn2_6/ptodata/2/pna/US0027_COMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	21	100.0	21	8	US-08-474-497-18	Sequence 18, Appl
2	21	100.0	21	14	US-09-016-464-18	Sequence 18, Appl
3	21	100.0	51	49	US-60-172-373-19826	Sequence 19826, A
4	21	100.0	81	19	US-09-509-152A-1732	Sequence 1732, Ap
5	21	100.0	279	13	US-08-999-861-2798	Sequence 2798, Ap
6	21	100.0	279	20	US-09-535-896-10947	Sequence 10947, A
7	21	100.0	279	34	US-60-028-852-197	Sequence 197, App
8	21	100.0	485	49	US-60-171-481-482	Sequence 482, App
9	21	100.0	558	19	US-09-515-128-5435	Sequence 5435, Ap
10	21	100.0	601	20	US-09-535-896-15759	Sequence 15759, A
11	21	100.0	738	49	US-60-172-373-19824	Sequence 19824, A
12	21	100.0	815	49	US-60-172-373-7658	Sequence 7658, Ap
13	21	100.0	815	51	US-60-195-106-197	Sequence 197, App
14	21	100.0	1278	8	US-08-430-121-17	Sequence 17, Appl
15	21	100.0	7033	19	US-09-509-152A-2411	Sequence 2411, Ap
16	20	95.2	339	16	US-09-234-611-10970	Sequence 10970, A
17	20	95.2	339	16	US-09-289-788-16116	Sequence 16116, A
18	19.4	92.4	505	50	US-60-180-489-1191	Sequence 1191, Ap
19	18.4	87.6	191	18	US-09-421-813-102	Sequence 102, App
20	18.4	87.6	362	27	US-09-699-997-5628	Sequence 5628, Ap
21	18.4	87.6	472	55	US-60-236-359-2973	Sequence 2973, Ap
22	18.4	87.6	32768	52	US-60-200-331-42	Sequence 42, Appl
23	18	85.7	464	19	US-09-513-991-463	Sequence 463, App
24	17.8	84.8	201	21	US-09-540-229-108754	Sequence 108754, A
25	17.8	84.8	262	16	US-09-283-466-3927	Sequence 3927, Ap
26	17.8	84.8	262	17	US-09-304-517A-282082	Sequence 282082, A
27	17.8	84.8	298	17	US-09-304-517A-269818	Sequence 269818, A
28	17.8	84.8	298	22	US-09-565-240-17996	Sequence 17996, A
29	17.8	84.8	380	17	US-09-304-517A-230787	Sequence 230787, A
30	17.8	84.8	380	17	US-09-333-535A-3843	Sequence 3843, Ap
31	17.8	84.8	422	25	US-09-652-127-431	Sequence 431, App
32	17.8	84.8	430	40	US-60-089-524-368	Sequence 368, App
33	17.8	84.8	443	19	US-09-528-409-5585	Sequence 5585, Ap
34	17.8	84.8	484	53	US-60-211-750-26467	Sequence 26467, A
35	17.8	84.8	498	25	US-09-654-617-407467	Sequence 407467, A
36	17.8	84.8	498	27	US-09-684-016-407467	Sequence 407467, A
37	17.8	84.8	500	49	US-60-172-377-3206	Sequence 3206, Ap
38	17.8	84.8	520	25	US-09-654-617-5649	Sequence 5649, Ap
39	17.8	84.8	520	27	US-09-684-016-5649	Sequence 5649, Ap
40	17.8	84.8	619	50	US-60-186-662-440	Sequence 440, App
41	17.8	84.8	626	18	US-09-491-404-2088	Sequence 2088, Ap
42	17.8	84.8	629	27	US-09-699-998-1202	Sequence 1202, Ap
43	17.8	84.8	698	27	US-09-699-998-8453	Sequence 8453, Ap
44	17.8	84.8	698	54	US-60-226-326-5164	Sequence 5164, Ap
45	17.8	84.8	713	51	US-60-196-718-2943	Sequence 2943, Ap

ALIGNMENTS

```

RESULT 1
US-08-474-497-18
; Sequence 18, Application US/08474497
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,497
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-474-497-18

Query Match 100.0%; Score 21; DB 8; Length 21;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGTCTGC 21
Db 1 CCTCCTTCCTGGTCTGTCTGC 21

RESULT 2
US-09-016-464-18
; Sequence 18, Application US/09016464
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```

```

; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/016,464
; FILING DATE: 30-Jan-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/474,497
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-016-464-18

Query Match 100.0%; Score 21; DB 14; Length 21;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGTCTGC 21
Db 1 CCTCCTTCCTGGTCTGTCTGC 21

RESULT 3
US-60-172-373-19826/C
; Sequence 19826, Application US/60172373
; GENERAL INFORMATION:
; APPLICANT: Morris, MacDonald
; APPLICANT: Lal, Preethi
; APPLICANT: Diep, Dinh
; TITLE OF INVENTION: Method for the Identification of Sequence Polymorphisms Using
; FILE REFERENCE: GX-0006 P
; CURRENT APPLICATION NUMBER: US/60/172,373
; CURRENT FILING DATE: 1999-12-16
; NUMBER OF SEQ ID NOS: 25,772
; SOFTWARE: PERL Program
; SEQ ID NO 19826
; LENGTH: 51
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc-feature
; OTHER INFORMATION: Incyte ID No: SNP00031285
; FEATURE:
; NAME/KEY: snp
; LOCATION: 26
; OTHER INFORMATION: 444532.1, 443, G->C
US-60-172-373-19826

Query Match 100.0%; Score 21; DB 49; Length 51;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGTCTGC 21
Db 51 CCTCCTTCCTGGTCTGTCTGC 31

```



```

RESULT 4
US-09-509-152A-1732
; Sequence 1732, Application US/09509152A
; GENERAL INFORMATION:
; APPLICANT: NYCE, JONATHAN W.
; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
; FORMULATIONS, KITS & APPLICATIONS
; NUMBER OF SEQUENCES: 2419
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 CLARKE DRIVE
; CITY: CRANBURY
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/509,152A
; FILING DATE: 17-Mar-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/059,160
; FILING DATE: 1997-09-17
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00991
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1732:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 81 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1732:
US-09-509-152A-1732

Query Match 100.0%; Score 21; DB 19; Length 81;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCTGCTGCTGCTGC 21
Db 1 CCTCCTTCTGCTGCTGCTGC 21

RESULT 5
US-09-999-861-2798/c
; Sequence 2798, Application US/08999861
; GENERAL INFORMATION:
; APPLICANT: Gooding, Douglas H.
; APPLICANT: Stuve, Laura L.
; APPLICANT: Stuart, Susan G.
; APPLICANT: Ito, Laura Y.
; APPLICANT: Akerblom, Ingrid E.
; APPLICANT: Delegeane, Angelo M.
; APPLICANT: Naughton, Rebecca E.
; APPLICANT: Klingler, Tod M.
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM
; HUMAN UMBILICAL CORD MONONUCLEAR CELLS
; NUMBER OF SEQUENCES: 3972
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: INCYTE PHARMACEUTICALS, INC.
; STREET: 3174 PORTER DRIVE
; CITY: PALO ALTO

```

```

; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Word Perfect 6.1 for Windows/MS-DOS 6.2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/999,861
; FILING DATE: HERewith
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/020,972
; FILING DATE: JUNE 28, 1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/028,852
; FILING DATE: OCTOBER 23, 1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: CERRONE, MICHAEL C.
; REGISTRATION NUMBER: 39,132
; REFERENCE/DOCKET NUMBER: PD-0194 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 855-0555
; TELEFAX: (415) 845-4166
; INFORMATION FOR SEQ ID NO: 2798:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 279 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; IMMEDIATE SOURCE:
; CLONE: 1970414H1
; US-08-999-861-2798

Query Match 100.0%; Score 21; DB 13; Length 279;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCTGCTGCTGCTGC 21
Db 228 CCTCCTTCTGCTGCTGCTGC 208

RESULT 6
US-09-535-896-10947/c
; Sequence 10947, Application US/09535896
; GENERAL INFORMATION:
; APPLICANT: Seilhamer, Jeffrey J.
; APPLICANT: Delegeane, Angelo M.
; APPLICANT: Stuart, Susan G.
; APPLICANT: Stuve, Laura L.
; APPLICANT: Mullahy, Sara J.
; APPLICANT: Naughton, Rebecca E.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING OR REGULATING HYDROLASES
; FILE REFERENCE: PD-1003 CIP
; CURRENT APPLICATION NUMBER: US/09/535,896
; CURRENT FILING DATE: 2000-03-24
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 46268
; SOFTWARE: PERL Program
; SEQ ID NO 10947
; LENGTH: 279
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: hu00056993
; NAME/KEY: unsure

```

; LOCATION: 42, 109
; OTHER INFORMATION: a, t, c, g, or other
US-09-535-896-10947

Query Match 100.0%; Score 21; DB 20; Length 279;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTGC 21
|||||
Db 228 CCTCCTTCCTGGTCTGTCTGC 208

RESULT 7

US-60-028-852-197/c
; Sequence 197, Application US/60028852
; GENERAL INFORMATION:
; APPLICANT: Gooding, Douglas H.
; APPLICANT: Stuve, Laura L.
; APPLICANT: Stuart, Susan G.
; APPLICANT: Ito, Laura Y.
; APPLICANT: Akerdion, Ingrid E.
; APPLICANT: Delegeane, Angelo M.
; APPLICANT: Naughton, Rebecca E.
; APPLICANT: Klingler, Tod M.
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM
; TITLE OF INVENTION: HUMAN UMBILICAL CORD MONONUCLEAR CELLS
; NUMBER OF SEQUENCES: 1371
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: INCYTE PHARMACEUTICALS, INC.
; STREET: 3174 PORTER DRIVE
; CITY: PALO ALTO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Word Perfect 6.1 for Windows/MS-DOS 6.2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/60/028,852
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: CERRONE, MICHAEL C.
; REGISTRATION NUMBER: 39,132
; REFERENCE/DOCKET NUMBER: PD-0272P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 855-0555
; TELEFAX: (415) 845-4166
; INFORMATION FOR SEQ ID NO: 197:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 279 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; IMMEDIATE SOURCE:
; CLONE: 1970414H1

US-60-028-852-197

Query Match 100.0%; Score 21; DB 34; Length 279;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTGC 21
|||||
Db 228 CCTCCTTCCTGGTCTGTCTGC 208

RESULT 8

US-60-171-481-482/c
; Sequence 482, Application US/60171481
; GENERAL INFORMATION:
; APPLICANT: Bonazzl, Vivien
; TITLE OF INVENTION: ISOLATED HUMAN SECRETED PROTEINS,
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED PROTEINS AND
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: CL000169
; CURRENT APPLICATION NUMBER: US/60/171,481
; CURRENT FILING DATE: 1999-12-22
; NUMBER OF SEQ ID NOS: 1898
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 482
; LENGTH: 485
; TYPE: DNA
; ORGANISM: Human
US-60-171-481-482

Query Match 100.0%; Score 21; DB 49; Length 485;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTGC 21
|||||
Db 428 CCTCCTTCCTGGTCTGTCTGC 408

RESULT 9

US-09-515-128-5435/c
; Sequence 5435, Application US/09515128
; GENERAL INFORMATION:
; APPLICANT: Arterburn, Matthew
; APPLICANT: Asghari, Vida
; APPLICANT: Damavandi, Simin
; APPLICANT: Dickson, Mark
; APPLICANT: Drake, Jim
; APPLICANT: Drmanac, Radoje
; APPLICANT: Engleman, Carrie
; APPLICANT: Faulkner, Brandy
; APPLICANT: Garcia, Veronica
; APPLICANT: Gledt, Gretchen
; APPLICANT: Hunter, Kelly
; APPLICANT: Jessen, Aaron
; APPLICANT: Jones, Lee
; APPLICANT: Kita, David
; APPLICANT: Labat, Ivan
; APPLICANT: Laroya, Mimi
; APPLICANT: Lomelli, Michelle
; APPLICANT: Nguyen, Phuong
; APPLICANT: Nogra, Margie
; APPLICANT: Palencia, Servando
; APPLICANT: Raisi, Fariba
; APPLICANT: Smith, Benjamin
; APPLICANT: Tkach, Joe
; APPLICANT: Tran, Lien
; APPLICANT: Verna, Ron
; APPLICANT: Yang, Fei
; APPLICANT: Yim, Kenneth
; TITLE OF INVENTION: Novel Nucleic Acid Sequences Obtained
; TITLE OF INVENTION: From a cDNA Library of Fetal Liver-Spleen
; FILE REFERENCE: 728CIP
; CURRENT APPLICATION NUMBER: US/09/515,128
; CURRENT FILING DATE: 2000-02-28
; EARLIER APPLICATION NUMBER: 09/034,341
; EARLIER FILING DATE: 1998-02-13
; NUMBER OF SEQ ID NOS: 24489
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 5435
; LENGTH: 558
; TYPE: DNA
; ORGANISM: Homo sapiens

```
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(558)
; OTHER INFORMATION: n = A,T,C or G
US-09-515-128-5435

Query Match      100.0%; Score 21; DB 19; Length 558;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCTGGTCTGCTGCG 21
    |||||
Db 472 CCTCCTTCTGGTCTGCTGCG 452

RESULT 10
US-09-535-896-15759/c
; Sequence 15759, Application US/09535896
; GENERAL INFORMATION:
; APPLICANT: Seilhamer, Jeffrey J.
; APPLICANT: Deleageane, Angelo M.
; APPLICANT: Stuart, Susan G.
; APPLICANT: Stuve, Laura L.
; APPLICANT: Mullahy, Sara J.
; APPLICANT: Naughton, Rebecca E.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING OR REGULATING HYDROLASES
; FILE REFERENCE: PD-1003 CIP
; CURRENT APPLICATION NUMBER: US/09/535,896
; CURRENT FILING DATE: 2000-03-24
; Prior application data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 46268
; SOFTWARE: PERL Program
; SEQ ID NO 15759
; LENGTH: 601
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: hu01099445
US-09-535-896-15759

Query Match      100.0%; Score 21; DB 20; Length 601;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCTGGTCTGCTGCG 21
    |||||
Db 442 CCTCCTTCTGGTCTGCTGCG 422

RESULT 11
US-60-172-373-19824/c
; Sequence 19824, Application US/60172373
; GENERAL INFORMATION:
; APPLICANT: Morris, MacDonald
; APPLICANT: Lal, Preeti
; APPLICANT: Diep, Dinh
; TITLE OF INVENTION: Method for the Identification of Sequence Polymorphisms Using
; FILE REFERENCE: GX-0006 P
; CURRENT APPLICATION NUMBER: US/60/172,373
; CURRENT FILING DATE: 1999-12-16
; NUMBER OF SEQ ID NOS: 25,772
; SOFTWARE: PERL Program
; SEQ ID NO 19824
; LENGTH: 738
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: 444532.1

US-09-016-464-18.rnmpm

US-60-172-373-19824

Query Match      100.0%; Score 21; DB 49; Length 738;
Best Local Similarity 100.0%; Pred. No. 38;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCTGGTCTGCTGCG 21
    |||||
Db 468 CCTCCTTCTGGTCTGCTGCG 448

RESULT 12
US-60-172-373-7658/c
; Sequence 7658, Application US/60172373
; GENERAL INFORMATION:
; APPLICANT: Morris, MacDonald
; APPLICANT: Lal, Preeti
; APPLICANT: Diep, Dinh
; TITLE OF INVENTION: Method for the Identification of Sequence Polymorphisms Using
; FILE REFERENCE: GX-0006 P
; CURRENT APPLICATION NUMBER: US/60/172,373
; CURRENT FILING DATE: 1999-12-16
; NUMBER OF SEQ ID NOS: 25,772
; SOFTWARE: PERL Program
; SEQ ID NO 7658
; LENGTH: 815
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: 444532.3
US-60-172-373-7658

Query Match      100.0%; Score 21; DB 49; Length 815;
Best Local Similarity 100.0%; Pred. No. 38;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCTGGTCTGCTGCG 21
    |||||
Db 565 CCTCCTTCTGGTCTGCTGCG 545

RESULT 13
US-60-195-106-197/c
; Sequence 197, Application US/60195106
; GENERAL INFORMATION:
; APPLICANT: Shiffman, Dov
; APPLICANT: Somogyi, Roland
; APPLICANT: Lawn, Richard M.
; APPLICANT: Seilhamer, Jeffrey J.
; APPLICANT: Porter, Gordon J.
; APPLICANT: Mikita, Thomas
; APPLICANT: Tai, Julie T.N.
; TITLE OF INVENTION: GENES EXPRESSED IN FOAM CELL DIFFERENTIATION
; FILE REFERENCE: PA-0025 P
; CURRENT APPLICATION NUMBER: US/60/195,106
; CURRENT FILING DATE: 2000-04-05
; NUMBER OF SEQ ID NOS: 276
; SOFTWARE: PERL Program
; SEQ ID NO 197
; LENGTH: 815
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: 997377.1
US-60-195-106-197

Query Match      100.0%; Score 21; DB 51; Length 815;
```

Best Local Similarity 100.0%; Pred. No. 38;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGTCTGC 21
Db 565 CCTCCTTCCTGGTCTGTCTGC 545

RESULT 14

US-08-430-121-17/c
; Sequence 17, Application US/08430121
; GENERAL INFORMATION:
; APPLICANT: Simonsen, Christian C.
; APPLICANT: McGrogan, Michael
; TITLE OF INVENTION: Recombinant Products of an Eosinophilic
; TITLE OF INVENTION: Gene Family
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/430.121
; FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/232.859
FILING DATE:

APPLICATION NUMBER: US 07/630.976
FILING DATE: 19-DEC-1990
ATTORNEY/AGENT INFORMATION:

NAME: Shetka, Debra A.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 24842-20058.00
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-813-5600
TELEFAX: 415-494-0792
TELEX: 706141

INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 1278 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-430-121-17

Query Match 100.0%; Score 21; DB 8; Length 1278;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGTCTGC 21
Db 951 CCTCCTTCCTGGTCTGTCTGC 931

RESULT 15

US-09-509-152A-2411
; Sequence 2411, Application US/09509152A
; GENERAL INFORMATION:
; APPLICANT: NYCE, JONATHAN W.
; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
; FORMULATIONS, KITS & APPLICATIONS
; NUMBER OF SEQUENCES: 2419
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 CLARKE DRIVE
; CITY: CRANBURY
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/509.152A
; FILING DATE: 17-Mar-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/059,160
; FILING DATE: 1997-09-17
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00991
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2411:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7033 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2411:
US-09-509-152A-2411

Query Match 100.0%; Score 21; DB 19; Length 7033;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCTCCTTCCTGGTCTGTCTGC 21
Db 1 CCTCCTTCCTGGTCTGTCTGC 21

Search completed: April 20, 2001, 03:21:25
Job time: 14172 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:15:40 ; Search time 101.94 Seconds
(without alignments)
28.506 Million cell updates/sec

Title: US-09-016-464-18
Perfect score: 21
Sequence: 1 CCTCCTTCCTGCTGCTCTGTC 21
Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 46985 seqs, 69187998 residues

Total number of hits satisfying chosen parameters: 93970

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending_Patents_NA_New: *
1: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq: *
2: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq: *
3: /cgn2_6/ptodata/1/pna/US07_NEW_COMB.seq: *
4: /cgn2_6/ptodata/1/pna/US08_NEW_COMB.seq: *
5: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq: *
6: /cgn2_6/ptodata/1/pna/US60_NEW_COMB.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	21	100.0	81	5	US-09-543-679A-1732
2	21	100.0	715	5	US-09-543-679A-2861
3	21	100.0	718	5	US-09-543-679A-2860
4	21	100.0	1452	5	US-09-543-679A-2862
5	21	100.0	2885	5	US-09-543-679A-2863
6	21	100.0	7033	5	US-09-543-679A-2411
7	21	100.0	209274	5	US-09-543-679A-3004
8	17.4	82.9	11579	6	US-60-248-505-470
9	16.8	80.0	562	1	PCT-US01-01350-37
10	16.4	78.1	98744	6	US-60-248-505-30
11	16.2	77.1	289	4	US-08-276-163D-12910
12	16.2	77.1	509	4	US-08-276-163D-1918
13	16.2	77.1	13491	6	US-60-248-505-337
14	16.2	77.1	21287	6	US-60-248-505-415
15	16.2	77.1	124647	6	US-60-248-505-285
16	16.2	77.1	203032	6	US-60-248-505-308
17	15.8	75.2	408	4	US-08-276-163D-1780
18	15.8	75.2	504	4	US-08-276-163D-14029
19	15.8	75.2	771	5	US-09-739-449-8040
20	15.8	75.2	850	5	US-09-739-449-2264
21	15.8	75.2	56642	6	US-60-248-505-263
22	15.8	75.2	56643	6	US-60-248-505-572
23	15.4	73.3	510	4	US-08-276-163D-8563
24	15.2	72.4	436	1	PCT-US01-01351-595
25	15.2	72.4	722	6	US-60-248-505-1445
26	15.2	72.4	1375	6	US-60-248-505-1983
27	15.2	72.4	2004	5	US-09-739-449-6218

c 28	15.2	72.4	2674	5	US-09-817-199-1	Sequence 1, Appli
c 29	15.2	72.4	9685	6	US-60-248-505-113	Sequence 113, App
c 30	15.2	72.4	13182	5	US-09-817-199-3	Sequence 3, Appli
c 31	15.2	72.4	20341	6	US-60-248-505-651	Sequence 651, App
c 32	15.2	72.4	32696	6	US-60-248-505-281	Sequence 281, App
c 33	15.2	72.4	33702	6	US-60-248-505-465	Sequence 465, App
c 34	15.2	72.4	54477	6	US-60-248-505-143	Sequence 143, App
c 35	15.2	72.4	64927	6	US-60-248-505-262	Sequence 262, App
c 36	15.2	72.4	88789	5	US-09-739-449-199	Sequence 199, App
c 37	15.2	72.4	283061	6	US-60-248-505-134	Sequence 134, App
c 38	15.2	72.4	449171	6	US-60-248-505-42	Sequence 42, Appl
c 39	15	71.4	213456	5	US-09-820-007-3	Sequence 3, Appli
c 40	15	71.4	239630	6	US-60-248-505-158	Sequence 158, App
c 41	14.8	70.5	396	5	US-09-442-385-339	Sequence 339, App
c 42	14.8	70.5	499	4	US-08-276-163D-13266	Sequence 13266, A
c 43	14.8	70.5	5123	6	US-60-248-505-117	Sequence 117, App
c 44	14.8	70.5	13295	6	US-60-248-505-348	Sequence 348, App
c 45	14.8	70.5	13769	6	US-60-248-505-385	Sequence 385, App

ALIGNMENTS

RESULT 1
US-09-543-679A-1732
; Sequence 1732, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Anzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1732:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 81 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1732:
US-09-543-679A-1732

Query Match 100.0%; Score 21; DB 5; Length 81;
Best Local Similarity 100.0%; Pred. No. 0.34;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

NUMBER OF SEQUENCES: 3111
CORRESPONDENCE ADDRESS:

PRIOR APPLICATION DATA:

; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2862:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1452 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2862:
US-09-543-679A-2862

Query Match 100.0%; Score 21; DB 5; Length 1452;
Best Local Similarity 100.0%; Pred. No. 0.45;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGCTGCTGTCGC 21
|||||
DB 951 CCTCCTTCCTGCTGCTGTCGC 931

RESULT 5
US-09-543-679A-2863/c
; Sequence 2863, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2863:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2885 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2863:
US-09-543-679A-2863

Query Match 100.0%; Score 21; DB 5; Length 2885;
Best Local Similarity 100.0%; Pred. No. 0.48;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGCTGCTGTCGC 21
|||||
DB 2384 CCTCCTTCCTGCTGCTGTCGC 2364

RESULT 6
US-09-543-679A-2411
; Sequence 2411, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2411:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7033 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2411:
US-09-543-679A-2411

Query Match 100.0%; Score 21; DB 5; Length 7033;
Best Local Similarity 100.0%; Pred. No. 0.53;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGCTGCTGTCGC 21
|||||
DB 1 CCTCCTTCCTGCTGCTGTCGC 21

RESULT 7
US-09-543-679A-3004
; Sequence 3004, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; US-09-543-679A-3004

; CURRENT APPLICATION NUMBER: US/08/276,163D
; CURRENT FILING DATE: 1994-07-15
; NUMBER OF SEQ ID NOS: 15314
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 12910
; LENGTH: 289
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (51)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (156)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (270)
; OTHER INFORMATION: n equals a,t,g, or c
US-08-276-163D-12910

Query Match 77.1%; Score 16.2; DB 4; Length 289;
Best Local Similarity 85.7%; Pred. No. 49;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTGC 21
||||| ||| ||||| |||
Db 69 cctccatccaggctgtctgcagc 89

RESULT 12

US-08-276-163D-1918/c
; Sequence 1918, Application US/08276163D
; GENERAL INFORMATION:
; APPLICANT: Adams, et. al.
; TITLE OF INVENTION: Human Genes, Sequences, and Expression Products
; FILE REFERENCE: P014
; CURRENT APPLICATION NUMBER: US/08/276,163D
; CURRENT FILING DATE: 1994-07-15
; NUMBER OF SEQ ID NOS: 15314
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1918
; LENGTH: 509
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (33)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (112)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (138)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (144)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (347)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (376)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (402)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (404)
; OTHER INFORMATION: n equals a,t,g, or c

; NAME/KEY: misc feature
; LOCATION: (410)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (425)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (428)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (434)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (437)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (441)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (445)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (456)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (465)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (485)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (490)
; OTHER INFORMATION: n equals a,t,g, or c
US-08-276-163D-1918

Query Match 77.1%; Score 16.2; DB 4; Length 509;
Best Local Similarity 85.7%; Pred. No. 52;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTGC 21
||||| ||| ||||| |||
Db 174 CTTCTTCCTTGTCTGTTCG 154

RESULT 13

US-60-248-505-337
; Sequence 337, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: cl000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 337
; LENGTH: 13491
; TYPE: DNA
; ORGANISM: human
US-60-248-505-337

Query Match 77.1%; Score 16.2; DB 6; Length 13491;
Best Local Similarity 85.7%; Pred. No. 72;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CCTCCTTCCTGGTCTGTCTGC 21
||||| ||| ||||| |||
Db 7801 cctccctctctgttctctctgc 7821

RESULT 14
US-60-248-505-415
; Sequence 415, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 415
; LENGTH: 21287
; TYPE: DNA
; ORGANISM: human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)....(21287)
; OTHER INFORMATION: n = A,T,C or G
US-60-248-505-415

Query Match 77.1%; Score 16.2; DB 6; Length 21287;
Best Local Similarity 85.7%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1 CCTCCTTCCTGGTCTGTCTGC 21
||||| ||||| ||| |||||
Db 16179 cctccctcctgttctctctgc 16199

RESULT 15
US-60-248-505-285/C
; Sequence 285, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 285
; LENGTH: 124647
; TYPE: DNA
; ORGANISM: human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)....(124647)
; OTHER INFORMATION: n = A,T,C or G
US-60-248-505-285

Query Match 77.1%; Score 16.2; DB 6; Length 124647;
Best Local Similarity 85.7%; Pred. No. 86;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1 CCTCCTTCCTGGTCTGTCTGC 21
||||| ||||| ||| |||||
Db 69282 CCTCCTTCCTGGCTCTCTGC 69262

Search completed: April 20, 2001, 00:15:48
Job time: 9485 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:00:28 ; Search time 2028.86 Seconds
(without alignments)
60.703 Million cell updates/sec

Title: US-09-016-464-19
Perfect score: 20
Sequence: 1 GCCCTGCTGCTTCTGCT 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1283235 seqs, 3078962356 residues

Total number of hits satisfying chosen parameters: 2566470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl: *
1: gb_ba1: *
2: gb_ba2: *
3: gb_ba3: *
4: gb_in1: *
5: gb_in2: *
6: gb_in3: *
7: gb_om: *
8: gb_ov: *
9: gb_pat1: *
10: gb_pat2: *
11: gb_ph: *
12: gb_pl1: *
13: gb_pl2: *
14: gb_pl3: *
15: gb_pl4: *
16: em_ba1: *
17: em_ba2: *
18: em_fun: *
19: em_htgo_hum: *
20: em_htgo_inv: *
21: em_htgo_rod: *
22: em_htg_hum1: *
23: em_htg_hum2: *
24: em_htg_hum3: *
25: em_htg_hum4: *
26: em_htg_hum5: *
27: em_htg_hum6: *
28: em_htg_hum7: *
29: em_htg_hum8: *
30: em_htg_inv1: *
31: em_htg_inv2: *
32: em_htg_other: *
33: em_htg_rod: *
34: em_hum1: *
35: em_hum2: *
36: em_hum3: *
37: em_hum4: *
38: em_hum5: *
39: em_hum6: *
40: em_hum7: *
41: em_in: *
42: em_om: *
43: em_or: *

44: em_ov: *
45: em_pat: *
46: em_ph: *
47: em_pl: *
48: em_ro: *
49: em_sts: *
50: em_sy: *
51: em_un: *
52: em_vi: *
53: gb_sts1: *
54: gb_sts2: *
55: gb_sts3: *
56: gb_sy: *
57: gb_un: *
58: gb_vi1: *
59: gb_vi2: *
60: gb_htg1: *
61: gb_htg2: *
62: gb_htg3: *
63: gb_htg4: *
64: gb_htg5: *
65: gb_htg6: *
66: gb_htg7: *
67: gb_htg8: *
68: gb_htg9: *
69: gb_htg10: *
70: gb_htg11: *
71: gb_htg12: *
72: gb_htg13: *
73: gb_htg14: *
74: gb_htg15: *
75: gb_htg16: *
76: gb_htg17: *
77: gb_htg18: *
78: gb_htg19: *
79: gb_htg20: *
80: gb_htg21: *
81: gb_htg22: *
82: gb_htg23: *
83: gb_htg24: *
84: gb_htg25: *
85: gb_pr1: *
86: gb_pr2: *
87: gb_pr3: *
88: gb_pr4: *
89: gb_pr5: *
90: gb_pr6: *
91: gb_pr7: *
92: gb_pr8: *
93: gb_pr9: *
94: gb_ro1: *
95: gb_ro2: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20	100.0	1199	88	AF294027 Pan trogl
C 2	20	100.0	1199	88	AF294028 Pan trogl
C 3	20	100.0	1203	88	AF294019 Homo sapi
C 4	20	100.0	1203	88	AF294020 Homo sapi
C 5	20	100.0	1203	88	AF294021 Homo sapi
C 6	20	100.0	1203	88	AF294022 Homo sapi
C 7	20	100.0	1203	88	AF294023 Homo sapi
C 8	20	100.0	1203	88	AF294024 Homo sapi
C 9	20	100.0	1203	88	AF294025 Homo sapi
C 10	20	100.0	1203	88	AF294026 Homo sapi
C 11	20	100.0	1214	88	AF294007 Homo sapi

```
c 12 20 100.0 1214 88 AF294008
c 13 20 100.0 1214 88 AF294009 Homo sapi
c 14 20 100.0 1214 88 AF294010 Homo sapi
c 15 20 100.0 1214 88 AF294011 Homo sapi
c 16 20 100.0 1214 88 AF294012 Homo sapi
c 17 20 100.0 1214 88 AF294013 Homo sapi
c 18 20 100.0 1214 88 AF294014 Homo sapi
c 19 20 100.0 1214 88 AF294015 Homo sapi
c 20 20 100.0 1214 88 AF294016 Homo sapi
c 21 20 100.0 1214 88 AF294017 Pan trogl
c 22 20 100.0 1214 88 AF294018 Pan trogl
c 23 20 100.0 1347 91 HHSECRPG
c 24 20 100.0 1452 92 HSECP1
c 25 20 100.0 1489 92 HSEQSDN
c 26 20 100.0 1501 92 HSEQNG
c 27 20 100.0 1669 92 HSECPG
c 28 20 100.0 4050 91 D86343
c 29 20 100.0 157981 83 CNS05TD4
c 30 20 100.0 162472 83 CNS01DUW
c 31 19 95.0 142260 79 AL353892
c 32 19 95.0 165930 67 AC021401
c 33 19 95.0 210837 64 AC016432
c 34 18.4 92.0 57056 82 AP000637
c 35 18.4 92.0 184555 76 AC078961
c 36 18.4 92.0 190191 66 AC019077
c 37 18.4 92.0 193170 74 AC068652
c 38 18 90.0 118338 87 AC010463
c 39 18 90.0 163401 75 AC073251
c 40 18 90.0 179141 66 AC019091
c 41 18 90.0 274095 63 AC012295
c 42 17.4 87.0 5652 66 AC020212
c 43 17.4 87.0 45000 85 AB039887
c 44 17.4 87.0 47919 64 AC015044
c 45 17.4 87.0 84871 92 HSDU54G6
```

ALIGNMENTS

```
RESULT 1
AF294027/c
LOCUS AF294027 1199 bp DNA PRI 19-DEC-2000
DEFINITION Pan troglodytes haplotype 1 eosinophil cationic protein (ECP) gene,
complete cds.
ACCESSION AF294027
VERSION AF294027.1 GI:9954419
KEYWORDS
SOURCE chimpanzee.
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.
REFERENCE
AUTHORS Zhang,J. and Rosenberg,H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE
AUTHORS Zhang,J. and Rosenberg,H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NTAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1. .1199
/organism="Pan troglodytes"
/db_xref="taxon:9598"
/haplotype="1"
join(<209..276,503..1169)
/gene="ECP"
/product="eosinophil cationic protein"
<209..1169
/gene="ECP"
508..990
Query Match 100.0%; Score 20; DB 88; Length 1199;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
BASE COUNT 308 a 305 c 292 g 294 t
ORIGIN
/gene="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG09050.1"
/db_xref="GI:9954420"
/translation="MVPKLTSTQICLLLLGLMCGVSLHARPPQFTRAQWFAIQHLS
LNPRCTIAMRVINNYRWCKNQNTFLRTTFANVNVCGNOSIRCPHNRTLNCHQSR
FRVPLLCDDLINFGAQNISNCRYADRGRRFYVACDNRDRDPSRPRYPVPVHLDATI
"
Query Match 100.0%; Score 20; DB 88; Length 1199;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 GCCCTGCTGCTTCTTCTGCT 20
Db 66 GCCCTGCTGCTTCTTCTGCT 47
RESULT 2
AF294028/c
LOCUS AF294028 1199 bp DNA PRI 19-DEC-2000
DEFINITION Pan troglodytes haplotype 2 eosinophil cationic protein (ECP) gene,
complete cds.
ACCESSION AF294028
VERSION AF294028.1 GI:9954421
KEYWORDS
SOURCE chimpanzee.
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.
REFERENCE
AUTHORS Zhang,J. and Rosenberg,H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE
AUTHORS Zhang,J. and Rosenberg,H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NTAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1. .1199
/organism="Pan troglodytes"
/db_xref="taxon:9598"
/haplotype="2"
join(<209..276,503..1169)
/gene="ECP"
/product="eosinophil cationic protein"
<209..1169
/gene="ECP"
508..990
/gene="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG09051.1"
/db_xref="GI:9954422"
/translation="MVPKLTSTQICLLLLGLMCGVSLHARPPQFTRAQWFAIQHLS
LNPRCTIAMRVINNYRWCKNQNTFLRTTFANVNVCGNOSIRCPHNRTLNCHQSR
FRVPLLCDDLINFGAQNISNCRYADRGRRFYVACDNRDRDPSRPRYPVPVHLDATI
"
BASE COUNT 308 a 306 c 292 g 293 t
ORIGIN
Query Match 100.0%; Score 20; DB 88; Length 1199;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 GCCTGCTGCTCTTTCTGCT 20
Db 66 GCCTGCTGCTCTTTCTGCT 47

RESULT 3
AF294019/c 1203 bp DNA PRI 19-DEC-2000
LOCUS Homo sapiens haplotype 1 eosinophil cationic protein gene, complete
DEFINITION cds.
ACCESSION AF294019
VERSION AF294019.1 GI:11139039
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
TITLE 1 (bases 1 to 1203)
JOURNAL Zhang, J. and Rosenberg, H.F.
PUBMED Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
1102386
REFERENCE 2 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NTAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="1"
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
join(209..276,507..1173)
5'UTR join(209..276,507..1173)
Intron 277..506
exon /number=1
507..1173
/number=2
CDS 512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG31589.1"
/db_xref="GI:11139040"
/translation="MVPKLTQSICLLGLMVGESLHARPPQFTRAQWFAIQHIS
LNPPRCTAMRAINNYRWCKNQNTFLRTFANVYVCGNQSIKCPHNRITLNNCHRSR
FRVPLHCDLINPGAQNTISNCTYADPGRRFYVACDNRDPRDSRPYPVPVHLDTTI
"
3'UTR 995..1173
BASE COUNT 317 a 306 c 285 g 295 t
ORIGIN

Query Match 100.0%; Score 20; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCTGCTGCTCTTTCTGCT 20
Db 66 GCCTGCTGCTCTTTCTGCT 47

RESULT 4
AF294020/c 1203 bp DNA PRI 19-DEC-2000
LOCUS Homo sapiens haplotype 2 eosinophil cationic protein gene, complete
DEFINITION cds.
ACCESSION AF294020
VERSION AF294020.1 GI:11139041
```

```
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
TITLE 1 (bases 1 to 1203)
JOURNAL Zhang, J. and Rosenberg, H.F.
PUBMED Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
1102386
REFERENCE 2 (bases 1 to 1203)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NTAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="2"
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
join(209..276,507..1173)
5'UTR join(209..276,507..1173)
Intron 277..506
exon /number=1
507..1173
/number=2
CDS 512..994
/note="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG31590.1"
/db_xref="GI:11139042"
/translation="MVPKLTQSICLLGLMVGESLHARPPQFTRAQWFAIQHIS
LNPPRCTAMRAINNYRWCKNQNTFLRTFANVYVCGNQSIKCPHNRITLNNCHRSR
FRVPLHCDLINPGAQNTISNCTYADPGRRFYVACDNRDPRDSRPYPVPVHLDTTI
"
3'UTR 995..1173
BASE COUNT 318 a 303 c 287 g 295 t
ORIGIN

Query Match 100.0%; Score 20; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCTGCTGCTCTTTCTGCT 20
Db 66 GCCTGCTGCTCTTTCTGCT 47

RESULT 5
AF294021/c 1203 bp DNA PRI 19-DEC-2000
LOCUS Homo sapiens haplotype 3 eosinophil cationic protein gene, complete
DEFINITION cds.
ACCESSION AF294021
VERSION AF294021.1 GI:11139043
KEYWORDS human.
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.
TITLE 1 (bases 1 to 1203)
JOURNAL Zhang, J. and Rosenberg, H.F.
PUBMED Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
1102386
REFERENCE 2 (bases 1 to 1203)
```

AUTHORS Zhang, J. and Rosenberg, H.F.
 TITLE Direct Submission
 JOURNAL Submitted (08-AUG-2000) LHD/NIH/NTIH, Building 10, Room 11N104,
 9000 Rockville Pike, Bethesda, MD 20892, USA

FEATURES
 source
 1. .1203
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /haplotype="3"
 join(209..276,507..1173)
 /product="eosinophil cationic protein"
 209..276
 /number=1
 join(209..276,507..511)
 277..506
 /number=1
 507..1173
 /number=2
 512..994
 /note="ECP"
 /codon_start=1
 /product="eosinophil cationic protein"
 /protein_id="AAG31591.1"
 /db_xref="GI:11139044"
 /translation="MVPKLFTSQICLLLLGLMGVEGSLHARPPQFTRAOWFAIQHIS
 LNPPRCTIAMRAINNYWRCKNONTFLRTTFANVNVCGNOSIRCPHNRITLNNCHRSR
 FRVPLHCDLLNPGAQNISCTYADRGRRFYVACDNRDRDPSRPYPVVPVHLDTTI
 "

3'UTR 995..1173 317 a 305 c 286 g 295 t
 BASE COUNT
 ORIGIN

Query Match 100.0%; Score 20; DB 88; Length 1203;
 Best Local Similarity 100.0%; Pred. No. 9.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTGCT 20
 |||||
 Db 66 GCCCTGCTGCTCTTCTGCT 47

RESULT 6
 AF294022/c
 LOCUS AF294022 1203 bp DNA PRI 19-DEC-2000
 DEFINITION Homo sapiens haplotype 4 eosinophil cationic protein gene, complete
 cds.
 ACCESSION AF294022
 VERSION AF294022.1 GI:11139045
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 Zhang, J. and Rosenberg, H.F.
 TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
 in Humans
 JOURNAL Genetics 156 (4), 1949-1958 (2000)
 PUBMED 11102386
 REFERENCE 2 (bases 1 to 1203)
 AUTHORS Zhang, J. and Rosenberg, H.F.
 TITLE Direct Submission
 JOURNAL Submitted (08-AUG-2000) LHD/NIH/NTIH, Building 10, Room 11N104,
 9000 Rockville Pike, Bethesda, MD 20892, USA

FEATURES
 source
 1. .1203
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /haplotype="4"
 join(209..276,507..1173)
 /product="eosinophil cationic protein"
 209..276

mrna
 exon
 5'UTR
 intron
 exon
 CDS

/number=1
 join(209..276,507..511)
 277..506
 /number=1
 507..1173
 /number=2
 512..994
 /note="ECP"
 /codon_start=1
 /product="eosinophil cationic protein"
 /protein_id="AAG31592.1"
 /db_xref="GI:11139046"
 /translation="MVPKLFTSQICLLLLGLMGVEGSLHARPPQFTRAOWFAIQHIS
 LNPPRCTIAMRAINNYWRCKNONTFLRTTFANVNVCGNOSIRCPHNRITLNNCHRSR
 FRVPLHCDLLNPGAQNISCRYADRGRRFYVACDNRDRDPSRPYPVVPVHLDTTI
 "

3'UTR 995..1173 317 a 304 c 287 g 295 t
 BASE COUNT
 ORIGIN

Query Match 100.0%; Score 20; DB 88; Length 1203;
 Best Local Similarity 100.0%; Pred. No. 9.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTGCT 20
 |||||
 Db 66 GCCCTGCTGCTCTTCTGCT 47

RESULT 7
 AF294023/c
 LOCUS AF294023 1203 bp DNA PRI 19-DEC-2000
 DEFINITION Homo sapiens haplotype 5 eosinophil cationic protein gene, complete
 cds.
 ACCESSION AF294023
 VERSION AF294023.1 GI:11139047
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 Zhang, J. and Rosenberg, H.F.
 TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
 in Humans
 JOURNAL Genetics 156 (4), 1949-1958 (2000)
 PUBMED 11102386
 REFERENCE 2 (bases 1 to 1203)
 AUTHORS Zhang, J. and Rosenberg, H.F.
 TITLE Direct Submission
 JOURNAL Submitted (08-AUG-2000) LHD/NIH/NTIH, Building 10, Room 11N104,
 9000 Rockville Pike, Bethesda, MD 20892, USA

FEATURES
 source
 1. .1203
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /haplotype="5"
 join(209..276,507..1173)
 /product="eosinophil cationic protein"
 209..276
 /number=1
 join(209..276,507..511)
 277..506
 /number=1
 507..1173
 /number=2
 512..994
 /note="ECP"
 /codon_start=1
 /product="eosinophil cationic protein"
 /protein_id="AAG31593.1"
 /db_xref="GI:11139048"


```
VERSION AF294026.1 GI:11139053
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 1203)
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE
AUTHORS 2 (bases 1 to 1203)
TITLE Direct Submission
AUTHORS Zhang, J. and Rosenberg, H.F.
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1..1203
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="8"
join(209..276,507..1173)
/product="eosinophil cationic protein"
209..276
/number=1
join(209..276,507..511)
5'UTR join(209..276,507..511)
Intron join(209..276,507..511)
exon 507..1173
CDS 512..994
/feature="ECP"
/codon_start=1
/product="eosinophil cationic protein"
/protein_id="AAG31596.1"
/db_xref="GI:11139054"
/translation="MVPKLETSQICLLLLGLMGVEGSLHARPPQFTRAQWFAIQHLS
LNPRPFIAMRAINNYRRCKNQNTFTFANVNVCGNOSICPNRTLNCHRRS
FRVPLHCDLNPQAQNSICRYADRGRRFYVACDNRDPRDSPRYVPVPHLDFTI
"
3'UTR 995..1173
BASE COUNT 316 a 305 c 287 g 295 t
ORIGIN
Query Match 100.0%; Score 20; DB 88; Length 1203;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 66 GCCCTGCTGCTCTTTCTGCT 47
RESULT 11
AF294007/c
LOCUS AF294007 1214 bp DNA PRI 19-DEC-2000
DEFINITION Homo sapiens haplotype 1 eosinophil-derived neurotoxin gene,
complete cds.
ACCESSION AF294007
VERSION AF294007.1 GI:11139015
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 1214)
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
```

```
REFERENCE 2 (bases 1 to 1214)
AUTHORS Zhang, J. and Rosenberg, H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1..1214
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="1"
join(245..314,541..1209)
/product="eosinophil-derived neurotoxin"
join(245..314,541..545)
245..314
/number=1
315..540
/number=1
541..1209
/number=2
546..1031
/feature="EDN; eosinophil-associated ribonuclease"
/codon_start=1
/product="eosinophil-derived neurotoxin"
/protein_id="AAG31577.1"
/db_xref="GI:11139016"
/translation="MVPKLETSQICLLLLGLLAVEGSLHVKPPQFTWAQWFFETQHIN
MTOQCCTNMQVNNYRRCKNQNTFTFANVNVCGNPNMTCPSNKRKNCCHSG
SQVPLIHCLNTTPSPQNSICRYAQTTPANMFYIVACDNRDQRRDPPQYPPVPHLDRI
I"
3'UTR 1032..1209
BASE COUNT 341 a 317 c 264 g 292 t
ORIGIN
Query Match 100.0%; Score 20; DB 88; Length 1214;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 66 GCCCTGCTGCTCTTTCTGCT 47
RESULT 12
AF294008/c
LOCUS AF294008 1214 bp DNA PRI 19-DEC-2000
DEFINITION Homo sapiens haplotype 2 eosinophil-derived neurotoxin gene,
complete cds.
ACCESSION AF294008
VERSION AF294008.1 GI:11139017
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 1214)
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE
AUTHORS 2 (bases 1 to 1214)
TITLE Direct Submission
AUTHORS Zhang, J. and Rosenberg, H.F.
JOURNAL Submitted (08-AUG-2000) LHD/NIAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1..1214
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="2"
join(245..314,541..1209)
/product="eosinophil-derived neurotoxin"
mrna
```


Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTGCT 20
Db 66 GCCCTGCTGCTCTTCTGCT 47

RESULT 15
AF294011/c 1214 bp DNA PRI 19-DEC-2000
LOCUS Homo sapiens haplotype 5 eosinophil-derived neurotoxin gene,
DEFINITION complete cds.
ACCESSION AF294011
VERSION AF294011.1 GI:11139023
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1214)
AUTHORS Zhang,J. and Rosenberg,H.F.
TITLE Sequence Variation at Two Eosinophil-Associated Ribonuclease Loci
in Humans
JOURNAL Genetics 156 (4), 1949-1958 (2000)
PUBMED 11102386
REFERENCE 2 (bases 1 to 1214)
AUTHORS Zhang,J. and Rosenberg,H.F.
TITLE Direct Submission
JOURNAL Submitted (08-AUG-2000) LHD/NTAID/NIH, Building 10, Room 11N104,
9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1. 1214
/organism="Homo sapiens"
/db_xref="taxon:9606"
/haplotype="5"
join(245..314,541..1209)
/product="eosinophil-derived neurotoxin"
join(245..314,541..545)
245..314
/number=1
315..540
/number=1
541..1209
/number=2
546..1031
/note="EDN; eosinophil-associated ribonuclease"
/codon_start=1
/product="eosinophil-derived neurotoxin"
/protein_id="AAG31581.1"
/db_xref="GI:11139024"
/translation="MVPKLETSOICLLLLGLLAVGSLHVKPQFTWAQWFEYOHIN
MTSQCTNMQVINYORRCKNONTFLTTFANVVVCGNPNTCPNSKTRKKCHHSG
SQVPLIHCNLTTPSPQNISCRYAQTAPNMFYIVACDNRDORRDPQYPPVPHLDRI
I"
3'UTR 1032..1209
BASE COUNT 341 a 318 c 264 g 291 t
ORIGIN

Query Match 100.0%; Score 20; DB 88; Length 1214;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTGCT 20
Db 66 GCCCTGCTGCTCTTCTGCT 47

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:12:59 ; Search time 547.68 Seconds
(without alignments) /
21.318 Million cell updates/sec

Title: US-09-016-464-19

Perfect score: 20

Sequence: 1 GCCTGCTGCTCTTCTGCT 20

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 678276 seqs, 291890651 residues

Total number of hits satisfying chosen parameters: 1356552

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_0401.*

- 1: /SIDS2/gcgdata/geneseq/geneseq/NA1980.DAT.*
- 2: /SIDS2/gcgdata/geneseq/geneseq/NA1981.DAT.*
- 3: /SIDS2/gcgdata/geneseq/geneseq/NA1982.DAT.*
- 4: /SIDS2/gcgdata/geneseq/geneseq/NA1983.DAT.*
- 5: /SIDS2/gcgdata/geneseq/geneseq/NA1984.DAT.*
- 6: /SIDS2/gcgdata/geneseq/geneseq/NA1985.DAT.*
- 7: /SIDS2/gcgdata/geneseq/geneseq/NA1986.DAT.*
- 8: /SIDS2/gcgdata/geneseq/geneseq/NA1987.DAT.*
- 9: /SIDS2/gcgdata/geneseq/geneseq/NA1988.DAT.*
- 10: /SIDS2/gcgdata/geneseq/geneseq/NA1989.DAT.*
- 11: /SIDS2/gcgdata/geneseq/geneseq/NA1990.DAT.*
- 12: /SIDS2/gcgdata/geneseq/geneseq/NA1991.DAT.*
- 13: /SIDS2/gcgdata/geneseq/geneseq/NA1992.DAT.*
- 14: /SIDS2/gcgdata/geneseq/geneseq/NA1993.DAT.*
- 15: /SIDS2/gcgdata/geneseq/geneseq/NA1994.DAT.*
- 16: /SIDS2/gcgdata/geneseq/geneseq/NA1995.DAT.*
- 17: /SIDS2/gcgdata/geneseq/geneseq/NA1996.DAT.*
- 18: /SIDS2/gcgdata/geneseq/geneseq/NA1997.DAT.*
- 19: /SIDS2/gcgdata/geneseq/geneseq/NA1998.DAT.*
- 20: /SIDS2/gcgdata/geneseq/geneseq/NA1999.DAT.*
- 21: /SIDS2/gcgdata/geneseq/geneseq/NA2000.DAT.*
- 22: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20	100.0	20	18 T76120	Human eosinophil d
2	20	100.0	20	20 X53926	Eosinophil derived
3	20	100.0	20	21 F19488	Human eosinophil d
4	20	100.0	20	21 A33366	Low adenosine anti
5	20	100.0	156	20 X54599	Eosinophil derived
6	20	100.0	156	21 F20168	Human eosinophil d
7	20	100.0	156	21 A34046	Human adenosine re
8	20	100.0	1452	21 F21295	Human low adenosin
9	20	100.0	1452	21 A35173	Human adenosine re
10	20	100.0	1489	21 F21298	Human low adenosin
11	20	100.0	1489	21 A35176	Human adenosine re

c 12	20	100.0	2885	21	F21296
c 13	20	100.0	2885	21	A35174
c 14	20	100.0	2918	21	F21300
c 15	20	100.0	2918	21	A35178
c 16	20	100.0	7033	21	F20844
c 17	20	100.0	7033	21	A34722
c 18	20	100.0	7036	20	X55274
c 19	20	100.0	114955	20	X53491
c 20	20	100.0	209273	21	F21437
c 21	16.8	84.0	1788	21	250894
c 22	16.8	84.0	2156	12	Q11562
c 23	16.8	84.0	24978	20	X60209
c 24	16.8	84.0	24979	21	A52321
c 25	16.4	82.0	112	16	T25011
c 26	16.4	82.0	483	21	253900
c 27	16.4	82.0	483	21	253901
c 28	16.4	82.0	483	21	253902
c 29	16.4	82.0	492	20	X25393
c 30	16.4	82.0	504	21	A08556
c 31	16.4	82.0	527	21	C50576
c 32	16.4	82.0	529	21	C34033
c 33	16.4	82.0	568	21	C36175
c 34	16.4	82.0	656	21	F12854
c 35	16.4	82.0	938	21	C54851
c 36	16.4	82.0	941	21	C52389
c 37	16.4	82.0	1273	21	T61417
c 38	16.4	82.0	2163	20	X25394
c 39	16.4	82.0	2290	19	V27356
c 40	16.4	82.0	2359	19	V52376
c 41	16.4	82.0	2478	21	A08557
c 42	16.4	82.0	2481	21	A05417
c 43	16.4	82.0	2523	21	A65731
c 44	16.4	82.0	2531	21	A47602
c 45	16.4	82.0	2531	21	A47605

ALIGNMENTS

RESULT 1	
T76120	ID T76120 standard; DNA; 20 BP.
XX	XX
AC	T76120;
XX	XX
DT	12-SEP-1997 (first entry)
XX	XX
DE	Human eosinophil derived neurotoxin antisense oligonucleotide.
XX	XX
KW	Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW	chronic obstructive pulmonary disease; bronchitis; ss.
XX	XX
OS	Synthetic.
XX	XX
PN	WO9640162-A1.
XX	XX
PD	19-DEC-1996.
XX	XX
PF	06-JUN-1996; 96WO-US09306.
XX	XX
PR	07-JUN-1995; 95US-0474497.
XX	XX
PA	(UYEC-) UNIV EAST CAROLINA.
XX	XX
PI	Metzger WJ, Nyce JW;
XX	XX
DR	WPI; 1997-051871/05.
XX	XX
PT	Treatment of airway diseases such as asthma - by topically applying
PT	adenosine-free antisense oligonucleotide to airway epithelium of
XX	subject
XX	XX
PS	Claim 5; Page 27; 71pp; English.

XX A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide
 CC HSPGONAS1 specific for the human eosinophil derived neurotoxin. The
 CC method can be used to treat airway diseases such as cystic fibrosis,
 CC asthma, chronic obstructive pulmonary disease, bronchitis and other
 CC airway diseases characterised by an inflammatory response. By
 CC eliminating adenosine from the antisense ON, its liberation upon
 CC antisense degradation is prevented, thereby preventing adenosine-
 CC induced bronchoconstriction in patients with hyper-reactive airways.
 XX
 SQ Sequence 20 BP; 0 A; 8 C; 4 G; 8 T; 0 other;
 Query Match 100.0%; Score 20; DB 18; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCCTGCTGCTCTTCTGCT 20
 Db 1 ggcctgctgctcttctgct 20
 RESULT 2
 X53926
 ID X53926 standard; DNA; 20 BP.
 XX
 AC X53926;
 XX
 DT 05-JUL-1999 (first entry)
 XX
 DE Eosinophil derived neurotoxin antisense oligonucleotide fragment.
 XX
 KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX
 OS Synthetic.
 XX
 PN WO9913886-A1.
 XX
 PD 25-MAR-1999.
 XX
 PF 17-SEP-1998; 98WO-US19419.
 XX
 PR 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW;
 XX
 DR WPI; 1999-229400/19.
 XX
 PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction
 XX
 PS Disclosure; Page 46; 120pp; English.
 XX
 CC The specification describes antisense oligonucleotides (X52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding

CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences X55272-74. These multiple target
 CC oligonucleotides (specifically X55180-271) can be used for the antisense
 CC treatment of diseases and conditions. Typical diseases and conditions
 CC are those associated with impaired respiration and inflammation,
 CC including lung diseases, pulmonary vasoconstriction, inflammation,
 CC allergic rhinitis, acute asthma, allergies, asthma, impeded respiration,
 CC respiratory distress syndrome, pain, cystic fibrosis, pulmonary
 CC hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic
 CC cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic
 CC metastases, as well as all types of cancers which may metastasize or have
 CC metastasized to the lungs, including breast and prostate cancer.
 XX
 SQ Sequence 20 BP; 0 A; 8 C; 4 G; 8 T; 0 other;
 Query Match 100.0%; Score 20; DB 20; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCCTGCTGCTCTTCTGCT 20
 Db 1 ggcctgctgctcttctgct 20
 RESULT 3
 F19488
 ID F19488 standard; DNA; 20 BP.
 XX
 AC F19488;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 DE Human eosinophil derived neurotoxin polynucleotide fragment #1055.
 XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200062736-A2.
 XX
 PD 26-OCT-2000.
 XX
 PR 24-MAR-2000; 2000WO-US08020.
 XX
 PR 06-APR-1999; 99US-0127958.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-679539/66.
 XX
 PT Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX
 PS Claim 14; Page 142; 1592pp; English.
 XX
 CC The present invention describes low adenosine (A) content antisense

CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiallergic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors and
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.

XX Sequence 20 BP; 0 A; 8 C; 4 G; 8 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTCTTCTGCT 20
 Db ||||||

RESULT 4
 A33366 ID A33366 standard; DNA; 20 BP.

XX A33366;

XX 28-JUL-2000 (first entry)

XX Low adenosine antisense oligonucleotide SEQ ID NO:1055.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

XX WO200009525-A2.

XX 24-FEB-2000.

XX 03-AUG-1999; 99WO-US17172.

XX 03-AUG-1998; 98US-0095212.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers

XX Claim 18; Page 397; 1343pp; English.

XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.

XX Sequence 20 BP; 0 A; 8 C; 4 G; 8 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTCTTCTGCT 20

Db ||||||

RESULT 5

X54599 ID X54599 standard; DNA; 156 BP.

XX X54599;

XX 05-JUL-1999 (first entry)

XX Eosinophil derived neurotoxin antisense oligonucleotide fragment.

XX Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.

XX Synthetic.

XX WO9913886-A1.

XX

PD 25-MAR-1999.
 XX 17-SEP-1998; 98WO-US19419.
 XX 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX (UYEC-) UNIV EAST CAROLINA.
 PA Nyce JW;
 XX WPI: 1999-229400/19.
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction
 PT Disclosure; Page 46; 120pp; English.
 PS The specification describes antisense oligonucleotides (X52869-X55271)
 XX directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences X55272-74. These multiple target
 CC oligonucleotides (specifically X55180-271) can be used for the antisense
 CC treatment of diseases and conditions. Typical diseases and conditions
 CC are those associated with impaired respiration and inflammation,
 CC including lung diseases, pulmonary vasoconstriction, inflammation,
 CC allergic rhinitis, acute asthma, allergies, asthma, impeded respiration,
 CC respiratory distress syndrome, pain, cystic fibrosis, pulmonary
 CC hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic
 CC cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic
 CC metastases, as well as all types of cancers which may metastasize or have
 CC metastasized to the lungs, including breast and prostate cancer.
 XX Sequence 156 BP; 0 A; 41 C; 44 G; 51 T; 20 other;
 SQ

Query Match 100.0%; Score 20; DB 20; Length 156;
 Best Local Similarity 100.0%; Pred. No. 9.4;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
 |||||
 Db 1 gccctgctgctcttctgct 20

RESULT 6
 F20168
 ID F20168 standard; DNA; 156 BP.
 XX F20168;
 AC
 XX 14-MAR-2001 (first entry)
 DT
 XX Human eosinophil derived neurotoxin polynucleotide fragment #1735.
 DE Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX Homo sapiens.
 OS

XX WO200062736-A2.
 XX 26-OCT-2000.
 XX 24-MAR-2000; 2000WO-US08020.
 PF 06-APR-1999; 99US-0127958.
 XX (UYEC-) UNIV EAST CAROLINA..
 PA (NYCE/) NYCE J W.
 XX Nyce JW;
 PI WPI: 2000-679539/66.
 DR Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX Claim 14; Page 142; 1592pp; English.
 PS The present invention describes low adenosine (A) content antisense
 XX oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.
 XX Sequence 156 BP; 0 A; 41 C; 44 G; 51 T; 20 other;

Query Match 100.0%; Score 20; DB 21; Length 156;
 Best Local Similarity 100.0%; Pred. No. 9.4;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
 |||||
 Db 1 gccctgctgctcttctgct 20

RESULT 7
 A34046
 ID A34046 standard; DNA; 156 BP.
 XX AC A34046;
 XX 28-JUL-2000 (first entry)
 DT
 XX Human adenosine receptor related polynucleotide SEQ ID NO:1735.
 DE

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX Homo sapiens.
 OS
 XX WO200009525-A2.
 PN
 XX 24-FEB-2000.
 PD
 XX 03-AUG-1999; 99WO-US17712.
 PF
 XX 03-AUG-1998; 98US-0095212.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Nyce JW;
 PI
 XX WPI; 2000-205971/18.
 DR
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension, or
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX
 XX Disclosure: Page 480; 1343pp; English.
 PS
 XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.
 XX
 SQ Sequence 156 BP; 0 A; 41 C; 44 G; 51 T; 20 other;

Query Match 100.0%; Score 20; DB 21; Length 156;
 Best Local Similarity 100.0%; Pred. No. 9.4; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0

QY 1 GCCCTGCTCTTCTTCTGCT 20
 |||||
 Db 1 gccctgctcttcttctgct 20

RESULT 8
 F21295/c

ID
 XX F21295 standard; DNA; 1452 BP.
 AC
 XX F21295;
 DT
 XX 14-MAR-2001 (first entry)
 DE
 XX Human low adenosine antisense oligonucleotide related sequence #2862.
 KW
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200062736-A2.
 XX
 XX 26-OCT-2000.
 PD
 XX 24-MAR-2000; 2000WO-US08020.
 XX
 PF 06-APR-1999; 99US-0127958.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX (NYCE/) NYCE J W.
 XX
 XX Nyce JW;
 PI
 XX WPI; 2000-679539/66.
 DR
 XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX
 XX Disclosure: Page 1288-1289; 1592pp; English.
 PS
 XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.
 XX
 XX Sequence 1452 BP; 380 A; 376 C; 323 G; 373 T; 0 other;

CC	differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
CC	to A33992) are specifically claimed ONS from the present invention.
CC	N.B. Sequences given in the disclosure of the present invention do not
CC	match up with their corresponding SEQ ID NO: sequences given in the
CC	sequence listing.
XX	
SQ	Sequence 1452 BP; 380 A; 376 C; 323 G; 373 T; 0 other;
Query Match	100.0%; Score 20; DB 21; Length 1452;
Best Local Similarity	100.0%; Pred. No. 11;
Matches 20; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	1 GCCCTGCTGCTCTTTCTGCT 20 TTTTTTTTTTTT
Db	110 GCCCTGCTGCTCTTTCTGCT 91
RESULT 10	
F21298/c	ID ID F21298 standard; DNA; 1489 BP.
XX	
AC	F21298;
XX	
DT	14-MAR-2001 (first entry)
DE	
XX	Human low adenosine antisense oligonucleotide related sequence #2865.
KW	Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW	human; airway disorder; bronchoconstriction; lung inflammation;
KW	surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW	immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW	respiratory obstruction; pulmonary vasoconstriction; impeded respiration;
KW	surfactant hypoproduction; pulmonary obstruction; asthma; RDS;
KW	respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW	pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW	chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW	cancer; ss.
OS	Homo sapiens.
XX	
PN	WO200062736-A2.
XX	
PD	26-OCT-2000.
XX	
PF	24-MAR-2000; 2000WO-US08020.
XX	
PR	06-APR-1999; 99US-0127958.
XX	
PA	(UYEC-) UNIV EAST CAROLINA.
PA	(NYCE/) NYCE J W.
XX	
PI	Nyce JW;
XX	
DR	WIPI; 2000-679539/66.
XX	
PT	Low adenosine (A) content antisense oligonucleotides which do not
PT	trigger adenosine receptors during metabolism, useful e.g. for treating
PT	cancers and respiratory obstructions -
XX	
PS	Disclosure; Page 1290; 1592pp; English.
XX	
CC	The present invention describes low adenosine (A) content antisense
CC	oligonucleotides and compositions (I) comprising them. In the antisense
CC	oligonucleotides the A is replaced by a 'universal' or alternative base.
CC	{I} can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC	immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC	The antisense oligonucleotides and (I) can be used to down-regulate the
CC	expression and/or activity of target polypeptides associated with
CC	lung/respiratory disorders and malignancies, such as stimulating and
CC	activating peptide factors and transmitters, transcription factors,
CC	immunoglobulins and antibodies, antibody receptors, cytokines and
CC	chemokines, endogenously produced specific and non-specific enzymes,

CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impaired respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.
 XX
 SQ Sequence 1489 BP: 411 A; 381 C; 320 G; 377 T; 0 other;
 Query Match 100.0%; Score 20; DB 21; Length 1489;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCCTGCTGCTTTCTGCT 20
 Db 110 GCCCTGCTGCTTTCTGCT 91
 RESULT 11
 ID A35176/c
 XX
 AC A35176;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Human adenosine receptor related polynucleotide 2nd SEQ ID NO:50.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 PN WO200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 03-AUG-1999; 99WO-US17712.
 XX
 PR 03-AUG-1998; 98US-0095212.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-205971/18.
 XX
 PT New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX
 PS Disclosure; Page 1207; 1343pp; English.
 XX

CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.
 XX
 SQ Sequence 1489 BP: 411 A; 381 C; 320 G; 377 T; 0 other;
 Query Match 100.0%; Score 20; DB 21; Length 1489;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 GCCCTGCTGCTTTCTGCT 20
 Db 110 GCCCTGCTGCTTTCTGCT 91
 RESULT 12
 ID F21296/c
 XX
 AC F21296;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 DE Human low adenosine antisense oligonucleotide related sequence #2863.
 XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 OS Homo sapiens.
 PN WO2000062736-A2.
 XX
 PD 26-OCT-2000.
 XX
 PF 24-MAR-2000; 2000WO-US08020.
 XX
 PR 06-APR-1999; 99US-0127958.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI (NYCE/) NYCE J W.
 XX
 PI Nyce JW;

XX WPI; 2000-679539/66.
XX
XX Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX
XX
PS Disclosure; Page 1289; 1592pp; English.
XX
XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impaired respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
CC and antisense oligonucleotides used in the exemplification of the
CC present invention.
XX
SQ Sequence 2885 BP; 752 A; 772 C; 608 G; 753 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 2885;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTCTTCTGCT 20
Db 1543 GCCCTGCTGCTCTTCTGCT 1524
|||||

RESULT 13
A35174/c
ID A35174 standard; DNA; 2885 BP.
XX
AC A35174;
XX
XX 28-JUL-2000 (first entry)
XX
XX Human adenosine receptor related polynucleotide 2nd SEQ ID NO:48.
XX
XX Human: adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200009525-A2.

XX 24-FEB-2000.
XX
XX 03-AUG-1999; 99WO-US17712.
XX
XX 03-AUG-1998; 98US-0095212.
XX
XX (UYEC-) UNIV EAST CAROLINA.
XX
XX Nyce JW;
XX
XX WPI; 2000-205971/18.
XX
XX New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers -
XX
XX Disclosure; Page 1206; 1343pp; English.
XX
XX The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiasthmatic,
CC antiasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. A32313 to A35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
CC to A39992) are specifically claimed ONs from the present invention.
CC N.B. Sequences given in the disclosure of the present invention do not
CC match up with their corresponding SEQ ID NO: sequences given in the
CC sequence listing.
XX
SQ Sequence 2885 BP; 752 A; 772 C; 608 G; 753 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 2885;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTCTTCTGCT 20
Db 1543 GCCCTGCTGCTCTTCTGCT 1524
|||||

RESULT 14
F21300/c
ID F21300 standard; DNA; 2918 BP.
XX
XX F21300;
XX
XX 14-MAR-2001 (first entry)
XX
XX Human low adenosine antisense oligonucleotide related sequence #2867.
DE
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;

KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.
 XX WO200062736-A2.
 XX 26-OCT-2000.
 XX 24-MAR-2000; 2000WO-US08020.
 XX 06-APR-1999; 99US-0127958.
 XX (UYEC-) UNIV EAST CAROLINA.
 XX (NYCE/) NYCE J W.
 XX Nyce JW;
 XX WPI; 2000-679539/66.
 XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX Disclosure; Page 1291; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors and
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.

XX Sequence 2918 BP; 815 A; 786 C; 569 G; 748 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 2918;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCTGCTGCTCTTCGCT 20
 |||||
 Db 804 GCCCTGCTGCTCTTCGCT 785

RESULT 15
 A35178/c

ID A35178 standard; DNA; 2918 BP.
 AC A35178;
 XX 28-JUL-2000 (first entry)
 DT
 XX Human adenosine receptor related polynucleotide 2nd SEQ ID NO:52.
 DE
 XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX Homo sapiens.
 OS
 XX WO200009525-A2.
 PN
 XX 24-FEB-2000.
 PD
 XX 03-AUG-1999; 99WO-US17712.
 PF
 XX 03-AUG-1998; 98US-0095212.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Nyce JW;
 XX WPI; 2000-205971/18.
 DR
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension, or
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX Disclosure; Page 1208; 1343pp; English.
 PS
 XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33992) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.
 XX Sequence 2918 BP; 815 A; 786 C; 569 G; 748 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 2918;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTCTTTCTGCT 20
|||||
Db 804 GCCCTGCTCTTTCTGCT 785

Search completed: April 20, 2001, 00:13:00
Job time: 10022 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 19, 2001, 23:25:00 ; Search time 7150.85 Seconds
(without alignments)
0.409 Million cell updates/sec

Title: US-09-016-464-19
Perfect score: 20
Sequence: 1 GCCCTGCTGCTCTTCTGCT 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 9623517 seqs, 73081774 residues

Total number of hits satisfying chosen parameters: 19247034

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: gb_est1:*
2: gb_est2:*
3: gb_est3:*
4: gb_est4:*
5: gb_est5:*
6: gb_est6:*
7: gb_est7:*
8: gb_est8:*
9: gb_est9:*
10: gb_est10:*
11: gb_est11:*
12: gb_est12:*
13: gb_est13:*
14: gb_est14:*
15: gb_est15:*
16: gb_est16:*
17: gb_est17:*
18: gb_est18:*
19: gb_est19:*
20: gb_est20:*
21: gb_est21:*
22: gb_est22:*
23: gb_est23:*
24: gb_est24:*
25: gb_est25:*
26: gb_est26:*
27: gb_est27:*
28: gb_est28:*
29: gb_est29:*
30: gb_est30:*
31: gb_est31:*
32: gb_est32:*
33: gb_est33:*
34: gb_est34:*
35: gb_est35:*
36: gb_est36:*
37: gb_est37:*
38: gb_est38:*
39: gb_est39:*
40: gb_est40:*
41: gb_est41:*
42: gb_est42:*
43: gb_est43:*
44: gb_est44:*
45: gb_est45:*
46: gb_est46:*
47: gb_est47:*

44: em_esthum10:*
45: em_esthum11:*
46: em_esthum12:*
47: em_esthum13:*
48: em_esthum14:*
49: em_esthum15:*
50: em_esthum16:*
51: em_esthum17:*
52: em_esthum18:*
53: em_esthum19:*
54: em_esthum20:*
55: em_esthum21:*
56: em_esthum22:*
57: em_esthum23:*
58: em_esthum24:*
59: em_esthum25:*
60: em_esthum26:*
61: em_esthum27:*
62: em_esthum28:*
63: em_estin1:*
64: em_estin2:*
65: em_estin3:*
66: em_estin4:*
67: em_estin5:*
68: em_estom1:*
69: em_estom2:*
70: em_estov1:*
71: em_estov2:*
72: em_estp11:*
73: em_estp12:*
74: em_estp13:*
75: em_estp14:*
76: em_estp15:*
77: em_estp16:*
78: em_estp17:*
79: em_estp18:*
80: em_estp19:*
81: em_estp110:*
82: em_estro1:*
83: em_estro2:*
84: em_estro3:*
85: em_estro4:*
86: em_estro5:*
87: em_estro6:*
88: em_estro7:*
89: em_estro8:*
90: em_estro9:*
91: em_estro10:*
92: em_estro11:*
93: em_estro12:*
94: em_estro13:*
95: em_estro14:*
96: em_estro15:*
97: em_estro16:*
98: em_estro17:*
99: em_estro18:*
100: em_estro19:*
101: em_estro20:*
102: gb_est25:*
103: gb_est26:*
104: gb_est27:*
105: gb_est28:*
106: gb_est29:*
107: gb_est30:*
108: gb_est31:*
109: gb_est32:*
110: gb_est41:*
111: gb_est42:*
112: gb_est43:*
113: gb_est44:*
114: gb_est45:*
115: gb_est46:*
116: gb_est47:*


```
19 17.4 87.0 438 119 AW724357 AW724357 f5b08nm.f
20 17.4 87.0 447 162 BE062895 QV0-BT026
21 17.4 87.0 448 119 AW715244 AW715244 g3b09nm.f
22 17.4 87.0 451 15 AI021580 AI021580 ub13c10.r
23 17.4 87.0 460 18 AI318817 AI318817 a2e08nm.f
24 17.4 87.0 460 20 AI407401 AI407401 ES22335690
25 17.4 87.0 463 22 AI594063 AI594063 vo77d07.y
26 17.4 87.0 473 18 AI318698 AI318698 ala04nm.f
27 17.4 87.0 478 18 AI294680 AI294680 LP08109.5
28 17.4 87.0 480 223 AZ506583 AZ506583 LM0347L15
29 17.4 87.0 490 119 AW724800 AW724800 f8c06nm.f
30 17.4 87.0 496 148 BF441502 BF441502 257716 MA
31 17.4 87.0 506 18 AI321811 AI321811 e3604nm.f
32 17.4 87.0 509 116 AW523661 AW523661 UI-R-BOO-
33 17.4 87.0 518 9 AA611081 AA611081 vo77d07.r
34 17.4 87.0 520 206 AQ040731 AQ040731 HS_5048.A
35 17.4 87.0 529 139 BE749431 BE749431 200359 MA
36 17.4 87.0 533 30 AV431740 AV431740 AV431740
37 17.4 87.0 535 122 AW941497 AW941497 LD02310.3
38 17.4 87.0 538 30 AV433719 AV433719 AV433719
39 17.4 87.0 541 139 BE749430 BE749430 200358 MA
40 17.4 87.0 543 30 AV432475 AV432475 AV432475
41 17.4 87.0 544 30 AV434870 AV434870 AV434870
42 17.4 87.0 552 30 AV434421 AV434421 AV434421
43 17.4 87.0 586 162 BE061063 BE061063 QV0-BT004
44 17.4 87.0 613 148 BF467953 BF467953 UI-M-CCO-
45 17.4 87.0 709 216 AZ137266 AZ137266 SP_0173.A
```

ALIGNMENTS

```
RESULT 1
BF065220/c 827 bp mRNA EST 17-OCT-2000
LOCUS HV_CEB0024E19f Hordeum vulgare seedling green leaf EST library
DEFINITION HV_CEB0024E19f (Erysiphe infected & control) Hordeum vulgare cDNA clone
```

```
ACCESSION BF065220
VERSION BF065220.1 GI:10841859
```

```
KEYWORDS EST
SOURCE barley.
```

```
ORGANISM Hordeum vulgare
Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
Magnoliophyta; Liliopsida; Poales; Poaceae; Triticeae;
```

```
REFERENCE 1 (bases 1 to 827)
AUTHORS Wing,R., Close,T.J., Kleinhofs,A., Wise,R., Begum,D., Frisch,D., Yu
,Y., Anderson,H., Dale,J., Henry,D., Kernodle,S., Palmer,M., Rambo
,T., Saski,C., Schwartzbeck,J., Simmons,J., Choi,D.W., Main,D. and
Wood,T.
```

```
TITLE Development of a genetically and physically anchored EST resource
for barley genomics
```

```
JOURNAL Unpublished (2000)
COMMENT Contact: Wing RA
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
```

```
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: AATTACCTCTACTAAAGGG
High quality sequence start: 2
High quality sequence stop: 644.
```

```
FEATURES
source
Location/Qualifiers
1..827
/organism="Hordeum vulgare"
/cultivar="CI16155 (Mla13)"
/db_xref="taxon:4513"
/clone="HV_CEB0024E19f"
/clone_lib="Hordeum vulgare seedling green leaf EST
library HV_CEB0024E19f (Erysiphe infected & control)"
/tissue_type="seedling green leaf"
```

```
/lab_host="TJCL121"
/Note="Vector: lambdaZAP; Site_1: EcoRI; Site_2: XhoI"
BASE COUNT 166 a 268 c 265 g 128 t
ORIGIN
Query Match 92.0%; Score 18.4; DB 143; Length 827;
Best Local Similarity 95.0%; Pred. No. 5.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GCCTGCTGCTCTTCTGCT 20
|||||
Db 657 GCCCTGCTGCTGTTCTGCT 638
```

```
RESULT 2
LOCUS AW725116 239 bp mRNA EST 19-APR-2000
DEFINITION f9h03nm.f1 Neurospora crassa morning cDNA library Neurospora crassa
cDNA clone f9h03nm 5', mRNA sequence.
```

```
ACCESSION AW725116
VERSION AW725116.1 GI:7619676
```

```
KEYWORDS EST.
SOURCE Neurospora crassa.
```

```
ORGANISM Neurospora crassa
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
Sordariales; Sordariaceae; Neurospora.
```

```
REFERENCE 1 (bases 1 to 239)
AUTHORS Zhu,H., Lai,H., Kupfer,D., Dunlap,J.C. and Roe,B.A.
```

```
TITLE Two Neurospora crassa EST Databases
JOURNAL Unpublished (1998)
COMMENT Contact: Bruce A. Roe, University of Oklahoma, broe@ou.edu
Department of Chemistry and Biochemistry
Advanced Center for Genome Technology, University of Oklahoma
```

```
620 Parlington Oval, Norman, OK 73019, USA
Tel: 405 325 4912
Fax: 405 325 7762
Email: broe@ou.edu
```

```
We anticipate the future release of the cDNA clones to the Fungal
Genetics Stock Center
```

```
Seq primer: Universal Forward Primer
High quality sequence stop: 208.
```

```
FEATURES
source
Location/Qualifiers
1..239
/organism="Neurospora crassa"
/strain="bd, frq7 A"
/db_xref="taxon:5141"
/clone="f9h03nm"
/clone_lib="Neurospora crassa morning cDNA library"
/tissue_type="tissue harvested following 22hr growth in
dark"
```

```
/note="Vector: pBluescript SK-; Site_1: XbaI; Site_2:
EcoRI; See: Bell-Pedersen,D., et al. PNAS 93:13096,1996.
5' end of cDNA cloned into XbaI site of pBluescript; 3'
end of cDNA cloned into EcoRI site of pBluescript"
```

```
BASE COUNT 74 a 79 c 28 g 58 t
ORIGIN
```

```
Query Match 87.0%; Score 17.4; DB 119; Length 239;
Best Local Similarity 94.7%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2 CCCTGCTGCTCTTCTGCT 20
|||||
Db 214 CACTGCTGCTCTTCTGCT 232
```

```
RESULT 3
LOCUS BG091258 317 bp mRNA EST 26-JAN-2001
DEFINITION mac22a01.y1 Soares mouse 3NDMS Mus musculus cDNA clone
IMAGE:4000393 5', mRNA sequence.
```

```
ACCESSION   BG091258
VERSION     BG091258.1  GI:12573821
KEYWORDS
SOURCE      house mouse.
ORGANISM    Mus musculus
REFERENCE   1 (bases 1 to 317)
AUTHORS     NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE       National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
JOURNAL
COMMENT     Contact: Robert Strausberg, Ph.D.
            Tel: (301) 496-1550
            Email: Robert_Strausberg@nih.gov
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            MGI:1498121
            Seq primer: -40RP from Gibco
            High quality sequence stop: 310.
FEATURES    Location/Qualifiers
             1..317
             /organism="Mus musculus"
             /strain="C57BL/6J"
             /db_xref="taxon:10090"
             /clone="IMAGE:4000393"
             /clone_lib="Soares mouse 3NbMS"
             /sex="male"
             /tissue_type="Spleen"
             /dev_stage="4 weeks"
             /lab_host="DH10B"
             /note="vector: pT73D-Pac (Pharmacia) with a modified
             polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
             was primed with a Not I - oligo(dT) primer [5',
             TGTACCAATCTGAAGTGGGAGCGCGCGCTGTTTTTTTTTTTTTTT
             3']; double-stranded cDNA was ligated to Eco RI adaptors
             (Pharmacia), digested with Not I and cloned into the Not I
             and Eco RI sites of the modified pT73 vector. RNA
             provided by Dr. Bertrand Jordan. Library went through
             three rounds of normalization, and was constructed by
             Bento Soares and M.Fatima Bonaldo."
BASE COUNT  70 a 100 c 58 g 89 t
ORIGIN

Query Match      87.0%; Score 17.4; DB 173; Length 317;
Best Local Similarity 94.7%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy  2  CCCTGCTCTCTTTCTGCT 20
      ||||| ||||| ||||| |||||
Db   245 CCCTGCTCTCTTTCTGCT 263

RESULT  4
AV606933
LOCUS      AV606933 355 bp mRNA EST 30-AUG-2000
DEFINITION AV606933 Bos taurus kidney fetus Bos taurus cDNA clone EI1037G08
5', mRNA sequence.
ACCESSION  AV606933
VERSION    AV606933.1 GI:9737306
KEYWORDS   EST.
SOURCE     cow.
ORGANISM   Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
Bovidae; Bovinae; Bos.
1 (bases 1 to 355)
Smith,T.P.L., Casas,E., Stone,R.T., Heston,M.P., Grosse,W.M.,
Bennett,G.A., Fahrnerkrug,S.C., Freking,B.A., Rohrer,G.A., Laegreid
,W.W. and Keele,J.W.
Design and use of four pooled tissue normalized cDNA libraries for
EST discovery in cattle
Unpublished (2000)
Contact: Smith TPL
USDA, ARS, US Meat Animal Research Center
PO Box 166, Clay Center, NE 68933-0166, USA
Tel: 402 762 4366
Fax: 402 762 4390
Email: smith@email.marc.usda.gov
Single pass sequencing. Bases called and alt_trimmed with phred
v0.980904.e. Vector identified by cross_match with the -minscore 18
and -minmatch 12 options.
PCR Primers
FORWARD: AGGAAACAGCTATGACCAT
BACKWARD: GTTTTCCCAGTCACGACG
Plate: 50 row: B column: 5
Seq primer: ATTTAGGTGACACTATAG.
Location/Qualifiers
             1..355
             /organism="Bos taurus"
             /db_xref="taxon:9913"
             /clone_lib="MARC 3BOV"
             /tissue_type="pooled"
             /lab_host="DH10B"
             /note="vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;

Animal Genetics Division
Shirakawa Institute of Animal Genetics
Odakura, Nishigo, Nishi-shirakawa, Fukushima 961-8061, Japan
Tel: 81-248-25-5641
Fax: 81-248-25-5725
Email: kazusugi@cococ.ocn.ne.jp
Single pass sequencing.
This clone was obtained from a polyA-deleted cDNA library.
FEATURES    Location/Qualifiers
             1..355
             /organism="Bos taurus"
             /db_xref="taxon:9913"
             /clone="EI1037G08"
             /clone_lib="Bos taurus kidney fetus"
             /tissue_type="kidney"
             /dev_stage="fetus"
             /lab_host="DH10B"
             /note="vector: pZLL; Site_1: SalI; Site_2: NotI; Poly A
             was deleted from a NotI site"
BASE COUNT  53 a 124 c 72 g 105 t
ORIGIN

Query Match      87.0%; Score 17.4; DB 30; Length 355;
Best Local Similarity 94.7%; Pred. No. 1.3e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy  2  CCCTGCTGCTCTTTCTGCT 20
      ||||| ||||| ||||| |||||
Db   71 CCCTGCTGCTCTTTCTGCT 89

RESULT  5
BF603899/c
LOCUS      BF603899 355 bp mRNA EST 13-DEC-2000
DEFINITION 269522 MARC 3BOV Bos taurus cDNA 5', mRNA sequence.
ACCESSION  BF603899
VERSION    BF603899.1 GI:11701973
KEYWORDS   EST.
SOURCE     cow.
ORGANISM   Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
Bovidae; Bovinae; Bos.
1 (bases 1 to 355)
Smith,T.P.L., Casas,E., Stone,R.T., Heston,M.P., Grosse,W.M.,
Bennett,G.A., Fahrnerkrug,S.C., Freking,B.A., Rohrer,G.A., Laegreid
,W.W. and Keele,J.W.
Design and use of four pooled tissue normalized cDNA libraries for
EST discovery in cattle
Unpublished (2000)
Contact: Smith TPL
USDA, ARS, US Meat Animal Research Center
PO Box 166, Clay Center, NE 68933-0166, USA
Tel: 402 762 4366
Fax: 402 762 4390
Email: smith@email.marc.usda.gov
Single pass sequencing. Bases called and alt_trimmed with phred
v0.980904.e. Vector identified by cross_match with the -minscore 18
and -minmatch 12 options.
PCR Primers
FORWARD: AGGAAACAGCTATGACCAT
BACKWARD: GTTTTCCCAGTCACGACG
Plate: 50 row: B column: 5
Seq primer: ATTTAGGTGACACTATAG.
Location/Qualifiers
             1..355
             /organism="Bos taurus"
             /db_xref="taxon:9913"
             /clone_lib="MARC 3BOV"
             /tissue_type="pooled"
             /lab_host="DH10B"
             /note="vector: pCMV SPORT6; Site_1: XbaI; Site_2: XhoI;
```

LOCUS	AW717816	366 bp	mRNA	EST	19-APR-2000
DEFINITION	ilf04nm.f1	Neurospora crassa	morning	cDNA library	Neurospora

We anticipate the future release of the cDNA clones to the Fungal
Email: broe@ou.edu
Fax: 405 325 7702


```

REFERENCE
AUTHORS      Sordariales; Sordariaceae; Neurospora.
TITLE        1. (bases 1 to 404)
JOURNAL      Two Neurospora crassa EST Databases
COMMENT      Unpublished (1998)
             Contact: Bruce A. Roe, University of Oklahoma, broe@ou.edu
             Department of Chemistry and Biochemistry
             Advanced Center for Genome Technology, University of Oklahoma
             620 Parrington Oval, Norman, OK 73019, USA
             Tel: 405 325 4912
             Fax: 405 325 7762
             Email: broe@ou.edu
             We anticipate the future release of the cDNA clones to the Fungal
             Genetics Stock Center
             Seq primer: Universal Forward Primer
             High quality sequence stop: 184.

FEATURES
source
1. .404
/organism="Neurospora crassa"
/strain="bd, frq7 A"
/db_xref="taxon:5141"
/clone="h5e04nm"
/clone_lib="Neurospora crassa morning cDNA library"
/tissue_type="tissue harvested following 22hr growth in
dark"
/note="Vector: pBluescript SK-; Site_1: XbaI; Site_2:
EcoRI; See: Bell-Pedersen,D., et al. PNAS 93:13096,1996.
5' end of cDNA cloned into XbaI site of pBluescript; 3'
end of cDNA cloned into EcoRI site of pBluescript"

BASE COUNT      104 a 128 c 67 g 105 t
ORIGIN

Query Match      87.0%; Score 17.4; DB 119; Length 404;
Best Local Similarity 94.7%; Pred. No. 1.3e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
   1 |||||
Db 214 CACTGCTGCTCTTTCTGCT 232

RESULT 12
AI321994
LOCUS      AI321994      419 bp      mRNA      EST      18-DEC-1998
DEFINITION e6d01nm.fl Neurospora crassa morning cDNA library Neurospora crassa
ACCESSION  AI321994
VERSION     AI321994.1 GI:4037976
KEYWORDS   EST.
SOURCE     Neurospora crassa.
ORGANISM   Neurospora crassa
            Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
            Sordariales; Sordariaceae; Neurospora.
            1 (bases 1 to 419)
            Zhu,H., Lai,H., Kupfer,D., Dunlap,J.C. and Roe,B.A.
            Two Neurospora crassa EST Databases
            Unpublished (1998)
            Contact: Bruce A. Roe, University of Oklahoma, broe@ou.edu
            Department of Chemistry and Biochemistry
            Advanced Center for Genome Technology, University of Oklahoma
            620 Parrington Oval, Norman, OK 73019, USA
            Tel: 405 325 4912
            Fax: 405 325 7762
            Email: broe@ou.edu
            We anticipate the future release of the cDNA clones to the Fungal
            Genetics Stock Center
            Seq primer: Universal Forward Primer
            High quality sequence stop: 279.

FEATURES
source
1. .419
/organism="Neurospora crassa"
/strain="bd, frq7 A"
/db_xref="taxon:5141"
/clone="h5e04nm"
/clone_lib="Neurospora crassa morning cDNA library"
/tissue_type="tissue harvested following 22hr growth in
dark"
/note="Vector: pBluescript SK-; Site_1: XbaI; Site_2:
EcoRI; See: Bell-Pedersen,D., et al. PNAS 93:13096,1996.
5' end of cDNA cloned into XbaI site of pBluescript; 3'
end of cDNA cloned into EcoRI site of pBluescript"

BASE COUNT      107 a 131 c 70 g 109 t 4 others
ORIGIN

Query Match      87.0%; Score 17.4; DB 18; Length 421;
Best Local Similarity 94.7%; Pred. No. 1.3e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
   1 |||||
Db 213 CACTGCTGCTCTTTCTGCT 231

```

```

/db_xref="taxon:5141"
/clone="e6d01nm"
/clone_lib="Neurospora crassa morning cDNA library"
/tissue_type="tissue harvested following 22hr growth in
dark"
/note="Vector: pBluescript SK-; Site_1: XbaI; Site_2:
EcoRI; See: Bell-Pedersen,D., et al. PNAS 93:13096,1996.
5' end of cDNA cloned into XbaI site of pBluescript; 3'
end of cDNA cloned into EcoRI site of pBluescript"

BASE COUNT      107 a 135 c 69 g 108 t
ORIGIN

Query Match      87.0%; Score 17.4; DB 18; Length 419;
Best Local Similarity 94.7%; Pred. No. 1.3e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
   1 |||||
Db 214 CACTGCTGCTCTTTCTGCT 232

RESULT 13
AI321511
LOCUS      AI321511      421 bp      mRNA      EST      18-DEC-1998
DEFINITION d8h04nm.fl Neurospora crassa morning cDNA library Neurospora crassa
ACCESSION  AI321511
VERSION     AI321511.1 GI:4037493
KEYWORDS   EST.
SOURCE     Neurospora crassa.
ORGANISM   Neurospora crassa
            Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
            Sordariales; Sordariaceae; Neurospora.
            1 (bases 1 to 421)
            Zhu,H., Lai,H., Kupfer,D., Dunlap,J.C. and Roe,B.A.
            Two Neurospora crassa EST Databases
            Unpublished (1998)
            Contact: Bruce A. Roe, University of Oklahoma, broe@ou.edu
            Department of Chemistry and Biochemistry
            Advanced Center for Genome Technology, University of Oklahoma
            620 Parrington Oval, Norman, OK 73019, USA
            Tel: 405 325 4912
            Fax: 405 325 7762
            Email: broe@ou.edu
            We anticipate the future release of the cDNA clones to the Fungal
            Genetics Stock Center
            Seq primer: Universal Forward Primer
            High quality sequence stop: 337.

FEATURES
source
1. .421
/organism="Neurospora crassa"
/strain="bd, frq7 A"
/db_xref="taxon:5141"
/clone="d8h04nm"
/clone_lib="Neurospora crassa morning cDNA library"
/tissue_type="tissue harvested following 22hr growth in
dark"
/note="Vector: pBluescript SK-; Site_1: XbaI; Site_2:
EcoRI; See: Bell-Pedersen,D., et al. PNAS 93:13096,1996.
5' end of cDNA cloned into XbaI site of pBluescript; 3'
end of cDNA cloned into EcoRI site of pBluescript"

BASE COUNT      107 a 131 c 70 g 109 t 4 others
ORIGIN

Query Match      87.0%; Score 17.4; DB 18; Length 421;
Best Local Similarity 94.7%; Pred. No. 1.3e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
   1 |||||
Db 213 CACTGCTGCTCTTTCTGCT 231

```

RESULT	14
AW724312	
LOCUS	426 bp mRNA EST 19-APR-2000
DEFINITION	f4h06nm.f2 Neurospora crassa morning cDNA library Neurospora crassa cDNA clone f4h06nm 5', mRNA sequence.
ACCESSION	AW724312
VERSION	AW724312.1 GI:7618872
KEYWORDS	EST.
SOURCE	Neurospora crassa.
ORGANISM	Neurospora crassa
REFERENCE	Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
AUTHORS	Sordariales; Sordariaceae; Neurospora.
TITLE	1 (bases 1 to 426)
JOURNAL	Zhu H., Lai H., Kupfer D., Dunlap J.C. and Roe B.A. Two Neurospora crassa EST Databases Unpublished (1998)
COMMENT	Contact: Bruce A. Roe, University of Oklahoma, broe@ou.edu Department of Chemistry and Biochemistry Advanced Center for Genome Technology, University of Oklahoma 620 Parrington Oval, Norman, OK 73019, USA Tel: 405 325 4912 Fax: 405 325 7762 Email: broe@ou.edu We anticipate the future release of the cDNA clones to the Fungal Genetics Stock Center Seq primer: Universal Forward Primer High quality sequence stop: 347.

```

FEATURES
source
      1. .426
      Location/Qualifiers
      /organism="Neurospora crassa"
      /strain="bd, frq7 A"
      /db_xref="taxon:5141"
      /clone="f4h06nm"
      /clone_lib="Neurospora crassa morning cDNA library"
      /tissue_type="tissue harvested following 22hr growth in
      dark"
      /note="Vector: pBluescript SK-; Site_1: XbaI; Site_2:
      EcoRI; See: Bell-pedersen,D., et al. PNAS 93:13096,1996.
      5', end of cDNA cloned into XbaI site of pBluescript; 3',
      end of cDNA cloned into EcoRI site of pBluescript"
      109 a 138 c 70 g 109 t
BASE COUNT

```

Query Match	87.0%	Score 17.4;	DB 119;	Length 426;
Best Local Similarity	94.7%;	Pred. No. 1.3e+03;		
Matches 18;	Conservative	0;	Mismatches 1;	Indels 0;
QY	2	CCCTGCTGCTCTTTCTGCT	20	
Db	214	CACGTGCTGCTCTTTCTGCT	232	

RESULT	15
AW716525	
LOCUS	429 bp mRNA EST
DEFINITION	h2ho3nm.f1 Neurospora crassa morning cDNA library Neurospora crassa
	EST
ACCESSION	AW716525
VERSION	AW716525.1
KEYWORDS	GI:7605743
SOURCE	EST.
ORGANISM	Neurospora crassa.
	Neurospora crassa.
	Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
	Sordariales; Sordariaceae; Neurospora.
	I. (bases 1 to 429)
REFERENCE	Zhu,H., Lai,H., Kupfer,D., Dunlap,J.C. and Roe,B.A.
AUTHORS	Two Neurospora crassa EST Databases
TITLE	Unpublished (1998)
JOURNAL	Contact: Bruce A. Roe, University of Oklahoma, broesou.edu
COMMENT	Department of Chemistry and Biochemistry

Advanced Center for Genome Technology, University of Oklahoma
620 Parrington Oval, Norman, OK 73019, USA
Tel: 405 325 4912
Fax: 405 325 7762
Email: broe@ou.edu
We anticipate the future release of the cDNA clones to the Fungal
Genetics Stock Center
Seq primer: Universal Forward primer
High quality sequence stop: 228.

FEATURES	SOURCE
----------	--------

```

1. .429
/organism="Neurospora crassa"
/strain="bd, frq7 A"
/db_xref="taxon:5141"
/clone="h2h03nm"
/clone_lib="Neurospora crassa morning CDNA library"
/tissue_type="tissue harvested following 22hr growth in
dark"
/notes="Vector: pBluescript SK-; Site.1: XbaI; Site.2:
EcoRI; See: Bell-Pedersen,D., et al. PNAS 93:13096:1996.
5' end of cDNA cloned into XbaI site of pBluescript; 3'
end of cDNA cloned into EcoRI site of pBluescript"
109 a 140 c 70 g 110 t

```

BASE COUNT
ORIGIN

Query Match 87.0%; Score 17.4; DB 119; Length 429;
Best Local Similarity 94.7%; Pred. NO. 1.3e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 CCCTGCTGCTCTTTCTGCT 20
 | |||||
Db 214 CACTGCTGCTCTTTCTGCT 232

Search completed: April 19, 2001, 23:25:03
Job time: 8180 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:03:45 ; Search time 280.46 Seconds
(without alignments)
12.451 Million cell updates/sec

Title: US-09-016-464-19

Perfect score: 20

Sequence: 1 GCCCTGCTGCTTTCGCT 20

Scoring table:

IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 302621 seqs, 87301344 residues

Total number of hits satisfying chosen parameters: 605242

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_NA.*

- 1: /cgn2.6/ptodata/2/ina/5A_COMB.seq.*
- 2: /cgn2.6/ptodata/2/ina/5B_COMB.seq.*
- 3: /cgn2.6/ptodata/2/ina/6A_COMB.seq.*
- 4: /cgn2.6/ptodata/2/ina/6B_COMB.seq.*
- 5: /cgn2.6/ptodata/2/ina/PCTUS_COMB.seq.*
- 6: /cgn2.6/ptodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed; and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	ID	Description
C 1	20	100.0	1314	1	US-07-662-005A-15
C 2	16.8	84.0	24979	2	US-08-147-777-3
C 3	16.8	84.0	24979	3	US-08-452-872-3
C 4	16.8	84.0	24979	5	PCT-US93-03985-3
C 5	16.4	82.0	2290	4	US-08-961-083-65
C 6	16.4	82.0	5816	4	US-09-220-641-4
C 7	15.8	79.0	441	2	US-08-975-316-60
C 8	15.8	79.0	1272	3	US-08-952-664-9
C 9	15.8	79.0	1680	1	US-08-234-783-3
C 10	15.8	79.0	1680	1	US-08-456-907-3
C 11	15.8	79.0	1680	5	PCT-US95-05523-3
C 12	15.8	79.0	1809	1	US-08-453-956-24
C 13	15.8	79.0	1809	1	US-08-086-631-24
C 14	15.8	79.0	1809	2	US-08-452-930-24
C 15	15.8	79.0	1809	5	PCT-US93-08174-24
C 16	15.4	77.0	94	1	US-08-123-343A-3
C 17	15.4	77.0	372	2	US-08-822-573-1
C 18	15.4	77.0	798	1	US-08-123-343A-1
C 19	15.4	77.0	1080	1	US-07-954-840A-11
C 20	15.4	77.0	1080	1	US-07-954-840A-17
C 21	15.4	77.0	1799	2	US-08-453-848-10
C 22	15.4	77.0	2201	4	US-09-330-970-2
C 23	15.4	77.0	2242	3	US-09-400-742-1
C 24	15.4	77.0	2242	4	US-08-618-651A-1
C 25	15.4	77.0	3336	4	US-09-330-970-4
C 26	15.4	77.0	3611	2	US-08-727-118-1
C 27	15.4	77.0	6306	1	US-08-466-390-3

C 28	15.4	77.0	6306	1	US-08-470-950-3	Sequence 3, Appli
C 29	15.4	77.0	6306	1	US-08-467-781-3	Sequence 3, Appli
C 30	15.4	77.0	6306	1	US-08-195-487-3	Sequence 3, Appli
C 31	15.4	77.0	6306	2	US-08-483-924-3	Sequence 3, Appli
C 32	15.4	77.0	6306	5	PCT-US93-06160-3	Sequence 3, Appli
C 33	15.2	76.0	105	2	US-08-476-176B-19	Sequence 19, Appl
C 34	15.2	76.0	105	3	US-08-127-721A-19	Sequence 19, Appl
C 35	15.2	76.0	105	3	US-08-485-246A-19	Sequence 19, Appl
C 36	15.2	76.0	286	2	US-08-332-766A-6	Sequence 6, Appli
C 37	15.2	76.0	378	3	US-07-765-830A-3	Sequence 3, Appli
C 38	15.2	76.0	378	3	US-07-765-830A-8	Sequence 8, Appli
C 39	15.2	76.0	424	2	US-08-476-176B-5	Sequence 5, Appli
C 40	15.2	76.0	424	2	US-08-476-176B-7	Sequence 7, Appli
C 41	15.2	76.0	424	2	US-08-476-176B-9	Sequence 9, Appli
C 42	15.2	76.0	424	3	US-08-127-721A-5	Sequence 5, Appli
C 43	15.2	76.0	424	3	US-08-127-721A-7	Sequence 7, Appli
C 44	15.2	76.0	424	3	US-08-127-721A-9	Sequence 9, Appli
C 45	15.2	76.0	424	3	US-08-485-246A-5	Sequence 5, Appli

ALIGNMENTS

RESULT 1
US-07-662-005A-15/c
; Sequence 15, Application US/07662005A
; Patent No. 5246838
; GENERAL INFORMATION:
; APPLICANT: Van Dijk, Jan M.
; APPLICANT: Smith, Hilde E.
; APPLICANT: Bron, Sierd
; APPLICANT: Quax, Wilhelmus J.
; TITLE OF INVENTION: IMPROVED PROCESSING OF PROTEINS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: PALO ALTO
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/662,005A
; FILING DATE: 19910228
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 246152002300
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-813-5600
; TELEFAX: 415-494-0792
; TELEX: 34-0154
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1314 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-07-662-005A-15

Query Match 100.0%; Score 20; DB 1; Length 1314;
Best Local Similarity 100.0%; Pred. No. 2.7;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCTGCTGCTTTCGCT 20
|||||

Db 110 GCCCTGCTGCTCTTCTGCT 91

RESULT 2

US-08-147-777-3
; Sequence 3, Application US/0814777
; Patent No. 5914265
; GENERAL INFORMATION:
; APPLICANT: Roop, Dennis R.
; APPLICANT: Rothnagel, Joseph A.
; APPLICANT: Greenhalgh, David A.
; APPLICANT: Yuspa, Stuart H.
; TITLE OF INVENTION: KERATIN K1 EXPRESSION VECTORS
; TITLE OF INVENTION: AND METHODS OF USE
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/147,777
; FILING DATE:
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA: Including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 07/876,289
; FILING DATE: April 30, 1992
; APPLICATION NUMBER: Unassigned (204/144)
; FILING DATE: October 29, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 204/153
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24979 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-147-777-3

Query Match 84.0%; Score 16.8; DB 2; Length 24979;
Best Local Similarity 90.0%; Pred. No. 76;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTGCT 20
|||||
Db 5578 GCCCTGCTGCTCTTCTGCT 5597

RESULT 3

US-08-452-872-3
; Sequence 3, Application US/08452872
; Patent No. 6057298
; GENERAL INFORMATION:
; APPLICANT: Roop, Dennis R.
; APPLICANT: Rothnagel, Joseph A.
; APPLICANT: Greenhalgh, David A.

; APPLICANT: Yuspa, Stuart H.
; TITLE OF INVENTION: KERATIN K1 EXPRESSION VECTORS
; TITLE OF INVENTION: AND METHODS OF USE
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,872
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA: US/08/147,777
; APPLICATION NUMBER: 07/876,289
; FILING DATE: April 30, 1992
; APPLICATION NUMBER: Unassigned (204/144)
; FILING DATE: October 29, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 204/153
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24979 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-452-872-3

Query Match 84.0%; Score 16.8; DB 3; Length 24979;
Best Local Similarity 90.0%; Pred. No. 76;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTGCT 20
|||||
Db 5578 GCCCTGCTGCTCTTCTGCT 5597

RESULT 4

PCT-US93-03985-3
; Sequence 3, Application PC/TUS9303985
; GENERAL INFORMATION:
; APPLICANT: Roop, Dennis R.
; APPLICANT: Rothnagel, Joseph A.
; APPLICANT: Greenhalgh, David A.
; APPLICANT: Yuspa, Stuart H.
; TITLE OF INVENTION: DEVELOPMENT OF A VECTOR TO TARGET GENE
; TITLE OF INVENTION: EXPRESSION TO THE EPIDERMIS OF TRANSGENIC ANIMALS
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/03985
; FILING DATE: 19930428
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5478
; TELEPHONE: 713/651-5325
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24979 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US93-03985-3

Query Match 84.0%; Score 16.8; DB 5; Length 24979;
Best Local Similarity 90.0%; Pred. No. 76;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTGCT 20
|||||
Db 5578 GCCCTGCTGCTCTTCTGCT 5597

RESULT 5
US-08-961-083-65/c
; Sequence 65, Application US/08961083
; Patent No. 6159469
; GENERAL INFORMATION:
; APPLICANT: Choi et. al.
; TITLE OF INVENTION: Streptococcus pneumoniae Antigenes and Vaccines
; NUMBER OF SEQUENCES: 452
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Human Genome Sciences, Inc.
; STREET: 9410 Key West Avenue
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage
; COMPUTER: HP Vectra 486/33
; OPERATING SYSTEM: MSDOS version 6.2
; SOFTWARE: ASCII Text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/961,083
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Brookes, A. Anders
; REGISTRATION NUMBER: 36,373
; REFERENCE/DOCKET NUMBER: PB340P2
; TELEPHONE: (301) 309-8504
; TELEFAX: (301) 309-8512
; INFORMATION FOR SEQ ID NO: 65:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 2290 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-08-961-083-65

Query Match 82.0%; Score 16.4; DB 4; Length 2290;
Best Local Similarity 94.4%; Pred. No. 89;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 CCTGCTGCTCTTTCTGCT 20
|||||
Db 1203 CCTGCTGCTTTCTGCT 1186

RESULT 6
US-09-220-641-4/c
; Sequence 4, Application US/09220641
; Patent No. 6210923
; GENERAL INFORMATION:
; APPLICANT: Lee, Cheng-Chi
; APPLICANT: Sun, Zhong Sheng
; APPLICANT: Albrecht, Urs
; TITLE OF INVENTION: Mammalian Circadian Regulator M-RIGUI2 (M-PER2)
; FILE REFERENCE: D6067
; CURRENT APPLICATION NUMBER: US/09/220,641
; CURRENT FILING DATE: 1998-12-24
; EARLIER APPLICATION NUMBER: US 60/068,886
; EARLIER FILING DATE: 1997-12-26
; NUMBER OF SEQ ID NOS: 5
; SEQ ID NO 4
; LENGTH: 5816
; TYPE: DNA
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 145..3918
; OTHER INFORMATION: m-rigu2 cdna Sequence
US-09-220-641-4

Query Match 82.0%; Score 16.4; DB 4; Length 5816;
Best Local Similarity 94.4%; Pred. No. 97;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTCTG 18
|||||
Db 2340 GCCCTGCTCTCTTCTG 2323

RESULT 7
US-08-975-316-60/c
; Sequence 60, Application US/08975316
; Patent No. 5952486
; GENERAL INFORMATION:
; APPLICANT: BLOKSBERG, Leonard N., HAVUKKALA, Ilkka
; APPLICANT: and GRIERSON, Alastair W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR
; TITLE OF INVENTION: THE MODIFICATION OF PLANT LIGNIN CONTENT
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Ann W. Speckman
; STREET: 2601 Elliott Avenue, Suite 4185
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98121
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS

```
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/975.316
; FILING DATE:
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/713,000
; FILING DATE: September 11, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SLEATH, Janet
; REGISTRATION NUMBER: 37,007
; REFERENCE/DOCKET NUMBER: 11000/1003C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-269-0565
; TELEFAX: 206-269-0563
; TELEX:
; INFORMATION FOR SEQ ID NO: 60:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 441 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-975-316-60

Query Match          79.0%; Score 15.8; DB 2; Length 441;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 CCCTGCTCTCTTTCTGCT 20
   || ||||| |||||
Db 404 CCATGCTGCTTTTCTGCT 386

RESULT 8
; US-08-952-664-9/c
; Sequence 9, Application US/08952664
; Patent No. 6034235
; GENERAL INFORMATION:
; APPLICANT: SUGIYAMA, Haruo
; APPLICANT: YAMAGAMI, Tamotsu
; APPLICANT: INOUE, Kazushi
; TITLE OF INVENTION: GROWTH INHIBITOR FOR LEUKEMIA CELLS
; TITLE OF INVENTION: COMPRISING ANTISENSE OLIGONUCLEOTIDE DERIVATIVE TO WILMS
; TITLE OF INVENTION: TUMOR GENE (WT1)
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY & LARDNER
; STREET: 3000 K Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/952.664
; FILING DATE: 01-DEC-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP96/01394
; FILING DATE: 24-MAY-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 7-156672
; FILING DATE: 01-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wegner, Harold C.
; REGISTRATION NUMBER: 25,258
; REFERENCE/DOCKET NUMBER: 053466/0223
; TELECOMMUNICATION INFORMATION:
```

```
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1272 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Synthetic DNA"
; US-08-952-864-9

Query Match          79.0%; Score 15.8; DB 3; Length 1272;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 CCCTGCTCTCTTTCTGCT 20
   ||||| ||||| |||||
Db 1268 CCCTGCTCTCTGCTGCT 1250

RESULT 9
; US-08-234-783-3/c
; Sequence 3, Application US/08234783
; Patent No. 5622835
; GENERAL INFORMATION:
; APPLICANT: Herlyn, Meenhard
; APPLICANT: Morris, Jennifer
; APPLICANT: Rauscher III, Frank J.
; APPLICANT: Rodeck, Ulrich
; TITLE OF INVENTION: WT1 Monoclonal Antibodies and Methods of
; TITLE OF INVENTION: Use Therefor
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howson and Howson
; STREET: Spring House Corporate Cntr, PO Box 457
; CITY: Spring House
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/234,783
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215
; REFERENCE/DOCKET NUMBER: WST48USA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-540-9200
; TELEFAX: 215-540-5818
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1680 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: unknown
; MOLECULE TYPE: cdna
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 381..1670
; US-08-234-783-3

Query Match          79.0%; Score 15.8; DB 1; Length 1680;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 2 CCTGCTGCTCTTTCTGCT 20
|||||
Db 271 CCTGCTGCTCTGGCTGCT 253

RESULT 10

US-08-456-907-3/c
; Sequence 3, Application US/08456907
; Patent No. 5633142
; GENERAL INFORMATION:
; APPLICANT: Herlyn, Meenhard
; APPLICANT: Morris, Jennifer
; APPLICANT: Rauscher III, Frank J.
; APPLICANT: Rodeck, Ulrich
; TITLE OF INVENTION: Wt1 Monoclonal Antibodies and Methods of
; TITLE OF INVENTION: Use Therefor
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howson and Howson
; STREET: Spring House Corporate Cntr, PO Box 457
; CITY: Spring House
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/456,907
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/234,783
; FILING DATE: 28-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215
; REFERENCE/DOCKET NUMBER: WST48AUSA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-540-9200
; TELEFAX: 215-540-5818
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1680 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 381..1670

PCT-US95-05523-3/c

Query Match 79.0%; Score 15.8; DB 1; Length 1680;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 CCTGCTGCTCTTTCTGCT 20
|||||
Db 271 CCTGCTGCTCTGGCTGCT 253
RESULT 11
PCT-US95-05523-3/c
; Sequence 3, Application PC/TUS9505523
; GENERAL INFORMATION:
; APPLICANT: The Wistar Institute of Anatomy and Biology
; TITLE OF INVENTION: Wt1 Monoclonal Antibodies and
; TITLE OF INVENTION: Methods of Use Therefor

; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Howson and Howson
; STREET: Spring House Corporate Cntr, PO Box 457
; CITY: Spring House
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/05523
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/234,783
; FILING DATE: 28-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215
; REFERENCE/DOCKET NUMBER: WST48PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-540-9200
; TELEFAX: 215-540-5818
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1680 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 381..1670
; PCT-US95-05523-3

Query Match 79.0%; Score 15.8; DB 5; Length 1680;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 CCTGCTGCTCTTTCTGCT 20
|||||
Db 271 CCTGCTGCTCTGGCTGCT 253

RESULT 12

US-08-453-956-24
; Sequence 24, Application US/08453956
; Patent No. 5770445
; GENERAL INFORMATION:
; APPLICANT: Kindsvogel, Wayne R.
; TITLE OF INVENTION: GLUCAGON RECEPTORS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED AND BERRY
; STREET: 6300 COLUMBIA CENTER
; CITY: SEATTLE
; STATE: WA
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/453,956
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 530

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/086,631
;; FILING DATE: July 1, 1993
;; APPLICATION NUMBER: US 07/938,331
;; FILING DATE: 28-AUG-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Mcmasters, David D.
;; REGISTRATION NUMBER: 33,963
;; REFERENCE/DOCKET NUMBER: 990008.424C1
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-622-4900
;; TELEFAX: 206-682-6031
;; INFORMATION FOR SEQ ID NO: 24:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 1809 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: cdna
;; ORIGINAL SOURCE:
;; ORGANISM: Homo sapiens
;; IMMEDIATE SOURCE:
;; CLONE: pLJ6'
;; FEATURE:
;; NAME/KEY: CDS
;; LOCATION: 53..1486
US-08-453-956-24

Query Match 79.0%; Score 15.8; DB 1; Length 1809;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 CCCTGCTGCTCTTTCTGCT 20
|||||
Db 78 CCCTGCTGCTGTTGCTGCT 96

RESULT 13
US-08-086-631-24
;; Sequence 24, Application US/08086631
;; Patent No. 5776725
;; GENERAL INFORMATION:
;; APPLICANT: Kindsvogel, Wayne R.
;; TITLE OF INVENTION: GLUCAGON RECEPTORS
;; NUMBER OF SEQUENCES: 25
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: SEED AND BERRY
;; STREET: 6300 COLUMBIA CENTER
;; CITY: SEATTLE
;; STATE: WA
;; COUNTRY: USA
;; ZIP: 99104-7092
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/086,631
;; FILING DATE: July 1, 1993
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/938,331
;; FILING DATE: 28-AUG-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Mcmasters, David D.
;; REGISTRATION NUMBER: 33,963
;; REFERENCE/DOCKET NUMBER: 990008.424C1
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-622-4900
;; TELEFAX: 206-682-6031
;; INFORMATION FOR SEQ ID NO: 24:

;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 1809 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: cdna
;; ORIGINAL SOURCE:
;; ORGANISM: Homo sapiens
;; IMMEDIATE SOURCE:
;; CLONE: pLJ6'
;; FEATURE:
;; NAME/KEY: CDS
;; LOCATION: 53..1486
US-08-086-631-24

Query Match 79.0%; Score 15.8; DB 1; Length 1809;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 CCCTGCTGCTCTTTCTGCT 20
|||||
Db 78 CCCTGCTGCTGTTGCTGCT 96

RESULT 14
US-08-452-930-24
;; Sequence 24, Application US/08452930
;; Patent No. 5919635
;; GENERAL INFORMATION:
;; APPLICANT: Kindsvogel, Wayne R.
;; TITLE OF INVENTION: GLUCAGON RECEPTORS
;; NUMBER OF SEQUENCES: 25
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: SEED AND BERRY
;; STREET: 6300 COLUMBIA CENTER
;; CITY: SEATTLE
;; STATE: WA
;; COUNTRY: USA
;; ZIP: 99104-7092
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/452,930
;; FILING DATE: 30-MAY-1995
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/086,631
;; FILING DATE: July 1, 1993
;; APPLICATION NUMBER: US 07/938,331
;; FILING DATE: 28-AUG-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Mcmasters, David D.
;; REGISTRATION NUMBER: 33,963
;; REFERENCE/DOCKET NUMBER: 990008.424C1
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-622-4900
;; TELEFAX: 206-682-6031
;; INFORMATION FOR SEQ ID NO: 24:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 1809 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: cdna
;; ORIGINAL SOURCE:
;; ORGANISM: Homo sapiens
;; IMMEDIATE SOURCE:
;; CLONE: pLJ6'
;; FEATURE:

NAME/KEY: CDS
LOCATION: 53..1486
US-08-452-930-24

Query Match 79.0%; Score 15.8; DB 2; Length 1809;
Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
||||| |||
Db 78 CCCTGCTGCTGTGCTGCT 96

RESULT 15

PCT-US93-08174-24
; Sequence 24, Application PC/TUS9308174
; GENERAL INFORMATION:
; APPLICANT:
; APPLICANT: NAME: ZymoGenetics, Inc.
; APPLICANT: STREET: 4225 Roosevelt Way North East
; APPLICANT: CITY: Seattle, Washington
; APPLICANT: COUNTRY: United States
; APPLICANT: POSTAL CODE: 98105
; APPLICANT: TELEPHONE: (206) 547-80808
; TITLE OF INVENTION: GLUCAGON RECEPTORS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED AND BERRY
; STREET: 6300 COLUMBIA CENTER
; CITY: SEATTLE
; STATE: WA
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08174
; FILING DATE: 30-AUG-1993
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/086,631
; FILING DATE: July 1, 1993
; APPLICATION NUMBER: US 07/938,331
; FILING DATE: 28-AUG-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 990008.424C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-622-4900
; TELEFAX: 206-682-6031
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1809 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; IMMEDIATE SOURCE:
; CLONE: pLJ6'
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 53..1486
PCT-US93-08174-24

Query Match 79.0%; Score 15.8; DB 5; Length 1809;

Best Local Similarity 89.5%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 CCCTGCTGCTCTTTCTGCT 20
||||| |||
Db 78 CCCTGCTGCTGTGCTGCT 96
Search completed: April 20, 2001, 00:03:47
Job time: 9684 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 03:21:25 ; Search time 11165 Seconds
(without alignments)
9.327 Million cell updates/sec

Title: US-09-016-464-19

Perfect score: 20

Sequence: 1 GCCCTGCTGCTCTTCGCT 20

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 13168883 seqs, 2603265903 residues

Total number of hits satisfying chosen parameters: 26337766

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_NA_Main.*

- 1: /cgn2_6/ptodata/2/pna/PCTUS_COMB.seq.*
- 2: /cgn2_6/ptodata/2/pna/US06_COMB.seq.*
- 3: /cgn2_6/ptodata/2/pna/US07_COMB.seq.*
- 4: /cgn2_6/ptodata/2/pna/US080_COMB.seq.*
- 5: /cgn2_6/ptodata/2/pna/US081_COMB.seq.*
- 6: /cgn2_6/ptodata/2/pna/US082_COMB.seq.*
- 7: /cgn2_6/ptodata/2/pna/US083_COMB.seq.*
- 8: /cgn2_6/ptodata/2/pna/US084_COMB.seq.*
- 9: /cgn2_6/ptodata/2/pna/US085_COMB.seq.*
- 10: /cgn2_6/ptodata/2/pna/US086_COMB.seq.*
- 11: /cgn2_6/ptodata/2/pna/US087_COMB.seq.*
- 12: /cgn2_6/ptodata/2/pna/US088_COMB.seq.*
- 13: /cgn2_6/ptodata/2/pna/US089_COMB.seq.*
- 14: /cgn2_6/ptodata/2/pna/US090_COMB.seq.*
- 15: /cgn2_6/ptodata/2/pna/US091_COMB.seq.*
- 16: /cgn2_6/ptodata/2/pna/US092_COMB.seq.*
- 17: /cgn2_6/ptodata/2/pna/US093_COMB.seq.*
- 18: /cgn2_6/ptodata/2/pna/US094_COMB.seq.*
- 19: /cgn2_6/ptodata/2/pna/US095A_COMB.seq.*
- 20: /cgn2_6/ptodata/2/pna/US095B_COMB.seq.*
- 21: /cgn2_6/ptodata/2/pna/US095C_COMB.seq.*
- 22: /cgn2_6/ptodata/2/pna/US095D_COMB.seq.*
- 23: /cgn2_6/ptodata/2/pna/US096A_COMB.seq.*
- 24: /cgn2_6/ptodata/2/pna/US096B_COMB.seq.*
- 25: /cgn2_6/ptodata/2/pna/US096C_COMB.seq.*
- 26: /cgn2_6/ptodata/2/pna/US096D_COMB.seq.*
- 27: /cgn2_6/ptodata/2/pna/US096E_COMB.seq.*
- 28: /cgn2_6/ptodata/2/pna/US097A_COMB.seq.*
- 29: /cgn2_6/ptodata/2/pna/US097B_COMB.seq.*
- 30: /cgn2_6/ptodata/2/pna/US097C_COMB.seq.*
- 31: /cgn2_6/ptodata/2/pna/US098_COMB.seq.*
- 32: /cgn2_6/ptodata/2/pna/US099_COMB.seq.*
- 33: /cgn2_6/ptodata/2/pna/US0001_COMB.seq.*
- 34: /cgn2_6/ptodata/2/pna/US0002_COMB.seq.*
- 35: /cgn2_6/ptodata/2/pna/US0003_COMB.seq.*
- 36: /cgn2_6/ptodata/2/pna/US0004_COMB.seq.*
- 37: /cgn2_6/ptodata/2/pna/US0005_COMB.seq.*
- 38: /cgn2_6/ptodata/2/pna/US0006_COMB.seq.*
- 39: /cgn2_6/ptodata/2/pna/US0007_COMB.seq.*
- 40: /cgn2_6/ptodata/2/pna/US0008_COMB.seq.*
- 41: /cgn2_6/ptodata/2/pna/US0009_COMB.seq.*
- 42: /cgn2_6/ptodata/2/pna/US0010_COMB.seq.*
- 43: /cgn2_6/ptodata/2/pna/US0011_COMB.seq.*

- 44: /cgn2_6/ptodata/2/pna/US6012_COMB.seq.*
- 45: /cgn2_6/ptodata/2/pna/US6013_COMB.seq.*
- 46: /cgn2_6/ptodata/2/pna/US6014_COMB.seq.*
- 47: /cgn2_6/ptodata/2/pna/US6015_COMB.seq.*
- 48: /cgn2_6/ptodata/2/pna/US6016_COMB.seq.*
- 49: /cgn2_6/ptodata/2/pna/US6017_COMB.seq.*
- 50: /cgn2_6/ptodata/2/pna/US6018_COMB.seq.*
- 51: /cgn2_6/ptodata/2/pna/US6019_COMB.seq.*
- 52: /cgn2_6/ptodata/2/pna/US6020_COMB.seq.*
- 53: /cgn2_6/ptodata/2/pna/US6021_COMB.seq.*
- 54: /cgn2_6/ptodata/2/pna/US6022_COMB.seq.*
- 55: /cgn2_6/ptodata/2/pna/US6023_COMB.seq.*
- 56: /cgn2_6/ptodata/2/pna/US6024_COMB.seq.*
- 57: /cgn2_6/ptodata/2/pna/US6025_COMB.seq.*
- 58: /cgn2_6/ptodata/2/pna/US6026_COMB.seq.*
- 59: /cgn2_6/ptodata/2/pna/US6027_COMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	20	100.0	20	8	US-08-474-497-19
2	20	100.0	20	14	US-09-016-464-19
3	20	100.0	20	19	US-09-509-152A-1055
4	20	100.0	156	19	US-09-509-152A-1735
5	20	100.0	1278	8	US-08-430-121-17
6	20	100.0	1310	8	US-08-430-121-18
7	20	100.0	1314	8	US-08-430-121-16
8	20	100.0	1493	17	US-09-359-922-10109
9	20	100.0	1493	17	US-09-359-922-10109
10	20	100.0	7033	19	US-09-509-152A-2411
11	18	90.0	118773	53	US-60-212-664-10
12	18	90.0	118773	53	US-60-212-664-302
13	18	90.0	118773	53	US-60-212-664-251
14	17.4	87.0	50	53	US-60-217-080-9433
15	17.4	87.0	305	21	US-09-540-733-6246
16	17.4	87.0	305	26	US-09-668-683-10057
17	17.4	87.0	305	47	US-60-156-625-3251
18	17.4	87.0	782	29	US-09-739-449-1514
19	17.4	87.0	867	16	US-09-221-017B-791
20	17.4	87.0	871	24	US-09-620-392-25784
21	17.4	87.0	871	28	US-09-702-134-38385
22	17.4	87.0	1125	16	US-09-270-767-13983
23	17.4	87.0	1478	51	US-60-195-534-14
24	17.4	87.0	1937	48	US-60-167-217-8100
25	17.4	87.0	1937	49	US-60-173-464-6498
26	17.4	87.0	2679	51	US-60-191-637-8003
27	17.4	87.0	2679	51	US-60-191-681-6248
28	17.4	87.0	4868	48	US-60-167-217-8099
29	17.4	87.0	4868	49	US-60-173-464-6497
30	17.4	87.0	13632	51	US-60-191-637-8002
31	17.4	87.0	13632	51	US-60-191-681-6247
32	17.4	87.0	66484	19	US-09-528-237A-902
33	17.4	87.0	257574	19	US-09-528-237A-1454
34	17	85.0	273	13	US-08-923-861-58
35	17	85.0	273	20	US-09-539-813-27
36	17	85.0	273	34	US-60-024-690-58
37	17	85.0	296	25	US-09-654-617-384753
38	17	85.0	296	27	US-09-684-016-384753
39	17	85.0	368	19	US-09-528-409-83109
40	17	85.0	376	16	US-09-271-122-7842
41	17	85.0	376	28	US-09-713-841-7842
42	17	85.0	382	16	US-09-205-070-283
43	17	85.0	382	16	US-09-271-122-7843
44	17	85.0	382	17	US-09-340-623-283
45	17	85.0	382	28	US-09-713-841-7843

ALIGNMENTS

```
RESULT 1
US-08-474-497-19
; Sequence 19, Application US/08474497
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; TITLE OF INVENTION: Using Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,497
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-474-497-19

Query Match 100.0%; Score 20; DB 8; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
Db 1 GCCCTGCTGCTCTTTCTGCT 20

RESULT 2
US-09-016-464-19
; Sequence 19, Application US/09016464
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; TITLE OF INVENTION: Using Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/016,464
; FILING DATE: 30-Jan-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/474,497
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-016-464-19

Query Match 100.0%; Score 20; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
Db 1 GCCCTGCTGCTCTTTCTGCT 20

RESULT 3
US-09-509-152A-1055
; Sequence 1055, Application US/09509152A
; GENERAL INFORMATION:
; APPLICANT: NYCE, JONATHAN W.
; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
; FORMULATIONS, KITS & APPLICATIONS
; NUMBER OF SEQUENCES: 2419
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 CLARKE DRIVE
; CITY: CRANBURY
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/509,152A
; FILING DATE: 17-Mar-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/059,160
; FILING DATE: 1997-09-17
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00991
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1055:
; SEQUENCE CHARACTERISTICS:
```

```

; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1055:
US-09-509-152A-1055

```

Query Match 100.0%; Score 20; DB 19; Length 20;
Best Local Similarity 100.0%; Pred. NO. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0 Indels

QY 1 GCCCTGCTGCTCTTTCTGCT 20
|||||

Db 1 GCCCTGCTGCTCTTTCTGCT 20

```

RESULT      4
US-09-509-152A-1735
; Sequence 1735, Application US/09509152A
; GENERAL INFORMATION:
; APPLICANT: NYCE, JONATHAN W.
; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
; FORMULATIONS, KITS & APPLICATIONS

```

NUMBER OF SEQUENCES: 2419
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC
STREET: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
COUNTRY: USA

```

; ZLF:00012
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII

```

SOL NUMBER: RSC11
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/509,152A
FILING DATE: 17-Mar-2000
CLASSIFICATION: UNKNOWN

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/059,160
FILING DATE: 1997-09-17
ATTORNEY/AGENT INFORMATION:

NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00991
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245

TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1735:

```

;
; SEQUENCE CHARACTERISTICS:
;     LENGTH: 156 base pairs
;

```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1735:
US-09-509-152A-1735

```

```
Query Match      100.0%; Score 20; DB 19; Length 156;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 1 GCCCTGCTGCTCTTTCTGCT 20

RESULT 5
US-08-430-121-17/c

```

; Sequence 17, Application US/08430121
;
; GENERAL INFORMATION:
; APPLICANT: Simonsen, Christian C.
; APPLICANT: McGrogan, Michael
; TITLE OF INVENTION: Recombinant Products of an Eosinophilic
; TITLE OF INVENTION: Gene Family
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1018
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/430,121
; FILING DATE:
;
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,859
; FILING DATE:
; APPLICATION NUMBER: US 07/630,976
; FILING DATE: 19-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Shetka, Debra A.
; REGISTRATION NUMBER: 33,208
; REFERENCE/DOCKET NUMBER: 24842-20058.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-813-5600
; TELEFAX: 415-494-0792
; TELEX: 706141
;
; INFORMATION FOR SEQ ID NO: 17:
;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1278 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; PS-08-430-121-17

```

Query Match	100.0%;	Score 20;	DB 8;	Length 1278;
Best Local Similarity	100.0%;	Pred. No. 1.9e+02;		
Matches 20;	Conservative 0;	Mismatches 0;	Indels 0;	

Qy 1 GCCCTGCTGCTCTTCTGCT 20
pb 110 GCCCTGCTGCTCTTCTGCT 91

```

RESULT      6
US-08-430-121-18/c
; Sequence 18, Application US/08430121
; GENERAL INFORMATION:
; APPLICANT: Simonsen, Christian C.
; APPLICANT: McGrogan, Michael
; TITLE OF INVENTION: Recombinant Products of an Eosinophilic
; TITLE OF INVENTION: Gene Family
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Mortlison & Foerster
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/430,121
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/232,859
FILING DATE:
APPLICATION NUMBER: US 07/630,976
FILING DATE: 19-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Shetka, Debra A.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 24842-20058.00
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-813-5600
TELEFAX: 415-494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 1310 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-430-121-16

Query Match 100.0%; Score 20; DB 8; Length 1310;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
| | | | | | | | | | | | | | | | | | | | | |
Db 110 GCCCTGCTGCTCTTTCTGCT 91

RESULT 7
US-08-430-121-16/c
; Sequence 16, Application US/08430121
; GENERAL INFORMATION:
; APPLICANT: Simonsen, Christian C.
; APPLICANT: McGrogan, Michael
; TITLE OF INVENTION: Recombinant Products of an Eosinophilic
; TITLE OF INVENTION: Gene Family
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/430,121
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/232,859
FILING DATE:
APPLICATION NUMBER: US 07/630,976
FILING DATE: 19-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Shetka, Debra A.
REGISTRATION NUMBER: 33,208
REFERENCE/DOCKET NUMBER: 24842-20058.00
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-813-5600

TELEFAX: 415-494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 1314 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-430-121-16

Query Match 100.0%; Score 20; DB 8; Length 1314;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
| | | | | | | | | | | | | | | | | | | | | |
Db 110 GCCCTGCTGCTCTTTCTGCT 91

RESULT 8
US-09-359-922-10109/c
; Sequence 10109, Application US/09359922
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL CONTIGS OBTAINED FROM VARIOUS CDNA
; TITLE OF INVENTION: LIBRARIES
; FILE REFERENCE: 20411-752CON1
; CURRENT APPLICATION NUMBER: US/09/359,922
; CURRENT FILING DATE: 1999-07-22
; EARLIER APPLICATION NUMBER: US 09/205,155
; EARLIER FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 13203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10109
; LENGTH: 1493
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-359-922-10109

Query Match 100.0%; Score 20; DB 17; Length 1493;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
| | | | | | | | | | | | | | | | | | | | | |
Db 111 GCCCTGCTGCTCTTTCTGCT 92

RESULT 9
US-09-359-922-10109/c
; Sequence 10109, Application US/09359922A
; GENERAL INFORMATION:
; APPLICANT: Leshkowitz, Dana
; APPLICANT: Liu, Jin
; TITLE OF INVENTION: NOVEL CONTIGS OBTAINED FROM VARIOUS CDNA
; TITLE OF INVENTION: LIBRARIES
; FILE REFERENCE: 20411-752CON1
; CURRENT APPLICATION NUMBER: US/09/359,922A
; CURRENT FILING DATE: 1999-07-22
; EARLIER APPLICATION NUMBER: US 09/205,155
; EARLIER FILING DATE: 1998-12-03
; EARLIER APPLICATION NUMBER: US 09/034,341
; EARLIER FILING DATE: 1998-02-13
; NUMBER OF SEQ ID NOS: 13203
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10109
; LENGTH: 1493
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-359-922-10109

Query Match 100.0%; Score 20; DB 17; Length 1493;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 111 GCCCTGCTGCTCTTTCTGCT 92

RESULT 10
US-09-509-152A-2411
; Sequence 2411, Application US/09509152A
; GENERAL INFORMATION:
; APPLICANT: NYCE, JONATHAN W.
; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
; FORMULATIONS, KITS & APPLICATIONS
; NUMBER OF SEQUENCES: 2419
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 CLARKE DRIVE
; CITY: CRANBURY
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/509,152A
; FILING DATE: 17-Mar-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/059,160
; FILING DATE: 1997-09-17
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00991
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2411:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7033 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2411:
US-09-509-152A-2411

Query Match 100.0%; Score 20; DB 19; Length 7033;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 82 GCCCTGCTGCTCTTTCTGCT 101

RESULT 11
US-60-212-664-10/c
; Sequence 10, Application US/60212664
; GENERAL INFORMATION:
; APPLICANT: Ladunga, Steve
; APPLICANT: Spier, Gene
; APPLICANT: Greenberg, Simon
; APPLICANT: Rabkin, Steven
; APPLICANT: Wang, Yu

; TITLE OF INVENTION: ISOLATED HUMAN SECRETED PROTEINS,
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED PROTEINS, AND
; FILE REFERENCE: CL000687
; CURRENT APPLICATION NUMBER: US/60/212,664
; CURRENT FILING DATE: 2000-06-20
; NUMBER OF SEQ ID NOS: 636
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 118773
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(118773)
; OTHER INFORMATION: n = A,T,C or G
US-60-212-664-10

Query Match 90.0%; Score 18; DB 53; Length 118773;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 CCTGCTGCTCTTTCTGCT 20
|||||
Db 60216 CCTGCTGCTCTTTCTGCT 60199

RESULT 12
US-60-212-664-251/c
; Sequence 251, Application US/60212664
; GENERAL INFORMATION:
; APPLICANT: Ladunga, Steve
; APPLICANT: Spier, Gene
; APPLICANT: Greenberg, Simon
; APPLICANT: Rabkin, Steven
; APPLICANT: Wang, Yu
; TITLE OF INVENTION: ISOLATED HUMAN SECRETED PROTEINS,
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED PROTEINS, AND
; FILE REFERENCE: CL000687
; CURRENT APPLICATION NUMBER: US/60/212,664
; CURRENT FILING DATE: 2000-06-20
; NUMBER OF SEQ ID NOS: 636
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 251
; LENGTH: 118773
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(118773)
; OTHER INFORMATION: n = A,T,C or G
US-60-212-664-251

Query Match 90.0%; Score 18; DB 53; Length 118773;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 CCTGCTGCTCTTTCTGCT 20
|||||
Db 60216 CCTGCTGCTCTTTCTGCT 60199

RESULT 13
US-60-212-664-302/c
; Sequence 302, Application US/60212664
; GENERAL INFORMATION:
; APPLICANT: Ladunga, Steve
; APPLICANT: Spier, Gene
; APPLICANT: Greenberg, Simon
; APPLICANT: Rabkin, Steven

```

; APPLICANT: Wang, Yu
; TITLE OF INVENTION: ISOLATED HUMAN SECRETED PROTEINS,
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED PROTEINS, AND
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: CL000887
; CURRENT APPLICATION NUMBER: US/60/212,664
; CURRENT FILING DATE: 2000-06-20
; NUMBER OF SEQ ID NOS: 636
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 302
; LENGTH: 118773
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(118773)
; OTHER INFORMATION: n = A,T,C or G
US-60-212-664-302

```

```

Query Match      90.0%; Score 18; DB 53; Length 118773;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 CCTGCTGCTCTTTCTGCT 20
    |||||
Db 60216 CCTGCTGCTCTTTCTGCT 60199

```

```

RESULT 14
US-60-217-080-9433/c
; Sequence 9433, Application US/60217080
; GENERAL INFORMATION:
; APPLICANT: Glenn, Matthew R.
; APPLICANT: Grigor, Murray R.
; TITLE OF INVENTION: Compositions isolated from bovine tissue
; TITLE OF INVENTION: and methods for their use.
; FILE REFERENCE: 1051P2
; CURRENT APPLICATION NUMBER: US/60/217,080
; CURRENT FILING DATE: 2000-07-10
; NUMBER OF SEQ ID NOS: 35169
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9433
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Bovine
US-60-217-080-9433

```

```

Query Match      87.0%; Score 17.4; DB 53; Length 50;
Best Local Similarity 94.7%; Pred. No. 1.6e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
    |||||
Db 23 CCCTGCTGCTCTTTCTGCT 5

```

```

RESULT 15
US-09-540-733-6246
; Sequence 6246, Application US/09540733
; GENERAL INFORMATION:
; APPLICANT: Seilhamer, Jeffrey J.
; APPLICANT: Delegeane, Angelo M.
; APPLICANT: Stuart, Susan G.
; APPLICANT: Stuve, Laura L.
; APPLICANT: Mullahy, Sara J.
; APPLICANT: Naughton, Rebecca E.
; TITLE OF INVENTION: POLYNUCLEOTIDES OF SKIN TISSUE
; FILE REFERENCE: PD-1035 CIP
; CURRENT APPLICATION NUMBER: US/09/540,733
; CURRENT FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 08/731,034

```

```

; PRIOR FILING DATE: October 2, 1996
; PRIOR APPLICATION NUMBER: 60/004,674
; PRIOR FILING DATE: October 2, 1995
; PRIOR APPLICATION NUMBER: 08/962,919
; PRIOR FILING DATE: October 23, 1997
; PRIOR APPLICATION NUMBER: 60/029,306
; PRIOR FILING DATE: October 25, 1996
; PRIOR APPLICATION NUMBER: 60/036,403
; PRIOR FILING DATE: January 21, 1997
; PRIOR APPLICATION NUMBER: 08/806,593
; PRIOR FILING DATE: February 26, 1997
; PRIOR APPLICATION NUMBER: 60/012,243
; PRIOR FILING DATE: February 26, 1996
; PRIOR APPLICATION NUMBER: 08/941,884
; PRIOR FILING DATE: September 30, 1997
; PRIOR APPLICATION NUMBER: 60/026,759
; PRIOR FILING DATE: October 3, 1996
; NUMBER OF SEQ ID NOS: 7282
; SOFTWARE: PERL Program
; SEQ ID NO 6246
; LENGTH: 305
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID NO: hu01126643
US-09-540-733-6246

```

```

Query Match      87.0%; Score 17.4; DB 21; Length 305;
Best Local Similarity 94.7%; Pred. No. 2e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
    |
Db 197 cactgctgctctttctgct 215

Search completed: April 20, 2001, 03:21:32
Job time: 14179 sec

```


THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:15:48 ; Search time 101.94 Seconds
(without alignments)
27.149 Million cell updates/sec

Title: US-09-016-464-19
Perfect score: 20
Sequence: 1 GCCCTGCTGCTCTTCGCT 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 46985 seqs, 69187998 residues

Total number of hits satisfying chosen parameters: 93970

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending_Patents_NA_New.*

- 1: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq.*
- 2: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq.*
- 3: /cgn2_6/ptodata/1/pna/US07_NEW_COMB.seq.*
- 4: /cgn2_6/ptodata/1/pna/US08_NEW_COMB.seq.*
- 5: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq.*
- 6: /cgn2_6/ptodata/1/pna/US60_NEW_COMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	20	100.0	20	5	US-09-543-679A-1055
2	20	100.0	156	5	US-09-543-679A-1735
3	20	100.0	1452	5	US-09-543-679A-2862
4	20	100.0	1489	5	US-09-543-679A-2865
5	20	100.0	2885	5	US-09-543-679A-2863
6	20	100.0	2918	5	US-09-543-679A-2867
7	20	100.0	7033	5	US-09-543-679A-2411
8	20	100.0	209274	5	US-09-543-679A-3004
9	17.4	87.0	782	5	US-09-739-449-1514
10	17.4	87.0	123654	6	US-60-248-505-41
11	16	80.0	8124	5	US-09-543-679A-2467
12	16	80.0	9372	5	US-09-543-679A-3015
13	16	80.0	35459	5	US-09-543-679A-3003
14	15.8	79.0	40090	5	US-09-820-004-3
15	15.8	79.0	58565	6	US-60-248-505-518
16	15.8	79.0	60415	6	US-60-248-505-194
17	15.8	79.0	68264	6	US-60-248-505-506
18	15.8	79.0	69428	6	US-60-248-505-576
19	15.8	79.0	140825	6	US-60-248-505-571
20	15.8	79.0	163502	6	US-60-248-505-221
21	15.8	79.0	449171	6	US-60-248-505-42
22	15.8	79.0	479874	6	US-60-248-505-72
23	15.4	77.0	756	5	US-09-739-449-4605
24	15.4	77.0	4474	6	US-60-248-505-1477
25	15.4	77.0	4651	6	US-60-248-505-1787
26	15.4	77.0	63957	5	US-09-739-449-196
27	15.4	77.0	90133	6	US-60-248-505-145

28	15.4	77.0	92126	6	US-60-248-505-455	Sequence 455, App
29	15.4	77.0	101880	6	US-60-248-505-650	Sequence 650, App
c 30	15.4	77.0	142631	6	US-60-248-505-477	Sequence 477, App
c 31	15.4	77.0	183820	5	US-09-739-449-209	Sequence 209, App
c 32	15.4	77.0	259200	6	US-60-248-505-199	Sequence 199, App
c 33	15.2	76.0	236	4	US-08-276-163D-10433	Sequence 10433, A
34	15.2	76.0	270	4	US-08-276-163D-15031	Sequence 15031, A
35	15.2	76.0	502	4	US-08-276-163D-1181	Sequence 1181, Ap
c 36	15.2	76.0	1113	5	US-09-739-449-1530	Sequence 1530, Ap
c 37	15.2	76.0	1758	6	US-60-248-505-1408	Sequence 1408, Ap
38	15.2	76.0	2022	5	US-09-813-206-882	Sequence 882, App
39	15.2	76.0	5692	6	US-60-248-505-1982	Sequence 1982, Ap
40	15.2	76.0	29445	6	US-60-248-505-76	Sequence 76, Appl
41	15.2	76.0	32071	6	US-60-248-505-399	Sequence 399, App
c 42	15.2	76.0	101880	6	US-60-248-505-650	Sequence 650, App
c 43	15	75.0	257	4	US-08-276-163D-13103	Sequence 13103, A
c 44	14.8	74.0	377	5	US-09-487-566A-2214	Sequence 2214, Ap
45	14.8	74.0	462	5	US-09-815-343-62	Sequence 62, Appl

ALIGNMENTS

RESULT 1
US-09-543-679A-1055
; Sequence 1055, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1055:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1055:
US-09-543-679A-1055

Query Match 100.0%; Score 20; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 1 GCCCTGCTGCTCTTTCTGCT 20

RESULT 2

US-09-543-679A-1735
; Sequence 1735, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958
FILING DATE: 1998-08-03
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-0067191b
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 1735:
SEQUENCE CHARACTERISTICS:
LENGTH: 156 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 1735:
US-09-543-679A-1735

Query Match 100.0%; Score 20; DB 5; Length 156;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 1 GCCCTGCTGCTCTTTCTGCT 20

RESULT 3

US-09-543-679A-2862/c
; Sequence 2862, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512

ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: NJ
COUNTRY: USA
ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958
FILING DATE: 1998-08-03
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-0067191b
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 2862:
SEQUENCE CHARACTERISTICS:
LENGTH: 1452 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 2862:
US-09-543-679A-2862

Query Match 100.0%; Score 20; DB 5; Length 1452;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 110 GCCCTGCTGCTCTTTCTGCT 91

RESULT 4
US-09-543-679A-2865/c
; Sequence 2865, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958
FILING DATE: 1998-08-03
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-0067191b
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 1735:
SEQUENCE CHARACTERISTICS:
LENGTH: 156 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 1735:
US-09-543-679A-1735

Query Match 100.0%; Score 20; DB 5; Length 156;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCCTGCTGCTCTTTCTGCT 20
|||||
Db 1 GCCCTGCTGCTCTTTCTGCT 20

RESULT 3
US-09-543-679A-2862/c
; Sequence 2862, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958

COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958

```

; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2865:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1489 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2865:
US-09-543-679A-2865

Query Match 100.0%; Score 20; DB 5; Length 1489;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCTGCTGCTCTTTCTGCT 20
Db 110 GCCTGCTGCTCTTTCTGCT 91

RESULT 5
US-09-543-679A-2863/c
; Sequence 2863, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2863:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2885 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2863:
US-09-543-679A-2863

```

```

Query Match 100.0%; Score 20; DB 5; Length 2885;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCTGCTGCTCTTTCTGCT 20
Db 1543 GCCTGCTGCTCTTTCTGCT 1524

RESULT 6
US-09-543-679A-2867/c
; Sequence 2867, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2867:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2918 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2867:
US-09-543-679A-2867

Query Match 100.0%; Score 20; DB 5; Length 2918;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCTGCTGCTCTTTCTGCT 20
Db 804 GCCTGCTGCTCTTTCTGCT 785

RESULT 7
US-09-543-679A-2411
; Sequence 2411, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,

```

COMPOSITIONS, KIT & METHOD FOR TREATMENT
OF AIRWAY DISORDERS ASSOCIATED WITH
BRONCHOCONSTRICTION, LUNG INFLAMMATION,
NUMBER OF SEQUENCES: 3111
CORRESPONDENCE ADDRESS:

ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: NJ
COUNTRY: USA
ZIP: 08512

COMPUTER READABLE FORM:

MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/127,958
FILING DATE: 1998-08-03

ATTORNEY/AGENT INFORMATION:

NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930

REFERENCE/DOCKET NUMBER: EPI-0067191b

TELECOMMUNICATION INFORMATION:

TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

SEQUENCE CHARACTERISTICS:

LENGTH: 7033 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

INFORMATION FOR SEQ ID NO: 2411:
SEQUENCE DESCRIPTION: SEQ ID NO: 2411:

US-09-543-679A-2411

Query Match 100.0%; Score 20; DB 5; Length 7033;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTTTCTGCT 20
|||||
DB 82 GCCCTGCTGCTTTCTGCT 101

RESULT 8

US-09-543-679A-3004

Sequence 3004, Application US/09543679A

GENERAL INFORMATION:

APPLICANT: NYCE, Jonathan W.
TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
COMPOSITIONS, KIT & METHOD FOR TREATMENT
OF AIRWAY DISORDERS ASSOCIATED WITH
BRONCHOCONSTRICTION, LUNG INFLAMMATION,

NUMBER OF SEQUENCES: 3111

CORRESPONDENCE ADDRESS:

ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: NJ
COUNTRY: USA
ZIP: 08512

COMPUTER READABLE FORM:

MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/127,958
FILING DATE: 1998-08-03

ATTORNEY/AGENT INFORMATION:

NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930

REFERENCE/DOCKET NUMBER: EPI-0067191b

TELECOMMUNICATION INFORMATION:

TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 3004:

SEQUENCE CHARACTERISTICS:

LENGTH: 209274 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 3004:

US-09-543-679A-3004

Query Match 100.0%; Score 20; DB 5; Length 209274;

Best Local Similarity 100.0%; Pred. No. 2.3;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCTGCTGCTTTCTGCT 20
|||||
DB 82 GCCCTGCTGCTTTCTGCT 101

RESULT 9

US-09-739-449-1514/c

Sequence 1514, Application US/09739449

GENERAL INFORMATION:

APPLICANT: Hinkle, Gregory J.
TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof

FILE REFERENCE: 38-10(15490)C

CURRENT APPLICATION NUMBER: US/09/739,449

CURRENT FILING DATE: 2000-12-19

PRIOR APPLICATION NUMBER: US 09/514,000

PRIOR FILING DATE: 2000-02-23

NUMBER OF SEQ ID NOS: 13351

SEQ ID NO 1514

LENGTH: 782

TYPE: DNA

ORGANISM: Agrobacterium tumefaciens

FEATURE:

NAME/KEY: unsure

LOCATION: (1)..(782)

OTHER INFORMATION: unsure at all n locations

US-09-739-449-1514

Query Match 87.0%; Score 17.4; DB 5; Length 782;

Best Local Similarity 94.7%; Pred. No. 19;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTTCTGCT 20
|||||
DB 449 CCCTGCTGCTCTTTCTGCT 431

RESULT 10

US-60-248-505-41/c

Sequence 41, Application US/60248505

GENERAL INFORMATION:

APPLICANT: Beasley, Ellen

TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED

TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR

;; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
;; FILE REFERENCE: cl000918
;; CURRENT APPLICATION NUMBER: US/60/248,505
;; CURRENT FILING DATE: 2000-11-15
;; NUMBER OF SEQ ID NOS: 1998
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 41
;; LENGTH: 123654
;; TYPE: DNA
;; ORGANISM: human
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)...(123654)
;; OTHER INFORMATION: n = A,T,C or G
US-60-248-505-41

Query Match 87.0%; Score 17.4; DB 6; Length 123654;
Best Local Similarity 94.7%; Pred. No. 28;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CCCTGCTGCTCTTCTGCT 20
|||||
Db 49152 CCCTGCTGCTCTTCTGCT 49134

RESULT 11
US-09-543-679A-2467
; Sequence 2467, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2467:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8124 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2467:

US-09-543-679A-2467
; Sequence 2467, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2467:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8124 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2467:

Query Match 80.0%; Score 16; DB 5; Length 8124;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 CCCTGCTGCTCTTCT 17
|||||
Db 5177 CCCTGCTGCTCTTCT 5192

RESULT 12
US-09-543-679A-3015
; Sequence 3015, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 3015:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9372 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 3015:
US-09-543-679A-3015

Query Match 80.0%; Score 16; DB 5; Length 9372;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 CCCTGCTGCTCTTCT 17
|||||
Db 5744 CCCTGCTGCTCTTCT 5759

RESULT 13
US-09-543-679A-3003
; Sequence 3003, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 3003:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8124 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 3003:

BRONCHOCONSTRICTION, LUNG INFLAMMATION,
NUMBER OF SEQUENCES: 3111
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESTS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: NJ
COUNTRY: USA
ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/127,958
FILING DATE: 1998-08-03
ATTORNEY/AGENT INFORMATION:
NAME: Anzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-0067191b
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 3003:
SEQUENCE CHARACTERISTICS:
LENGTH: 35459 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 3003:
US-09-543-679A-3003

```

Query Match      80.0%; Score 16; DB 5; Length 35459;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2  CCCTGCTGCTCTTCT 17
          |||||
Db      15877  CCCGCTGCTCTTCT 15892

```

```

RESULT 14
US-09-820-004-3/c
; Sequence 3, Application us/09820004
; GENERAL INFORMATION:
; APPLICANT: WEL, Ming-Hui et al.
; TITLE OF INVENTION: ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC
; TITLE OF INVENTION: ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES
; FILE REFERENCE: CL001201
; CURRENT APPLICATION NUMBER: US/09/820,004
; CURRENT FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 40090
; TYPE: DNA
; ORGANISM: Human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(40090)
; OTHER INFORMATION: n = A,T,C or G
US-09-820-004-3

```

Query Match 79.0%; Score 15.8; DB 5; Length 40090;

```

Best Local Similarity 89.5%, Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2  CCCTGCTGCTCTCTTTCCT 20
          ||| ||| ||| ||| ||| ||| |||
Db      5696  CCCTGCTGCTCTCTTTCCT 5678

RESULT 15
US-60-248-505-518
; Sequence 518, Application US/60248505
; GENERAL INFORMATION:
; APPLICANT: Beasley, Ellen
; TITLE OF INVENTION: ISOLATED HUMAN G-PROTEIN COUPLED
; TITLE OF INVENTION: RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
; TITLE OF INVENTION: PROTEINS, AND USES THEREOF
; FILE REFERENCE: c1000918
; CURRENT APPLICATION NUMBER: US/60/248,505
; CURRENT FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 1998
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 518
; LENGTH: 58565
; TYPE: DNA
; ORGANISM: human
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(58565)
; OTHER INFORMATION: n = A,T,C or G
US-60-248-505-518

```

```

Query Match      79.0%; Score 15.8; DB 6; Length 58565;
Best Local Similarity 89.5%; Prsd. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1  GCCCTGCTGCTCTTTCTGC 19
      ||| ||||| ||||| |||||
Db 26422 accttgatgactctcctac 26440

```

Search completed: April 20, 2001, 00:15:57
Job time: 9494 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:00:29 ; Search time 2028.86 Seconds
(without alignments)
57.668 Million cell updates/sec

Title: US-09-016-464-20

Perfect score: 19
Sequence: 1 GCGCTCGCGCTGTCCTCCGG 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1283235 seqs, 3078962356 residues

Total number of hits satisfying chosen parameters: 2566470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

- GenEmbl:*
- 1: gb_ba1:*
 - 2: gb_ba2:*
 - 3: gb_ba3:*
 - 4: gb_in1:*
 - 5: gb_in2:*
 - 6: gb_in3:*
 - 7: gb_om:*
 - 8: gb_ov:*
 - 9: gb_pat1:*
 - 10: gb_pat2:*
 - 11: gb_ph:*
 - 12: gb_pl1:*
 - 13: gb_pl2:*
 - 14: gb_pl3:*
 - 15: gb_pl4:*
 - 16: em_bal:*
 - 17: em_ba2:*
 - 18: em_fun:*
 - 19: em_htgo_hum:*
 - 20: em_htgo_inv:*
 - 21: em_htgo_rod:*
 - 22: em_htg_hum1:*
 - 23: em_htg_hum2:*
 - 24: em_htg_hum3:*
 - 25: em_htg_hum4:*
 - 26: em_htg_hum5:*
 - 27: em_htg_hum6:*
 - 28: em_htg_hum7:*
 - 29: em_htg_hum8:*
 - 30: em_htg_inv1:*
 - 31: em_htg_inv2:*
 - 32: em_htg_other:*
 - 33: em_htg_rod:*
 - 34: em_hum1:*
 - 35: em_hum2:*
 - 36: em_hum3:*
 - 37: em_hum4:*
 - 38: em_hum5:*
 - 39: em_hum6:*
 - 40: em_hum7:*
 - 41: em_in:*
 - 42: em_om:*
 - 43: em_or:*

- 44: em_ov:*
- 45: em_pat:*
- 46: em_ph:*
- 47: em_pl:*
- 48: em_rod:*
- 49: em_sts:*
- 50: em_sy:*
- 51: em_un:*
- 52: em_vi:*
- 53: gb_sts1:*
- 54: gb_sts2:*
- 55: gb_sts3:*
- 56: gb_sy:*
- 57: gb_un:*
- 58: gb_vil:*
- 59: gb_vil2:*
- 60: gb_htg1:*
- 61: gb_htg2:*
- 62: gb_htg3:*
- 63: gb_htg4:*
- 64: gb_htg5:*
- 65: gb_htg6:*
- 66: gb_htg7:*
- 67: gb_htg8:*
- 68: gb_htg9:*
- 69: gb_htg10:*
- 70: gb_htg11:*
- 71: gb_htg12:*
- 72: gb_htg13:*
- 73: gb_htg14:*
- 74: gb_htg15:*
- 75: gb_htg16:*
- 76: gb_htg17:*
- 77: gb_htg18:*
- 78: gb_htg19:*
- 79: gb_htg20:*
- 80: gb_htg21:*
- 81: gb_htg22:*
- 82: gb_htg23:*
- 83: gb_htg24:*
- 84: gb_htg25:*
- 85: gb_pr1:*
- 86: gb_pr2:*
- 87: gb_pr3:*
- 88: gb_pr4:*
- 89: gb_pr5:*
- 90: gb_pr6:*
- 91: gb_pr7:*
- 92: gb_pr8:*
- 93: gb_pr9:*
- 94: gb_rol:*
- 95: gb_ro2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	19	100.0	429	93	M29906 Homo sapien
C 2	19	100.0	2558	92	X14346 Human mRNA
C 3	19	100.0	162083	86	AC005962 Homo sapi
C 4	17.4	91.6	4265	1	AB028210 Streptomy
C 5	17.4	91.6	17856	3	AL450450 Streptomy
C 6	17.4	91.6	32274	3	AL356892 Streptomy
C 7	17.4	91.6	191877	86	AC007207 Homo sapi
C 8	17.4	91.6	201290	77	AC084375 Homo sapi
C 9	17.4	91.6	300691	60	AC005842 Homo sapi
C 10	16.4	86.3	2963	11	X87627 Bacterioph
C 11	16.4	86.3	3611	1	AF099190 Caulobact

C	12	16.4	86.3	4988	3	U18133	U18133 Comamonas t
	13	16.4	86.3	6927	2	AF319543	AF319543 Streptomyce
	14	16.4	86.3	8300	3	SCARGGH	Z49111 Streptomyce
	15	16.4	86.3	36583	3	SC5H1	AL049863 Streptomy
C	16	16.4	86.3	40476	3	SC75A	AL133220 Streptomy
	17	16.4	86.3	44109	3	SC5F1	AL450165 Streptomy
C	18	16.4	86.3	139544	92	HSDJ85M6	AL121926 Human DNA
C	19	16.4	86.3	147664	78	AL138691	AL138691 Homo sapi
C	20	16.4	86.3	176306	71	AC032013	AC032013 Mus muscu
C	21	16.4	86.3	178353	63	AC012334	AC012334 Homo sapi
C	22	16.4	86.3	183663	80	AL356961	AL356961 Homo sapi
C	23	16	84.2	17124	1	AE004789	AE004789 Pseudomon
C	24	16	84.2	68000	78	AC090053	AC090053 Leishmani
C	25	16	84.2	110000	84	LMFLCHR32_09	Continuation (10 o
C	26	16	84.2	349116	2	AP03003	AP03003 Mesorhizo
C	27	15.8	83.2	400	54	G16330	G16330 human STS S
C	28	15.8	83.2	593	2	AF228524	AF228524 Streptomy
C	29	15.8	83.2	632	12	AF058476	AF058476 Eucalyptu
C	30	15.8	83.2	719	53	CNS01NOQ	AL152553 Anopheles
C	31	15.8	83.2	996	53	CNS01LFY	AL149583 Anopheles
C	32	15.8	83.2	1046	53	CNS01LCF	AL149456 Anopheles
C	33	15.8	83.2	1200	94	RATCELF	M65149 Rat CELF mR
C	34	15.8	83.2	1284	3	PAZAUZ	X07317 Pseudomonas
C	35	15.8	83.2	1287	3	PSEAUZ	M30389 Pseudomonas
C	36	15.8	83.2	1401	9	AR058223	AR058223 Sequence
C	37	15.8	83.2	1401	93	HUMNUCTIAR	M96954 Homo sapien
C	38	15.8	83.2	1826	88	AF113527	AF113527 Homo sapi
C	39	15.8	83.2	1837	1	AF010151	AF010151 Pseudomon
C	40	15.8	83.2	2059	7	AF319658	AF319658 Sus scrof
C	41	15.8	83.2	2417	3	PDNORNOZ	X74792 P.denitrifi
C	42	15.8	83.2	2628	1	AF193856	AF193856 Streptomy
C	43	15.8	83.2	2750	15	ZMUR2481	U82481 Zea mays KI
C	44	15.8	83.2	2988	8	GJUNDG	X60063 G.domesticu
C	45	15.8	83.2	3395	94	MWECK	X78339 M.musculus

RESULT	1	HUMEPP03	429 bp	DNA	PRI	23-OCT-2000
LOCUS		Homo sapiens	eosinophil peroxidase (EPP)	gene, exons 4 and 5.		
DEFINITION		M29906	M86682			
ACCESSION		M29906.1	GI:182137			
VERSION		eosinophil peroxidase.				
KEYWORDS		3 of 10				
SEGMENT		human.				
SOURCE		human.				
ORGANISM		Homo sapiens				
REFERENCE		1	..429			
AUTHORS		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
TITLE		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
JOURNAL		Sakamaki, K., Tomonaga, M., Tsukui, K. and Nagata, S.				
MEDLINE		Molecular cloning and characterization of a chromosomal gene for				
FEATURES		human eosinophil peroxidase				
		J. Biol. Chem. 264 (28), 16828-16836 (1989)				
		89380315				
		Location/Qualifiers				
		1. .429				
		/organism="Homo sapiens"				
		/db_xref="taxon:9606"				
		/chromosome="17"				
		/clone="lambda-601"				
		/tissue_type="placenta"				
		/tissue_lib="M.Shibuya"				
		<1. .13				
		/gene="EPP"				
		/number=3				
		14. .131				
		/gene="EPP"				
		/number=4				
		132. .262				
		/gene="EPP"				
Intron						
exon						
Intron						

<

misc_feature /note="light chain (AA 1 - 111)"
 715..2106
 /note="heavy chain (AA 112 - 575)"
 polyA_signal 2538..2543
 /note="pot. polyA signal"
 BASE COUNT 527 a 820 c 698 g 513 t
 ORIGIN

Query Match 100.0%; Score 19; DB 92; Length 2558;
 Best Local Similarity 100.0%; Pred. No. 2.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTGTCCTCGG 19
 |||||
 Db 384 GCGCTCGGCTGTGTCCTCGG 366

RESULT 3
 AC005962/c
 LOCUS AC005962 162083 bp DNA PRI 24-NOV-1998
 DEFINITION Homo sapiens chromosome 17, clone hRPK.506_H_21, complete sequence.
 ACCESSION AC005962
 VERSION HTG.
 KEYWORDS AC005962.1 GI:3924656
 SOURCE human.

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 162083)

AUTHORS Birren,B., Linton,L., Nusbaum,C. and Lander,E.

TITLE Homo sapiens chromosome 17, clone hRPK.506_H_21

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 162083)

AUTHORS Birren,B., Linton,L., Nusbaum,C., Lander,E., Allen,N., Anderson,M.,

Baker,J., Baldwin,J., Barna,N., Beckerly,R., Benn,J., Boutwell,C.,
 Brown,A., Castle,A., Cerny,J., Colangelo,M., Collins,S.,
 Collymore,A., Cooke,P., Corliss,D., Depayre,E., Devon,K., Dewar,K.,
 Donelan,L., Ferreira,P., FitzHugh,W., Forrest,C., Funke,R.,
 Gage,D., Gardyna,S., Geraghty,K., Grant,G., Hagos,B., Heaford,A.,
 Herena,L., Horton,L., Howland,J.C., Jacotot,L., Jones,C., Kann,L.,
 Karatas,A., Lehoczy,J., Macdonald,P., Marquis,N., McEwan,P.,
 McGurk,A., McKernan,K., Meldrum,J., Molla,M., Morris,W., Morrow,J.,
 Mychalecky,J., Nahf,R., Naylor,J., Nilloff,M., O'Connor,T.,
 O'Donnell,P., Pavlin,B., Peterson,K., Riley,R., Roberts,D., Roy,A.,
 Severy,P., Stange-Thomann,N., Stilwell,J., Stojanovic,N., Stone,C.,
 Subramanian,A., Tesfaye,S., Tichovolsky,N., Torruella-Miller,I.,
 Vassiliev,H., Vo,A., Wagner,A., Wheeler,J., Wu,Y., Wyman,D.,
 Ye,W.J., Zhao,J. and Zody,M.

Direct Submission

Submitted (11-NOV-1998) Whitehead Institute/MIT Center for Genome
 Research, 320 Charles Street, Cambridge, MA 02141, USA

REFERENCE 3 (bases 1 to 162083)

AUTHORS Birren,B., Linton,L., Nusbaum,C., Lander,E., Allen,N., Anderson,M.,
 Baker,J., Baldwin,J., Barna,N., Beckerly,R., Benn,J., Boutwell,C.,
 Brown,A., Castle,A., Cerny,J., Colangelo,M., Collins,S.,
 Collymore,A., Cooke,P., Corliss,D., Depayre,E., Devon,K., Dewar,K.,
 Donelan,L., Ferreira,P., FitzHugh,W., Forrest,C., Funke,R.,
 Gage,D., Gardyna,S., Geraghty,K., Grant,G., Hagos,B., Heaford,A.,
 Herena,L., Horton,L., Howland,J.C., Jacotot,L., Jones,C., Kann,L.,
 Karatas,A., Lehoczy,J., Macdonald,P., Marquis,N., McEwan,P.,
 McGurk,A., McKernan,K., Meldrum,J., Molla,M., Morris,W., Morrow,J.,
 Mychalecky,J., Nahf,R., Naylor,J., Nilloff,M., O'Connor,T., Roy,A.,
 O'Donnell,P., Pavlin,B., Peterson,K., Riley,R., Roberts,D., Roy,A.,
 Severy,P., Stange-Thomann,N., Stilwell,J., Stojanovic,N., Stone,C.,
 Subramanian,A., Tesfaye,S., Tichovolsky,N., Torruella-Miller,I.,
 Vassiliev,H., Vo,A., Wagner,A., Wheeler,J., Wu,Y., Wyman,D.,
 Ye,W.J., Zhao,J. and Zody,M.

Direct Submission

Submitted (24-NOV-1998) Whitehead Institute/MIT Center for Genome
 Research, 320 Charles Street, Cambridge, MA 02141, USA

COMMENT On Nov 24, 1998 this sequence version replaced gi:3907449.

All repeats were identified using RepeatMasker: Smit, A.F.A. &

Green, P. (1996-1997)
 http://ftp.genome.washington.edu/RM/RepeatMasker.html
 Only the first 162083 base pairs of this clone are being submitted.
 The remainder overlaps accession number AC004687 (WICGR project
 L319).

FEATURES	Location/Qualifiers
Source	1..162083 /organism="Homo sapiens" /db_xref="taxon:9606" /clone="hRPK.506_H_21" /clone_lib="RPC1-II human BAC library" /map="17"
repeat_region	/chromosome="17" complement(109..159) /rpt_family="MIR"
repeat_region	complement(276..570) /rpt_family="AluSg"
repeat_region	complement(1137..1872) /rpt_family="L2"
repeat_region	complement(1880..2081) /rpt_family="MIR"
repeat_region	complement(2134..2309) /rpt_family="L2"
repeat_region	2679..2929 /rpt_family="MIR"
repeat_region	2985..3005 /rpt_family="MIR"
repeat_region	complement(3193..3382) /rpt_family="MIR"
repeat_region	complement(4898..5004) /rpt_family="MIR"
repeat_region	5080..5099 /rpt_family="MIR"
repeat_region	5764..5813 /rpt_family="MIR"
repeat_region	complement(7859..8011) /rpt_family="MIR"
repeat_region	complement(8060..8213) /rpt_family="MIR"
repeat_region	complement(8232..8391) /rpt_family="MIR"
repeat_region	complement(9047..9072) /rpt_family="MIR"
repeat_region	complement(11837..11884) /rpt_family="MIR"
unsure	13391..13510 /note="Single-stranded coverage."
repeat_region	complement(14183..14381) /rpt_family="MIR"
repeat_region	14484..14775 /rpt_family="MIR"
repeat_region	15750..15950 /rpt_family="MIR"
repeat_region	complement(16067..16163) /rpt_family="MIR"
repeat_region	complement(16265..16719) /rpt_family="MIR"
repeat_region	complement(16769..16981) /rpt_family="MIR"
repeat_region	17025..17066 /rpt_family="MIR"
repeat_region	complement(17414..17844) /rpt_family="MIR"
repeat_region	complement(17845..19356) /rpt_family="MIR"
repeat_region	complement(19375..19919) /rpt_family="MIR"
repeat_region	19920..20207 /rpt_family="MIR"
repeat_region	complement(20208..20219) /rpt_family="MIR"
repeat_region	complement(20220..20512) /rpt_family="MIR"

TSEAHANGRLPEALRRRPGAVRSRHPDVSIALGASAPALMDAHPWDDPHGPGSPILA
RLVALGKRVLLGAPDTMTLLHHAELAQAAPGRFVYTYEQPIEAGVGVWRTFRDID
SEHAGFYSSAVPGQDPFAVIVGSMLAGIGREGFYGAARSRLFDAAPAVFVGVRMI
EEHLNRDR"

BASE COUNT 612 a 1516 c 1543 g 594 t

ORIGIN

Query Match 91.6%; Score 17.4; DB 1; Length 4265;

Best Local Similarity 94.7%; Pred. No. 9.4e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GGGCTCGGCTGCTCCCG 19

|||||

Db 3493 GGGCTCGGCTGCTCCCG 3475

RESULT 5

SCK20

LOCUS SCK20 17856 bp DNA BCT 01-DEC-2000

DEFINITION Streptomyces coelicolor cosmid K20.

ACCESSION AL450450

VERSION AL450450.1 GI:11544744

KEYWORDS ECF sigma factor; integral membrane protein; lipoprotein; membrane protein; monooxygenase; mutA2, methylmalonyl CoA mutase; secreted hydrolase; tetr-family transcriptional regulator; transferase. Streptomyces coelicolor.

SOURCE Streptomyces coelicolor

ORGANISM

Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;

Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.

1 (bases 1 to 17856)

Redenbach, M., Kieser, H.M., Denapait, D., Eichner, A., Cullum, J.,

Kinashi, H., and Hopwood, D.A.

A set of ordered cosmids and a detailed genetic and physical map

for the 8 Mb Streptomyces coelicolor A3(2) chromosome

Mol. Microbiol. 21 (1), 77-96 (1996)

79700351

REFERENCE 2 (bases 1 to 17856)

Seeger, K. and Harris, D.

Unpublished

3 (bases 1 to 17856)

Cerdeno, A.M., Parkhill, J., Barrell, B.G. and Rajandream, M.A.

Submitted

Direct Submission

Submitted (30-NOV-2000) Streptomyces coelicolor sequencing project,

Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge

CB10 1SA E-mail: barrell@sanger.ac.uk Cosmids supplied by Prof.

David A. Hopwood, [3] John Innes Centre, Norwich Research Park,

Colney, Norwich, Norfolk NR4 7UH, UK

Notes:

Streptomyces coelicolor sequencing at The Sanger Centre is funded

by the BBSRC and Beowulf Genomics

Details of S. coelicolor sequencing at the Sanger Centre are

available on the World Wide Web.

(URL: http://www.sanger.ac.uk/projects/S_coelicolor/) CDS are

numbered using the following system eg SC7B7.01c. SC (S.

coelicolor), 7B7 (cosmid name), .01 (first CDS), c (complementary

strand).

The more significant matches with motifs in the PROSITE database

are also included but some of these may be fortuitous. The length

in codons is given for each CDS.

Usually the highest scoring match found by fasta -o is given for

CDS which show significant similarity to other CDS in the database.

The position of possible ribosome binding site sequences are given

where these have been used to deduce the initiation codon. Gene

prediction is based on positional base preference in codons using a

specially developed Hidden Markov Model (Krogh et al., Nucleic

Acids Research, 22(22):4768-4778(1994)) and the Frameplot program

of Bibb et al., Gene 30:157-66(1984) as implemented at

<http://www.nih.go.jp/jun/cgi-bin/frameplot.pl>

CAUTION: We may not have predicted the

correct initiation codon. Where possible we choose an initiation

codon (atg, gtg, ttg or (att)) which is preceded by an upstream

ribosome binding site sequence (optimally 5-13bp before the

initiation codon). If this cannot be identified we choose the most

upstream initiation codon.

IMPORTANT: This sequence MAY NOT be the entire insert of the

sequenced clone. It may be shorter because we only sequence

overlapping sections once, or longer, because we arrange for a

small overlap between neighbouring submissions. Cosmid K20 overlaps

with cosmid St588 and cosmid 2Str8.

FEATURES

source

1..17856

/organism="Streptomyces coelicolor"

/db_xref="taxon:1902"

1..1398

/gene="SCK20.01"

1..17856

/organism="Streptomyces coelicolor A3(2)"

/strain="A3(2)"

/db_xref="taxon:100236"

/clone="cosmid K20"

1..1398

/gene="SCK20.01"

/note="SCK20.01, probable secreted hydrolase (fragment),

len: >465 aa; similar to C-terminal region of

SW-HEXA_DICDI (EMBL:J04065) Dictyostelium discoideum

beta-hexosaminidase A precursor (EC 3.2.1.52) NagA, 532

aa; fasta scores: opt: 343 z-score: 387.7 E(): 4.6e-14;

25.4% identity in 393 aa overlap. Contains Pfam match to

entry PF00728 Glyco_hydro_20, Glycosyl hydrolase family

20"

/codon_start=1

/transl_table=11

/product="putative secreted hydrolase (fragment)"

/protein_id="CAC17648.1"

/db_xref="GI:11544745"

/translation="PAVREHTAARGPGWQPEKGNRVVADSLADEGKQIAGDLGMY

AGEKDDERAGLLLDVNAKANGANPESYMTYRDGRVTVTGAEGVYVGTTLQAQVD

GGTAPGEVVADEPAKPRGSLDIARKHSADWIKRIRGLGDLKNELGHEFSDQD

AFRIEDSHPEIVSEHLTKAEKKEIIDLAASRHTVVVPEIDSPGHGAVAAHPDQQ

LYNTAAARKAYGSGTVAADITGTGLNGRAKTVMAHDTPRAMNDGPKFTSVPELKD

IKVAYWTCKEIGARPRAEYLGEGRQVLYNDEFLYVVGOPQTFVYPTGERIYEQWTP

IKVLTGTAVDAKYDDQILGGSFAVWGDFPNAQTQAVNAEGRILPLAATVQKLWDPGKP

ELSWTDFAAALANRLD"

1..1108

/gene="SCK20.01"

/note="nominal overlap with Streptomyces coelicolor cosmid

SC568"

205..792

/gene="SCK20.01"

/note="Pfam match to entry PF00728 Glyco_hydro_20,

Glycosyl hydrolase family 20, score 71.80, E-value

1.9e-18"

1517..2062

/gene="SCK20.02"

1517..2062

/gene="SCK20.02"

/note="SCK20.02, unknown, len: 181 aa"

/codon_start=1

/transl_table=11

/product="hypothetical protein SCK20.02"

/protein_id="CAC17649.1"

/db_xref="GI:11544746"

/translation="MGVNGYFVWGRAERPLAELEALSGADMTLRQSPDGWVEFP

GGGDGVNMNDLAGOTGAPALFGYVMDSDCVVVEAAAPESCAWTTCRLARTAMAGYLG

ERDGLTLEDYFLPRDRAERAYANAAEAGCAAPAEAGLVLSDDPAEPADGGRVLA

PGPVAENLFFRDLRLGVVPL"

2139..2143

2150..2719

/gene="SCK20.03"

2150..2719

/gene="SCK20.03"

/note="SCK20.03, unknown, len: 189 aa"

/codon_start=1

/transl_table=11

/product="hypothetical protein SCK20.03"
/protein_id="CAC17650.1"
/db_xref="GI:11544747"
/translation="MSIVELIARADTRGLAASGLACLDRCVPLLDGDDEALRPLWATL
ADASGASLPDMALCAQVRDKLAGPGATGEDEAAVLARRMLAAAPAECSGPLYRTWA
DACVASLRHRLAPAAAGAAPEADVPDAGTEGLPLVAAELRRQAIVLELLAGHGA
AGVPALESTEGRRVLRVAVVSRARGR"
2887. 3309
/gene="SCK20.04"
2887. 3309
/note="SCK20.04"
/note="SCK20.04, unknown, len: 140 aa"
/codon_start=1
/transl_table=11
/product="hypothetical protein SCK20.04"
/protein_id="CAC17651.1"
/db_xref="GI:11544748"
/translation="MTSLTSGWTSQPPRPSAAAPVRWAADAVATMRGARL
RLDYSAGSLMRVDRMIDIRGEAPYAAVETALRGAYGEIVIRQSGGEWMTTGGD
HWRTPGRLWDPIDEARRCFAGDGLRLLCRDATAPR"
3376. 4053
/gene="SCK20.05"
3376. 4053
/note="SCK20.05"
/note="SCK20.05, possible ECF sigma factor, len: 225 aa;
similar to TR:Q9RIT1 (EMBL:AJ010584) Streptomyces
coellicolor ECF sigma factor, 264 aa; fasta scores: Opt:
296 z-score: 342.7 E(): 1.5e-11; 34.0% identity in 212 aa
overlap and to Streptomyces coellicolor putative ECF sigma
factor SCK20.07, 220 aa; fasta scores: Opt: 671 z-score:
656.4 E(): 6.9e-31; 59.5% identity in 185 aa overlap.
Contains Pfam match to entry PF00776 Sigma70_ECF, Sigma-70
factor (ECF subfamily)"
/codon_start=1
/transl_table=11
/product="putative ECF sigma factor"
/protein_id="CAC17652.1"
/db_xref="GI:11544749"
/translation="MTLGGARSRRTYGRGRFLGGRPRRVOAYDGLGAAVARA
QOGDEAFAYALVOPGLLYVGLGEDAEADAWLEIARDLRRFGDGAGFRG
WPTIARHRLHRLRQKVRPRPTALQDVLDPGPHSTHEVLETLSTRAALGLVAA
LPDQABAVLLRVVGLDGPSSAAKVLGKRGPAVRTAYRGLKRLARQLGADGVTDGP
RTLGEST"
3568. 3732
/gene="SCK20.05"
/note="Pfam match to entry PF00776 Sigma70_ECF, Sigma-70
factor (ECF subfamily), score 34.80, E-value 1.9e-06"
4041. 4044
/gene="SCK20.05"
4050. 4970
/gene="SCK20.06"
4050. 4970
/gene="SCK20.06"
/note="SCK20.06, unknown, len: 306 aa. High G+C content
(82.13%)"
/codon_start=1
/transl_table=11
/product="hypothetical protein SCK20.06"
/protein_id="CAC17653.1"
/db_xref="GI:11544750"
/translation="MRGAGGPDADRAGAEADMGARHEAGDGRDTPRPAPGVPQTE
ALLAMARASAGTEGERRALAAFPRAADAPARATRRDDRRPDGRHOGRTPT
ALSVLLASLTGLGVAAVMGGSGASDGDGPDTRPPAVSDDAPAPATPPGTTGCP
GTTGPATTPGASSEGSTAPPRVSTPPGPPSVGRDTEACQRIERLAGNKSLEDA
WRLLAAGAARVEYTCADQLDLGLPTGPGSPGTAGNGTGNAGNGGTGDTGTGEG
GAGGILGDGADPEADGGTAAQVPDLDPH"
4446. 4622
/gene="SCK20.06"
/note="High content in proline, threonine and alanine
amino acid residues. High content in G+C (86.44%)"
5334. 6016
/gene="SCK20.07"
5334. 6016

misc_feature

RBS

gene

CDS

misc_feature

gene

CDS

Query Match 91.6% Score 17.4; DB 3; Length 17856;
Best Local Similarity 94.7% Pred. No. 5.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 CGCGTCGGCCTGGTCCCGG 19
|||||
Db 3835 CGCGTCGGCCTGGTCCCGG 3853
|||||
RESULT 6
SCC8A/c 32274 bp DNA BCT 26-MAY-2000
LOCUS Streptomyces coelicolor cosmid G8.
DEFINITION AL356892
ACCESSION AL356892.1 GI:8246783
VERSION
KEYWORDS integral membrane transport; lipoprotein; peptidoglycan-binding;
pyruvate dehydrogenase E1 component; sensor kinase; tcmA;
tetracycline C efflux protein; thiol-specific antioxidant; CRNA;
two-component response regulator.
SOURCE Streptomyces coelicolor A3(2).
ORGANISM Streptomyces coelicolor A3(2)
Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.
REFERENCE 1 (bases 1 to 32274)
AUTHORS Redenbach, M., Kleser, H.M., Denapate, D., Eichner, A., Cullum, J.,
Kinashi, H. and Hopwood, D.A.
TITLE A set of ordered cosmids and a detailed genetic and physical map
for the 8 Mb Streptomyces coelicolor A3(2) chromosome
Mol. Microbiol. 21 (1), 77-96 (1996)
JOURNAL 97000351
MEDLINE
REFERENCE 2 (bases 1 to 32274)
AUTHORS Brown, S.P. and Harris, D.
JOURNAL Unpublished
REFERENCE 3 (bases 1 to 32274)
AUTHORS Bentley, S.D., Parkhill, J., Barrell, B.G. and Rajandream, M.A.
TITLE Direct Submission
JOURNAL Submitted (25-MAY-2000) Streptomyces coelicolor sequencing project,
Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge
CB10 1SA E-mail: barrell@sanger.ac.uk Cosmids supplied by Prof.
David A. Hopwood, [3] John Innes Centre, Norwich Research Park,
Colney, Norwich, Norfolk NR4 7UH, UK
Notes:
Streptomyces coelicolor sequencing at The Sanger Centre is funded
by the BBSRC and Beowulf Genomics
Details of S. coelicolor sequencing at the Sanger Centre are
available on the World Wide Web.
(URL: <http://www.sanger.ac.uk/Projects/S-coelicolor/>)
CDS are numbered using the following system eg SC7B7, 01c. SC (S.
coelicolor), 7B7 (cosmid name), .01 (first CDS), c (complementary
strand).
The more significant matches with motifs in the PROSITE database
are also included but some of these may be fortuitous.
The length in codons is given for each CDS.
Usually the highest scoring match found by fasta -o is given for
CDS which show significant similarity to other CDS in the database.
The position of possible ribosome binding site sequences are given
where these have been used to deduce the initiation codon.
Gene prediction is based on positional base preference in codons
using a specially developed Hidden Markov Model (Krogh et al.,
Nucleic Acids Research, 22(22):4768-4778(1994)) and the Frameplot
program of Bibb et al., Gene 30:157-66(1984) as implemented at
<http://www.nih.gov/jp/jun/cgi-bin/frameplot.pl>. CAUTION: We may not have predicted the
correct initiation codon. Where possible we choose an initiation
codon (atg, gtg, ttg or att) which is preceded by an upstream
ribosome binding site sequence (optimally 5-13bp before the
initiation codon). If this cannot be identified we choose the most
upstream initiation codon.
IMPORTANT: This sequence MAY NOT be the entire insert of the
sequenced clone. It may be shorter because we only sequence
overlapping sections once, or longer, because we arrange for a

small overlap between neighbouring submissions.

Cosmid C8A.

FEATURES

source

Location/Qualifiers
1..32274
/organism="Streptomyces coelicolor A3(2)"
/strain="A3(2)"
/db_xref="taxon:100226"
/clone="cosmid C8A"

misc_feature

1..100
/note="Nominal overlap with Streptomyces coelicolor cosmid C53"

gene

184..717

CDS

184..717

/gene="SCC8A.01"
/note="SCC8A.01, possible acetyltransferase, len: 177aa; similar to many of undefined function eg. TR:CAB59671 (EMBL:AL132674) putative acetyltransferase from Streptomyces coelicolor (161 aa) fasta scores; opt: 194, z-score: 245.6, E(): 3.2e-06, 33% identity in 165 aa overlap. Contains Pfam match to entry PF00583 Acetyltransf, Acetyltransferase (GNAT) family, score 44.30, E-value 2.7e-09."

/codon_start=1

/transl_table=11
/product="putative acetyltransferase"

/protein_id="CAB92819.1"

/db_xref="GI:8246784"

/translation="MTWTVDPEDYDSPVAAALWRAYTYTEVSDRWYRLHEGRATDPDEL ERETAYPGADLPVPRGVLVARYGGEPAGSGVRLDHTTAELTRFLYGPMDRGGG AALIVRAEDAAALGAERMLVDTRGDILVEARALYARLGYTETAYNESPYAEHFAK RLRSRDYRRPRSRGS"

misc_feature

193..612

/gene="SCC8A.01"

/note="Pfam match to entry PF00583 Acetyltransf, Acetyltransferase (GNAT) family, score 44.30, E-value 2.7e-09"

674..754

/note="3x CCGACCGCGactCctGACGgCgcCGCT repeat"

complement(754..2823)

/gene="SCC8A.02c"

complement(754..2823)

/gene="SCC8A.02c"

/note="SCC8A.02c, possible integral membrane transport protein, len: 689aa; similar to many eg. TR:CAB99031 (EMBL:AL353870) putative membrane transport protein from Streptomyces coelicolor (714 aa) fasta scores; opt: 1767, z-score: 1907.0, E(): 0, 46.1% identity in 670 aa overlap and TR:P96712 (EMBL:D50098) multidrug transporter from Bacillus subtilis (512 aa) fasta scores; opt: 1168, z-score: 1262.8, E(): 0, 37.6% identity in 495 aa overlap. Contains Pfam match to entry PF00083 sugar_tr, Sugar (and other) transporter and possible membrane-spanning hydrophobic regions."

/codon_start=1

/transl_table=11

/product="putative integral membrane transport protein"

/protein_id="CAB92820.1"

/db_xref="GI:8246785"

/translation="MAGDVREATESPPDAPAPGEREQVSSGVLVISGALLGLML AALDTIVSTALPTIVSDGLGHLSSWVTAYLLAATAATPLWGLDQYGRKKLFLP AIGIPVSGALCGTAQMGQITAFRALGGLGGIMVLSMAIVGLDVPVPRGRYQGL FGAVPGVSVLGLPGVFTLHLSWRVFTYINLPIGVVALAVIAAVLHI PRRTTRHVI DYLGPLLASVTSVLVLSLGGTTWASSPQILGLAVLVAVLFLVAVERRAEPV LPLKLFVRTRTALSAVISIVGIFAMFGATYLPFLQVVRGVTPTMSGYMLPWVFG LLLSVTSVTSRSGRWKVPVAGTAVTTGLLLHLDQDENSATAEMGAYFFVFGGL GLVMQVLIIVQNAVYEDLGVATSGATFFRISGASFGVAIFGTIFASRLGDQTLDAF RGAALPPGVSDTGLKADPRGIGALPPALRPEAIHAYASSITDVFVIAAPVALLAPLLA WLLKEDRLSGVTPDATQTLASNPVRSDDVCRLSVLGTREGREIYRRITARA GYDLLPASPWWMLLRVKKYGRPEPAQLAERSVPVPLATVMAAARQVEERHLAVREGPDIV LTRQGVRAERIALAESLAEGLDWMWGPDRPTDLVRLVRELTELGCSESRERPHEG RTPARAG"

complement(1363..2727)

misc_feature

RBS

2859..2862

gene

2872..4230

CDS

2872..4230

/gene="SCC8A.02c"
/note="Pfam match to entry PF00083 sugar_tr, Sugar (and other) transporter, score -80.20, E-value 0.00054"
complement(2828..2833)
2859..2862
2872..4230
/gene="SCC8A.03"
/note="SCC8A.03"
/note="SCC8A.03, possible peptidodoglycan-binding membrane protein, len: 452aa; contains Pfam match to entry PF01471 PG_binding_1, Putative peptidoglycan binding domain, score 35.30, E-value 1.4e-06 and possible membrane-spanning hydrophobic region."
/codon_start=1
/transl_table=11
/product="putative peptidodoglycan-binding membrane protein"

/protein_id="CAB92821.1"

/db_xref="GI:8246786"

/translation="MAVSVLREAGIPGACPKYGEDLHNLWRSRGREGREDVRVDDQK EPSODRPAGAACPCGTAAADNTPSCACGTRASDALRDARTAOAAAEDDPRLRIRP YVELDGTAGDSPGAPDASDAAGASGEHLVPPASPTPPASPGSDPDATWTLRA VGAGAGAGAGAGAGAGAGTGAGSGSDPRRRRRGVLVLSAAGVAVVYIGAAGFASGLFSYD FDSATTPLPRADPGRGAGGDDGPPRRRRGVLVLSAAGVAVVYIGAAGFASGLFSYD TSPRDGAMPDEVRAVSPDPSTGESPPSAEPASASPSASPSASPSASPSASPSASPSASPSASPSASPTSPSPASPSQSTTTPADDAPOESGDDSDPGGTLSDRGDQGPVV ELQORLKEKMYWGDLDGDYDQVEDAVRQYQWENRIITDRGVYVGPDRRKLSETR EP"

misc_feature

4030..4218

/gene="SCC8A.03"

/note="Pfam match to entry PF01471 PG_binding_1, Putative peptidoglycan binding domain, score 35.30, E-value 1.4e-06"

complement(4269..4934)

/gene="SCC8A.04c"

complement(4269..4934)

/gene="SCC8A.04c"

/note="SCC8A.04c, possible hydrolase, len: 221aa; similar to many eg. TR:P96428 (EMBL:Z79692) ORF24 from Sinorhizobium meliloti (233 aa) fasta scores; opt: 526, z-score: 576.9, E(): 1.1e-24, TR:AAF18566 (EMBL:AF043232) glycerol-3-phosphate phosphatase from Escherichia nidulans (Aspergillus nidulans) (236 aa) fasta scores; opt: 352, z-score: 390.2, E(): 2.9e-14, 31.8% identity in 233 aa overlap. Contains Pfam match to entry PF00702 Hydrolase, haloacid dehalogenase-like hydrolase and Prosite match to PS01228 Hypothetical cof family signature 1."

/codon_start=1

/transl_table=11

/product="putative hydrolase"

/protein_id="CAB92822.1"

/db_xref="GI:8246787"

/translation="MTASTVLPARALLMDGTLVNSDAVDRVWRWRRDRHGLDG DEVMKVHVRQGYASMLLLPDRPNEHNADNARMLAEETADTEGVVAIPGAEEFLAS LRGPLHALVTADVALSTARMAAAGLAQPDVTRVTAESYGASKPDPEGLKGAEEGLIA PADCVVFDSDSGAIIAAGRAAGRVVGVGPRAGFHGPDVVVEDLTRVRVEADADGGLRL HIG"

complement(4365..4904)

/gene="SCC8A.04c"

/note="Pfam match to entry PF00702 Hydrolase, haloacid dehalogenase-like hydrolase, score 135.50, E-value 9.9e-37"

complement(4863..4898)

/gene="SCC8A.04c"

/note="PS01228 Hypothetical cof family signature 1"

Query Match 91.6%; Score 17.4; DB 3; Length 32274;

Best Local Similarity 94.7%; Pred. No. 4.4e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTCCCGG 19

|||||iiiiiiiiiii |||

Db 24795 GCGCTGGCGCTGGTCGCG 24777

RESULT 7
AC007207/c

LOCUS AC007207 191877 bp DNA PRI 23-NOV-1999
 DEFINITION Homo sapiens 12p13.3-4.6-10.5 BAC RP11-320N7 (Roswell Park Cancer
 Institute Human BAC Library) complete sequence.
 AC007207
 VERSION AC007207.22 GI:6466489
 KEYWORDS HTG.
 SOURCE human.

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 191877)
 Muzny,D.M., Adams,C., Bailey,M., Barbaria,J., Blankenburg,K.,
 Bodota,B., Bouck,J., Bowie,S., Brooks,A., Buhay,C., Bunac,C.,
 Burkett,C., Burrows,J., Carter,M., Chacko,J., Chen,Z., Cox,C.,
 David,R., Delgado,O., Deshazo,D., Ding,Y., Domah-Rashid,N.,
 Dugan-Rocha,S., Durbin,K.J., Fernandez,C., Ferraguto,D.,
 Forcum-Tansey,J., Frantz,P., Ganesh,R., Gorrell,J.H., Gorrell,L.L.,
 Guevara,W., Harris,K., Hernandez,J., Hodgson,A., Hogue,M.,
 Holloway,C., Hosak,H., Issar,A., Jackson,L.E., Jackson,L., Jia,Y.,
 Jones,M., Kelly,S., Kneitz,S., Kondajewski,N., Kong,Y., Kovar,C.,
 Lau,S., Leal,B., Lee,E., Li,Z., Lichtarge,O., Liu,J., Liu,W.,
 Logan,O., Lu,J., Lucier,R., Marondel,I., Martin,R., Martinez,C.,
 McLeod,M.P., Mei,G., Merscher,S., Miller,A., Montgomery,K.T.,
 Morgan,M., Morris,S., Nash,S., Nelson,A., Nguyen,R., Nguyen,N.,
 Nguyen,S., Oswal,G., Parish,B., Paxton,S., Payton,B., Perez,L.,
 Pu,L.L., Quiles,M., Reiter,D., Rives,M., Samuel,S., Say,J.,
 Scherer,S., Shah,E., Shen,H., Shim,C., Simon,M., Sparks,A.,
 Stamps,A., Sucgang,R., Tabor,P., Taylor,T., Vasquez,L., Vinson,R.,
 Vo,Q., Wahbah,M., Watlington,S., Weinstein,G., Weinstein,I.R.,
 Yang,R., Yu,W., Zhou,X., Kucherlapati,R., Nelson,D. and Gibbs,R.
 Direct Submission
 Unpublished
 2 (bases 1 to 191877)
 Worley,K.C.

TITLE
JOURNAL

REFERENCE Direct Submission
 AUTHORS Worley,K.C.

TITLE
JOURNAL

Submitted (05-APR-1999) Molecular and Human Genetics, Baylor
 College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
 3 (bases 1 to 191877)
 Worley,K.C.

REFERENCE
AUTHORS

Direct Submission
 Submitted (23-NOV-1999) Human Genome Sequencing Center, Department
 of Molecular and Human Genetics, Baylor College of Medicine, One
 Baylor Plaza, Houston, TX 77030, USA

REFERENCE
AUTHORS

On Nov 23, 1999 this sequence version replaced gi:6091647.
 INFORMATION: <http://www.hgsc.bcm.tmc.edu/> or email
 gc-help@bcm.tmc.edu

COMMENT

CLONE LENGTH: This sequence does not necessarily represent the
 entire insert of this clone. Overlapping regions of clones are only
 sequenced and submitted once, so the sequence for the remainder of
 the insert may be found in the record for the adjacent clones.
 Overlapping clones are noted at the beginning and end of the
 Features listing.

ANNOTATION OF FEATURES:

STSs are identified using ePCR (Genome Res. 7:541-550) searches
 of a local database that includes entries from dbSTS, GDB, and
 local mapping efforts.

Repeats are identified using RepeatMasker (A. Smit and P. Green,
 unpublished.) for Human and Mouse sequences.

Genes and Region of sequence similarity are identified by BLAST
 (Nuc. Acids Res. 25:3389-3402) similarity (expect < 1e-34) to the
 EST and cDNA sequences. Genes demonstrate at least two exons
 flanked by consensus splice sites that maintained sequence
 continuity across the splice junctions. Sequences that are not
 identical matches are annotated as similar.

SEQUENCING READ COVERAGE: Sequencing is completed to a minimum
 standard of double strand coverage with a minimum of 2 clones and 2
 reads with no ambiguities or 2 chemistries with a minimum of 2
 clones and 3 reads with no ambiguities. If the sequence quality for
 a region does not meet this standard, it will be indicated in the
 annotation as Low Coverage.

QUALITY OF INDIVIDUAL BASES: This sequence meets stringent quality
 standards - estimated error rate less than 1 per 10,000 bases.
 Reports of lowest quality individual bases and measures of base
 quality are listed below. Description of the metrics can be found
 at URL: <http://gc.bcm.tmc.edu:8088/quality.info/genbank.annotation.html>.

QUALSTAT-REPORT.

FEATURES	Source	Location/Qualifiers
repeat_region	STS	1..191877 /organism="Homo sapiens" /db_xref="taxon:9606" /chromosome="12p13.3" /clones="RP11-320N7" 1..127 /rpt_family="MIR"
repeat_region	STS	68..150 /standard_name="G42642" /db_xref="dbSTS:64729" 143..593 /rpt_family="LTR7"
repeat_region	STS	3545..3691 /rpt_family="HERVH"
repeat_region	STS	3694..3835 /rpt_family="HERVH"
repeat_region	STS	3835..4244 /rpt_family="HERVH"
repeat_region	STS	4246..4469 /rpt_family="HERVH"
repeat_region	STS	4468..4847 /rpt_family="HERVH"
repeat_region	STS	4848..5296 /rpt_family="LTR7"
repeat_region	STS	5342..5624 /rpt_family="AluSp"
repeat_region	STS	5625..5661 /rpt_family="CAAA)n"
repeat_region	STS	5670..5801 /rpt_family="L2"
repeat_region	STS	6021..6322 /rpt_family="AluSp"
repeat_region	STS	complement(7807..7918) /rpt_family="MIR"
repeat_region	STS	7824..8255 /note="Region: Similar to clone qz35g10.x1 Homo sapiens cDNA, A1261608"
repeat_region	STS	complement(8360..8503) /rpt_family="L2"
repeat_region	STS	9758..10113 /rpt_family="L2"
repeat_region	STS	10219..10344 /rpt_family="L2"
repeat_region	STS	10636..10663 /rpt_family="(TTTA)n"
repeat_region	STS	complement(10664..10938) /rpt_family="AluSp"
repeat_region	STS	11027..11333 /rpt_family="AluJb"
repeat_region	STS	11336..11398 /rpt_family="(TA)n"
repeat_region	STS	11580..11627 /rpt_family="L2"
repeat_region	STS	11787..11889 /rpt_family="MIR"
repeat_region	STS	complement(11918..12199) /rpt_family="L2"

Estimated insert size: 198628; sum-of-contigs estimation
Quality coverage: 0x in Q20 bases; agarose-fp estimation
Quality coverage: 6.5x in Q20 bases; sum-of-contigs estimation

* NOTE: Estimated insert size may differ from sequence length
(see http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html).
* NOTE: This is a 'working draft' sequence. It currently
* consists of 6 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

* 1 79976: contig of 79976 bp in length
* 79977 80076: gap of unknown length
* 80077 155732: contig of 75656 bp in length
* 155732 155833: gap of unknown length
* 155833 180188: contig of 24356 bp in length
* 180188 180289: gap of unknown length
* 180289 190769: contig of 10481 bp in length
* 190769 190869: gap of unknown length
* 190869 200072: contig of 9203 bp in length
* 200072 200172: gap of unknown length
* 200172 201290: contig of 1118 bp in length.

FEATURES

Source

1. 201290
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="12p"
/clone="RP11-664D1"

BASE COUNT 57512 a 44184 c 43798 g 55259 t 537 others

ORIGIN

Query Match 91.6%; Score 17.4; DB 77; Length 201290;

Best Local Similarity 94.7%; Pred. No. 2.2e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GCGCTCGCGCTGGTCCCGG 19

|||||

Db 120723 GCGCTCGCGCTGGTCCCGG 120741

RESULT 9

AC005842/c

LOCUS

DEFINITION AC005842 300691 bp DNA HTG 11-NOV-2000.
Homo sapiens clone RP11-303E5, WORKING DRAFT SEQUENCE, 20 unordered
pieces.

AC005842

VERSION AC005842.11 GI:11136692

KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT.

SOURCE

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 300691)

Muzny D.M., Adams C., Adio-Oduola B., Ali-osman F.R., Allen C.,
Alsbrooks S.L., Amarantunge H.C., Are J.R., Banks T., Barbara J.,
Benton J., Blmage K., Blankenburg K., Bonnin D., Bouck J.,
Bowie S., Brieva M., Brown E., Brown M., Bryant N.P., Buhay C.,
Burch P., Burkett C., Burrell K.L., Byrd N.C., Carron T.F.,
Carter M., Cavazos S.R., Chacko J., Chavez D., Chen G., Chen R.,
Chen Z., Chowdhry I., Christopoulos C., Cleveland C.D., Cox C.,
Coyle M.D., Dathorne S.R., David R., Davila M.L., Davis C.,
Davy-Carroll L., Dederich D.A., Delaney K.R., Delgado O.,
Denn A.L., Ding Y., Dinh H.H., Douthwaite K.J., Draper H.,
Duan-Rocha S., Durbin K.J., Earnhart C., Edgar D., Edwards C.C.,
Elhaj C., Escotto M., Falls T., Ferraguto D., Flagg N., Ford J.,
Foster P., Franz P., Gabisi A., Gao J., Garcia A., Garner T.,
Garza N., Gill R., Gorrell J.H., Guevara W., Gunaratne P., Hale S.,
Hamilton K., Harris C., Harris K., Hart M., Havlak P., Hawes A.,
Hernandez J., Hernandez O., Hodgson A., Hognes M., Holloway C.,

Hollins B., Homsli F., Howard S., Huber J., Hulyk S., Hume J.,
Jackson L.E., Jacobson B., Jia Y., Johnson R., Jolivet S.,
Joudah S., Karlsson E., Kelly S., Khan U., King L., Korvah J.,
Kovar C., Kratovic J., Kureshi A., Landry N., Leal B., Lewis L.C.,
Lewis L., Li J., Li Z., Lichtarge O., Lieu C., Liu J., Liu W.,
Loulsged H., Lozado R.J., Lu X., Lucier A., Lucier R., Luna R.,
Ma J., Maheshwari M., Mapua P., Martin R., Martindale A.,
Martinez E., Massey E., Mawhney E., McLeod M.P., Meador M.,
Mei G., Metzker M., Miner G., Miner Z., Mitchell T., Mohabbat K.,
Morgan M., Morris S., Moser M., Neal D., Newton J., Newton N.,
Nguyen A., Nguyen N., Nguyen N., Nickerson E., Nwokenkwo S.,
Ogih M., Okwuonu G., Oragunye N., Oviedo R., Pace A., Payton B.,
Peery J., Perez L., Peters L., Pickens R., Primus E., Pu L.L.,
Quiles M., Ren Y., Rives M., Rojas A., Rojubokan I., Rolfe M.,
Ruiz S., Savery G., Scherer S., Scott G., Shen H., Shooshitari N.,
Sisson I., Sodergren E., Sonalke T., Sparks A., Stanley H.,
Stone H., Sutton A., Svatek A., Tabor P., Tamerisa A., Tamerisa K.,
Tang H., Tansey J., Taylor C., Taylor T., Telford B., Thomas N.,
Thomas S., Usmani K., Vasquez L., Vera V., Villalón D., Vinson R.,
Wall R., Wang S., Ward-Moore S., Warren R., Washington C.,
Watlington S., Williams G., Williamson A., Wleczek R., Woodson S.,
Worley K., Wu C., Wu Y., Wu Y.F., Zhou J., Zorrilla S., Nelson D.
and Gibbs R.

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished
2 (bases 1 to 300691)

Worley K.C.

Direct Submission

Submitted (22-OCT-1998) Molecular and Human Genetics, Baylor
College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

On Nov 10, 2000 this sequence version replaced gi:11094657.

----- Genome Center

Center: Baylor College of Medicine

Center code: BCM

Web site: <http://www.hgsc.bcm.tmc.edu/>

Contact: hgsc-help@bcm.tmc.edu

----- Project Information

Center project name: YO

Center clone name: RP11-303E5

----- Summary Statistics

Sequencing vector: Plasmid; M77789

Chemistry: Dye-terminator Big Dye; 46% of reads

Assembly program: Phrap; version 0.990329

Consensus quality: 288810 bases at least Q40

Consensus quality: 293327 bases at least Q30

Consensus quality: 295549 bases at least Q20

Estimated insert size: 290790; sum-of-contigs estimation

Quality coverage: 11.9x in Q20 bases; sum-of-contigs estimation

* NOTE: Estimated insert size may differ from sequence length
* (see http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html)
* NOTE: This sequence may represent more than one clone.
* NOTE: This is a 'working draft' sequence. It currently
* consists of 20 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.

* 1 86260: contig of 86260 bp in length
* 86261 86360: gap of unknown length
* 86361 148996: contig of 62636 bp in length
* 148997 149096: gap of unknown length
* 149097 173517: contig of 24421 bp in length
* 173518 173617: gap of unknown length
* 173618 186953: contig of 13336 bp in length
* 186954 187053: gap of unknown length
* 187054 201262: contig of 14209 bp in length
* 201263 201362: gap of unknown length
* 201363 212476: contig of 11114 bp in length

* 212477 212576: gap of unknown length
* 212577 236938: contig of 24362 bp in length
* 236939 237038: gap of unknown length
* 237039 247120: contig of 10082 bp in length
* 247121 247220: gap of unknown length
* 247221 261011: contig of 13791 bp in length
* 261012 261111: gap of unknown length
* 261112 272260: contig of 11149 bp in length
* 272261 272360: gap of unknown length
* 272361 278249: contig of 5889 bp in length
* 278250 278349: gap of unknown length
* 278350 282170: contig of 3821 bp in length
* 282171 282270: gap of unknown length
* 282271 287119: contig of 4849 bp in length
* 287120 287219: gap of unknown length
* 287220 291139: contig of 4079 bp in length
* 291140 291398: gap of unknown length
* 291399 293375: contig of 1977 bp in length
* 293376 293475: gap of unknown length
* 293476 295309: contig of 1834 bp in length
* 295310 295409: gap of unknown length
* 295410 296608: contig of 1199 bp in length
* 296609 296708: gap of unknown length
* 296709 298055: contig of 1347 bp in length
* 298056 298155: gap of unknown length
* 298156 299353: contig of 1198 bp in length
* 299354 299453: gap of unknown length
* 299454 300691: contig of 1238 bp in length.

FEATURES

Source
1...300691
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="Rp11-303ES"

BASE COUNT 83346 a 63543 c 63933 g 87891 t 1978 others
ORIGIN

Query Match 91.6%; Score 17.4; DB 60; Length 300691;
Best Local Similarity 94.7%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GCCTCGGCTGGTCCCG 19
|||||
Db 45619 GCCTCGGCTGGTCCCG 45601

RESULT 10

BPD3112AB/c 2963 bp DNA PHG 11-APR-1996
LOCUS Bacteriophage D3112 A and B genes.
DEFINITION X87627
ACCESSION X87627.1 GI:974768
VERSION B protein; transposase.
KEYWORDS Bacteriophage D3112.
SOURCE Bacteriophage D3112
ORGANISM Viruses; dsDNA viruses, no RNA stage; Tailed phages; Siphoviridae;
Lambda phage group.
REFERENCE 1 (bases 1 to 2963)
AUTHORS Ulyczynj,P.I., Salmon,K.A., Douillard,H. and DuBow,M.S.
TITLE Characterization of the pseudomonas aeruginosa transposable
Bacteriophage D3112 A and B genes
JOURNAL Biochim. Biophys. Acta 1264 (3), 249-253 (1995)
MEDLINE 96138540
REFERENCE 2 (bases 1 to 2963)
AUTHORS Ulyczynj,P.I.
TITLE Direct Submission
JOURNAL Submitted (26-MAY-1995) P.I. Ulyczynj, McGill University, Dept of
Microbiology & Immunology, 3775 University St., Montreal, Quebec
H3A 2B4, CANADA

FEATURES

source
1..2963
/organism="Bacteriophage D3112"
/strain="cts15"

gene
RBS
CDS

/db_xref="taxon:10708"
/map="2521-5483bp"
8..2091
/gene="A"
8..13
/gene="A"
19..2091
/gene="A"
/codon_start=1
/transl_table=11
/product="transposase"
/protein_id="CAA60956.1"
/db_xref="GI:974769"
/db_xref="SPTREMBL:Q38013"
/translation="MSEWFMPTKLAGLPTTDGRVKRLAEREGWKQKHSGRGGY
EYHSALPKETRAALLNAALGEVATKAVQETQLALVETNRQQLVADARQGVHLALDL
MMARTGYSKRKSIITLMDMARLGOVEPOLLAAMKARDPRGRPSADGPSVRSLEPFL
DOAERGALYPKVRPDMSPWAPAFMTIYOGPEKRSARAAHLEKHQOMPSLDQ
YVAFLRKGVNSREVGRMEHEIKALRFFIRRDFTKLLPTDIYSCDGHTFDAEVOHPM
HGRPFPEITTIIDIRRIIPGWTGLAESALVVVDALRDACIKGGVPAIFYVDSG
YVNMMRDEAVGLMGLRGIDMKNSLPYNSQARQVIERVHQSLWRAAKELPGYIGADM
DROAKLATFKLTRAIAKGSTPLMSWESVAFCEQOIAEYNDPRHSLPRTVDPNTG
RRHMTPEANALHEAEGFSPMRTDDEARPLFRFOVLTVRRCLELEFIGNRYAREL
EEFGDQVAVGYDHDASRVVYDGEGRFLCTAELNGSRDYMSPASYVERAREKRAEA
REKRALAHLDEIRAERDGGYALEMDAPLSPGLGTTTPEQLRSAAATLEVOAERIDE
PHPTAATTQATTAAQVFTLTAPQRYQWCELAERQSRGLPIEDPAAQFFVYPKSKE
FAAQORQA"
repeat_region 1693..1709
/rpt_type=DIRECT
repeat_region 1714..1730
/rpt_type=DIRECT
2093..2858
/gene="B"
2093..2098
/gene="B"
2106..2858
/gene="B"
/codon_start=1
/transl_table=11
/product="B protein"
/protein_id="CAA60957.1"
/db_xref="GI:974770"
/db_xref="SPTREMBL:Q38014"
/translation="MTTPKTTQLANGMADIANIALCDIALEKALSRSTLPLGLVCFYQ
PSGFGKSVSAAIANRRAYVQAKSVWTRKHTLKSILGEMIKIPAGTIPEMADQIAE
ELAASGRPLIIDMDHLVAAGOVELIRDLYESOASILLIGEMLPTKLKFRPHGR
VLSWVPAQVSVLEDAARNLAPVSPGVALADLLAHLVKKSLGSRVRAVNLEQLAEAA
TVQGRRDVELADQLKLNLELYTGAPSPRTSK"

BASE COUNT 558 a 1033 c 927 g 445 t
ORIGIN
Query Match 86.3%; Score 16.4; DB 11; Length 2963;
Best Local Similarity 94.4%; Pred. No. 2.7e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2 CGCTCGGCTGGTCCCG 19
|||||
Db 512 CGCTCGGCTGGTCCAGG 495

RESULT 11

AF099190/c 3611 bp DNA BCT 10-NOV-1999
LOCUS AF099190
DEFINITION Caulobacter crescentus penicillin binding protein B (divA) gene,
complete cds; and unknown genes.
ACCESSION AF099190
VERSION AF099190.1 GI:6318312
KEYWORDS
SOURCE Caulobacter crescentus.
ORGANISM Caulobacter crescentus
Bacteria; Proteobacteria; alpha subdivision; Caulobacter group;
Caulobacter.

/db_xref="GI:2073552"	
/translation="MRIGVVGLGKAFMLMLPTFLMDRRVOLVAASDTPDLSLRQKFAK FPAAAVGHGDTESLCKNPDDVVVYIGTPHQFHAVHAEIALNAGKHVLEKPMAYLTLED CRNNAOARAGKYLIIVGHSHSFDPISRAKELIDSGRGVRFRFHSWNYTDFLYRPRR AEELNTDLGGVVFNQASHOLDVIRLLAOGSRVVDVSYLGRWDAARTEGAYSAALKIF DNGVAANYISGVAHNSDVRMGWVNELGKQFERRLFPRRLDEVLNKGSGSAAYAK EMSYGRGWSAHGLPKWARNHQHFGHLVISCEDADIVPKAEKIEVFANGETVHCENFSMP DFPQREVMDLEFADISGTRPPVHTGEWAMETDLCLALLEGGKPELIGMRATAVACAG RSSGR"	
BASE COUNT	1005 a 1422 c 1535 g 1026 t
ORIGIN	
Query Match	86.3%; Score 16.4; DB 3; Length 4988;
Best Local Similarity	94.4%; Pred. No. 2.3e+03;
Matches	17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	1 GCGTCGGCGCTGTCCTCG 18
Db	3332 GCGTCGGCCAGCTCCG 3315
RESULT 13	
AF319543	6927 bp DNA BCT 11-JAN-2001
LOCUS	Streptomyces venezuelae putative acetyl-CoA acetyltransferase and cystathionine beta-synthase (CbsSV) genes, complete cds.
DEFINITION	
ACCESSION	AF319543
VERSION	AF319543.1 GI:12082814
KEYWORDS	
SOURCE	Streptomyces venezuelae.
ORGANISM	Streptomyces venezuelae Bacteria; Firmicutes: Actinobacteria: Actinobacteridae: Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces. 1. (bases 1 to 6927) Chang, Z. Genes for cysteine biosynthesis and metabolism in Streptomyces venezuelae ISP5230: cloning, sequencing, functional analysis and relevance to chloramphenicol biosynthesis Thesis (1999) Dalhousie University, Biology, Halifax, NS, Canada 2. (bases 1 to 6927) Chang, Z. and Vining, L.C. Cystathionine beta-synthase in Streptomyces venezuelae ISP5230: an alternative pathway of cysteine biosynthesis Unpublished 3. (bases 1 to 6927) Chang, Z. and Vining, L.C. Direct Submission Submitted (05-NOV-2000) Biology, Dalhousie University, Halifax, NS B3H 4J1, Canada
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
AUTHORS	
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
FEATURES	
source	1. 6927 /organism="Streptomyces venezuelae" /strain="ISP5230" /db_xref="taxon:54571" complement(1974..3194) /codon_start=1 /transl_table=11 /product="putative acetyl-CoA acetyltransferase" /protein_id="AAG48622.1" /db_xref="GI:12082814" /translation="MPEAVIVSTARSPIGRAFKGLKDLRPDDLTAIVQAAALAKVPE LDRPDDLLMGCLGCGEGGNNLGRIVAVQMGMDLPGCTIIRYCSSLQTSRMALH AIRAGEDVFIAGVENRVRVNGNSDLPDTHNPLFADAEARTAAVAASGEGSWHDPTV REDGLVPDVIAMQTAENLRKWTIRQEMDFGVRSONLAEOAIKNGFWEREITFV TLDPDVTWDDGPRAGVTLEGVSGLKPVRPDGLVTAGNCCPLNHGAAALVIMSDTK ARELGTPLARIIVSTGVSGLSPETMGLGPVEASKQALQRAGLTIGDIDLAEINEFAAF QVTPSYQELGLDLDKNNVNGSAIVAGHPFCMTGARITGTILNSLQFDHKQFGLETMCV GGQGGHAWVIERLS" 4460..5851 /gene="CbsSV" 4460..5851 /gene="CbsSV"
CDS	
gene	
CDS	

/function="catalyses the formation of cystathionine from
homocysteine and serine"
/codon_start=1
/transl_table=11
/product="cystathionine beta-synthase"
/protein_id="AAG48621.1"
/db_xref="GI:12082815"

/translation="MORHDSMSLVGNTPLVKLNNTAGIOATVLAKVEYFNPGSVK
DRIAVRMEARQSGELKPGCTIVPTSGNTGVGLAIVAQKGYKICFCDKYSLDK
INVLKAYGAEVVCTAVDPHPDSYINVSRVLRTPGAWKPDQSYNPNRSHYET
TGPELWEGDTHIFVAGVGTGTSIGNYLKAEAGSGVKIIGADPEGSVSGSG
RPLYVEGGEFTAYDNTDRIVAVSDKDSFQMTRRRLAKEGLLVGGSCGMAVVA
ALEVARELGPDDVVVLLPDSRGYMSKIFSDENMAGHGFLEDTSSATVADVLRKEG
GTMPSLVHMHPDETGVQAI EYLVREYGVQMPIVKPGAGHPDVMVAEVVGSVERDVL
ALFTQASLSDLSHMSAPLPQVSGEPVAALMSVLGDADAALVLEGRPTGVSR
QDLAFLANGAK"

BASE COUNT 945 a 2483 c 2539 g 960 t

ORIGIN

Query Match 86.3%; Score 16.4; DB 2; Length 6927;
Best Local Similarity 94.4%; Pred. No. 2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 CGCTCGGCTGCTGCCGG 19

|||||

Db 6273 CGCTCGGCTGCTGCCAG 6290

RESULT 14

SCARGGH

LOCUS

DEFINITION

Streptomyces clavuligerus arginine biosynthesis cluster (argCJBDRGH

genes).

249111 M83659 Y11134

249111.2 GI:7328261

acetylglutamate kinase; acetylornithine aminotransferase; argB gene;

argC gene; argD gene; argG gene; argH gene; arginine regulator;

argininosuccinate lyase; argininosuccinate synthetase; argJ gene;

argR gene; glutamate N-acetyltransferase;

N-acetyl-gamma-glutamyl-phosphate reductase.

Streptomyces clavuligerus.

Streptomyces clavuligerus

Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;

Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.

1 (bases 1 to 8300)

Ludovice, M., Martin, J.F., Carrachas, P. and Liras, P.

Characterization of the Streptomyces clavuligerus argC gene

encoding N-acetylglutamyl-phosphate reductase: expression in

Streptomyces lividans and effect on clavulanic acid production

J. Bacteriol. 174 (14), 4606-4613 (1992)

92325051

2 (bases 1 to 8300)

Rodriguez-Garcia, A., Martin, J.F. and Liras, P.

The argC gene of Streptomyces clavuligerus has low homology to

unstable argC from other actinomycetes: effect of amplification on

clavulanic acid biosynthesis

Gene 167 (1-2), 9-15 (1995)

96144242

3 (bases 1 to 8300)

Rodriguez-Garcia, A., Ludovice, M., Martin, J.F. and Liras, P.

Arginine boxes and the argC gene in Streptomyces clavuligerus:

evidence for a clear regulation of the arginine pathway

Mol. Microbiol. 25 (2), 219-228 (1997)

97426030

4 (bases 1 to 8300)

Rodriguez-Garcia, A., de la Fuente, A., Perez-Redondo, R., Martin, J.F.

and Liras, P.

Characterization and expression of the arginine biosynthesis gene

cluster of Streptomyces clavuligerus

Unpublished

5 (bases 1 to 8300)

AUTHORS

Rodriguez-Garcia, A.

TITLE

Direct Submission

JOURNAL

Submitted (25-APR-1995)

Rodriguez-Garcia A.,

Facultad de Biologia, Area de Microbiologia, Campus de Vegazana,

Leon, Spain, 24071

Revised by [6]

6 (bases 1 to 8300)

Rodriguez-Garcia, A.

Direct Submission

TITLE

Submitted (22-MAR-2000)

Rodriguez-Garcia A.,

Facultad de Biologia, Leon, 24071, SPAIN

On Apr 11, 2000 this sequence version replaced gi:1839024

gi:886905.

FEATURES

Location/Qualifiers

source

1..8300

/organism="Streptomyces clavuligerus"

/strain="ATCC 27064"

/db_xref="taxon:1901"

misc_feature

43

/gene="argC"

/note="Transcription start point"

/citation=[1]

/evidence=experimental

43..1148

/gene="argC"

71..88

/gene="argC"

/note="first arg-box of the argC operator"

/citation=[3]

/bound_moiety="ArgR repressor"

/function="transcription control"

/evidence=experimental

91..108

/gene="argC"

/note="second arg-box of the argC operator"

/citation=[3]

/bound_moiety="ArgR repressor"

/function="transcription control"

/evidence=experimental

114..118

/gene="argC"

/citation=[1]

123..1148

/gene="argC"

/EC_number="1.2.1.38"

/function="arginine biosynthesis"

/citation=[1]

/codon_start=1

/transl_table=11

/evidence=experimental

/product="N-acetyl-gamma-glutamyl-phosphate reductase"

/protein_id="CAB82479.1"

/db_xref="GI:7328262"

/translation="MTVRVAVAGASGVAGGEVVRLLCHHPAESWVALTAFSQAGAVG

HPHGLPVAGRVFEPISQAQPLAGHDVVFLALPPAQASALAEAGARVVDNRMGDFRL

RDAGVWERFSGSPWRGCPYGLPESPGAREALAGARRIAPGCCYPTATVLAIFPAVGA

GLDREVVYATVSGTAGRALKPHLLGAENMGVSYPYAVGGTHRRHTPEIAQNSTAVTD

GPVSYSFTPLAAPMPRGILATCSARLTGPDARQVAVYEKTYADEFPVLLPEGVW

PSTGAVLGSQVQVQVAVDPAADRLVVYSAIDNLTGTAGGALQSMNLALGLPETTGL

PRTGLAP"

193..217

/note="unknown function, calculated free energy=-20.8

kcal/mol"

/citation=[4]

/rpt_unit=193..202

/rpt_type=INVERTED

1100..1127

/citation=[4]

/rpt_unit=1100..1109

/rpt_type=DIRECT

1210..1214

/gene="arg3"

1210..2370

repeat_region

repeat_region

RBS

gene

```
/gene="argJ"
1219..2370
/gene="argJ"
/EC_number="2.3.1.35"
/function="arginine biosynthesis"
/citation=[1]
/citation=[4]
/codon_start=1
/transl_table=11
/evidence=experimental
/product="glutamate N-acetyltransferase"
/protein_id="CAB82480.1"
/db_xref="GI:7328263"
/translation="MTVTAPKSGTGGCGRRGSKESGQDPLALVNVNEPRRAAAGVFTA
NRKAAPIVWQQVLRGESAVVLNSGGANACTGPKGFQDTHATAERAAALGHSA
EIVASTGLICTYLPMDRLPGIDKAAALSPHGERAAIAIRTTDTHVKTAVRAGEG
WSVGMAKGAGMLAPGLATLLVLTDDADLAPPVLDKAVRDARTTERVDSDCMST
NDTVLLASAGSDPGYEEFADVLREVCEDLARKLIGDAEGASKDIRIEVHAATED
DAVEVRTIARNLLKCAIHGEDPNMGRVLSAIGTTAAVFPERLNVAINWVWCREG
SAGDRDLVDRFRFVRITADLDAGTHSAVIWANDLTAEYVHENSAYSS"
2423..2451
/gene="argB"
2423..2451
/gene="argB"
/citation=[4]
/rpt_unit=2423..2433
/rpt_type=DIRECT
join(2474..2478,2485..3393)
/gene="argB"
2474..2478
/gene="argB"
2485..3393
/gene="argB"
/EC_number="2.7.2.8"
/function="arginine biosynthesis"
/citation=[4]
/transl_table=11
/evidence=experimental
/product="acetylglutamate kinase"
/protein_id="CAB82481.1"
/db_xref="GI:7328264"
/translation="MTRKNALPKARTLIEALPWLTRHGHKTIYVKGGNAMVNEELK
GAFAPSLVHAGLPVYVHGGPQISAEIDRYGLVSEFAGRLVTTDEAMDYVRVY
LAGQVRDWCSTGVHSGVITGDEAHPIASATRHPLIDGEPVDIGRGVETRIDT
GAVLALDEGRIPVYSSTARAEEDGHVYNNADTAAALAAALGAETLWLTVDVGLY
EDWNSDRLVISRLTASELTLLPDLSSGVMPKMECLHAVRNGVYRTARVIDGRVPHSI
LLEIFTDGGVTMVVDPSPVSEGTG"
3379..3382
/gene="argD"
3379..3382
/gene="argD"
3390..4592
/gene="argD"
3390..4592
/gene="argD"
/EC_number="2.6.1.11"
/function="arginine biosynthesis"
/citation=[4]
/codon_start=1
/transl_table=11
/evidence=experimental
/product="acetylornithine aminotransferase"
/protein_id="CAB82482.1"
/db_xref="GI:7328265"
/translation="MSNOEFAQRWQGVMSIDYGTPLGSFVRGEGSTLWDAGTAYTDF
VSGLAHNAHAPVAVGASVQISALGHSINFSYSAEPTITLAERLIELFGRGPRVF
CNSGAENATFKIGRLTGRSRIVAASQGFHGTMSIALTCQPAKRPFLPLPGDVT
HVPYGDALRAAATEDFAMVILPEIQGESGVVPPKGYLRAAREITEATGTLVLVDE
VQTGIGRTGHFNAQAGVEADVTLAKGLGGGLPLGAFAFGRAAELMTGHASTF
CGNPVSCARTVLOTIADGLDRVKLGSDPMSVRDAAAIIRNPSMAGMLGIV
LNEPIAPQVLAQAOKAGFLVNPAPDVVVRLLPPLVIEETEVDALQALPLGLDAVHER
DREGQTGE"
```

```
gene 4594..5136
/misc_feature /gene="argR"
4594 /gene="argR"
/note="Transcription start point"
/citation=[4]
/evidence=experimental
4600..5136
/gene="argR"
/function="arginine metabolism regulation"
/citation=[3]
/codon_start=1

Query Match 86.3%; Score 16.4; DB 3; Length 8300;
Best Local Similarity 94.4%; Pred. No. 1.9e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CGCTCGGCCTGTCGCCG 19
|||||
Db 7320 CGCTCGGCCTGGACCCG 7337

RESULT 15
SC5H1 36583 bp DNA BCT 06-JUN-2000
LOCUS Streptomyces coelicolor cosmid 5H1.
DEFINITION AL049863
ACCESSION AL049863
VERSION AL049863.2 GI:8347022
KEYWORDS add; adenosine deaminase; ATP-dependent Clp protease; bldA codon;
chf; chitinase; clpP3; clpP4; DNA-binding protein; hydroxylase;
ion channel subunit; isomerase; myo-inositol dehydrogenase;
oxidoreductase; protease; ribonuclease H; RNA polymerase sigma
factor; rnhA; serine/threonine protein kinase; transcriptional
regulator.
Streptomyces coelicolor A3(2).
Streptomyces coelicolor A3(2)
Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.
REFERENCE 1 (bases 1 to 36583)
AUTHORS Redenbach,M., Kieser,H.M., Denapait,D., Eichner,A., Cullum,J.,
Kinashi,H. and Hopwood,D.A.
A set of ordered cosmids and a detailed genetic and physical map
for the 8 Mb Streptomyces coelicolor A3(2) chromosome
Mol. Microbiol. 21 (1), 77-96 (1996)
97000351
2 (bases 1 to 36583)
AUTHORS Oliver,K. and Harris,D.
Unpublished
REFERENCE 3 (bases 1 to 36583)
AUTHORS James,K.D., Parkhill,J., Barrell,B.G. and Rajandream,M.A.
Submitted (10-MAY-1999) Streptomyces coelicolor sequencing project,
Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge
CB10 1SA E-mail: barrell@sanger.ac.uk Cosmids supplied by Prof.
David A. Hopwood, [3] John Innes Centre, Norwich Research Park,
Colney, Norwich, Norfolk NR4 7UH, UK
On Jun 8, 2000 this sequence version replaced gi:4835303.
Notes:
Streptomyces coelicolor sequencing at The Sanger Centre is funded
by the BBSRC.
Details of S. coelicolor sequencing at the Sanger Centre are
available on the World Wide Web.
(URL: http://www.sanger.ac.uk/projects/s.coelicolor/)
CDS are numbered using the following system eg SC7B7.01c. SC (S.
coelicolor), 7B7 (cosmid name), .01 (first CDS), c (complementary
strand).
The more significant matches with motifs in the PROSITE database
are also included but some of these may be fortuitous.
The length in codons is given for each CDS.
Usually the highest scoring match found by fasta -o is given for
CDS which show significant similarity to other CDS in the database.
The position of possible ribosome binding site sequences are given
where these have been used to deduce the initiation codon.
```

Gene prediction is based on positional base preference in codons using a specially developed Hidden Markov Model (Krogh et al., Nucleic Acids Research, 22(22):4768-4778(1994)) and the FramePlot program of Bibb et al., Gene 30:157-66(1984) as implemented at <http://www.nih.gov/jb/jun/cgi-bin/frameplot.pl>. CAUTION: We may not have predicted the correct initiation codon. Where possible we choose an initiation codon (atg, gtg, ttg or att) which is preceded by an upstream ribosome binding site sequence (optimally 5-13bp before the initiation codon). If this cannot be identified we choose the most upstream initiation codon.

IMPORTANT: This sequence MAY NOT be the entire insert of the sequenced clone. It may be shorter because we only sequence overlapping sections once, or longer, because we arrange for a small overlap between neighbouring submissions.

Cosmid 5H1 lies between 262 and 5f8 on the AseI-A genomic restriction fragment.

FEATURES

source	Location/Qualifiers	gene	CDS	misc_feature
1. 36583	/organism="Streptomyces coelicolor A3(2)"			
	/strain="A3(2)"			
	/db_xref="taxon:100226"			
repeat_unit	/clone="cosmid 5H1"			
gene	/note="55 bp imperfect inverted repeat"			
	/complement(209..1246)			
CDS	/gene="SC5H1.41"			
	/complement(209..1246)			
	/gene="SC5H1.41"			
	/note="SC5H1.41, hypothetical protein, len: 345 aa; unknown function, similar to part of SCE29.03 (EMBL:AL035707) S.coelicolor putative phosphotransferase (300 aa), fasta scores; opt: 433 z-score: 437.4 E(): 4.9e-17, 37.2% identity in 269 aa overlap. Contains TPA (leucine) codon, possible target for bldA regulation. There are imperfect inverted repeats at each end of the CDS"			
	/codon_start=1			
	/label="SC5H1.41"			
	/product="hypothetical protein"			
	/protein_id="CAB42966.1"			
	/db_xref="GI:4835344"			
	/db_xref="SPTREMBL:Q9X7U8"			
	/translation="MLGAGRARLGGPGTQPLSGRIDLSGPGQALRTATAVHRICP EFSPQVLRRSGRSLVLTGTRSTAVAKLVHDSPAWAKSRHEIGAYRSFVQRQRP VRPRLAADPDNLTVIERNPGRVAALQRHPLEAPPRAIDIRAAIGAVCRUNAWRPPA GTFDAPLDYAAIRISRYHELGLLTDRLDGLKQLHGHAGRGQMGQFCGHDALLSN VLMSPAGPVLVDWEHAGWLPGLPYDLATLWAVLGPAPVARQISOIAQSTGTAARDAPFL VNLMLVLTRETIVETAVQRSMDHPVCAATGPAHPGAAPGEEQRLRLRLHDDCQLA RRAVRAVGRP"			
	/complement(1022..1024)			
misc_feature	/gene="SC5H1.41"			
	/note="TTA (leucine) codon, possible target for bldA regulation"			
	/complement(1287..1346)			
repeat_unit	/note="55 bp imperfect inverted repeat"			
gene	1648..3156			
	/gene="SC5H1.40c"			
CDS	1648..3156			
	/gene="SC5H1.40c"			
	/note="SC5H1.40c, possible regulatory protein, len: 502 aa; similar to e.g. SW:SP15_STRGR (EMBL:M32687) Streptomyces griseus sporulation protein (529 aa), fasta scores; opt: 394 z-score: 452.2 E(): 7.2e-18, 27.9% identity in 530 aa. Similar to SC7A1.26 (EMBL:AL034447) S.coelicolor possible transcriptional regulator (500 aa) (43.0% identity in 491 aa overlap)"			
	/codon_start=1			
	/label="SC5H1.40c"			
	/product="putative regulatory protein"			
	/protein_id="CAB42965.1"			
	/db_xref="SPTREMBL:Q9X7U7"			
	/translation="MSKEPTRLSDLFLGLAGMSKGEARLVNROAAAGHGHQPLATDTS RVRWIDMGEIPRDPVPRVLAALFTEGLGRVVTIEDLGLVRHGRAGRPHDGSSEHPD GVPWAPRTAAVLTEFTGMDLNNRGLVGAGALAGSALSAMHDLWHTDPAALAD APDLHQPLHADPAGFDRYEAAPIGSQEVEELSERSEVFRAWDAARGGLGAKRAVVGQL NEVGMALYHPHPLQRHMGVAANLAVLAGMSHDVGLPTAQKYFYVIAAHAREGG DRPAGALSRAARQMHVILGKPDALDLMLKQSGSGVQLPRTKMLTYTTEAWAQAAS MKGQAMRRTLGRAEDLFSVDKADVPDPDMOTKEEDLYGMOALAYRTLAEFEPGAA AHQYADKALALRIDGRORSKIFDYLMSACACFIADDPQADRYARLALYSMSGSSS QRTWDRURQMYRLTAETAYGSKIODELREELKALPKGSKPGKPGGTGTVAPA"			
	/complement(3176..4492)			
	/gene="SC5H1.39"			
	/complement(3176..4492)			
	/gene="SC5H1.39"			
	/note="SC5H1.39, hypothetical protein, len: 438 aa; unknown function, probable CDS suggested by positional base preference, GC frame analysis and amino acid composition"			
	/codon_start=1			
	/label="SC5H1.39"			
	/product="hypothetical protein"			
	/protein_id="CAB42964.1"			
	/db_xref="GI:4835342"			
	/db_xref="SPTREMBL:Q9X7U6"			
	/translation="MSSHLSADHPAAQSPGCGSVEALISQTRRLRGDGDVAVRRSQDD TTDPRGRWRALYDLALHQLDLDAAQLRDGPAPAPRAGSLRSRVGSAGNLLTDE AEMSAELFHILGRDPASVPSLDELPSLVLTEDRPKLTAMVTDCLVGRPIDGFEFVV RPDGSVRTVHMMGPEVLADAGDSTAMMAVLRDVGLRRSRVASETRDSLRRRPAFV HGLLRFDEGRGLDLAGAILPPTSATGRRSREGWYDACPLGAGETLITVIGDFGLP EADAYGPAVLIGALGLAAGTRPRGRDLRAELLRATAPADVPDGVYCGVYRPDHTL TWASGAPALLFRGCTGHALSGDPGAGQDGPSCGEAENTLEAGDLLLLHTGALPEPA VEHLLTUALRLTAADSAGDGVRLTREDLFGPRQDACVLIARVTP"			
	/complement(4765..5793)			
	/gene="SC5H1.38"			
	/complement(4765..5793)			
	/gene="SC5H1.38"			
	/note="SC5H1.38, probable myo-inositol dehydrogenase, len: 342 aa; similar to many e.g. SW:MI2D_BACSU (EMBL:M76431), idh, Bacillus subtilis myo-inositol 2-dehydrogenase (344 aa), fasta scores; opt: 864 z-score: 958.5 E(): 0, 38.1% identity in 336 aa overlap. Also similar to SW:STRI_STRGR (EMBL:Y00459), strI, Streptomyces griseus streptomycin biosynthesis myo-inositol oxidoreductase (348 aa) (32.7% identity in 343 aa overlap). Weakly similar to FR:069945 (EMBL:AL023862) S.coelicolor possible oxidoreductase (430 aa) (29.8% identity in 228 aa overlap). Contains Pfam match to entry PF01408 GFO_IDH_MocA, Oxidoreductase family, score 153.50, E-value 3.6e-42"			
	/codon_start=1			
	/label="SC5H1.38"			
	/product="putative myo-inositol dehydrogenase"			
	/protein_id="CAB42963.1"			
	/db_xref="GI:4835341"			
	/db_xref="SPTREMBL:Q9X7U5"			
	/translation="MSELLGVAVLGAGHMGADHIRRVDDQVYVGARVAADPDPAERAK EAVGGIGGTGTRITVTDVEAALDAPGAEVLIASPGFAHEEALNAARGLVLCCKP MAPNSAGALRVAEARLGRRLAQIGFMRRYDAEYRQLKSLDGGRLGRPLMHCVHR NVSSPPTSMALINSSVSHEDIAARWLLGQELSAVTVLRPPRSAGAPGLLDPLQVLV FETEGGAVDVEVFVNCGFCGYEVRCEAVCGASARICAAHTMVTAAAGGAREEVPQDY LVRFADAYDREVQSVWDATRRGLVTGCTWDGYAAAAVAEAGVRALEDGTGVRTPYDMP RPSUDHRA"			
	/complement(5062..5781)			
	/gene="SC5H1.38"			
	/note="Pfam match to entry PF01408 GFO_IDH_MocA, Oxidoreductase family, score 153.50, E-value 3.6e-42"			
	/complement(5804..5808)			
	/note="possible RBS"			
	/complement(5917..7011)			
	/gene="SC5H1.37"			
	/complement(5917..7011)			
	/misc_feature			
	/complement(5962..5781)			
	/gene="SC5H1.38"			
	/note="Pfam match to entry PF01408 GFO_IDH_MocA, Oxidoreductase family, score 153.50, E-value 3.6e-42"			
	/complement(5804..5808)			
	/note="possible RBS"			
	/complement(5917..7011)			
	/gene="SC5H1.37"			
	/complement(5917..7011)			


```

/gene="SC5H1.37"
/note="SC5H1.37, hypothetical protein, len: 364 aa;
unknown function, similar to TR:P73120 (EMBL:D90903)
Synchocystis sp. hypothetical protein (358 aa), fasta
scores; Opt: 492 z-score: 559.6 E(): 7.6e-24, 31.6%

Query Match      86.3%; Score 16.4; DB 3; Length 36583;
Best Local Similarity 94.4%; Pred. No. 1.le+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2  CGCTCGGCGCTGTCGGG 19
    ||||| ||||| |||||
Db  7826 CGCTCGACCTGTCGGG 7843

```

Search completed: April 20, 2001, 00:00:44
Job time: 9521 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:13:00 ; Search time 547.68 Seconds ;
(without alignments)
20.252 Million cell updates/sec

Title: US-09-016-464-20

Perfect score: 19
Sequence: 1 GCGTCGGCCTGGTCCGG 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 678276 seqs, 291890651 residues

Total number of hits satisfying chosen parameters: 1356552

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_0401.*
1: /SIDS2/gcgdata/geneseq/geneseq/NA1980.DAT.*
2: /SIDS2/gcgdata/geneseq/geneseq/NA1981.DAT.*
3: /SIDS2/gcgdata/geneseq/geneseq/NA1982.DAT.*
4: /SIDS2/gcgdata/geneseq/geneseq/NA1983.DAT.*
5: /SIDS2/gcgdata/geneseq/geneseq/NA1984.DAT.*
6: /SIDS2/gcgdata/geneseq/geneseq/NA1985.DAT.*
7: /SIDS2/gcgdata/geneseq/geneseq/NA1986.DAT.*
8: /SIDS2/gcgdata/geneseq/geneseq/NA1987.DAT.*
9: /SIDS2/gcgdata/geneseq/geneseq/NA1988.DAT.*
10: /SIDS2/gcgdata/geneseq/geneseq/NA1989.DAT.*
11: /SIDS2/gcgdata/geneseq/geneseq/NA1990.DAT.*
12: /SIDS2/gcgdata/geneseq/geneseq/NA1991.DAT.*
13: /SIDS2/gcgdata/geneseq/geneseq/NA1992.DAT.*
14: /SIDS2/gcgdata/geneseq/geneseq/NA1993.DAT.*
15: /SIDS2/gcgdata/geneseq/geneseq/NA1994.DAT.*
16: /SIDS2/gcgdata/geneseq/geneseq/NA1995.DAT.*
17: /SIDS2/gcgdata/geneseq/geneseq/NA1996.DAT.*
18: /SIDS2/gcgdata/geneseq/geneseq/NA1997.DAT.*
19: /SIDS2/gcgdata/geneseq/geneseq/NA1998.DAT.*
20: /SIDS2/gcgdata/geneseq/geneseq/NA1999.DAT.*
21: /SIDS2/gcgdata/geneseq/geneseq/NA2000.DAT.*
22: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	ID	Description
1	19	100.0	19	18	Human eosinophil p
2	19	100.0	19	20	Eosinophil peroxid
3	19	100.0	19	21	Human eosinophil p
4	19	100.0	19	21	Low adenose anti
5	19	100.0	60	18	Human eosinophil p
6	19	100.0	60	20	Intercellular adhe
7	19	100.0	60	21	Human eosinophil p
8	19	100.0	60	21	Low adenose anti
9	19	100.0	272	20	Eosinophil peroxid
10	19	100.0	272	21	Human low adenosi
11	19	100.0	272	21	Human adenose re

c	12	19	100.0	2272	21	Z45456
c	13	19	100.0	2558	21	F20923
c	14	19	100.0	2558	21	A34801
c	15	19	100.0	6103	21	F21441
c	16	19	100.0	6103	21	F21441
c	17	19	100.0	7033	21	F20844
c	18	19	100.0	7033	21	A34722
c	19	19	100.0	7036	20	A55274
c	20	19	100.0	35384	21	F21436
c	21	19	100.0	114955	20	X53491
c	22	19	100.0	209273	21	F21437
c	23	15.8	83.2	1185	19	V05039
c	24	15.8	83.2	1185	20	Z08784
c	25	15.8	83.2	1185	21	A71692
c	26	15.8	83.2	1251	21	C44041
c	27	15.8	83.2	1401	14	Q34556
c	28	15.8	83.2	3012	21	Z52054
c	29	15.8	83.2	4738	14	Q50997
c	30	15.8	83.2	8908	21	Z52055
c	31	15.8	83.2	9960	19	V58939
c	32	15.8	83.2	29879	14	Q46806
c	33	15.8	83.2	35099	19	V27112
c	34	15.4	81.1	1332	21	C55830
c	35	15.4	81.1	1776	21	A71636
c	36	15.4	81.1	2094	21	A71623
c	37	15.4	81.1	2575	20	Z10654
c	38	15.4	81.1	3293	17	T05810
c	39	15.4	81.1	4052	16	O87791
c	40	15.4	81.1	38734	20	Z32020
c	41	15.4	81.1	38734	22	C90077
c	42	15.4	81.1	53500	21	C55842
c	43	15	78.9	15	20	X54604
c	44	15	78.9	15	21	F20173
c	45	15	78.9	15	21	A34051

ALIGNMENTS

RESULT 1
T76133
ID T76133 standard; DNA; 19 BP.
AC
T76133;
XX
DT 12-SEP-1997 (first entry)
XX
DE Human eosinophil peroxidase antisense oligonucleotide HSEPAS1.
XX
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW Chronic obstructive pulmonary disease; bronchitis; ss.
XX
OS Synthetic.
XX
PN WO9640162-A1.
XX
PD 19-DEC-1996.
XX
PF 06-JUN-1996; 96WO-US09306.
XX
PR 07-JUN-1995; 95US-0474497.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Metzger WJ, Nyce JW;
XX
DR WPI; 1997-051871/05.
XX
PT Treatment of airway diseases such as asthma - by topically applying
PT adenosine-free antisense oligo:nucleotide to airway epithelium of
XX subject
PS Claim 5; Page 27; 71pp; English.

XX A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide
 CC HSEPA1 specific for the human eosinophil peroxidase. The method
 CC can be used to treat airway diseases such as cystic fibrosis, asthma,
 CC chronic obstructive pulmonary disease, bronchitis and other
 CC airway diseases characterised by an inflammatory response. By
 CC eliminating adenosine from the antisense ON, its liberation upon
 CC antisense degradation is prevented, thereby preventing adenosine-
 CC induced bronchoconstriction in patients with hyper-reactive airways.
 XX
 SQ Sequence 19 BP; 0 A; 8 C; 8 G; 3 T; 0 other;

Query Match 100.0%; Score 19; DB 18; Length 19;
 Best Local Similarity 100.0%; Pred. No. 9.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCGG 19
 Db 1 ggcctcgccgtgtcccg 19
 |||||

RESULT 2
 X53932
 ID X53932 standard; DNA; 19 BP.
 XX
 AC X53932;
 XX
 DT 05-JUL-1999 (first entry)
 DT
 DE Eosinophil peroxidase antisense oligonucleotide fragment.
 XX
 KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 KW
 XX Synthetic.
 OS
 XX WO9913886-A1.
 PN
 XX 25-MAR-1999.
 XX
 PF 17-SEP-1998; 98WO-US19419.
 XX
 PR 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW;
 XX
 DR WPI; 1999-229400/19.
 XX
 PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
 XX vasoconstriction
 XX
 PS Disclosure; Page 46; 120pp; English.
 XX
 CC The specification describes antisense oligonucleotides (X52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding

CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences X55272-74. These multiple target
 CC oligonucleotides (specifically X55180-271) can be used for the antisense
 CC treatment of diseases and conditions. Typical diseases and conditions
 CC are those associated with impaired respiration and inflammation,
 CC including lung diseases, pulmonary vasoconstriction, inflammation,
 CC allergic rhinitis, acute asthma, allergies, asthma, impeded respiration,
 CC respiratory distress syndrome, pain, cystic fibrosis, pulmonary
 CC hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic
 CC cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic
 CC metastases, as well as all types of cancers which may metastasize or have
 CC metastasized to the lungs, including breast and prostate cancer.
 XX
 SQ Sequence 19 BP; 0 A; 8 C; 8 G; 3 T; 0 other;

Query Match 100.0%; Score 19; DB 20; Length 19;
 Best Local Similarity 100.0%; Pred. No. 9.3;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCGG 19
 Db 1 ggcctcgccgtgtcccg 19
 |||||

RESULT 3
 F19494
 ID F19494 standard; DNA; 19 BP.
 XX
 AC F19494;
 XX
 DT 14-MAR-2001 (first entry)
 DT
 DE Human eosinophil peroxidase polynucleotide fragment #1061.
 XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 KW
 XX Homo sapiens.
 OS
 XX WO200062736-A2.
 PN
 XX 26-OCT-2000.
 PD
 XX 24-MAR-2000; 2000WO-US08020.
 PF
 XX 06-APR-1999; 99US-0127958.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-679539/66.
 XX
 PT Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX
 PS Claim 14; Page 145; 1592pp; English.
 XX
 CC The present invention describes low adenosine (A) content antisense

CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiallergic, antispasmodic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies).
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impaired respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
 CC and antisense oligonucleotides used in the exemplification of the
 CC present invention.

SQ Sequence 19 BP; 0 A; 8 C; 8 G; 3 T; 0 other;

Query Match 100.0%; Score 19; DB 21; Length 19;

Best Local Similarity 100.0%; Pred. No. 9.3; Mismatches 0; Gaps 0;

QY 1 GCGCTCGGCTGTGTCCTCCGG 19

Db 1 ggcgtcgccctggtcccg 19

RESULT 4

ID A33372 standard; DNA; 19 BP.

AC A33372;

XX 28-JUL-2000 (first entry)

DE Low adenosine antisense oligonucleotide SEQ ID NO:1061.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiallergic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX Homo sapiens.

XX WO200009525-A2.

XX 24-FEB-2000.

XX 03-AUG-1999; 99WO-US17712.

XX 03-AUG-1998; 98US-0095212.

XX (UYEC-) UNIV EAST CAROLINA.

XX Nyce JW;

XX

DR WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers

XX Claim 18; Page 398; 1343pp; English.

XX The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. A32313 to A35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
 CC to A33952) are specifically claimed ONs from the present invention.
 CC N.B. Sequences given in the disclosure of the present invention do not
 CC match up with their corresponding SEQ ID NO: sequences given in the
 CC sequence listing.

XX Sequence 19 BP; 0 A; 8 C; 8 G; 3 T; 0 other;

Query Match 100.0%; Score 19; DB 21; Length 19;

Best Local Similarity 100.0%; Pred. No. 9.3; Mismatches 0; Gaps 0;

QY 1 GCGCTCGGCTGTGTCCTCCGG 19

Db 1 ggcgtcgccctggtcccg 19

RESULT 5

T76132

ID T76132 standard; DNA; 60 BP.

XX T76132;

XX 12-SEP-1997 (first entry)

XX Human eosinophil peroxidase antisense oligonucleotide.

XX Asthma; airway epithelium; adenosine free; cystic fibrosis;
 KW chronic obstructive pulmonary disease; bronchitis; ss.

XX Synthetic.

XX WO9640162-A1.

XX 19-DEC-1996.

XX 06-JUN-1996; 96WO-US09306.

XX 07-JUN-1995; 95US-0474497.

XX (UYEC-) UNIV EAST CAROLINA.

PT Metzger WJ, Nyce JW;
 XX WPI; 1997-051871/05.
 XX
 XX Treatment of airway diseases such as asthma - by topically applying
 PT adenosine-free antisense oligonucleotide to airway epithelium of
 PT subject
 XX
 XX Claim 5; Page 27; 71pp; English.
 PS
 CC A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide specific
 CC for the human eosinophil peroxidase, targeted at the initiation
 CC codon. The method can be used to treat airway diseases such as cystic
 CC fibrosis, asthma, chronic obstructive pulmonary disease, bronchitis and
 CC other airway diseases characterised by an inflammatory response. By
 CC eliminating adenosine from the antisense ON, its liberation upon
 CC antisense degradation is prevented, thereby preventing adenosine-
 CC induced bronchoconstriction in patients with hyper-reactive airways.
 XX
 XX Sequence 60 BP; 0 A; 19 C; 22 G; 12 T; 7 other;
 SQ

Query Match 100.0%; Score 19; DB 18; Length 60;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGTCGCCG 19
 Db 37 gcgctcgcgctggtcccg 55

RESULT 6
 X53942
 ID X53942 standard; DNA; 60 BP.
 AC X53942;
 XX
 XX 05-JUL-1999 (first entry)
 DT
 XX
 DE Intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide.
 KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX
 OS Synthetic.
 XX
 XX WO9913886-A1.
 XX
 XX 25-MAR-1999.
 PD
 XX
 PF 17-SEP-1998; 98WO-US19419.
 XX
 XX
 PR 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Nyce JW;
 PI
 XX WPI; 1999-229400/19.
 DR
 XX New antisense oligonucleotides used in treatment of, e.g. pulmonary

PT vasoconstriction
 XX
 XX Disclosure; Page 47; 120pp; English.
 XX
 CC The specification describes antisense oligonucleotides (X52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences X5272-74. These multiple target
 CC oligonucleotides (specifically X55180-271) can be used for the antisense
 CC treatment of diseases and conditions. Typical diseases and conditions
 CC are those associated with impaired respiration and inflammation,
 CC including lung diseases, pulmonary vasoconstriction, inflammation,
 CC allergic rhinitis, acute asthma, allergies, asthma, impeded respiration,
 CC respiratory distress syndrome, pain, cystic fibrosis, pulmonary
 CC hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic
 CC cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic
 CC metastases, as well as all types of cancers which may metastasize or have
 CC metastasized to the lungs, including breast and prostate cancer.
 XX
 SQ Sequence 60 BP; 0 A; 19 C; 22 G; 12 T; 7 other;

Query Match 100.0%; Score 19; DB 20; Length 60;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGTCGCCG 19
 Db 37 gcgctcgcgctggtcccg 55

RESULT 7
 F19504
 ID F19504 standard; DNA; 60 BP.
 XX
 AC F19504;
 XX
 XX 14-MAR-2001 (first entry)
 DT
 XX
 DE Human eosinophil peroxidase polynucleotide fragment #1071.
 XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; anti-inflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200062736-A2.
 PN
 XX
 XX 26-OCT-2000.
 PD
 XX
 XX 24-MAR-2000; 2000WO-US08020.
 PR
 PF 06-APR-1999; 99US-0127958.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX (NYCE/) NYCE J W.
 XX
 XX Nyce JW;
 PI

DR WPI; 2000-679539/66.
XX
PT Low adenosome (A) content antisense oligonucleotides which do not
PT trigger adenosome receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions
XX
XX
PS Claim 14; Page 145; 1592pp; English.
XX
CC The present invention describes low adenosome (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and/or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosome receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergies (ies).
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impaired respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
CC and antisense oligonucleotides used in the exemplification of the
CC present invention.
XX
XX Sequence 60 BP; 0 A; 19 C; 22 G; 12 T; 7 other;
SQ

Query Match 100.0%; Score 19; DB 21; Length 60;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTCCGG 19
|||||
Db 37 gcgctggcgtgtccgg 55

RESULT 8
A33382
ID A33382 standard; DNA; 60 BP.
XX
AC A33382;
XX
XX 28-JUL-2000 (first entry)
XX
XX Low adenosome antisense oligonucleotide SEQ ID NO:1071.
XX
XX Human; adenosome receptor; low adenosome antisense oligonucleotide;
KW phosphothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200009525-A2.
PN
XX

PD 24-FEB-2000.
XX
XX 03-AUG-1999; 99WO-US17712.
XX
XX 03-AUG-1998; 98US-0095212.
XX
XX (UYEC-) UNIV EAST CAROLINA.
XX
XX Nyce JW;
XX
XX WPI; 2000-205971/18.
XX
XX New antisense oligonucleotides useful for treating e.g. pulmonary
XX vasoconstriction, inflammation, allergies, asthma, hypertension, or
XX bronchitis, emphysema, respiratory distress syndrome, ischemia or
XX cancers
XX
XX Claim 18; Page 399; 1343pp; English.
XX
XX The present invention describes a new composition comprising an antisense
XX oligonucleotide (ON) with low adenosome (up to 15%), which targets
XX nucleic acids involved in bronchoconstriction, allergies, and/or
XX inflammation. The ON can have antiinflammatory, antiallergic,
XX antiasthmatic, cytostatic and analgesic activities. The compositions are
XX useful for the treatment of diseases associated with inflammation,
XX impaired airways, including lung disease and diseases whose secondary
XX effects afflict the lungs of a subject. They can be used for treating
XX e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
XX impaired respiration, respiratory distress syndrome, pain, cystic
XX fibrosis, pulmonary hypertension, emphysema, chronic obstructive
XX pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
XX carcinomas, and cancers which may metastasize to the lungs, including
XX breast and prostate cancer. The reduction of the adenosome content of the
XX ONs reduces side effects. The A-containing ONs break down with the
XX release of deoxyadenosine which activates adenosine receptors causing
XX bronchoconstriction and inflammation. A33313 to A33312 represent the
XX nucleotide sequences given in the sequence listing from the present
XX invention, which correspond to SEQ ID NO:1 to 2815, and then the last
XX 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
XX differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323
XX to A33992) are specifically claimed ONs from the present invention.
XX N.B. Sequences given in the disclosure of the present invention do not
XX match up with their corresponding SEQ ID NO: sequences given in the
XX sequence listing.
XX
XX Sequence 60 BP; 0 A; 19 C; 22 G; 12 T; 7 other;
SQ

Query Match 100.0%; Score 19; DB 21; Length 60;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTCCGG 19
|||||
Db 37 gcgctggcgtgtccgg 55

RESULT 9
X54603
ID X54603 standard; DNA; 272 BP.
XX
XX X54603;
XX
XX 05-JUL-1999 (first entry)
XX
XX Eosinophil peroxidase antisense oligonucleotide fragment.
XX
XX Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;

KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX Synthetic.
 OS
 PN WO9913886-A1.
 XX
 XX
 PD 25-MAR-1999.
 XX
 PF 17-SEP-1998; 98WO-US19419.
 XX
 PR 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX
 XX Nyce JW;
 PI
 XX
 DR WPI; 1999-229400/19.
 XX
 PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction
 XX
 XX
 XX Disclosure; Page 46; 120pp; English.
 XX
 CC The specification describes antisense oligonucleotides (X52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences X5272-74. These multiple target
 CC oligonucleotides (specifically X55180-271) can be used for the antisense
 CC treatment of diseases and conditions. Typical diseases and conditions
 CC are those associated with impaired respiration and inflammation,
 CC including lung diseases, pulmonary vasoconstriction, inflammation,
 CC allergic rhinitis, acute asthma, allergies, asthma, impeded respiration,
 CC respiratory distress syndrome, pain, cystic fibrosis, pulmonary
 CC hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas e.g. colon cancer, breast cancer, lung cancer, pancreatic
 CC cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic
 CC metastases, as well as all types of cancers which may metastasize or have
 CC metastasized to the lungs, including breast and prostate cancer...
 XX
 SQ Sequence 272 BP; 0 A; 85 C; 98 G; 82 T; 7 other;

Query Match 100.0%; Score 19; DB 20; Length 272;
 Best Local Similarity 100.0%; Pred. No. 7.8;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGTCCTCCGG 19
 Db 1 GCGCTCGCGCTGTCCTCCGG 19

RESULT 10
 F20172
 ID F20172 standard; DNA; 272 BP.
 XX
 AC F20172;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 XX Human low adenosine antisense oligonucleotide #1739.
 DE
 XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;

KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200062736-A2.
 PN
 XX 26-OCT-2000.
 PD
 XX 24-MAR-2000; 2000WO-US08020.
 PF
 XX 06-APR-1999; 99US-0127958.
 XX
 PR (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX
 XX Nyce JW;
 PI
 XX
 DR WPI; 2000-679539/66.
 XX
 PT Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX
 XX Claim 14; Page 547; 1592pp; English.

The present invention describes low adenosine (A) content antisense oligonucleotides and compositions (I) comprising them. In the antisense oligonucleotides the A is replaced by a 'universal' or alternative base. (I) can have respiratory, bronchodilator, antiinflammatory, analgesic, immunosuppressive, antiasthmatic, hypotensive and cytostatic activities. The antisense oligonucleotides and (I) can be used to down-regulate the expression and or activity of target polypeptides associated with lung/respiratory disorders and malignancies, such as stimulating and activating peptide factors and transmitters, transcription factors, immunoglobulins and antibodies, antibody receptors, cytokines and chemokines, endogenously produced specific and non-specific enzymes, binding proteins, adhesion molecules and their receptors, cytokine and chemokine receptors, adenosine receptors, bradykinin receptors, central nervous system (CNS) and peripheral nervous and non-nervous system receptors, CNS and peripheral nervous and non-nervous system peptide transmitters, binding proteins and malignancy associated proteins. The antisense oligonucleotides may be used in this way to treat disorders including respiratory obstruction (especially pulmonary obstruction and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or surfactant hypoproduction which are associated with a disease or condition selected from pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), pulmonary transplantation rejection, pulmonary infections, bronchitis, and/or cancer. F18434 to F21543 represent human polynucleotide fragments and antisense oligonucleotides used in the exemplification of the present invention.

SQ Sequence 272 BP; 0 A; 85 C; 98 G; 82 T; 7 other;

Query Match 100.0%; Score 19; DB 21; Length 272;
 Best Local Similarity 100.0%; Pred. No. 7.8;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGTCCTCCGG 19
 Db 1 GCGCTCGCGCTGTCCTCCGG 19

Matches	19;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1	CGCGTCGGCCTGGTCCCGG	19						
Db	1	gcgctcgccctggtcccg	19						
RESULT 12									
Z45456/c									
ID		Z45456 standard; DNA; 2272 BP.							
XX									
AC		Z45456;							
XX									
DT									
XX		06-APR-2000 (first entry)							
DE									
XX		Nucleotide sequence of the human eosinophil peroxidase (EPO).							
XX									
KW		Human; eosinophil peroxidase; EPO; blood; oxydo-reductase;							
KW		respiratory system tissue; ss.							
XX									
OS		Homo sapiens.							
XX									
PN		FR2780412-A1.							
XX									
PD		31-DEC-1999.							
XX									
PF		30-JUN-1998; 98FR-0008280.							
XX									
PR		30-JUN-1998; 98FR-0008280.							
XX									
PA		(HELI-) HELIX BIOTECHNOLOGIES SARL.							
XX									
PI		Gautier C, Duport JM;							
XX									
DR		WPI; 2000-118775/11.							
XX									
PT		New human recombinant eosinophil peroxidase, useful for replacing human							
PT		eosinophil peroxidase -							
XX									
PS		Claim 3; Fig 1; 29pp; French.							
XX									
CC		The present sequence represents an expression cassette of a human							
CC		eosinophil peroxidase (EPO). The sequence is derived from a							
CC		BamHI-HindIII fragment. The specification describes the production of							
CC		human EPO fragments by genetic engineering. The sequence was obtained							
CC		from total RNA isolated from human blood. The EPO protein is from the							
CC		family of oxydo-reductases. The molecular mass of the protein is							
CC		about 71 kDa. The human EPO can be used in large scale industrial							
CC		applications, especially for the research of new medicaments, e.g. the							
CC		toxic effects of natural eosinophil peroxidase on the tissues of the							
CC		respiratory system could be diminished or modulated by using a							
CC		medicament directly acting on the EPO. Antibodies against the EPO							
CC		protein can be used for immunodetection of the protein.							
XX									
SQ		Sequence 2272 BP; 461 A; 732 C; 627 G; 452 T; 0 other;							
Query Match		100.0%;		Score 19;		DB 21;		Length 2272;	
Best Local Similarity		100.0%;		Pred. No. 6.8;					
Matches	19;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1	CGCGTCGGCCTGGTCCCGG	19						
Db	444	CGCGTCGGCCTGGTCCCGG	426						
RESULT 13									
F20923/c									
ID		F20923 standard; DNA; 2558 BP.							
XX									
AC		F20923;							
XX									
DT		14-MAR-2001 (first entry)							

XX DE Human eosinophil peroxidase polynucleotide fragment #2490.

XX KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;

XX KW human; airway disorder; bronchoconstriction; lung inflammation;

XX KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;

XX KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;

XX KW respiratory obstruction; pulmonary obstruction; impeded respiration;

XX KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;

XX KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;

XX KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;

XX KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;

XX KW cancer; ss.

XX OS Homo sapiens.

XX PN WO200062736-A2.

XX PD 26-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US08020.

XX PR 06-APR-1999; 98US-0127958.

XX PA (UYEC-) UNIV EAST CAROLINA.

XX PA (NYCE/) NYCE J W.

XX PI Nyce JW;

XX PI WPI; 2000-679539/66.

XX DR Low adenosine (A) content antisense oligonucleotides which do not

XX PT trigger adenosine receptors during metabolism, useful e.g. for treating

XX PT cancers and respiratory obstructions -

XX PS Disclosure: Page 144-145; 1592pp; English.

XX CC The present invention describes low adenosine (A) content antisense

XX CC oligonucleotides and compositions (I) comprising them. In the antisense

XX CC oligonucleotides the A is replaced by a 'Universal' or alternative base.

XX CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,

XX CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.

XX CC The antisense oligonucleotides and (I) can be used to down-regulate the

XX CC expression and/or activity of target polypeptides associated with

XX CC lung/respiratory disorders and malignancies, such as stimulating and

XX CC activating peptide factors and transmitters, transcription factors,

XX CC immunoglobulins and antibodies, antibody receptors, cytokines and

XX CC chemokines, endogenously produced specific and non-specific enzymes,

XX CC binding proteins, adhesion molecules and their receptors, cytokine and

XX CC chemokine receptors, adenosine receptors, bradykinin receptors, central

XX CC nervous system (CNS) and peripheral nervous and non-nervous system

XX CC receptors, CNS and peripheral nervous and non-nervous system peptide

XX CC transmitters, defensins, growth factors, vasoactive peptides and

XX CC receptors, binding proteins and malignancy associated proteins. The

XX CC antisense oligonucleotides may be used in this way to treat disorders

XX CC including respiratory obstruction (especially pulmonary obstruction

XX CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)

XX CC and/or surfactant hypoproduction which are associated with a disease or

XX CC condition selected from pulmonary vasoconstriction, inflammation,

XX CC allergies, asthma, impeded respiration, respiratory distress syndrome

XX CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary

XX CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),

XX CC pulmonary transplantation rejection, pulmonary infections, bronchitis,

XX CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments

XX CC and antisense oligonucleotides used in the exemplification of the

XX CC present invention.

XX SQ Sequence 2558 BP; 527 A; 820 C; 698 G; 513 T; 0 other;

Query Match 100.0%; Score 19; DB 21; Length 2558;

Best Local Similarity 100.0%; Pred. No. 6.8;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19

Db 384 GCGCTCGGCTGGTCCCGG 366

RESULT 14

A34801/c

ID A34801 standard; DNA; 2558 BP.

XX A34801;

XX 28-JUL-2000 (first entry)

XX Human adenosine receptor related polynucleotide SEQ ID NO:2490.

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;

XX KW phosphorothioate; impaired respiration; inflammation; allergy;

XX KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;

XX KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;

XX KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;

XX KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;

XX KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;

XX KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX OS Homo sapiens.

XX PN WO200009525-A2.

XX PD 24-FEB-2000.

XX PF 03-AUG-1999; 99WO-US17712.

XX PR 03-AUG-1998; 98US-0095212.

XX PA (UYEC-) UNIV EAST CAROLINA.

XX PI Nyce JW;

XX PI WPI; 2000-205971/18.

XX New antisense oligonucleotides useful for treating e.g. pulmonary

XX vasoconstriction, inflammation, allergies, asthma, hypertension,

XX bronchitis, emphysema, respiratory distress syndrome, ischemia or

XX cancers -

XX Disclosure: Page 647-648; 1343pp; English.

XX The present invention describes a new composition comprising an antisense

XX oligonucleotide (ON) with low adenosine (up to 15%), which targets

XX nucleic acids involved in bronchoconstriction, allergies, and/or

XX inflammation. The ON can have antiinflammatory, antiallergic,

XX antiasthmatic, cytostatic and analgesic activities. The compositions are

XX useful for the treatment of diseases associated with inflammation,

XX impaired airways, including lung disease and diseases whose secondary

XX effects afflict the lungs of a subject. They can be used for treating

XX e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,

XX impeded respiration, respiratory distress syndrome, pain, cystic

XX fibrosis, pulmonary hypertension, emphysema, chronic obstructive

XX pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,

XX carcinomas, and cancers which may metastasize to the lungs, including

XX breast and prostate cancer. The reduction of the adenosine content of the

XX ONs reduces side effects. The A-containing ONs break down with the

XX release of deoxyadenosine which activates adenosine receptors causing

XX bronchoconstriction and inflammation. A32313 to A35312 represent the

XX nucleotide sequences given in the sequence listing from the present

XX invention, which correspond to SEQ ID NO:1 to 2815, and then the last

XX 185 sequences are also called SEQ ID NO:1 to 185, but the sequences

XX differ from the previously named sequences. SEQ ID NO:11 to 1680 (A32323

XX to A33992) are specifically claimed ONs from the present invention.

XX N.B. Sequences given in the disclosure of the present invention do not

XX match up with their corresponding SEQ ID NO: sequences given in the

XX sequence listing.

XX Sequence 2558 BP; 527 A; 820 C; 698 G; 513 T; 0 other;
SQ Query Match 100.0%; Score 19; DB 21; Length 2558; Mismatches 0; Indels 0; Gaps 0;
Best Local Similarity 100.0%; Pred. No. 6.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCGG 19
|||||
Db 384 GCGCTCGGCTGGTCCGG 366

RESULT 15
F21441
ID F21441 standard; DNA; 6103 BP.
AC F21441;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human eosinophil peroxidase polynucleotide fragment #3008.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
XX 24-MAR-2000; 2000WO-US08020.
XX
PF 06-APR-1999; 99US-0127958.
XX
PR (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
XX Nyce JW;
PI
XX
XX WPI; 2000-679539/66.
DR
XX
XX Low adenosine (A) content antisense oligonucleotides which do not
PT trigger adenosine receptors during metabolism, useful e.g. for treating
PT cancers and respiratory obstructions -
XX
XX Disclosure; Page 142-143; 1592pp; English.
PS
XX
XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and

CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. F18434 to F21543 represent human polynucleotide fragments
CC and antisense oligonucleotides used in the exemplification of the
CC present invention.
XX
SQ Sequence 6103 BP; 1218 A; 1863 C; 1727 G; 1287 T; 8 other;
Query Match 100.0%; Score 19; DB 21; Length 6103;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCGG 19
|||||
Db 1 gcgctcggcctggtccgg 19

Search completed: April 20, 2001, 00:13:01
Job time: 10023 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 19, 2001, 23:25:03 ; Search time 7150.85 Seconds
(without alignments)
0.388 Million cell updates/sec

Title: US-09-016-464-20
Perfect score: 19
Sequence: 1 GCGCTGGCCTGTCCGG 19

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 9623517 seqs, 73081774 residues

Total number of hits satisfying chosen parameters: 19247034

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*

1:	gb_estl1:
2:	gb_est2:
3:	gb_est3:
4:	gb_est4:
5:	gb_est5:
6:	gb_est6:
7:	gb_est7:
8:	gb_est8:
9:	gb_est9:
10:	gb_est10:
11:	gb_est11:
12:	gb_est12:
13:	gb_est13:
14:	gb_est14:
15:	gb_est15:
16:	gb_est16:
17:	gb_est17:
18:	gb_est18:
19:	gb_est19:
20:	gb_est20:
21:	gb_est21:
22:	gb_est22:
23:	gb_est23:
24:	gb_est24:
25:	gb_est33:
26:	gb_est34:
27:	gb_est35:
28:	gb_est36:
29:	gb_est37:
30:	gb_est38:
31:	gb_est39:
32:	gb_est40:
33:	em_estba:
34:	em_estfun:
35:	em_esthum1:
36:	em_esthum2:
37:	em_esthum3:
38:	em_esthum4:
39:	em_esthum5:
40:	em_esthum6:
41:	em_esthum7:
42:	em_esthum8:
43:	em_esthum9:

44:	em_esthum10:
45:	em_esthum11:
46:	em_esthum12:
47:	em_esthum13:
48:	em_esthum14:
49:	em_esthum15:
50:	em_esthum16:
51:	em_esthum17:
52:	em_esthum18:
53:	em_esthum19:
54:	em_esthum20:
55:	em_esthum21:
56:	em_esthum22:
57:	em_esthum23:
58:	em_esthum24:
59:	em_esthum25:
60:	em_esthum26:
61:	em_esthum27:
62:	em_esthum28:
63:	em_estin1:
64:	em_estin2:
65:	em_estin3:
66:	em_estin4:
67:	em_estin5:
68:	em_estom1:
69:	em_estom2:
70:	em_estov1:
71:	em_estov2:
72:	em_estpl1:
73:	em_estpl2:
74:	em_estpl3:
75:	em_estpl4:
76:	em_estpl5:
77:	em_estpl6:
78:	em_estpl7:
79:	em_estpl8:
80:	em_estpl9:
81:	em_estpl10:
82:	em_estro1:
83:	em_estro2:
84:	em_estro3:
85:	em_estro4:
86:	em_estro5:
87:	em_estro6:
88:	em_estro7:
89:	em_estro8:
90:	em_estro9:
91:	em_estro10:
92:	em_estro11:
93:	em_estro12:
94:	em_estro13:
95:	em_estro14:
96:	em_estro15:
97:	em_estro16:
98:	em_estro17:
99:	em_estro18:
100:	em_estro19:
101:	em_estro20:
102:	gb_est25:
103:	gb_est26:
104:	gb_est27:
105:	gb_est28:
106:	gb_est29:
107:	gb_est30:
108:	gb_est31:
109:	gb_est32:
110:	gb_est41:
111:	gb_est42:
112:	gb_est43:
113:	gb_est44:
114:	gb_est45:
115:	gb_est46:
116:	gb_est47:

```

117: gb_est48:*
118: gb_est49:*
119: gb_est50:*
120: gb_est51:*
121: gb_est52:*
122: gb_est53:*
123: gb_est54:*
124: gb_est55:*
125: gb_est56:*
126: gb_est57:*
127: gb_est58:*
128: gb_est59:*
129: gb_est60:*
130: gb_est61:*
131: gb_est62:*
132: gb_est63:*
133: gb_est64:*
134: gb_est65:*
135: gb_est66:*
136: gb_est67:*
137: gb_est68:*
138: gb_est69:*
139: gb_est70:*
140: gb_est71:*
141: gb_est72:*
142: gb_est73:*
143: gb_est74:*
144: gb_est75:*
145: gb_est76:*
146: gb_est77:*
147: gb_est78:*
148: gb_est79:*
149: gb_est80:*
150: gb_est81:*
151: gb_est82:*
152: gb_est83:*
153: gb_est84:*
154: gb_est85:*
155: gb_est86:*
156: gb_est87:*
157: gb_est88:*
158: gb_est89:*
159: gb_est90:*
160: gb_est91:*
161: gb_est92:*
162: gb_est93:*
163: gb_est94:*
164: gb_est95:*
165: gb_est96:*
166: gb_est97:*
167: gb_est98:*
168: gb_est99:*
169: gb_est100:*
170: gb_est101:*
171: gb_est102:*
172: gb_est103:*
173: gb_est104:*
174: gb_est105:*
175: gb_est106:*
176: gb_est107:*
177: gb_est108:*
178: gb_est109:*
179: gb_est110:*
180: gb_est111:*
181: gb_est112:*
182: gb_est113:*
183: gb_est114:*
184: gb_est115:*
185: gb_est116:*
186: gb_est117:*
187: gb_est118:*
188: gb_est119:*
189: gb_est120:*

```

```

190: em_gss_pln1:*
191: em_gss_pln2:*
192: em_gss_pro:*
193: em_gss_rod1:*
194: em_gss_rod2:*
195: em_gss_rod3:*
196: em_gss_rod4:*
197: em_gss_rod5:*
198: em_gss_vrt1:*
199: em_gss_vrt2:*
200: em_gss_vrt3:*
201: gb_gss1:*
202: gb_gss2:*
203: gb_gss3:*
204: gb_gss4:*
205: gb_gss5:*
206: gb_gss6:*
207: gb_gss7:*
208: gb_gss8:*
209: gb_gss9:*
210: gb_gss10:*
211: gb_gss11:*
212: gb_gss12:*
213: gb_gss13:*
214: gb_gss14:*
215: gb_gss15:*
216: gb_gss16:*
217: gb_gss17:*
218: gb_gss18:*
219: gb_gss19:*
220: gb_gss20:*
221: gb_gss21:*
222: gb_gss22:*
223: gb_gss23:*
224: gb_gss24:*
225: gb_gss25:*
226: gb_gss26:*
227: gb_gss27:*
228: gb_gss28:*
229: gb_gss29:*
230: gb_gss30:*
231: gb_gss31:*
232: gb_gss32:*
233: gb_gss33:*
234: gb_gss34:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	17.4	91.6	493	21	AI521798	AI521798 t182e09.x
2	17.4	91.6	649	165	BE298972	BE298972 601119505
3	16.4	86.3	293	131	BB360288	BB360288 BB360288
C 4	16.4	86.3	450	161	BE014616	BE014616 126415 MA
C 5	16.4	86.3	468	103	AI891550	AI891550 u131e08.x
C 6	16.4	86.3	528	209	AQ650598	AQ650598 Sheared D
C 7	16.4	86.3	546	233	TA70F120	TA70F120 T. brucei
C 8	16.4	86.3	547	145	BF189303	BF189303 234766 MA
C 9	16.4	86.3	1086	138	BE730153	BE730153 601560672
10	16	84.2	490	146	BE268451	BE268451 GA_Eb000
C 11	16	84.2	810	139	BE741923	BE741923 601593721
12	16	84.2	860	146	BF278046	BF278046 GA_Eb003
13	16	84.2	908	119	AW729536	AW729536 GA_Ea002
C 14	15.8	83.2	109	14	AA971455	AA971455 op81c03.s
C 15	15.8	83.2	127	168	BF721315	BF721315 mab65d09.
C 16	15.8	83.2	154	143	BF058495	BF058495 7k31d11.x
17	15.8	83.2	163	160	BB564618	BB564618 BB564618
C 18	15.8	83.2	195	22	AI602991	AI602991 UI-R-AC1-

```

19 15.8 83.2 197 168 BF730625
20 15.8 83.2 244 24 A1717676
c 21 15.8 83.2 245 24 A1713617
22 15.8 83.2 268 23 A1699091
c 23 15.8 83.2 283 24 A1709707
c 24 15.8 83.2 310 116 AW525396
c 25 15.8 83.2 314 110 AW045268
c 26 15.8 83.2 338 115 AW445253
c 27 15.8 83.2 351 158 W30194
c 28 15.8 83.2 358 147 BF396472
c 29 15.8 83.2 360 113 AW321852
c 30 15.8 83.2 362 231 CNS03XVU
c 31 15.8 83.2 364 162 BE109821
c 32 15.8 83.2 366 1 AA024123
c 33 15.8 83.2 390 17 A1177468
c 34 15.8 83.2 393 169 BF777094
c 35 15.8 83.2 402 13 AA924731
c 36 15.8 83.2 402 23 A1704042
c 37 15.8 83.2 406 19 A1325344
c 38 15.8 83.2 422 30 AV606734
c 39 15.8 83.2 425 168 BF708484
c 40 15.8 83.2 433 14 AA956707
c 41 15.8 83.2 444 115 AW435374
c 42 15.8 83.2 455 24 A1712459
c 43 15.8 83.2 457 24 A1710976
c 44 15.8 83.2 463 162 BE100455
c 45 15.8 83.2 464 17 A1226787

```

ALIGNMENTS

```

RESULT 1
A1521798
LOCUS A1521798 493 bp mRNA EST 13-APR-1999
DEFINITION t182e09.x1 NCI_CGAP_Kid1 Homo sapiens cDNA clone IMAGE:2138536 3',
mRNA sequence.
ACCESSION A1521798
VERSION A1521798.1 GI:4435933
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 493)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D.
DNA Sequencing by: Greg Lennon, Ph.D.
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.llnl.gov/dbrrp/image/image.html
Insert Length: 903 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 464.
Location/Qualifiers
1..493
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2138536"
/clone_lib="NCI_CGAP_Kid1"
/lab_host="DH10B"
/note="Organ: kidney; Vector: pT73D-Pac (Pharmacia) with
a modified polylinker; Site_1: Not 1; Site_2: Eco RI;
Plasmid DNA from the normalized library NCI_CGAP_Kid3 was

```

FEATURES

```

source
1..493
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2138536"
/clone_lib="NCI_CGAP_Kid1"
/lab_host="DH10B"
/note="Organ: kidney; Vector: pT73D-Pac (Pharmacia) with
a modified polylinker; Site_1: Not 1; Site_2: Eco RI;
Plasmid DNA from the normalized library NCI_CGAP_Kid3 was

```

```

prepared, and ss circles were made in vitro. Following HAP
purification, this DNA was used as tracer in a subtractive
hybridization reaction. The driver was PCR-amplified cDNAs
from a pool of 5,000 clones made from the same library
(cloneIDs 1322376-132911, 1456007-1456775, and
1500352-1502855). Subtraction by Bento Soares and M.
Fatima Bonaldo. "

```

```

BASE COUNT 75 a 168 c 175 g 74 t 1 others
ORIGIN

```

```

Query Match 91.6%; Score 17.4; DB 21; Length 493;
Best Local Similarity 94.7%; Pred. No. 5.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1 GGCCTCGGCTGTGCCCGG 19
|||||

```

```

Db 387 GGCCTCGGCTGTGCCCGG 405
|||||

```

RESULT 2

```

LOCUS BE298972 649 bp mRNA EST 20-JUL-2000
DEFINITION 60119505F1 NIH_MGC_17 Homo sapiens cDNA clone IMAGE:3029448 5',
mRNA sequence.
ACCESSION BE298972
VERSION BE298972.1 GI:9182719
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 649)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Ling Hong/Rubin Laboratory
DNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov
Plate: L1CM89 row: i column: 01
High quality sequence stop: 449.
Location/Qualifiers
1..649
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:3029448"
/clone_lib="NIH_MGC_17"
/tissue_type="rhabdomyosarcoma"
/note="Organ: muscle; Vector: pOTB7; Site_1: EcoRI;
Site_2: XhoI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(c). Size-selected >500bp
for average insert size 1.8kb. Library constructed by
Ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies)."

```

BASE COUNT

```

BASE COUNT 124 a 241 c 169 g 115 t
ORIGIN
Query Match 91.6%; Score 17.4; DB 165; Length 649;
Best Local Similarity 94.7%; Pred. No. 5.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GGCCTCGGCTGTGCCCGG 19
|||||

```

Db 496 GCGCTGGCGCTGGCCCCG 514

RESULT 3

LOCUS BB360288 293 bp mRNA EST 12-JUL-2000

DEFINITION BB360288 RIKEN full-length enriched, adult male corpus striatum Mus musculus cDNA clone C030046E07 3' similar to AF039218 Rattus norvegicus postsynaptic density protein (citron) mRNA, mRNA sequence.

ACCESSION BB360288

VERSION BB360288.1 GI:9072116

KEYWORDS EST.

SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE

AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 293)

P., Endo, T., Fukuda, S., Fukunishi, Y., Hara, A., Hayatsu, N., Hirozane, T., Hori, F., Ishii, Y., Ishikawa, J., Ishikawa, T., Itoh, M., Izawa, M., Kadota, K., Kagawa, I., Kai, C., Kawai, J., Kikuchi, N., Kiyosawa, H., Kojima, Y., Kondo, S., Koya, S., Kurihara, C., Kusakabe, M., Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y., Ono, T., Owa, C., Saito, H., Sakai, C., Sato, K., Shibata, K., Shibata, Y., Shigemoto, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Sugahara, Y., Suzuki, H., Suzuki, H., Tagawa, A., Takahashi, F., Tominaga, N., Toya, T., Tsunoda, Y., Watanabe, S., Watanabe, S., Yamamura, T., Yamana, I., Yano, R., Yasunishi, A., Yokota, T., Yoshida, K., Yoshiki, A., Yoshino, M., Muramatsu, M., and Hayashizaki, Y.

RIKEN Mouse ESTs (Konno, H., et al.)

Unpublished (2000)

Contact: Yoshihide Hayashizaki

Genome Exploration Research Group, Life Science Tsukuba Center, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center

3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

Tel: +81-298-36-9013

Fax: +81-298-36-9098

Email: genome-res@rtc.riken.go.jp,

URL: http://genome.rtc.riken.go.jp/

Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagao, S., Sasaki, N., Okazaki, Y., Muramatsu, M., and Hayashizaki, Y.

Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)

Itoh, M., Katsunai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J., Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki, Y., and Hayashizaki, Y.

Automated filtration-based high-throughput plasmid preparation system. Genome Res. 9 (5), 463-470 (1999)

Carninci, P. and Hayashizaki, Y.

High-efficiency full-length cDNA cloning. Methods Enzymol. 303, 19-44 (1999)

Please visit our web site (<http://genome.rtc.riken.go.jp>) for further details.

FEATURES

source

1. .293

Location/Qualifiers

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="C030046E07"

/clone_lib="RIKEN full-length enriched, adult male corpus striatum"

/sex="male"

/tissue_type="corpus striatum"

/dev_stage="adult"

/lab_host="DH10B"

/note="Site 1: Sall; Site 2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in

BASE COUNT 71 a 84 c 65 g 73 t

ORIGIN

Query Match 86.3%; Score 16.4; DB 131; Length 293;

Best Local Similarity 94.4%; Pred. No. 1.6e+03;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2 CGCTCGCGCTGGTCCGG 19

Db 184 CTCTCGCGCTGGTCCGG 201

RESULT 4

LOCUS BE014616/c 450 bp mRNA EST 09-JUL-2000

DEFINITION 126415 MARC 1P1G Sus scrofa cDNA 5', mRNA sequence.

ACCESSION BE014616

VERSION BE014616.1 GI:8275635

KEYWORDS EST.

SOURCE pig.

ORGANISM Sus scrofa

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus. 1 (bases 1 to 450)

Fahrenkrug, S.C., Freking, B.A., Rohrer, G.A., Smith, T.P.L., Casas, E., Stone, R.T., Heaton, M.P., Grosse, W.M., Bennett, G.A., Laegreid, W.W., and Keele, J.W.

Design and use of two pooled tissue normalized cDNA libraries for EST discovery in swine

Unpublished (2000)

Contact: Smith TPL

USDA, ARS, US Meat Animal Research Center

PO Box 166, Clay Center, NE 68933-0166, USA

Tel: 402 762 4366

Fax: 402 762 4390

Email: smith@email.marc.usda.gov

Single pass sequencing. Bases called and alt_trimmed with phred v0.980904.e. Vector identified by cross_match with the -minscore 18 and -minmatch 12 options.

PCR Primers

FORWARD: AGGAACACGCTATGACCAT

BACKWARD: GTTTCCAGTCACGACG

Plate: 55 row: H column: 20

Seq primer: ATTAGGTGACACTATAG.

Location/Qualifiers

1. .450

/organism="Sus scrofa"

/db_xref="taxon:9823"

/clone_lib="MARC 1P1G"

/tissue_type="pooled"

/lab_host="DH10B"

/note="vector: pCMV SPORT6; Site 1: XbaI; Site 2: XhoI; Library made from pooled tissue from day 11, 13, 15, 20, and 30 embryos."

BASE COUNT 85 a 143 c 145 g 77 t

ORIGIN

Query Match 86.3%; Score 16.4; DB 161; Length 450;
 Best Local Similarity 94.4%; Pred. No. 1.5e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CGCTCGGCTGTCGCCG 19
 ||||| ||||| ||||| |||||

Db 380 CGCTCGGCCAGTTCGCCG 363

RESULT 5
 AI891550/c
 LOCUS
 DEFINITION ul31e08.xl Sugano mouse kidney mkia Mus musculus cDNA clone
 IMAGE:2099942 3', mRNA sequence.
 ACCESSION AI891550
 VERSION AI891550.1 GI:5597452
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 468)
 AUTHORS Marra, M., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wylie, T.,
 Underwood, K., Steptoe, M., Theising, B., Allen, M., Bowers, X., Person,
 B., Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk, R., Ritter,
 E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R.,
 Waterston, R. and Wilson, R.
 TITLE The WashU-NCI Mouse EST Project 1999
 JOURNAL Unpublished (1999)
 COMMENT Other_ESTs: ul31e08.y1
 Contact: Marra M/WashU-NCI Mouse EST Project 1999
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 MGI:996874
 Seq primer: custom primer used.

FEATURES
 source
 1..468
 /organism="Mus musculus"
 /strain="C57BL"
 /db_xref="taxon:10090"
 /clone="IMAGE:2099942"
 /clone_lib="Sugano mouse kidney mkia"
 /sex="female"
 /dev_stage="adult"
 /lab_host="DH108"
 /note="Organ: Kidney; Vector: pME18S-FL3; Site:1: DraIII
 (CACTGTGTG); Site:2: DraIII (CACCATGTG); 1st strand cDNA
 was primed with an oligo(dT) primer
 [ATGTGGCTTTTTTTTTTTTTTTT]; double-stranded cDNA was
 ligated to a DraIII adaptor [TGTGGCTACTGG], digested
 and cloned into distinct DraIII sites of the pME18S-FL3
 vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
 be used to isolate the cDNA insert. Size selection was
 performed to exclude fragments <1.5kb. Library
 constructed by Dr. Sumio Sugano (University of Tokyo
 Institute of Medical Science). Custom primers for
 sequencing: 5' end primer CTTTGTCTCTAAAGTGGC and 3' end
 primer CGACCTGCAGCTCGAGACA."
 BASE COUNT 107 a 113 c 127 g 121 t
 ORIGIN

Query Match 86.3%; Score 16.4; DB 103; Length 468;
 Best Local Similarity 94.4%; Pred. No. 1.5e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2 CGCTCGGCTGTCGCCG 19
 | ||||| ||||| ||||| |||||

Db 110 CTCTCGGCTGTCGCCG 93

RESULT 6

AI891550/c

LOCUS

DEFINITION

AI891550

VERSION

AI891550.1

KEYWORDS

AI891550.1

ORGANISM

Trypanosoma brucei.

Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;

Trypanosoma.

REFERENCE 1 (bases 1 to 528)

AUTHORS El-Sayed, N., Zhao, S.,

Gerrard, C., Leech, V., de Jong, P., Ullu, E., Melville, S., Donelson, J.,

Fraser, C. and Adams, M.

Other_GSSs: Sheared DNA-16011.TF

Contact: Najib M. El-Sayed

Department of Eukaryotic Genomics

The Institute for Genomic Research

9712 Medical Center Dr., Rockville, MD 20850, USA

Tel: 301 838 0200

Fax: 301 838 0208

Email: nelsayed@tigr.org

Clones are derived from the Trypanosoma brucei GUTat 10.1 sheared

DNA library constructed at TIGR. Clones will be available for

distribution through ATCC. Sheared DNA end sequences search page:

http://www.tigr.org/tldb/mdb/tldb/.

Seq primer: M13-Reverse

Class: shotgun.

Location/Qualifiers

1..528

/organism="Trypanosoma brucei"

/strain="TREU927/4 GUTat 10.1"

/db_xref="taxon:5691"

/clone="Sheared DNA-16011"

/note="Vector: pUC18; Site:1: SmaI; Constructed at The

Institute for Genomic Research (TIGR), Rockville, MD.

Genomic DNA isolated from a cloned population of

Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically

sheared to give a tight size distribution (approx 2 kb).

The v + i method used for the library construction is

described in detail in Smith, H.O. and Venter, J.C.

(Making small insert libraries for whole genome shotgun

sequencing projects. In Genome Sequencing: A Practical

Approach, eds. M. Vaudin and B. Borell, Oxford University

Press, 1999).

BASE COUNT 162 a 122 c 128 g 116 t

ORIGIN

Query Match 86.3%; Score 16.4; DB 209; Length 528;

Best Local Similarity 94.4%; Pred. No. 1.5e+03;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTCGCCG 18

||||| ||||| ||||| |||||

Db 266 GCGCTCAGCCTGTCGCCG 249

RESULT 7

TA70F12Q/c

LOCUS

DEFINITION

TA70F12Q

546 bp DNA

T. brucei sheared genomic DNA clone 70f12, reverse sequence,

genomic survey sequence.

ACCESSION AL458174

```

VERSION      AL458174.1  GI:11859936
KEYWORDS
SOURCE       Trypanosoma brucei.
ORGANISM     Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
             Trypanosoma.
REFERENCE    1 (bases 1 to 546)
AUTHORS      Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R.,
             Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,
             Melville, S.E., Rajandream, M.A. and Barrall, B.G.
TITLE        Direct Submission
JOURNAL
COMMENT      Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
             project, Sanger Centre. The Wellcome Trust Genome Campus, Hinxton,
             Cambridge CB10 1SA, E-mail: barrall@sanger.ac.uk and
             nh@sanger.ac.uk
             Constructed at the Institute for Genomic Research (TIGR),
             Rockville, MD. Genomic DNA isolated from a cloned population of
             Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
             to give a tight size distribution (
             4 kb). The v + i method used for the library construction is
             described in detail in Smith, H. and Venter, J.C. (Making small
             insert libraries for whole genome shotgun sequencing projects. In
             Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
             Barrall, Oxford University Press, 1999).
             Email: nelsayed@tigr.org
             Details of T. brucei sequencing at the Sanger Centre are available
             at http://www.sanger.ac.uk/Projects/T_brucei/.
FEATURES     Location/Qualifiers
             source
               1..546
               /organism="Trypanosoma brucei"
               /strain="TREU927"
               /db_xref="taxon:5691"
               /clone="70f12"
BASE COUNT   152 a 149 c 134 g 111 t
ORIGIN
Query Match      86.3%; Score 16.4; DB 233; Length 546;
Best Local Similarity 94.4%; Pred. No. 1.5e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGGTCCCG 18
      ||||| ||||| |||||
Db 460 GCGCTCAGCTGGTCCCG 443

RESULT 8
LOCUS    BF189303 547 bp mRNA EST 02-NOV-2000
DEFINITION 234766 MARC 2P1G Sus scrofa cDNA 5', mRNA sequence.
ACCESSION BF189303
VERSION BF189303.1 GI:11072672
KEYWORDS EST.
SOURCE    pig.
ORGANISM  Sus scrofa
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 547)
AUTHORS    Fahrenkrug, S.C., Freking, B.A., Rohrer, G.A., Smith, T.P.L., Casas, E.,
             Stone, R.T., Heaton, M.P., Grosse, W.M., Bennett, G.A., Laegreid, W.W.
             and Keele, J.W.
TITLE      Design and use of two pooled tissue normalized cDNA libraries for
             EST discovery in swine
JOURNAL    Unpublished (2000)
COMMENT    Contact: Smith TPL
             USDA, ARS, US Meat Animal Research Center
             PO Box 166, Clay Center, NE 68933-0166, USA
             Tel: 402 762 4366
             Fax: 402 762 4390
             Email: smith@mail.marc.usda.gov
             Single pass sequencing. Bases called and alt_trimmed with phred
             v0.980904.e. Vector identified by cross_match with the -minscore 18
             and -minmatch 12 options.

```

```

PCR Primers
FORWARD: AGGAACAGCTATGACCAT
BACKWARD: GTTTCCTCAGTCAGCAG
Plate: 57 row: B column: 1
Seq primer: ATTTAGGTGACACTATAG.
FEATURES     Location/Qualifiers
             source
               1..547
               /organism="Sus scrofa"
               /db_xref="taxon:9823"
               /clone_lib="MARC 2P1G"
               /tissue_type="pooled"
               /lab_host="DH10B"
               /note="vector: pCMV SPORT6; Site.1: XbaI; Site.2: XhoI;
             Library made from pooled tissue from testis, ovary,
             endometrium, hypothalamus, pituitary, and placenta."
BASE COUNT   90 a 176 c 174 g 107 t
ORIGIN
Query Match      86.3%; Score 16.4; DB 145; Length 547;
Best Local Similarity 94.4%; Pred. No. 1.5e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CGCTCGCGCTGGTCCCG 19
      ||||| ||||| |||||
Db 145 CGCTCGCGCAGTCCCG 128

RESULT 9
LOCUS    BE730153 1086 bp mRNA EST 15-SEP-2000
DEFINITION 601560672F1 NIH_MGC_20 Homo sapiens cDNA clone IMAGE:3830632 5',
             mRNA sequence.
ACCESSION BE730153
VERSION BE730153.1 GI:10144145
KEYWORDS EST.
SOURCE    human.
ORGANISM  Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1086)
AUTHORS    NIH-MGC http://mgc.nci.nih.gov/.
TITLE      National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL    Unpublished (1999)
COMMENT    Contact: Robert Strausberg, Ph.D.
             Tel: (301) 496-1550
             Email: Robert_Strausberg@nih.gov
             Tissue Procurement: ATCC/DCTD/DTp
             CDNA Library Preparation: Ling Hong/Rubin Laboratory
             CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
             DNA Sequencing by: Incyte Genomics, Inc.
             Clone distribution: MGC clone distribution information can be
             found through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov
             Plate: LLCM504 row: O column: 17
             High quality sequence start: 125
             High quality sequence stop: 593.
FEATURES     Location/Qualifiers
             source
               1..1086
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /clone="IMAGE:3830632"
               /clone_lib="NIH_MGC_20"
               /tissue_type="melanotic melanoma"
               /lab_host="DH10B (phage-resistant)"
               /note="Organ: skin; Vector: pOTB7; Site.1: XhoI; Site.2:
             EcoRI; CDNA made by oligo-dT priming. Directionally
             cloned into EcoRI/XhoI sites using the following 5'
             adaptor: GGCACGAG(G). Size-selected >500bp for average
             insert size 1.8kb. Library constructed by Ling Hong in
             the laboratory of Gerald M. Rubin (University of
             California, Berkeley) using ZAP-cDNA synthesis kit
             (Stratagene) and Superscript II RT (Life Technologies)."
BASE COUNT   147 a 403 c 351 g 185 t

```

```

ORIGIN

Query Match      86.3%; Score 16.4; DB 138; Length 1086;;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GCGTCGGCCTGCTCCCG 18
|||||
Db 609 GCGCGCGCCTGCTCCCG 626

RESULT 10
BF268451
LOCUS
DEFINITION
GA_Eb0001N06f Gossypium arboreum 7-10 dpa fiber library Gossypium
arboreum cDNA clone GA_Eb0001N06f, mRNA sequence.
BF268451
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Gossypium arboreum.
Gossypium arboreum
Gossypium arboreum
Eukaryota; Viridiplantae; Embryophyta; Tracheophyta; Spermatophyta;
Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids II;
Malvales; Malvaceae; Gossypium.
1 (bases 1 to 490)
Wing,R.A., Frisch,D., Yu,Y., Main,D., Rambo,T., Simmons,J., Henry
,D., Wood,T.C., Leslie,A. and Wilkins,T.A.
An integrated analysis of the genetics, development, and evolution
of the cotton fiber
Unpublished (2000)
Contact: Wing RA
Clemson University
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: TAATACGACTCACTATAGGG
High quality sequence start: 23
High quality sequence stop: 466.
High quality sequence stop: 466.
Location/Qualifiers
1..490
/organism="Gossypium arboreum"
/strain="AKA"
/cultivar="8400"
/db_xref="taxon:29729"
/clone="GA_Eb0001N06f"
/clone_lib="Gossypium arboreum 7-10 dpa fiber library"
/tissue_type="Fibers isolated from bolls harvested 7-10
dpa"
/lab_host="F. coli"
/note="Vector: pBK-CMV; Site_1: EcoRI; Site_2: XhoI"

BASE COUNT 90 a 196 c 77 g 126 t 1 others
ORIGIN

Query Match      84.2%; Score 16; DB 146; Length 490;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCTCGGCCTGCTCCCG 18
|||||
Db 440 GCTCGGCCTGCTCCCG 455

RESULT 11
BF741923/c
LOCUS
DEFINITION
601593721F1 NIH_MGC_9 Homo sapiens cDNA clone IMAGE:3947620 5',
mRNA sequence.
BF741923
ACCESSION
VERSION
BF741923.1 GI:10155915

ORIGIN

```


IMAGE:3975209 5', mRNA sequence.
ACCESSION BF721315
VERSION BF721315.1 GI:12022317
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 127)
AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:1475241

Seq primer: -40RP from Gibco.
FEATURES
Location/Qualifiers
1..127
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="IMAGE:3975209"
/clone_lib="Soares_thymus_2NDMT"
/sex="male"
/tissue_type="Thymus"
/dev_stage="4 weeks"
/lab_host="DH10B"
/note="Vector: pT7T3D-pac (Pharmacia) with a modified
polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
was primed with a Not I - oligo(dT) primer [5'
TCTTACCAATCTGAAGTCGACGCGCGGTTTTTTTTTTTTTTTTTTT
3']; double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT7T3 vector, RNA
provided by Dr. Bertrand Jordan. Library went through two
rounds of normalization, and was constructed by Bento
Soares and M.Fatima Bonaldo."

BASE COUNT 20 a 49 c 48 g 10 t
ORIGIN

Query Match 83.2%; Score 15.8; DB 168; Length 127;
Best Local Similarity 89.5%; Pred. No. 3.1e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCCTCGGCTGTGTCCTCGG 19
|||||
Db 41 GCCTCGGCTGTGTCCTCGG 23

Search completed: April 19, 2001, 23:25:06
Job time: 8183 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:03:47 ; Search time 280.46 Seconds
(without alignments)
11.829 Million cell updates/sec

Title: US-09-016-464-20

Perfect score: 19

Sequence: 1 GCCTCGGCGCTGTCCGG 19

Scoring table:

IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 302621 seqs, 87301344 residues

Total number of hits satisfying chosen parameters: 605242

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued_Patents_NA.*
1: /cgn2_6/ptodata/2/ina/5A_COMB.seq.*
2: /cgn2_6/ptodata/2/ina/5B_COMB.seq.*
3: /cgn2_6/ptodata/2/ina/6A_COMB.seq.*
4: /cgn2_6/ptodata/2/ina/6B_COMB.seq.*
5: /cgn2_6/ptodata/2/ina/PCTUS_COMB.seq.*
6: /cgn2_6/ptodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	%	Query Match	Length	ID	Description
1	15.8	83.2	1185	2	US-08-628-039-9	Sequence 9, Appli
2	15.8	83.2	1185	3	US-08-912-205-9	Sequence 9, Appli
3	15.8	83.2	1401	1	US-07-843-949A-3	Sequence 3, Appli
4	15.8	83.2	1401	2	US-08-218-978-3	Sequence 3, Appli
5	15.8	83.2	9960	3	US-08-822-586-46	Sequence 46, Appli
6	15.8	83.2	20235	1	US-07-642-734C-3	Sequence 3, Appli
7	15.8	83.2	20235	3	US-08-439-009A-3	Sequence 3, Appli
8	15.8	83.2	35081	2	US-08-752-760A-1	Sequence 1, Appli
9	15.4	81.1	3293	2	US-08-442-809A-75	Sequence 75, Appli
10	14.8	77.9	24	3	US-08-840-316-93	Sequence 93, Appli
11	14.8	77.9	24	4	US-08-809-523-93	Sequence 93, Appli
12	14.8	77.9	24	5	PCT-US93-08849A-93	Sequence 93, Appli
13	14.8	77.9	24	1	PCT-US93-08849-93	Sequence 93, Appli
14	14.8	77.9	99	1	US-08-240-049B-9	Sequence 9, Appli
15	14.8	77.9	99	5	PCT-US95-13703-11	Sequence 11, Appli
16	14.8	77.9	102	1	US-08-259-148A-11	Sequence 11, Appli
17	14.8	77.9	102	1	US-08-484-054-11	Sequence 11, Appli
18	14.8	77.9	102	2	US-07-876-941A-11	Sequence 11, Appli
19	14.8	77.9	372	1	US-08-240-049B-3	Sequence 3, Appli
20	14.8	77.9	372	5	PCT-US95-13703-9	Sequence 9, Appli
21	14.8	77.9	1457	4	US-09-444-053-3	Sequence 3, Appli
22	14.8	77.9	1554	1	US-08-469-486-1	Sequence 1, Appli
23	14.8	77.9	1554	2	US-08-469-658-1	Sequence 1, Appli
24	14.8	77.9	1983	1	US-08-240-049B-1	Sequence 1, Appli
25	14.8	77.9	2049	1	US-08-259-148A-3	Sequence 3, Appli
26	14.8	77.9	2049	1	US-08-484-054-3	Sequence 3, Appli
27	14.8	77.9	2049	2	US-07-876-941A-3	Sequence 3, Appli

c 28	14.8	77.9	2049	5	PCT-US95-13703-1	Sequence 1, Appli
c 29	14.8	77.9	2094	1	US-08-259-148A-1	Sequence 1, Appli
c 30	14.8	77.9	2094	1	US-08-484-054-1	Sequence 1, Appli
c 31	14.8	77.9	2094	2	US-07-876-941A-1	Sequence 1, Appli
c 32	14.8	77.9	7168	3	US-08-840-316-4	Sequence 4, Appli
c 33	14.8	77.9	7168	4	US-08-809-523-4	Sequence 4, Appli
c 34	14.8	77.9	7168	5	PCT-US93-08849A-4	Sequence 4, Appli
c 35	14.8	77.9	7168	5	PCT-US93-08849-4	Sequence 4, Appli
c 36	14.8	77.9	7195	4	US-08-478-507-6	Sequence 6, Appli
c 37	14.8	77.9	14636	4	US-09-173-914-6	Sequence 6, Appli
c 38	14.8	77.9	30001	1	US-08-125-468-1	Sequence 1, Appli
c 39	14.8	77.9	30001	2	US-08-474-933-1	Sequence 1, Appli
c 40	14.4	75.8	525	3	US-08-911-853-18	Sequence 18, Appli
c 41	14.4	75.8	1288	2	US-08-743-637B-171	Sequence 171, App
c 42	14.4	75.8	1288	3	US-08-526-840B-171	Sequence 171, App
c 43	14.4	75.8	7171	4	US-08-478-507-10	Sequence 10, Appli
c 44	14.4	75.8	7210	2	US-08-257-963B-10	Sequence 10, Appli
c 45	14.4	75.8	7210	5	PCT-US95-07201-10	Sequence 10, Appli

ALIGNMENTS

RESULT 1
US-08-628-039-9
; Sequence 9, Application US/08628039
; Patent No. 5942660
; GENERAL INFORMATION:
; APPLICANT: Gruys, Kenneth J.
; APPLICANT: Mitsky, Timothy A.
; APPLICANT: Kishore, Ganesh M.
; APPLICANT: Slater, Steven C.
; APPLICANT: Padgett, Stephen R.
; APPLICANT: Stark, David M.
; APPLICANT: Hinchee, Maud A. W.
; APPLICANT: Clemente, Thomas E.
; APPLICANT: Connor-Ward, Dannette V.
; APPLICANT: Fedele, Mary J.
; APPLICANT: Fry, Joyce E.
; APPLICANT: Howe, Arlene R.
; APPLICANT: Rozman, Renee J.
; TITLE OF INVENTION: Methods of Optimizing Substrate Pools and
; TITLE OF INVENTION: Biosynthesis of Poly-B-hydroxybutyrate-co-poly-B-hydroxyval
; TITLE OF INVENTION: in Bacteria and Plants
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Gary M. Bond, Monsanto Company, A3SB
; STREET: 800 No. 5942660th Lindbergh Boulevard
; CITY: St. Louis
; STATE: Missouri
; COUNTRY: USA
; ZIP: 63167
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/628,039
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE: 13-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Bond, Gary
; REGISTRATION NUMBER: 29,283
; REFERENCE/DOCKET NUMBER: 38-21(13585)A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (314)694-3412
; TELEFAX: (314)695-5435
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:

```
; LENGTH: 1185 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-628-039-9

Query Match      83.2%; Score 15.8; DB 2; Length 1185;
Best Local Similarity 89.5%; Pred. No. 74;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGTCGCCGG 19
    ||||| ||||| |||||
Db 991 GCGCTCGGCTGTCGCCGG 1009

RESULT 2
US-08-912-205-9
; Sequence 9, Application US/08912205
; Patent No. 6091002
; GENERAL INFORMATION:
; APPLICANT: Asrar, Jawed
; APPLICANT: Mitsky, Timothy A.
; APPLICANT: Shah, Devang T.
; TITLE OF INVENTION: Polyhydroxyalkanoates of narrow molecular
; weight distribution prepared in transgenic plants
; NUMBER OF SEQUENCES: 11
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION NUMBER: US/08/912.205
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/673.388
; FILING DATE: 28-JUN-1996
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1185 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-912-205-9

Query Match      83.2%; Score 15.8; DB 3; Length 1185;
Best Local Similarity 89.5%; Pred. No. 74;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGTCGCCGG 19
    ||||| ||||| |||||
Db 991 GCGCTCGGCTGTCGCCGG 1009

RESULT 3
US-07-843-949A-3
; Sequence 3, Application US/07843949A
; Patent No. 5340935
; GENERAL INFORMATION:
; APPLICANT: Anderson, Paul J.
; APPLICANT: Streuli, Michel
; APPLICANT: Schlossman, Stuart F.
; TITLE OF INVENTION: DNAS ENCODING PROTEINS ACTIVE IN
; LYMPHOCYTE-MEDIATED CYTOTOXICITY
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
```

```
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/843.949A
; FILING DATE: 19920219
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/460.678
; FILING DATE: January 5, 1990
; APPLICATION NUMBER: 07/726.607
; FILING DATE: July 10, 1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Fraser, Janis K.
; REGISTRATION NUMBER: 34,819
; REFERENCE/DOCKET NUMBER: 00530/021003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1401
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-07-843-949A-3

Query Match      83.2%; Score 15.8; DB 1; Length 1401;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGTCGCCGG 19
    || ||||| ||||| |||||
Db 6 GCGCTCGGCTGTCGCCGG 24

RESULT 4
US-08-218-978-3
; Sequence 3, Application US/08218978
; Patent No. 5837811
; GENERAL INFORMATION:
; APPLICANT: Anderson, Paul J.
; APPLICANT: Streuli, Michel
; APPLICANT: Schlossman, Stuart F.
; TITLE OF INVENTION: DNAS ENCODING PROTEINS ACTIVE IN
; LYMPHOCYTE-MEDIATED CYTOTOXICITY
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/218.978
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/843.949
```


; FILING DATE: February 19, 1992
 ; APPLICATION NUMBER: 07/460.678
 ; FILING DATE: January 5, 1990
 ; APPLICATION NUMBER: 07/726.607
 ; FILING DATE: July 10, 1991
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Fraser, Janis K.
 ; REGISTRATION NUMBER: 34,819
 ; REFERENCE/DOCKET NUMBER: 00530/021003
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (617) 542-5070
 ; TELEFAX: (617) 542-8906
 ; TELEX: 200154
 ; INFORMATION FOR SEQ ID NO: 3:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 1401
 ; TYPE: nucleic acid
 ; STRANDEDNESS: double
 ; TOPOLOGY: linear
 ;
 US-08-218-978-3

Query Match 83.2%; Score 15.8; DB 2; Length 1401;
 Best Local Similarity 89.5%; Pred. No. 73;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGGCGTGTCCCGG 19
 ||||||| |||||
 Db 6 GCGCTCGGCGTGTCCCGG 24

RESULT 5
 US-08-822-586-46
 ; Sequence 46, Application US/08822586
 ; Patent No. 6015890
 ; GENERAL INFORMATION:
 ; APPLICANT: WILLIAM R. JACOBS, JR., JAMES M. MUSSER AND
 ; APPLICANT: AMALIO TELENTI
 ; TITLE OF INVENTION: AN EMBAC OPERON OF MYCOBACTERIA AND
 ; TITLE OF INVENTION: MUTANTS THEREOF
 ; NUMBER OF SEQUENCES: 57
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: AMSTER, ROTHSTEIN & EBENSTEIN
 ; STREET: 90 PARK AVENUE
 ; CITY: NEW YORK
 ; STATE: NEW YORK
 ; COUNTRY: U.S.A.
 ; ZIP: 10016

; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5 INCH 1.44 Mb STORAGE
 ; MEDIUM TYPE: DISKETTE
 ; COMPUTER: IBM PC COMPATIBLE
 ; OPERATING SYSTEM: MS-DOS
 ; SOFTWARE: ASCII
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/822.586
 ; FILING DATE: MARCH 20, 1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: ELIZABETH A. BOGOSTAN
 ; REGISTRATION NUMBER: 39,911
 ; REFERENCE/DOCKET NUMBER: 96700/437
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212) 697-5995
 ; TELEFAX: (212) 286-0854 or 286-0082
 ; TELEX: TWX 710-581-4766
 ; INFORMATION FOR SEQ ID NO: 46:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 9960
 ; TYPE: nucleic acid
 ; STRANDEDNESS: double
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: Genomic DNA
 ; HYPOTHETICAL: NO

US-08-822-586-46

Query Match 83.2%; Score 15.8; DB 3; Length 9960;
 Best Local Similarity 89.5%; Pred. No. 62;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGGCGTGTCCCGG 19
 ||||||| ||||| |||||
 Db 2655 GCGCTCGGCGTGTCCCGG 2673

RESULT 6
 US-07-642-734C-3
 ; Sequence 3, Application US/07642734C
 ; Patent No. 5824513
 ; GENERAL INFORMATION:
 ; APPLICANT: Katz, L
 ; APPLICANT: Donadio, S
 ; APPLICANT: Mcalpine, J B
 ; TITLE OF INVENTION: Recombinant DNA Method for Producing
 ; TITLE OF INVENTION: Erythromycin Analogs
 ; NUMBER OF SEQUENCES: 27
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Edward H. Gorman
 ; STREET: Abbott Laboratories D377/AP6D-2 One Abbott
 ; STREET: Park Rd
 ; CITY: Abbott Park
 ; STATE: IL
 ; COUNTRY: US
 ; ZIP: 60064-3500
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patentin Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/07/642.734C
 ; FILING DATE: 17-JAN-91
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Danckers, Andreas M
 ; REGISTRATION NUMBER: 32652
 ; REFERENCE/DOCKET NUMBER: 4952.US.01
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 708-937-9396
 ; TELEFAX: 708-938-2623
 ; INFORMATION FOR SEQ ID NO: 3:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 2035 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: double
 ; TOPOLOGY: unknown
 ; MOLECULE TYPE: DNA (genomic)
 ; HYPOTHETICAL: NO
 ; ANTI-SENSE: NO
 ; ORIGINAL SOURCE:
 ; ORGANISM: Saccharopolyspora erythraea
 ; STRAIN: NRRL 238
 ; FEATURE:
 ; NAME/KEY: CDS
 ; LOCATION: 19..10722
 ; OTHER INFORMATION: /codon_start= 19
 ; OTHER INFORMATION: /function= "gene eryA"
 ; OTHER INFORMATION: /product= "eryA ORF2 encoding modules 3 & 4 for
 ; OTHER INFORMATION: 6-deoxyerythronolide B"
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: 19..4470
 ; OTHER INFORMATION: /function= "approximate span of
 ; OTHER INFORMATION: module 3"
 ; FEATURE:
 ; NAME/KEY: misc_feature

```

; LOCATION: 97..1482
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: beta-ketoacyl ACP synthase of module 3"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1693..2670
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: acyltransferase domain module 3"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 3406..3921
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: beta-ketoreductase domain of module 3"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 4171..4428
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: acyl carrier domain of module 3"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 4471..10722
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: module 4"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 4471..5847
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: beta-ketoacylACPSynthase domain of module"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 6054..7026
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: acyltransferase domain of module 4"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 7165..9216
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: dehydratase and enoylreductase domains m"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 9433..9984
; OTHER INFORMATION: /function= "approximate span
; OTHER INFORMATION: beta-ketoreductase of module 4"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 10225..10483
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: acyl carrier domain of module 4"
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 10723..20235
; OTHER INFORMATION: /codon_start= 10723
; OTHER INFORMATION: /function= "gene -eryA"
; OTHER INFORMATION: /product= "orf3 encoding modules 5 & 6
; OTHER INFORMATION: 6-deoxyerythronolide B formatio"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 10723..15165
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: module 5"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 10831..12174
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: beta-ketoacylACPSynthase domain of modul"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 12379..13350
; OTHER INFORMATION: /function= "approximatr span of
; OTHER INFORMATION: acyltransferase domain of module 5"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 14062..14610

```

```

; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: beta-ketoreductase of module 5"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 14857..15114
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: acyl carrier domain of module 5"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 15166..20235
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: module 6"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 15172..16569
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: beta-ketoacylACPSynthase domain of modul"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 16768..17721
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: acyltransferase domain of module 6"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 18379..18921
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: beta-ketoreductase domain of module 6"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19149..19398
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: acyl carrier domain of module 6"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19492..20235
; OTHER INFORMATION: /function= "approximate span of
; OTHER INFORMATION: thioesterase domain of module 6"
; US-07-642-734C-3

Query Match      83.2%; Score 15.8; DB 1; Length 20235;
Best Local Similarity 89.5%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCGCTGGTCCCGG 19
    ||||| ||||| ||||| ||
Db 13732 GCGCTCGGCGCTGGTCCAGG 13750

RESULT 7
US-08-439-009A-3
; Sequence 3, Application US/08439009A
; Patent No. 6004787
; GENERAL INFORMATION:
; APPLICANT: Donadio, S
; APPLICANT: Katz, L
; APPLICANT: Mcalpine, J B
; TITLE OF INVENTION: Method of Directing Biosynthesis of
; TITLE OF INVENTION: Specific Polyketides
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Steven F. Weinstein
; STREET: Abbott Laboratories D377/AP6D-2 One Abbott
; STREET: Park Rd
; CITY: Abbott Park
; STATE: IL
; COUNTRY: US
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

```

```

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/439,009A
FILING DATE: 11-MAY-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Casuto, Dianne
REGISTRATION NUMBER: 40,943
REFERENCE/DOCKET NUMBER: 4952.US.D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 847-938-3137
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20235 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Saccharopolyspora erythraea
STRAIN: NRRL 238
FEATURE:
NAME/KEY: CDS
LOCATION: 19..10722
OTHER INFORMATION: /codon_start= 19
OTHER INFORMATION: /function= "gene eryA"
OTHER INFORMATION: /product= "eryA ORF2 encoding modules 3 & 4 for
OTHER INFORMATION: 6-deoxyerythronolide B"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19..4470
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: module 3"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 97..1482
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: beta-ketoacyl ACP synthase of module 3"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1693..2670
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyltransferase domain module 3"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 3406..3921
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: beta-ketoreductase domain of module 3"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 4171..4428
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyl carrier domain of module 3"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 4471..10722
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: module 4"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 4471..5847
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: beta-ketoacylACPsynthase domain of module"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 6054..7026
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyltransferase domain of module 4"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 7165..9216
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: thioesterase domain of module 6"
OTHER INFORMATION: dehydratase and enoylreductase domains m"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 9433..9984
OTHER INFORMATION: /function= "approximate span
OTHER INFORMATION: beta-ketoreductase of module 4"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10225..10483
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyl carrier domain of module 4"
FEATURE:
NAME/KEY: CDS
LOCATION: 10723..20235
OTHER INFORMATION: /codon_start= 10723
OTHER INFORMATION: /function= "gene eryA"
OTHER INFORMATION: /product= "orf3 encoding modules 5 & 6
OTHER INFORMATION: 6-deoxyerythronolide B formatio"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10723..15165
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: module 5"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10831..12174
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: beta-ketoacylACPsynthase domain of modul"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 12379..13350
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyltransferase domain of module 5"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 14062..14610
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: beta-ketoreductase of module 5"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 14857..15114
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyl carrier domain of module 5"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 15166..20235
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: module 6"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 15172..16569
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: beta-ketoacylACPsynthase domain of modul"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 16768..17721
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyltransferase domain of module 6"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 18379..18921
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: beta-ketoreductase domain of module 6"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19149..19398
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: acyl carrier domain of module 6"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19492..20235
OTHER INFORMATION: /function= "approximate span of
OTHER INFORMATION: thioesterase domain of module 6"
```

US-08-439-009A-3

Query Match 83.2%; Score 15.8; DB 3; Length 20235;
Best Local Similarity 89.5%; Pred. No. 50;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19
||||| ||||| ||

Db 13732 GCGCTCGGCTGGTCCAGG 13750

RESULT 8

US-08-752-760A-1
; Sequence 1, Application US/08752760A
; Patent No. 5877011
; GENERAL INFORMATION:
; APPLICANT: Armentano, Donna
; APPLICANT: Gregory, Richard J.
; APPLICANT: Smith, Alan E.
; TITLE OF INVENTION: CHIMERIC ADENOVIRAL VECTORS
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Baker & Botts, L.L.P.
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: NY
; COUNTRY: U.S.A.
; ZIP: 10112

COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/752.760A
; FILING DATE: 20-NOV-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Seide, Rochelle K
; REGISTRATION NUMBER: 32,300
; REFERENCE/DOCKET NUMBER: A31385
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-705-5000
; TELEFAX: 212-705-5020
; TELEX:

; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35081 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-752-760A-1

Query Match 83.2%; Score 15.8; DB 2; Length 35081;
Best Local Similarity 89.5%; Pred. No. 55;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19
||||| ||||| ||

Db 8391 GCGCTCGGCGAGTCCCGG 8409

RESULT 9

US-08-442-809A-75
; Sequence 75, Application US/08442809A
; Patent No. 5976873
; GENERAL INFORMATION:
; APPLICANT: Bohlnski, Robert J.,

; APPLICANT: Whitsett, Jeffrey A.
; TITLE OF INVENTION: Nucleic Acid Sequences
; TITLE OF INVENTION: Controlling Lung Cell -
; TITLE OF INVENTION: Specific Gene Expression
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/442.809A
; FILING DATE: 17-MAY-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245.356
; FILING DATE: 18-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 271010-360
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 75:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3293 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
; FEATURE:
; NAME/KEY: human TTF-1 gene
US-08-442-809A-75

Query Match 81.1%; Score 15.4; DB 2; Length 3293;
Best Local Similarity 94.1%; Pred. No. 99;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3 GCTCGGCTGGTCCCGG 19
||||| ||||| |||||

Db 1631 GCTCGGCTGGCCCGG 1647

RESULT 10

US-08-840-316-93
; Sequence 93, Application US/08840316
; Patent No. 6054567
; GENERAL INFORMATION:
; APPLICANT: Emerson, Suzanne U., Purcell, Robert H.,
; APPLICANT: Tsarev, Sergei. A., and Robinson, Robin A.
; TITLE OF INVENTION: Recombinant Proteins Of
; TITLE OF INVENTION: A Pakistani Strain Of Hepatitis E And Their
; TITLE OF INVENTION: Use In Diagnostic Methods And Vaccines
; NUMBER OF SEQUENCES: 111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK

COMPUTER: IBM PC COMPATIBLE
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WORDPERFECT 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/840,316
 FILING DATE: 11-APR-1997
 CLASSIFICATION: 424
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: Richard W. Bork
 REGISTRATION NUMBER: 36,459
 REFERENCE/DOCKET NUMBER: 2026-4255
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 758-4800
 TELEFAX: (212) 751-6849
 INFORMATION FOR SEQ ID NO: 93:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 24 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-840-316-93

Query Match 77.9%; Score 14.8; DB 3; Length 24;
 Best Local Similarity 88.9%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCG 18
 ||||| ||||| ||||| ||
 Db 2 GCGCTGGGCTGGTCACG 19

RESULT 11
 US-08-809-523-93
 Sequence 93, Application US/08809523
 Patent No. 6207416
 GENERAL INFORMATION:
 APPLICANT: Tsarev, Sergei. A., Emerson,
 APPLICANT: Suzanne U., Purcell, Robert H.
 TITLE OF INVENTION: Recombinant Proteins Of
 TITLE OF INVENTION: A Pakistani Strain Of Hepatitis E And Their
 NUMBER OF SEQUENCES: 107
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
 STREET: 345 PARK AVENUE
 CITY: NEW YORK
 STATE: NEW YORK
 COUNTRY: USA
 ZIP: 10154
 COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY DISK
 COMPUTER: IBM PC COMPATIBLE
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WORDPERFECT 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/809,523
 FILING DATE: 28-MAY-1997
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/13102
 FILING DATE: 03-OCT-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US08/316,765
 FILING DATE: 03-OCT-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/947,263
 FILING DATE: 18-SEP-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Richard W. Bork

REGISTRATION NUMBER: 36,459
 REFERENCE/DOCKET NUMBER: 2026-40320S4
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 758-4800
 TELEFAX: (212) 751-6849
 INFORMATION FOR SEQ ID NO: 93:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 24 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-809-523-93

Query Match 77.9%; Score 14.8; DB 4; Length 24;
 Best Local Similarity 88.9%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCG 18
 ||||| ||||| ||||| ||
 Db 2 GCGCTGGGCTGGTCACG 19

RESULT 12
 PCT-US93-08849A-93
 Sequence 93, Application PC/TUS9308849A
 GENERAL INFORMATION:
 APPLICANT:
 TITLE OF INVENTION: Recombinant Proteins Of
 TITLE OF INVENTION: A Pakistani Strain Of Hepatitis E And Their
 NUMBER OF SEQUENCES: 98
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORGAN & FINNEGAN
 STREET: 345 PARK AVENUE
 CITY: NEW YORK
 STATE: NEW YORK
 COUNTRY: USA
 ZIP: 10154
 COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY DISK
 COMPUTER: IBM PC COMPATIBLE
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: WORDPERFECT 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US93/08849A
 FILING DATE: 17-SEP-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US07/947,263
 FILING DATE: 18-SEP-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: William S. Feiler
 REGISTRATION NUMBER: 26,728
 REFERENCE/DOCKET NUMBER: 2026-4032 PCT
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 758-4800
 TELEFAX: (212) 751-6849
 INFORMATION FOR SEQ ID NO: 93:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 24 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 PCT-US93-08849A-93

Query Match 77.9%; Score 14.8; DB 5; Length 24;
 Best Local Similarity 88.9%; Pred. No. 2.7e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCG 18
 ||||| ||||| ||||| ||
 Db 2 GCGCTGGGCTGGTCACG 19

RESULT 13
PCT-US93-08849-93
; Sequence 93, Application PC/TUS9308849
; GENERAL INFORMATION:
; APPLICANT: Tsarev, Sergei A., Emerson,
; APPLICANT: Suzanne U., Purcell, Robert H.
; TITLE OF INVENTION: Recombinant Proteins Of
; TITLE OF INVENTION: A Pakistani Strain Of Hepatitis E And Their
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & PINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08849
; FILING DATE: 17-SEP-1993
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/947,263
; FILING DATE: 18-SEP-1992
; NAME:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bork, Richard, W.
; REGISTRATION NUMBER: 36,459
; REFERENCE/DOCKET NUMBER: 2026-4032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US93-08849-93

Query Match 77.9%; Score 14.8; DB 5; Length 24;
Best Local Similarity 88.9%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTGGCGCTGGTCCCG 18
||||| ||||| |||
Db 2 GCGCTGGCGCTGGTCCAG 19

RESULT 14
US-08-240-049B-9/c
; Sequence 9, Application US/08240049B
; Patent No. 5686239
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory R.
; APPLICANT: Tam, Albert W.
; TITLE OF INVENTION: Hepatitis E Virus Peptides and Methods
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genelabs Technologies, Inc.
; STREET: 505 Penobscot Drive
; CITY: Redwood City
; STATE: CA
; COUNTRY: USA

ZIP: 94063
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/240.049B
; FILING DATE: 09-MAY-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Charles K. Sholtz
; REGISTRATION NUMBER: 38,615
; REFERENCE/DOCKET NUMBER: 4600-0093.35; G32P4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 99 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)
; INDIVIDUAL ISOLATE: 406.4-2 region
US-08-240-049B-9

Query Match 77.9%; Score 14.8; DB 1; Length 99;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTGGCGCTGGTCCCG 18
||||| ||||| |||
Db 50 GCGCTGGCGCTGGTCCAG 33

RESULT 15
PCT-US95-13703-11/c
; Sequence 11, Application PC/TUS9513703
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: HEPATITIS E VIRUS ANTIGENS AND
; TITLE OF INVENTION: USES THEREFOR
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: P.O. Box 60850
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306-0850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/13703
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0293.41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:

```

; LENGTH: 99 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)
; INDIVIDUAL ISOLATE: 406.4-2 region
; PCT-US95-13703-11

```

```

Query Match      77.9%; Score 14.8; DB 5; Length 99;
Best Local Similarity 88.9%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1 GCGCTGGGCTGGTCCCG 18
Db 50 GCGCTGGGCTGGTCCCG 33

```

```

Search completed: April 20, 2001, 00:03:49
Job time: 9686 sec

```

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 03:21:32 ; Search time 11165 Seconds
(without alignments)
8.860 Million cell updates/sec

Title: US-09-016-464-20

Perfect score: 19

Sequence: 1 GCGTCGCGCTGTCGCCGG 19

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 13168883 seqs, 2603265903 residues

Total number of hits satisfying chosen parameters: 26337766

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending_Patents_NA_Main.*

- 1: /cgn2_6/ptodata/2/pna/ECTUS_COMB.seq.*
- 2: /cgn2_6/ptodata/2/pna/US06_COMB.seq.*
- 3: /cgn2_6/ptodata/2/pna/US07_COMB.seq.*
- 4: /cgn2_6/ptodata/2/pna/US080_COMB.seq.*
- 5: /cgn2_6/ptodata/2/pna/US081_COMB.seq.*
- 6: /cgn2_6/ptodata/2/pna/US082_COMB.seq.*
- 7: /cgn2_6/ptodata/2/pna/US083_COMB.seq.*
- 8: /cgn2_6/ptodata/2/pna/US084_COMB.seq.*
- 9: /cgn2_6/ptodata/2/pna/US085_COMB.seq.*
- 10: /cgn2_6/ptodata/2/pna/US086_COMB.seq.*
- 11: /cgn2_6/ptodata/2/pna/US087_COMB.seq.*
- 12: /cgn2_6/ptodata/2/pna/US088_COMB.seq.*
- 13: /cgn2_6/ptodata/2/pna/US089_COMB.seq.*
- 14: /cgn2_6/ptodata/2/pna/US090_COMB.seq.*
- 15: /cgn2_6/ptodata/2/pna/US091_COMB.seq.*
- 16: /cgn2_6/ptodata/2/pna/US092_COMB.seq.*
- 17: /cgn2_6/ptodata/2/pna/US093_COMB.seq.*
- 18: /cgn2_6/ptodata/2/pna/US094_COMB.seq.*
- 19: /cgn2_6/ptodata/2/pna/US095A_COMB.seq.*
- 20: /cgn2_6/ptodata/2/pna/US095B_COMB.seq.*
- 21: /cgn2_6/ptodata/2/pna/US095C_COMB.seq.*
- 22: /cgn2_6/ptodata/2/pna/US095D_COMB.seq.*
- 23: /cgn2_6/ptodata/2/pna/US096A_COMB.seq.*
- 24: /cgn2_6/ptodata/2/pna/US096B_COMB.seq.*
- 25: /cgn2_6/ptodata/2/pna/US096C_COMB.seq.*
- 26: /cgn2_6/ptodata/2/pna/US096D_COMB.seq.*
- 27: /cgn2_6/ptodata/2/pna/US096E_COMB.seq.*
- 28: /cgn2_6/ptodata/2/pna/US097A_COMB.seq.*
- 29: /cgn2_6/ptodata/2/pna/US097B_COMB.seq.*
- 30: /cgn2_6/ptodata/2/pna/US097C_COMB.seq.*
- 31: /cgn2_6/ptodata/2/pna/US097D_COMB.seq.*
- 32: /cgn2_6/ptodata/2/pna/US097E_COMB.seq.*
- 33: /cgn2_6/ptodata/2/pna/US097F_COMB.seq.*
- 34: /cgn2_6/ptodata/2/pna/US097G_COMB.seq.*
- 35: /cgn2_6/ptodata/2/pna/US097H_COMB.seq.*
- 36: /cgn2_6/ptodata/2/pna/US097I_COMB.seq.*
- 37: /cgn2_6/ptodata/2/pna/US097J_COMB.seq.*
- 38: /cgn2_6/ptodata/2/pna/US097K_COMB.seq.*
- 39: /cgn2_6/ptodata/2/pna/US097L_COMB.seq.*
- 40: /cgn2_6/ptodata/2/pna/US097M_COMB.seq.*
- 41: /cgn2_6/ptodata/2/pna/US097N_COMB.seq.*
- 42: /cgn2_6/ptodata/2/pna/US097O_COMB.seq.*
- 43: /cgn2_6/ptodata/2/pna/US097P_COMB.seq.*

- 44: /cgn2_6/ptodata/2/pna/US6012_COMB.seq.*
- 45: /cgn2_6/ptodata/2/pna/US6013_COMB.seq.*
- 46: /cgn2_6/ptodata/2/pna/US6014_COMB.seq.*
- 47: /cgn2_6/ptodata/2/pna/US6015_COMB.seq.*
- 48: /cgn2_6/ptodata/2/pna/US6016_COMB.seq.*
- 49: /cgn2_6/ptodata/2/pna/US6017_COMB.seq.*
- 50: /cgn2_6/ptodata/2/pna/US6018_COMB.seq.*
- 51: /cgn2_6/ptodata/2/pna/US6019_COMB.seq.*
- 52: /cgn2_6/ptodata/2/pna/US6020_COMB.seq.*
- 53: /cgn2_6/ptodata/2/pna/US6021_COMB.seq.*
- 54: /cgn2_6/ptodata/2/pna/US6022_COMB.seq.*
- 55: /cgn2_6/ptodata/2/pna/US6023_COMB.seq.*
- 56: /cgn2_6/ptodata/2/pna/US6024_COMB.seq.*
- 57: /cgn2_6/ptodata/2/pna/US6025_COMB.seq.*
- 58: /cgn2_6/ptodata/2/pna/US6026_COMB.seq.*
- 59: /cgn2_6/ptodata/2/pna/US6027_COMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	100.0	19	8	US-08-474-497-20
2	19	100.0	19	14	US-09-016-464-20
3	19	100.0	19	19	US-09-509-152A-1061
4	19	100.0	60	19	US-09-509-152A-1071
5	19	100.0	272	19	US-09-509-152A-1739
6	19	100.0	367	18	US-09-496-911-3525
7	19	100.0	454	17	US-09-306-350A-2131
8	19	100.0	465	17	US-09-306-350A-1791
9	19	100.0	468	17	US-09-306-350A-2747
10	19	100.0	470	48	US-60-169-840-164
11	19	100.0	520	24	US-09-637-888-5196
12	19	100.0	523	49	US-60-170-373-1322
13	19	100.0	2079	54	US-60-226-176-976
14	19	100.0	2079	55	US-60-233-468-976
15	19	100.0	2109	54	US-60-226-176-973
16	19	100.0	2109	55	US-60-233-468-973
17	19	100.0	2524	54	US-60-226-176-975
18	19	100.0	2524	55	US-60-233-468-975
19	19	100.0	2558	54	US-60-226-176-972
20	19	100.0	2558	55	US-60-233-468-972
21	19	100.0	2599	18	US-09-496-914A-5820
22	19	100.0	2718	25	US-09-652-121-6848
23	19	100.0	2718	25	US-09-652-124-9476
24	19	100.0	2718	25	US-09-652-814-9544
25	19	100.0	2718	29	US-09-736-119-1873
26	19	100.0	2732	49	US-60-172-373-15079
27	19	100.0	7033	19	US-09-509-152A-2411
28	19	100.0	162083	54	US-60-226-176-974
29	19	100.0	162083	55	US-60-233-468-974
30	17.4	91.6	425	48	US-60-169-840-304
31	17	89.5	237	17	US-09-304-517A-149744
32	17	89.5	963	25	US-09-652-124-8079
33	17	89.5	963	25	US-09-652-911-8273
34	16.4	86.3	250	25	US-09-654-617-380642
35	16.4	86.3	250	27	US-09-684-016-380642
36	16.4	86.3	533	52	US-60-209-830-3878
37	16.4	86.3	142530	53	US-60-212-664-303
38	16	84.2	246	17	US-09-304-517A-148348
39	16	84.2	246	25	US-09-654-617-48855
40	16	84.2	246	27	US-09-684-016-48855
41	16	84.2	246	29	US-09-733-089-10526
42	16	84.2	350	52	US-60-207-458-85721
43	16	84.2	555	50	US-60-182-316-9259
44	16	84.2	631	28	US-09-703-708-212
45	16	84.2	631	48	US-60-164-320-212

ALIGNMENTS

```

RESULT 1
US-08-474-497-20
; Sequence 20, Application US/08474497
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; TITLE OF INVENTION: Using Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-474-497-20

Query Match 100.0%; Score 19; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCGG 19
Db 1 GCGCTCGGCTGGTCCCGG 19

RESULT 2
US-09-016-464-20
; Sequence 20, Application US/09016464
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: Method of Treatment of Lung Diseases
; TITLE OF INVENTION: Using Antisense Oligonucleotides
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: NC
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-016-464-20

Query Match 100.0%; Score 19; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCGG 19
Db 1 GCGCTCGGCTGGTCCCGG 19

RESULT 3
US-09-509-152A-1061
; Sequence 1061, Application US/09509152A
; GENERAL INFORMATION:
; APPLICANT: NYCE, JONATHAN W.
; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
; FORMULATIONS, KITS & APPLICATIONS
; NUMBER OF SEQUENCES: 2419
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 CLARKE DRIVE
; CITY: CRANBURY
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/509,152A
; FILING DATE: 17-Mar-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/059,160
; FILING DATE: 1997-09-17
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00991
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1061:
; SEQUENCE CHARACTERISTICS:

```

```

; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/016,464
; FILING DATE: 30-Jan-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/474,497
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-32
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 881-3140
; TELEFAX: (919) 881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-016-464-20

Query Match 100.0%; Score 19; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCGG 19
Db 1 GCGCTCGGCTGGTCCCGG 19

RESULT 3
US-09-509-152A-1061
; Sequence 1061, Application US/09509152A
; GENERAL INFORMATION:
; APPLICANT: NYCE, JONATHAN W.
; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
; FORMULATIONS, KITS & APPLICATIONS
; NUMBER OF SEQUENCES: 2419
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 CLARKE DRIVE
; CITY: CRANBURY
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/509,152A
; FILING DATE: 17-Mar-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/059,160
; FILING DATE: 1997-09-17
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00991
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1061:
; SEQUENCE CHARACTERISTICS:

```

;; LENGTH: 19 base pairs
 ;; TYPE: nucleic acid
 ;; STRANDEDNESS: single
 ;; TOPOLOGY: linear
 ;; SEQUENCE DESCRIPTION: SEQ ID NO: 1061:
 US-09-509-152A-1061

Query Match 100.0%; Score 19; DB 19; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCGCTCGGCTGTGTCGG 19
 Db 1 GCGCTCGGCTGTGTCGG 19

RESULT 4
 US-09-509-152A-1071
 ; Sequence 1071, Application US/09509152A
 ; GENERAL INFORMATION:
 ; APPLICANT: NYCE, JONATHAN W.
 ; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
 ; FORMULATIONS, KITS & APPLICATIONS
 ; NUMBER OF SEQUENCES: 2419
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
 ; STREET: 7 CLARKE DRIVE
 ; CITY: CRANBURY
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 08512
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS
 ; SOFTWARE: ASCII
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/509,152A
 ; FILING DATE: 17-Mar-2000
 ; CLASSIFICATION: UNKNOWN
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/059,160
 ; FILING DATE: 1997-09-17
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Amzel, Viviana
 ; REGISTRATION NUMBER: 30,930
 ; REFERENCE/DOCKET NUMBER: EPI-00991
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 609-409-3035
 ; TELEFAX: 413-254-9245
 ; TELEX: <Unknown>
 ; INFORMATION FOR SEQ ID NO: 1071:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 60 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: Genomic DNA
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 1071:
 US-09-509-152A-1071

Query Match 100.0%; Score 19; DB 19; Length 60;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCGCTCGGCTGTGTCGG 19
 Db 37 GCGCTCGGCTGTGTCGG 55

RESULT 5

US-09-509-152A-1739
 ; Sequence 1739, Application US/09509152A
 ; GENERAL INFORMATION:
 ; APPLICANT: NYCE, JONATHAN W.
 ; TITLE OF INVENTION: MULTIPLE TARGET HYBRIDIZING COMPOSITION
 ; FORMULATIONS, KITS & APPLICATIONS
 ; NUMBER OF SEQUENCES: 2419
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
 ; STREET: 7 CLARKE DRIVE
 ; CITY: CRANBURY
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 08512
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS
 ; SOFTWARE: ASCII
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/509,152A
 ; FILING DATE: 17-Mar-2000
 ; CLASSIFICATION: UNKNOWN
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/059,160
 ; FILING DATE: 1997-09-17
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Amzel, Viviana
 ; REGISTRATION NUMBER: 30,930
 ; REFERENCE/DOCKET NUMBER: EPI-00991
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 609-409-3035
 ; TELEFAX: 413-254-9245
 ; TELEX: <Unknown>
 ; INFORMATION FOR SEQ ID NO: 1739:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 272 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 1739:
 US-09-509-152A-1739

Query Match 100.0%; Score 19; DB 19; Length 272;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCGCTCGGCTGTGTCGG 19
 Db 1 GCGCTCGGCTGTGTCGG 19

RESULT 6
 US-09-496-911-3525
 ; Sequence 3525, Application US/09496911
 ; GENERAL INFORMATION:
 ; APPLICANT: Hyseq, Inc.
 ; TITLE OF INVENTION: Novel Nucleic Acid Sequences Obtained
 ; FROM VARIOUS LIBRARIES
 ; FILE REFERENCE: 786
 ; CURRENT APPLICATION NUMBER: US/09/496,911
 ; CURRENT FILING DATE: 2000-02-03
 ; NUMBER OF SEQ ID NOS: 13944
 ; SOFTWARE: Hy-patent.pl Version 3.1
 ; SEQ ID NO 3525
 ; LENGTH: 367
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-496-911-3525

Query Match 100.0%; Score 19; DB 18; Length 367;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19
|||||
Db 227 ggcctcgccgtggtcccg 245

RESULT 7

US-09-306-350A-2131/c
; Sequence 2131, Application US/09306350A

; GENERAL INFORMATION:

; APPLICANT: Dickson, Mark C.

; APPLICANT: Drmanac, Radoje T.

; APPLICANT: Jones, Lee W.

; APPLICANT: Labat, Ivan

; APPLICANT: Stache-Crain, Birgit

; TITLE OF INVENTION: Novel Nucleic Acid Sequences Obtained

; TITLE OF INVENTION: From Various cDNA Libraries

; FILE REFERENCE: 20411-776

; CURRENT APPLICATION NUMBER: US/09/306,350A

; CURRENT FILING DATE: 1999-05-07

; NUMBER OF SEQ ID NOS: 41304

; SOFTWARE: pt_CT_1 Version 1.1

; SEQ ID NO 2131

; LENGTH: 454

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-306-350A-2131

Query Match 100.0%; Score 19; DB 17; Length 454;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19
|||||
Db 163 GCGCTCGGCTGGTCCCGG 145

RESULT 8

US-09-306-350A-1791/c

; Sequence 1791, Application US/09306350A

; GENERAL INFORMATION:

; APPLICANT: Dickson, Mark C.

; APPLICANT: Drmanac, Radoje T.

; APPLICANT: Jones, Lee W.

; APPLICANT: Labat, Ivan

; APPLICANT: Stache-Crain, Birgit

; TITLE OF INVENTION: Novel Nucleic Acid Sequences Obtained

; TITLE OF INVENTION: From Various cDNA Libraries

; FILE REFERENCE: 20411-776

; CURRENT APPLICATION NUMBER: US/09/306,350A

; CURRENT FILING DATE: 1999-05-07

; NUMBER OF SEQ ID NOS: 41304

; SOFTWARE: pt_CT_1 Version 1.1

; SEQ ID NO 1791

; LENGTH: 465

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)...(465)

; OTHER INFORMATION: n = a,t,c or g

US-09-306-350A-1791

Query Match 100.0%; Score 19; DB 17; Length 465;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19
|||||

Db 167 GCGCTCGGCTGGTCCCGG 149

RESULT 9

US-09-306-350A-2747/c

; Sequence 2747, Application US/09306350A

; GENERAL INFORMATION:

; APPLICANT: Dickson, Mark C.

; APPLICANT: Drmanac, Radoje T.

; APPLICANT: Jones, Lee W.

; APPLICANT: Labat, Ivan

; APPLICANT: Stache-Crain, Birgit

; TITLE OF INVENTION: Novel Nucleic Acid Sequences Obtained

; TITLE OF INVENTION: From Various cDNA Libraries

; FILE REFERENCE: 20411-776

; CURRENT APPLICATION NUMBER: US/09/306,350A

; CURRENT FILING DATE: 1999-05-07

; NUMBER OF SEQ ID NOS: 41304

; SOFTWARE: pt_CT_1 Version 1.1

; SEQ ID NO 2747

; LENGTH: 468

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)...(468)

; OTHER INFORMATION: n = a,t,c or g

US-09-306-350A-2747

Query Match 100.0%; Score 19; DB 17; Length 468;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19
|||||
Db 409 GCGCTCGGCTGGTCCCGG 391

RESULT 10

US-60-169-840-164/c

; Sequence 164, Application US/60169840

; GENERAL INFORMATION:

; APPLICANT: Bonazzi, Vivien

; TITLE OF INVENTION: ISOLATED HUMAN SECRETED PROTEINS,

; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED PROTEINS AND

; TITLE OF INVENTION: USES THEREOF

; FILE REFERENCE: CL000164

; CURRENT APPLICATION NUMBER: US/60/169,840

; CURRENT FILING DATE: 1999-12-09

; NUMBER OF SEQ ID NOS: 9628

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 164

; LENGTH: 470

; TYPE: DNA

; ORGANISM: Human

US-60-169-840-164

Query Match 100.0%; Score 19; DB 48; Length 470;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCGCTCGGCTGGTCCCGG 19
|||||
Db 369 GCGCTCGGCTGGTCCCGG 351

RESULT 11

US-09-637-888-5196/c

; Sequence 5196, Application US/09637888

; GENERAL INFORMATION:

; APPLICANT: Curtis, Rory A. J.

; APPLICANT: Gearing, David P.
; APPLICANT: Kingsbury, Gillian A.
; APPLICANT: Holzman, Douglas A.
; APPLICANT: Weich, Nadine S.
; APPLICANT: Fraser, Christopher C.
; APPLICANT: Villevall, Jean-Luc M.G.
; APPLICANT: Goodearl, Andrew
; APPLICANT: Silos-Santiago, Inmaculada
; APPLICANT: Pan, Yang
; APPLICANT: White, David
; APPLICANT: Hodge, Martin
; TITLE OF INVENTION: NOVEL NUCLEIC ACID MOLECULES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 1600.1153-001
; CURRENT APPLICATION NUMBER: US/09/637,888
; CURRENT FILING DATE: 2000-08-06
; PRIOR APPLICATION NUMBER: 60/147,937
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 10569
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5196
; LENGTH: 520
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(520)
; OTHER INFORMATION: n = A,T,C or G
US-09-637-888-5196

Query Match 100.0%; Score 19; DB 24; Length 520;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTGTCGG 19
|||||
DB 69 GCGCTCGGCTGTGTCGG 51

RESULT 12
US-60-170-373-1322/c
; Sequence 1322, Application US/60170373
; GENERAL INFORMATION:
; APPLICANT: Bonazzi, Vivien
; TITLE OF INVENTION: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
; TITLE OF INVENTION: ACID MOLECULES ENCODING HUMAN KINASE PROTEINS AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: CL000149
; CURRENT APPLICATION NUMBER: US/60/170,373
; CURRENT FILING DATE: 1999-12-13
; NUMBER OF SEQ ID NOS: 4282
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1322
; LENGTH: 523
; TYPE: DNA
; ORGANISM: Human
US-60-170-373-1322

Query Match 100.0%; Score 19; DB 49; Length 523;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTGTCGG 19
|||||
DB 285 GCGCTCGGCTGTGTCGG 267

RESULT 13
US-60-226-176-976/c
; Sequence 976, Application US/60226176
; GENERAL INFORMATION:

; APPLICANT: Ring, Huijun Z.
; APPLICANT: Malsen, Gareth
; APPLICANT: Townley, David
; APPLICANT: Morris, MacDonald
; TITLE OF INVENTION: Single Nucleotide Polymorphisms Associated With ADME Genes
; FILE REFERENCE: GX-0013-1 P
; CURRENT APPLICATION NUMBER: US/60/226,176
; CURRENT FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2447
; SOFTWARE: PERL Program
; SEQ ID NO 976
; LENGTH: 2079
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: EPX_cds.1
US-60-226-176-976

Query Match 100.0%; Score 19; DB 54; Length 2079;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTGTCGG 19
|||||
DB 351 GCGCTCGGCTGTGTCGG 333

RESULT 14
US-60-233-468-976/c
; Sequence 976, Application US/60233468
; GENERAL INFORMATION:
; APPLICANT: Ring, Huijun Z.
; APPLICANT: Malsen, Gareth
; APPLICANT: Townley, David
; APPLICANT: Morris, MacDonald
; APPLICANT: Valdes, Ana
; TITLE OF INVENTION: Single Nucleotide Polymorphisms Associated With ADME Genes
; FILE REFERENCE: GX-0013-2 P
; CURRENT APPLICATION NUMBER: US/60/233,468
; CURRENT FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 2488
; SOFTWARE: PERL Program
; SEQ ID NO 976
; LENGTH: 2079
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: EPX_cds.1
US-60-233-468-976

Query Match 100.0%; Score 19; DB 55; Length 2079;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGTGTCGG 19
|||||
DB 351 GCGCTCGGCTGTGTCGG 333

RESULT 15
US-60-226-176-973/c
; Sequence 973, Application US/60226176
; GENERAL INFORMATION:
; APPLICANT: Ring, Huijun Z.
; APPLICANT: Malsen, Gareth
; APPLICANT: Townley, David
; APPLICANT: Morris, MacDonald
; TITLE OF INVENTION: Single Nucleotide Polymorphisms Associated With ADME Genes
; FILE REFERENCE: GX-0013-1 P

```

; CURRENT APPLICATION NUMBER: US/60/226.176
; CURRENT FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2447
; SOFTWARE: PERL Program
; SEQ ID NO 973
; LENGTH: 2109
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: GB:HSEP.1
US-60-226-176-973

```

```

Query Match      100.0%; Score 19; DB 54; Length 2109;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCTGGTCCCG 19
   ||||||||||||||||
Db 384 GCGCTCGGCTGGTCCCG 366

```

Search completed: April 20, 2001, 03:21:33
Job time: 14180 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2001, 00:15:57 ; Search time 101.94 Seconds
(without alignments)
25.791 Million cell updates/sec

Title: US-09-016-464-20

Perfect score: 19

Sequence: 1 GCGTCGCGCTGTCGCGG 19

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 46985 seqs, 69187998 residues

Total number of hits satisfying chosen parameters: 93970

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Pending_Patents_NA_New.*
1: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq.*
2: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq.*
3: /cgn2_6/ptodata/1/pna/US07_NEW_COMB.seq.*
4: /cgn2_6/ptodata/1/pna/US08_NEW_COMB.seq.*
5: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq.*
6: /cgn2_6/ptodata/1/pna/US60_NEW_COMB.seq.*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	ID	Description
1	19	100.0	19	5	US-09-543-679A-1061 Sequence 1061, Ap
2	19	100.0	60	5	US-09-543-679A-1071 Sequence 1071, Ap
3	19	100.0	272	5	US-09-543-679A-1739 Sequence 1739, Ap
4	19	100.0	2558	5	US-09-543-679A-2490 Sequence 2490, Ap
5	19	100.0	6103	5	US-09-543-679A-3008 Sequence 3008, Ap
6	19	100.0	6103	5	US-09-543-679A-3008 Sequence 3008, Ap
7	19	100.0	7033	5	US-09-543-679A-2411 Sequence 2411, Ap
8	19	100.0	35459	5	US-09-543-679A-3003 Sequence 3003, Ap
9	19	100.0	209274	5	US-09-543-679A-3004 Sequence 3004, Ap
10	15.8	83.2	300	5	US-09-739-449-4003 Sequence 4003, Ap
11	15.8	83.2	2091	5	US-09-739-449-3607 Sequence 3607, Ap
12	15.8	83.2	183820	5	US-09-739-449-209 Sequence 209, Ap
13	15.4	81.1	974	5	US-09-819-308-9 Sequence 9, Appli
14	15	78.9	15	5	US-09-543-679A-1740 Sequence 1740, Ap
15	14.8	77.9	303	5	US-09-739-449-6709 Sequence 6709, Ap
16	14.8	77.9	504	4	US-08-276-163D-9185 Sequence 9185, Ap
17	14.4	75.8	933	5	US-09-739-449-6367 Sequence 6367, Ap
18	14.4	75.8	1077	1	PCT-US01-10246-1 Sequence 1, Appli
19	14.4	75.8	24390	6	US-60-248-505-56 Sequence 56, Appl
20	14.4	75.8	24391	6	US-60-248-505-406 Sequence 406, Appl
21	14.4	75.8	41100	6	US-60-248-822-5 Sequence 5, Appli
22	14.2	74.7	490	4	US-08-276-163D-10820 Sequence 10820, A
23	14.2	74.7	494	4	US-08-276-163D-10820 Sequence 7740, Ap
24	14.2	74.7	505	4	US-08-276-163D-14346 Sequence 14346, A
25	14.2	74.7	684	5	US-09-739-449-1933 Sequence 1933, Ap
26	14.2	74.7	759	5	US-09-739-449-3332 Sequence 3332, Ap
27	14.2	74.7	936	5	US-09-739-449-7872 Sequence 7872, Ap

Query Match 100.0%; Score 19; DB 5; Length 19;

Best Local Similarity 100.0%; Pred. No. 3; 0; Indels 0; Gaps 0;

Matches 19; Conservative 0; Mismatches 0; Length 19;

ALIGNMENTS

RESULT 1

US-09-543-679A-1061
; Sequence 1061, Application US/09543679A

; GENERAL INFORMATION:

; APPLICANT: NYCE, Jonathan W.

; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,

; NUMBER OF SEQUENCES: 3111

; CORRESPONDENCE ADDRESS:

; ADDRESS: EPIGENESIS PHARMACEUTICALS, INC.

; STREET: 7 Clarke Drive

; CITY: Cranbury

; STATE: NJ

; COUNTRY: USA

; Zip: 08512

; COMPUTER READABLE FORM:

; MEDIUM TYPE: CD-R

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: N/A

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/543,679A

; FILING DATE: 13-Apr-2000

; CLASSIFICATION: UNKNOWN

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/127,958

; FILING DATE: 1998-08-03

; ATTORNEY/AGENT INFORMATION:

; NAME: Amzel, Viviana

; REGISTRATION NUMBER: 30,930

; REFERENCE/DOCKET NUMBER: EPI-0067191b

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 609-409-3035

; TELEFAX: 413-254-9245

; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 1061:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 19 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; SEQUENCE DESCRIPTION: SEQ ID NO: 1061:

US-09-543-679A-1061

QY 1 GCGCTCGCCTGGTCCCGG 19
 |||||
 Db 1 GCGCTCGCCTGGTCCCGG 19

RESULT 2

US-09-543-679A-1071
 ; Sequence 1071, Application US/09543679A
 ; GENERAL INFORMATION:
 ; APPLICANT: NYCE, Jonathan W.
 ; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
 ; COMPOSITIONS, KIT & METHOD FOR TREATMENT
 ; OF AIRWAY DISORDERS ASSOCIATED WITH
 ; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
 ; NUMBER OF SEQUENCES: 3111
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
 ; STREET: 7 Clarke Drive
 ; CITY: Cranbury
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 08512

COMPUTER READABLE FORM:
 MEDIUM TYPE: CD-R
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: N/A

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/543,679A
 FILING DATE: 13-Apr-2000
 CLASSIFICATION: UNKNOWN
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 60/127,958
 FILING DATE: 1998-08-03
 ATTORNEY/AGENT INFORMATION:
 NAME: Amzel, Viviana
 REGISTRATION NUMBER: 30,930
 REFERENCE/DOCKET NUMBER: EPI-0067191b
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 609-409-3035
 TELEFAX: 413-254-9245
 TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 1071:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 60 base pairs
 TYPE: nucleic acid
 TOPOLOGY: linear
 MOLECULE TYPE: Genomic DNA
 SEQUENCE DESCRIPTION: SEQ ID NO: 1071:
 US-09-543-679A-1071

Query Match 100.0%; Score 19; DB 5; Length 60;
 Best Local Similarity 100.0%; Pred. No. 2.6;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGCCTGGTCCCGG 19
 |||||
 Db 37 GCGCTCGCCTGGTCCCGG 55

RESULT 3

US-09-543-679A-1739
 ; Sequence 1739, Application US/09543679A
 ; GENERAL INFORMATION:
 ; APPLICANT: NYCE, Jonathan W.
 ; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
 ; COMPOSITIONS, KIT & METHOD FOR TREATMENT
 ; OF AIRWAY DISORDERS ASSOCIATED WITH
 ; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
 ; NUMBER OF SEQUENCES: 3111

CORRESPONDENCE ADDRESS:
 ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
 STREET: 7 Clarke Drive
 CITY: Cranbury
 STATE: NJ
 COUNTRY: USA
 ZIP: 08512

COMPUTER READABLE FORM:
 MEDIUM TYPE: CD-R
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: N/A

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/543,679A
 FILING DATE: 13-Apr-2000
 CLASSIFICATION: UNKNOWN
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 60/127,958
 FILING DATE: 1998-08-03

ATTORNEY/AGENT INFORMATION:
 NAME: Amzel, Viviana
 REGISTRATION NUMBER: 30,930
 REFERENCE/DOCKET NUMBER: EPI-0067191b
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 609-409-3035
 TELEFAX: 413-254-9245
 TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 1739:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 272 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 1739:
 US-09-543-679A-1739

Query Match 100.0%; Score 19; DB 5; Length 272;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGCCTGGTCCCGG 19
 |||||
 Db 1 GCGCTCGCCTGGTCCCGG 19

RESULT 4

US-09-543-679A-2490/c
 ; Sequence 2490, Application US/09543679A
 ; GENERAL INFORMATION:
 ; APPLICANT: NYCE, Jonathan W.
 ; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
 ; COMPOSITIONS, KIT & METHOD FOR TREATMENT
 ; OF AIRWAY DISORDERS ASSOCIATED WITH
 ; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
 ; NUMBER OF SEQUENCES: 3111
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
 ; STREET: 7 Clarke Drive
 ; CITY: Cranbury
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 08512

COMPUTER READABLE FORM:
 MEDIUM TYPE: CD-R
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: N/A

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/543,679A
 FILING DATE: 13-Apr-2000
 CLASSIFICATION: UNKNOWN
 PRIOR APPLICATION DATA:


```

; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2490:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2558 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2490:
US-09-543-679A-2490

Query Match 100.0%; Score 19; DB 5; Length 2558;
Best Local Similarity 100.0%; Pred. No. 1.5;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCCTGGTCCGG 19
Db 384 GCGCTCGGCCTGGTCCGG 366

RESULT 5
US-09-543-679A-3008
; Sequence 3008, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION;
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/543,679A
; FILING DATE: 13-Apr-2000
; CLASSIFICATION: UNKNOWN
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 3008:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6103base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 3008:
US-09-543-679A-3008

Query Match 100.0%; Score 19; DB 5; Length 6103;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCCTGGTCCGG 19
Db 3929 GCGCTCGGCCTGGTCCGG 3911

RESULT 7
US-09-543-679A-2411
; Sequence 2411, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
```

US-09-543-679A-3008

Query Match 100.0%; Score 19; DB 5; Length 6103;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCCTGGTCCGG 19
Db 1 GCGCTCGGCCTGGTCCGG 19

RESULT 6

US-09-543-679A-3008/c
; Sequence 3008, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512

COMPUTER READABLE FORM:

MEDIUM TYPE: CD-R
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: N/A

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/543,679A
FILING DATE: 13-Apr-2000
CLASSIFICATION: UNKNOWN
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/127,958

ATTORNEY/AGENT INFORMATION:

NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-0067191b
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 3008:

SEQUENCE CHARACTERISTICS:
LENGTH: 6103base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 3008:
US-09-543-679A-3008

Query Match 100.0%; Score 19; DB 5; Length 6103;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGGCCTGGTCCGG 19
Db 3929 GCGCTCGGCCTGGTCCGG 3911

RESULT 7

US-09-543-679A-2411
; Sequence 2411, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.

```

; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: 60/127,958
; FILING DATE: 1998-08-03
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-0067191b
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2411:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7033 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 2411:
; US-09-543-679A-2411

Query Match 100.0%; Score 19; DB 5; Length 7033;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGGTCCCGG 19
Db 238 GCGCTCGCGCTGGTCCCGG 256

RESULT 8
US-09-543-679A-3003/c
; Sequence 3003, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; NUMBER OF SEQUENCES: 3111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: NJ
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-R
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: N/A

```

;
; LENGTH: 209274 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 3004:
US-09-543-679A-3004

Query Match 100.0%; Score 19; DB 5; Length 209274;
Best Local Similarity 100.0%; Pred. No. 0.77; 0; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 1 GCGCTCGCGCTGGTCCCGG 19
|||||
Db 238 GCGCTCGCGCTGGTCCCGG 256

RESULT 10

US-09-739-449-4003
; Sequence 4003, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 4003
; LENGTH: 300
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
US-09-739-449-4003

Query Match 83.2%; Score 15.8; DB 5; Length 300;
Best Local Similarity 89.5%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGGTCCCGG 19
|||||
Db 79 GCGCTCGCGCTGGTCCCGG 97

RESULT 11

US-09-739-449-3607/C
; Sequence 3607, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 3607
; LENGTH: 2091
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
US-09-739-449-3607

Query Match 83.2%; Score 15.8; DB 5; Length 2091;
Best Local Similarity 89.5%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGGTCCCGG 19
|||||
Db 975 GCGCTCGCGCTGGTCCCGG 957

RESULT 12

US-09-739-449-209
; Sequence 209, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 209
; LENGTH: 183820
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)-(183820)
; OTHER INFORMATION: unsure at all n locations
US-09-739-449-209

Query Match 83.2%; Score 15.8; DB 5; Length 183820;
Best Local Similarity 89.5%; Pred. No. 18;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGGTCCCGG 19
|||||
Db 23951 GCGCTCGCGCTGGTCCCGG 23969

RESULT 13

US-09-819-308-9
; Sequence 9, Application US/09819308
; GENERAL INFORMATION:
; APPLICANT: Noteborn, Mathieu
; APPLICANT: Danen-van Oorschot, Astrid
; APPLICANT: Roha, Jennifer
; TITLE OF INVENTION: APOPTIN-ASSOCIATING PROTEIN
; FILE REFERENCE: 2906-4820US
; CURRENT APPLICATION NUMBER: US/09/819,308
; CURRENT FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 974
; TYPE: DNA
; ORGANISM: AAP-5
US-09-819-308-9

Query Match 81.1%; Score 15.4; DB 5; Length 974;
Best Local Similarity 94.1%; Pred. No. 59;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GCGCTCGCGCTGGTCCCG 17
|||||
Db 21 GCGCTAGCGCTGGTCCCG 37

RESULT 14

US-09-543-679A-1740
; Sequence 1740, Application US/09543679A
; GENERAL INFORMATION:
; APPLICANT: INCE, Jonathan W.
; TITLE OF INVENTION: LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE,
; COMPOSITIONS, KIT & METHOD FOR TREATMENT
; OF AIRWAY DISORDERS ASSOCIATED WITH
; BRONCHOCONSTRICTION, LUNG INFLAMMATION,
; ;

Db 121 qcgcctcggcgtggcg 138

Search completed: April 20, 2001, 00:16:04
Job time: 9501 sec

```

Query Match      78.9%; Score 15; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      5 TCGGCCTGGTCCCGG 19
          |||||
Ddb      1 TCGGCCTGGTCCCGG 15

RESULT 15
US-09-739-449-6709
; Sequence 6709, Application US/09739449
; GENERAL INFORMATION:
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; TITLE OF INVENTION: Agrobacterium tumefaciens Genome Sequences and Uses Thereof
; FILE REFERENCE: 38-10(15490)C
; CURRENT APPLICATION NUMBER: US/09/739,449
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: US 09/514,000
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13351
; SEQ ID NO 6709
; LENGTH: 303
; TYPE: DNA
; ORGANISM: Agrobacterium tumefaciens
US-09-739-449-6709

Query Match      77.9%; Score 14.8; DB 5; Length 303;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 GCGCTCGGCCTGGTCCCG 18
          |||||

```

us-09-016-464-20.rnpn

Fri Apr 20 10:23:36 2001

THIS PAGE BLANK (USPTO)